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1  Preamble 273 
Guidelines summarize and evaluate all available evidence on a particular issue at the time of the writing process, 274 
with the aim of assisting health professionals in selecting the best management strategies for an individual 275 
patient with a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of 276 
particular diagnostic or therapeutic means. Guidelines and recommendations should help health professionals to 277 
make decisions in their daily practice. However, the final decisions concerning an individual patient must be 278 
made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate. 279 
A great number of Guidelines have been issued in recent years by the European Society of Cardiology (ESC) 280 
and by the European Association for Cardio-Thoracic Surgery (EACTS), as well as by other societies and 281 
organisations. Because of the impact on clinical practice, quality criteria for the development of guidelines have 282 
been established in order to make all decisions transparent to the user. The recommendations for formulating 283 
and issuing ESC Guidelines can be found on the ESC website (http://www.escardio.org/Guidelines-&-284 
Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). ESC Guidelines 285 
represent the official position of the ESC on a given topic and are regularly updated. 286 
Members of this Task Force were selected by the ESC, including representation from the European Heart 287 
Rhythm Association (EHRA), and EACTS as well as by the European Stroke Organisation (ESO) to represent 288 
professionals involved with the medical care of patients with this pathology. Selected experts in the field 289 
undertook a comprehensive review of the published evidence for management (including diagnosis, treatment, 290 
prevention and rehabilitation) of a given condition according to ESC Committee for Practice Guidelines (CPG) 291 
policy and approved by the EACTS and ESO. A critical evaluation of diagnostic and therapeutic procedures was 292 
performed, including assessment of the risk–benefit ratio. Estimates of expected health outcomes for larger 293 
populations were included, where data exist. The level of evidence and the strength of the recommendation of 294 
particular management options were weighed and graded according to predefined scales, as outlined in Tables 1 295 
and 2. 296 
The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that 297 
might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file 298 
and can be found on the ESC website (http://www.escardio.org/guidelines). Any changes in declarations of 299 
interest that arise during the writing period must be notified to the ESC and EACTS and updated. The Task 300 
Force received its entire financial support from the ESC and EACTS without any involvement from the 301 
healthcare industry. 302 
The ESC CPG supervises and coordinates the preparation of new Guidelines produced by task forces, expert 303 
groups or consensus panels. The Committee is also responsible for the endorsement process of these Guidelines. 304 
The ESC Guidelines undergo extensive review by the CPG and external experts, and in this case by EACTS and 305 
ESO-appointed experts. After appropriate revisions the Guidelines are approved by all the experts involved in 306 
the Task Force. The finalized document is approved by the CPG, EACTS and ESO for publication in the 307 
European Heart Journal, Europace, and in the European Journal of Cardio-Thoracic Surgery as well as in the 308 
International Journal of Stroke (TBC). The Guidelines were developed after careful consideration of the 309 
scientific and medical knowledge and the evidence available at the time of their dating. 310 
The task of developing ESC and EACTS Guidelines covers not only integration of the most recent research, but 311 
also the creation of educational tools and implementation programmes for the recommendations. To implement 312 
the guidelines, condensed pocket guideline versions, summary slides, booklets with essential messages, 313 
summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.) are 314 
produced. These versions are abridged and thus, if needed, one should always refer to the full text version, 315 
which is freely available on the ESC website. The National Societies of the ESC are encouraged to endorse, 316 
translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown 317 
that the outcome of disease may be favourably influenced by the thorough application of clinical 318 
recommendations. 319 
Surveys and registries are needed to verify that real-life daily practice is in keeping with what is recommended 320 
in the guidelines, thus completing the loop between clinical research, writing of guidelines, disseminating them 321 
and implementing them into clinical practice. 322 
Health professionals are encouraged to take the ESC and EACTS Guidelines fully into account when exercising 323 
their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or 324 
therapeutic medical strategies. However, the ESC and EACTS Guidelines do not override in any way 325 
whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in 326 
consideration of each patient’s health condition and in consultation with that patient and the patient’s caregiver 327 
where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and 328 
regulations applicable to drugs and devices at the time of prescription. 329 
 330 
 331 
 332 
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Table 1 Classes of recommendations 333 
 334 
 335 
Table 2 Levels of evidence 336 
 337 
 338 
 339 
2 Introduction 340 
Despite good progress in the management of patients with atrial fibrillation (AF), this arrhythmia remains one of 341 
the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. Furthermore, 342 
the number of patients with AF is predicted to rise steeply in the coming years. To meet the growing demand for 343 
effective care of patients with AF, new information is continually generated and published, and the last few 344 
years have seen substantial progress. It therefore seems timely to publish this 2nd edition of the ESC guidelines 345 
on AF.  346 
 347 
Reflecting the multidisciplinary input into the management of patients with AF, the Task Force includes 348 
cardiologists with varying subspecialty expertise, cardiac surgeons, stroke neurologists, and specialist nurses 349 
amongst its members. Supplementing the evidence review as outlined in the preamble, this task force identified 350 
three PICOT questions on relevant topics for the guideline. The ESC commissioned external systematic reviews 351 
to answer these three questions. These reviews informed specific recommendations. 352 
 353 
Further to adhering to the standards for generating recommendations that is common to all ESC guidelines (see 354 
preamble), this task force discussed each draft recommendation during web-based conference calls dedicated to 355 
specific chapters, followed by consensus modifications and an online vote on each recommendation. Only 356 
recommendations that were supported by at least 75% of the task force members were included in the guideline.  357 
 358 
We hope that this guideline will help to deliver good care to all patients with AF based on the current state-of-359 
the-art evidence in 2016.   360 
 361 
3 Epidemiology and impact for patients 362 
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3.1. Incidence and prevalence of atrial fibrillation 363 
In 2010, the estimated numbers of men and women with atrial fibrillation (AF) worldwide were 20.9 million 364 
and 12.6 million, respectively, with higher incidence and prevalence rates in developed countries.1, 2 One in four 365 
middle-aged adults in Europe and the United States (US) will develop AF.3-5 By 2030, 14–17 million AF 366 
patients are anticipated in the European Union, with 120,000–215,000 newly diagnosed patients per year.2, 6, 7 367 
Estimates suggest an AF prevalence of approximately 3% in adults age 20 years or older,8, 9 with more AF in 368 
elderly persons1 and in patients with conditions such as hypertension, heart failure, coronary artery disease 369 
(CAD), valvular heart disease, diabetes mellitus, and chronic kidney disease (CKD).7, 10-15 The increase in AF 370 
prevalence can be attributed to better detection of silent AF16-18 and increasing age and conditions predisposing 371 
to AF.19  372 
 373 
3.2. Morbidity, mortality, and healthcare burden of atrial fibrillation 374 
AF is independently associated with a twofold increased risk of all-cause mortality in women and a 1.5-fold 375 
increase in men20-22 (Table 3). Death due to stroke can largely be mitigated by anticoagulation, while other 376 
cardiovascular deaths, for example due to heart failure and sudden death, remain common even in AF patients 377 
treated according to the current evidence-base.23 AF is also associated with increased morbidity, such as heart 378 
failure and stroke.21, 24, 25 Contemporary studies show that 20–30% of patients with an ischaemic stroke have AF 379 
diagnosed before, during, or after the initial event.17, 26, 27 White matter lesions in the brain, cognitive 380 
impairment,28-30 decreased quality of life,31, 32 and depressed mood33 are common in AF patients, and between 381 
10% and 40% of AF patients are hospitalized each year.23, 34, 35 382 
 The direct costs of AF already amount to approximately 1% of total healthcare spending in the UK, and 383 
between $6.0 and $26.0 billion in the US for 2008,36, 37 driven by AF-related complications (e.g. stroke) and AF-384 
related treatment costs (e.g. hospitalizations). These costs will increase dramatically unless AF is prevented and 385 
treated in a timely and effective manner.  386 
 387 
Table 3 Cardiovascular morbidity and mortality associated with AF 388 
Event Association with AF 
Death Increased mortality, especially cardiovascular mortality due to sudden death, heart 
failure, or stroke 
Stroke 20–30% of all strokes are due to AF. A growing number of patients with stroke are 
diagnosed with ‘silent’, paroxysmal AF 
Hospitalizations 10–40% of AF patients are hospitalized every year 
Quality of life Quality of life is impaired in AF patients independent of other cardiovascular 
conditions 
LV dysfunction and 
heart failure 
LV dysfunction is found in 20–30% of all AF patients. AF causes or aggravates LV 
dysfunction in many AF patients, while others have completely preserved LV 
function despite long-standing AF 
Cognitive decline and 
vascular dementia 
Cognitive decline and vascular dementia increase even in anticoagulated patients. 
Brain white matter lesions are more common in AF patients than in patients without 
AF 
AF = atrial fibrillation; LV = left ventricular. 389 
 390 
3.3. Impact of evidence-based management on outcomes in atrial fibrillation 391 
patients 392 
Figure 1 depicts the major milestones in the management of AF. Despite these advances, substantial morbidity 393 
remains. Oral anticoagulation (OAC) with vitamin K antagonists (VKAs) or non-VKA oral anticoagulants 394 
(NOACs) markedly reduces stroke and mortality in AF patients.38, 39 Other interventions such as rhythm control 395 
and rate control improve AF-related symptoms and may preserve cardiac function, but have not demonstrated a 396 
reduction in long-term morbidity or mortality.40, 41  397 
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 399 
Figure 1 Timeline of major landmarks in AF management, including treatment of concomitant conditions and 400 
prevention (green), anticoagulation (blue), rate and rhythm control (orange and red), and surgical therapy 401 
(purple). 402 
ACEi = angiotensin-converting enzyme inhibitor; AF = atrial fibrillation; ARB = angiotensin receptor blocker; 403 
HF = heart failure; HFrEF = heart failure with reduced ejection fraction; LVH = left ventricular hypertrophy; 404 
NOAC = non-vitamin K antagonist oral anticoagulant; PUFA = polyunsaturated fatty acid; PVI = pulmonary 405 
vein isolation; QoL = quality of life; RACE = Rate Control Efficacy in Permanent Atrial Fibrillation; RF = 406 
radiofrequency; SR = sinus rhythm; VKA = vitamin K antagonist. 407 
 408 
In contemporary, well-controlled, randomized clinical trials in AF, the average annual stroke rate is about 1.5% 409 
and the annualized death rate is around 3%.40 In real life, the annual mortality can be different (both higher and 410 
lower).42 A minority of these deaths are related to stroke, while sudden cardiac death and death from progressive 411 
heart failure are more frequent, emphasizing the need for interventions beyond anticoagulation.43, 44 412 
Furthermore, AF is also associated with high rates of hospitalization, commonly for AF management, but often 413 
also for heart failure, myocardial infarction, and treatment-associated bleeding.34, 45  414 
 415 
3.4. Gender 416 
In both developed and developing countries, the age-adjusted incidence and prevalence of AF are lower in 417 
women, while the risk of death in women with AF is similar to or higher than that in men with AF.1, 46, 47 Female 418 
AF patients who have additional stroke risk factors (particularly older age) are also at greater risk than men of 419 
having a stroke,48, 49 even those anticoagulated with warfarin50 (see Chapter 8 for details). Women with 420 
diagnosed AF can be more symptomatic than men and are typically older with more comorbidities.51, 52 421 
Bleeding risk on anticoagulation is similar in both sexes,49, 50, 53 but women appear less likely to receive 422 
specialist care and rhythm control therapy,54 while the outcomes of catheter ablation or AF surgery are 423 
comparable to those in men.55, 56 These observations highlight the need to offer effective diagnostic tools and 424 
therapeutic management equally in women and men. 425 
 426 
Recommendations relating to gender 427 
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Recommendations Class a Level b Refs c 
AF clinicians must offer effective diagnostic tools and therapeutic 
management to women and men equally to prevent stroke and 
death 
I A 39, 46, 57 
Catheter or surgical ablation techniques should be regarded as 
equally effective in women and men 
IIa B 55, 56 
AF = atrial fibrillation 428 
aClass of recommendation. 429 
bLevel of evidence. 430 
cReference(s) supporting recommendations. 431 
 432 
4 Pathophysiological and genetic aspects that guide management 433 
4.1. Genetic predisposition 434 
AF, especially early-onset AF, has a strong heritable component, independent of concomitant cardiovascular 435 
conditions.58, 59 A few young AF patients suffer from inherited cardiomyopathies or channelopathies mediated 436 
by disease-causing mutations. These monogenic diseases also convey a risk for sudden death (see Chapter 5). 437 
Up to one-third of AF patients carry common genetic variants that predispose to AF, albeit with a relatively low 438 
added risk. At least 14 of these common variants, often single nucleotide polymorphisms, are known to increase 439 
the risk of prevalent AF in populations.60-62 The most important variants are located close to the paired-like 440 
homeodomain transcription factor 2 gene on chromosome 4q25.63, 64 These variants modify the risk of AF up to 441 
sevenfold.64 Several of the AF risk variants are also associated with cardioembolic or ischaemic stroke, possibly 442 
due to silent AF (see section 4.1).62, 65, 66 Changes in atrial action potential characteristics,67-70 atrial remodelling, 443 
and modified penetration of rare gene defects61 have been suggested as potential mechanisms mediating 444 
increased AF risk in carriers of common gene variants. Genetic variants could in the future become useful for 445 
patient selection of rhythm control strategies,71-73 but it is currently unknown whether common gene variants 446 
differentially affect the efficacy of antiarrhythmic drugs or rate control medication.74 While genomic analysis 447 
may provide an opportunity to improve diagnosis and management of AF in the future,75, 76 routine genetic 448 
testing for common gene variants associated with AF cannot be recommended at present.77  449 
 450 
4.2. Mechanisms leading to atrial fibrillation 451 
4.2.1. Remodelling of atrial structure and ion channel function  452 
External stressors such as structural heart disease, hypertension, possibly diabetes, but also AF itself induce a 453 
slow but progressive process of structural remodelling in the atria (Figure 2). Activation of fibroblasts, 454 
enhanced connective tissue deposition, and fibrosis are the hallmarks of this process.78-80 In addition, atrial fatty 455 
infiltration, inflammatory infiltrates, myocyte hypertrophy, necrosis, and amyloidosis are found in AF patients 456 
with concomitant conditions predisposing to AF.81-84 Structural remodelling results in electrical dissociation 457 
between muscle bundles and local conduction heterogeneities,85 favouring reentry and perpetuation of the 458 
arrhythmia.86 In many patients, the structural remodelling process occurs before the onset of AF.78 As some of 459 
the structural remodelling will be irreversible, early initiation of treatment seems desirable.87 Table 4 gives an 460 
overview of the most relevant pathophysiological alterations in atrial tissue associated with AF, and lists 461 
corresponding clinical conditions that can contribute to these changes. 462 
 The functional and structural changes in atrial myocardium and stasis of blood, especially in the left 463 
atrial appendage (LAA), generate a prothrombotic milieu. Furthermore, even short episodes of AF lead to 464 
myocardial damage and expression of prothrombotic factors on the atrial endothelial surface, and activation of 465 
platelets and inflammatory cells, and contribute to a generalized prothrombotic state.88, 89 The atrial and 466 
systemic activation of the coagulation system can partially explain why short episodes of AF convey a long-467 
term stroke risk. 468 
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Figure 2 Major mechanisms causing AF that can be considered when guiding therapy. The various aetiological 471 
factors (left) cause a complex array of pathophysiological changes in the atria, including stretch-induced atrial 472 
fibrosis, hypocontractility, fatty infiltration, inflammation, vascular remodelling, ischaemia, ion channel 473 
dysfunction, and Ca2+-instability. These changes enhance both ectopy and conduction disturbances, increasing 474 
the propensity of the atria to develop or maintain AF. At the same time, some of these alterations are involved in 475 
the occurrence of the hypercoagulable state associated with AF. For example, hypocontractility reduces local 476 
endothelial shear stress, which increases PAI-1 expression, and ischaemia-induced inflammation enhances the 477 
expression of endothelial adhesion molecules or promotes shedding of endothelial cells, resulting in tissue factor 478 
exposure to the blood stream. These changes contribute to the thrombogenic milieu in the atria of AF patients. 479 
AF in itself can aggravate many of the mechanisms shown, which may explain the progressive nature of the 480 
arrhythmia.  481 
AngII = angiotensin II; TF = tissue factor; FXII = factor XII; IL-6 = interleukin 6; PAI-1 = plasminogen 482 
activator inhibitor 1; VCAM-1 = vascular cell adhesion molecule 1. 483 
 484 
Table 4 Pathophysiological alterations in atrial tissue associated with AF and clinical conditions that 485 
could contribute to such alterations 486 
 487 
Pathophysiological 
alteration 
Clinical conditions contributing 
to the alteration 
Proarrhythmic mechanism/ 
functional consequence References 
 
Changes of the extracellular matrix, fibroblast function, and fat cells 
Interstitial and 
replacement fibrosis 
AF (especially forms with a high 
AF burden), hypertension, heart 
failure, valvular heart disease (via 
pressure and volume overload) 
Electrical dissociation, 
conduction block, enhanced AF 
complexity 
78, 79, 90, 91 
Inflammatory 
infiltration 
 Profibrotic responses, enhanced 
AF complexity 
81 
Fatty infiltration Obesity (fatty infiltration) Profibrotic/proinflammatory 
responses, localized conduction 
82, 92 
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block 
Amyloid deposition Ageing, heart failure, CAD (via 
atrial scarring), genetic factors 
Conduction disturbances 83, 93 
 
Ion channel alterations  
Ion channel 
remodelling 
AF (especially forms with a high 
AF burden), genetic 
predisposition to AF 
AF cycle shortening (if due to 
atrial tachycardia), AF cycle 
length prolongation (if due to 
heart failure), enhanced 
heterogeneity of atrial 
repolarization 
94-96 
Ca2+ handling 
instability 
AF (especially forms with a high 
AF burden), possibly heart failure 
and hypertension (possibly 
through increased sympathetic 
activation) 
Enhanced propensity to ectopy 97, 98 
Gap-junction 
redistribution 
AF Conduction disturbances 99 
 
Myocyte alterations 
Apoptosis and 
necrosis 
CAD, heart failure (through 
cardiomyocyte death and atrial 
scarring) 
May induce replacement 
fibrosis 
100 
Myocyte hypertrophy Atrial dilatation, AF Aggravates conduction 
disturbances 
84, 101 
 
Endothelial and vascular alterations 
Microvascular 
changes 
Atherosclerosis, CAD and 
peripheral artery disease, possibly 
AF 
Aggravation of atrial ischaemia, 
heterogeneity of electrical 
function, structural remodelling 
102 
Endocardial 
remodelling 
 Enhanced risk for thrombus 
formation 
103, 104 
 
Changes of the autonomic nervous system 
Sympathetic 
hyperinnervation 
Heart failure, hypertension Enhanced propensity to ectopy 80, 105 
AF = atrial fibrillation; CAD = coronary artery disease. 488 
 489 
3.2.1. Electrophysiological mechanisms of atrial fibrillation 490 
AF provokes a shortening of the atrial refractory period and AF cycle length during the first days of the 491 
arrhythmia, largely due to downregulation of the Ca2+-inward current and upregulation of inward rectifier K+ 492 
currents.94, 95 Structural heart disease, in contrast, tends to prolong the atrial refractory period, illustrating the 493 
heterogeneous nature of mechanisms that cause AF in different patients.96 Hyperphosphorylation of various 494 
Ca2+ handling proteins may contribute to enhanced spontaneous Ca2+ release events and triggered activity,97, 98 495 
thus causing ectopy and promoting AF. Although the concept of Ca2+ handling instability has been challenged 496 
recently,106, 107 it may mediate AF in structurally remodelled atria and explain how altered autonomic tone can 497 
generate AF.80, 105  498 
 499 
Focal initiation and maintenance of AF: The seminal observation by Haissaguerre et al108 was that a focal 500 
source in the pulmonary veins can trigger AF, and ablation of this source can extinguish the arrhythmia. The 501 
mechanism of focal activity might involve both triggered activity and localized reentry.109, 110 Hierarchic 502 
organization of AF with rapidly activated areas driving the arrhythmia has been documented in patients with 503 
paroxysmal AF,111, 112 but is more challenging in patients with persistent AF.113  504 
 505 
The multiple wavelet hypothesis and rotors as sources of AF: Moe and Abildskov114 proposed that AF can be 506 
perpetuated by continuous conduction of several independent wavelets propagating through the atrial 507 
musculature in a seemingly chaotic manner. As long as the number of wavefronts does not decline below a 508 
critical level, they will be capable of sustaining the arrhythmia. Numerous experimental and clinical 509 
observations can be reconciled with the multiple wavelet hypothesis.115 All localized sources of AF (ectopic 510 
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foci, rotors, or other stable reentry circuits) cause fibrillatory conduction remote from the source, which is 511 
difficult to distinguish from propagation sustaining AF by multiple wavelets, and either of these phenomena 512 
may generate ‘rotors’ picked up by intracardiac116, 117 or body surface117 recordings. 513 
 514 
 515 
5 Diagnosis and timely detection of atrial fibrillation 516 
5.1. Overt and silent atrial fibrillation 517 
The diagnosis of AF requires rhythm documentation using an electrocardiogram (ECG), with the typical pattern 518 
of AF. ECG-documented AF was the entry criterion in trials forming the evidence for these guidelines. By 519 
accepted convention, an episode lasting at least 30 seconds is diagnostic. Individuals with AF may be 520 
symptomatic or asymptomatic (‘silent AF’). Many AF patients have both symptomatic and asymptomatic 521 
episodes of AF.118-121  522 
 Silent, undetected AF is common,120, 122 with severe consequences such as stroke and death.123-125 523 
Prompt recording of an ECG is an effective and cost-effective method to document chronic forms of AF.126 The 524 
technology to detect paroxysmal, self-terminating AF episodes is rapidly evolving (see Chapter 5 for a 525 
definition of AF patterns). There is good evidence that prolonged ECG monitoring enhances the detection of 526 
undiagnosed AF, for 72 hours after a stroke,27, 127 for even longer periods,18, 128 or by daily short-term ECG 527 
recording in patients over 75 years of age129 (Web Addenda Figure 1). Ongoing studies will determine whether 528 
such early detection alters management (e.g. initiation of anticoagulation) and improves outcomes.  529 
 Once the ECG diagnosis of AF has been established, further ECG monitoring can inform management 530 
in the context of: (1) a change in symptoms or new symptoms; (2) suspected progression of AF; (3) monitoring 531 
of drug effects on ventricular rate; and (4) ECG monitoring of antiarrhythmic drug effects or catheter ablation 532 
for rhythm control. 533 
 534 
5.2. Screening for silent atrial fibrillation 535 
5.2.1. Screening for atrial fibrillation by electrocardiogram in the community 536 
Undiagnosed AF is common, especially in older populations and in patients with heart failure.130 Opportunistic 537 
screening for silent AF seems cost-effective in elderly populations (e.g. > 65 years),131 and similar effects have 538 
been reported using single-lead ECG screening in other at-risk populations.132, 133 Screening of elderly 539 
populations (mean age 64 years) yielded a prevalence of 2.3% for chronic forms of AF in 122,571 participants 540 
using either short-term ECG or pulse palpation (followed by ECG in those with an irregular pulse).134 541 
Previously undiagnosed AF was found in 1.4% of those aged > 65 years, suggesting a number needed to screen 542 
of 70. These findings encourage the further evaluation of systematic AF screening programmes in at-risk 543 
populations. 544 
 545 
5.2.2. Prolonged monitoring for paroxysmal atrial fibrillation 546 
Paroxysmal AF is often missed.120 Repeated daily ECG recordings increased the detection of silent, 547 
asymptomatic paroxysmal AF in an unselected Swedish population aged > 75 years.120, 135 Several patient-548 
operated devices136, 137 and extended continuous ECG monitoring using skin patch recorders138 have been 549 
validated for detection of paroxysmal AF.139 The detection rate of asymptomatic AF by new technologies such 550 
as smartphone cases with ECG electrodes, smart watches, and blood pressure machines with AF detection 551 
algorithms, has not yet been formally evaluated against an established arrhythmia detection method.140  552 
 553 
5.2.3. Patients with pacemakers and implanted devices 554 
Implanted pacemakers or defibrillators with an atrial lead allow continuous monitoring of atrial rhythm. Using 555 
this technology, patients with atrial high rate episodes (AHRE) can be identified. Depending on the risk profile 556 
of the population studied, such AHRE are detected in 10–15% of pacemaker patients.141 AHRE are associated 557 
with an increased risk of overt AF (hazard ratio [HR] 5.56; 95% confidence interval [CI] 3.78–8.17; P < 0.001) 558 
and ischaemic stroke or systemic embolism (HR 2.49; 95% CI 1.28–4.85; P = 0.007). The stroke risk in AHRE 559 
patients seems lower than the stroke risk in patients with diagnosed AF, and not all AHRE represent AF.142 560 
Strokes often occur without AHRE detected within 30 days before the event.143-147 Consequently, it is unclear 561 
whether AHRE imply the same therapeutic requirements as overt AF,148 and the benefit of OAC in patients with 562 
AHRE is being evaluation in ongoing clinical trials (e.g. ARTESiA [NCT01938248] and NOAH 563 
[NCT02618577]). At present, pacemakers and implanted devices should be interrogated on a regular basis for 564 
AHRE, and patients with AHRE should undergo further assessment of stroke risk factors and for overt AF, 565 
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including ECG monitoring (Figure 3).149566 
 567 
Figure 3 Management of AHRE detected on an implanted device. Adapted from the report of the 3rd 568 
AFNET/EHRA consensus conference.150 569 
AF = atrial fibrillation; AFNET = German Competence NETwork on Atrial Fibrillation; AHRE = atrial high 570 
rate episodes; bpm = beats per minute; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 571 
(doubled), Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); ECG = 572 
electrocardiogram; EHRA = European Heart Rhythm Association. 573 
 574 
5.2.4. Detection of atrial fibrillation in stroke survivors 575 
Sequential stratified ECG monitoring detected AF in 24% (95% CI 17–31) of stroke survivors,151 and in 11.5% 576 
(95% CI 8.9%–14.3%) in another meta-analysis,17 with large variations depending on the timing, duration, and 577 
method of monitoring. AF detection is not uncommon in unselected stroke patients (6.2%, 95% CI 4.4–8.3),128 578 
but is more likely in patients with cryptogenic stroke implanted with loop recorders or who have had ECG 579 
monitors for several weeks.18, 128, 152 Cryptogenic stroke is defined as a stroke in which the cause could not be 580 
identified after extensive investigations.153 A broader definition is embolic stroke of undetermined source.154 581 
Several studies have also found AF in patients in whom another competing cause for stroke has been identified 582 
clinically (e.g. hypertension or carotid artery stenosis).27, 127 Hence, prolonged ECG monitoring seems 583 
reasonable in all survivors of an ischaemic stroke without an established diagnosis of AF. 584 
 585 
Recommendations for screening for AF  586 
Recommendations Class a Level b Refs c 
Opportunistic screening for AF is recommended by pulse taking 
or ECG rhythm strip in patients > 65 years of age 
I B 130, 134, 155 
In patients with TIA or ischaemic stroke, screening for AF is 
recommended by short-term ECG recording followed by 
continuous ECG monitoring for at least 72 hours 
I B 27, 127  
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It is recommended to interrogate pacemakers and ICDs on a 
regular basis for atrial high rate episodes (AHRE). Patients with 
AHRE should undergo further ECG monitoring to document AF 
before initiating AF therapy 
I B 141, 156 
In stroke patients, additional ECG monitoring by long-term non-
invasive ECG monitors or implanted loop recorders should be 
considered to document silent AF 
IIa B 18, 128 
Systematic ECG screening may be considered to detect AF in 
patients aged > 75 years, or those at high stroke risk 
IIb B 130, 135, 157 
AF = atrial fibrillation; AHRE = atrial high rate episodes; ECG = electrocardiogram; ICD = implantable 587 
cardioverter defibrillator; TIA = transient ischaemic attack. 588 
aClass of recommendation. 589 
bLevel of evidence. 590 
cReference(s) supporting recommendations. 591 
 592 
5.3. Electrocardiogram detection of atrial flutter 593 
Right atrial isthmus-dependent flutter has a typical ECG pattern and ventricular rate.158 The prevalence of atrial 594 
flutter is less than one-tenth of the prevalence of AF.159 Atrial flutter often coexists with or precedes AF.160 In 595 
typical, isthmus-dependent flutter, P waves will often show a ‘saw tooth’ morphology, especially in the inferior 596 
leads (II, III, aVF). The ventricular rate can be variable (usual ratio of atrial to ventricular contraction 4:1 to 2:1, 597 
in rare cases 1:1) and macro-reentrant tachycardias may be missed in stable 2:1 conduction. Vagal stimulation 598 
or intravenous adenosine may be helpful to unmask atrial flutter. The management of atrial flutter is discussed 599 
in Section 12.7. Left or right atrial macro-reentrant tachycardia is usually confined to patients after catheter 600 
ablation for AF, AF surgery, or after open heart surgery.158  601 
 602 
6 Classification of atrial fibrillation 603 
6.1. Atrial fibrillation pattern 604 
In many patients, AF progresses from short, infrequent episodes to longer and more frequent attacks. Over time, 605 
many patients will develop sustained forms of AF. In a small proportion of patients, AF will remain paroxysmal 606 
over several decades (2–3% of AF patients).161 The distribution of paroxysmal AF recurrences is not random, 607 
but clustered.162 AF may also regress from persistent to paroxysmal AF. Furthermore, asymptomatic recurrences 608 
of AF are common in patients with symptomatic AF.120  609 
 610 
 Based on presentation, duration, and spontaneous termination of AF episodes, five types of AF are 611 
traditionally distinguished: first diagnosed, paroxysmal, persistent, long-standing persistent, and permanent AF 612 
(Table 5). If patients suffer from both paroxysmal and persistent AF episodes, the more common type should be 613 
used for classification. Clinically determined AF patterns do not correspond well to the AF burden measured by 614 
long-term ECG monitoring.163 Even less is known about the response to therapy in patients with long-standing 615 
persistent AF or long-standing paroxysmal AF. Despite these inaccuracies, the distinction between paroxysmal 616 
and persistent AF has been used in many trials and therefore still forms the basis of some recommendations.  617 
 There is some evidence suggesting that AF burden may influence stroke risk44, 124, 164 and could modify 618 
the response to rhythm control therapy.76, 165 The evidence for this is weak. Therefore, AF burden should not be 619 
a major factor in deciding on the usefulness of an intervention that is deemed suitable for other reasons.  620 
 621 
Table 5 Patterns of AF  622 
AF pattern Definition 
First diagnosed AF AF that has not been diagnosed before, irrespective of the duration of 
the arrhythmia or the presence and severity of AF-related symptoms. 
Paroxysmal AF Self-terminating, in most cases within 48 hours. Some AF paroxysms 
may continue for up to 7 days.a Most AF episodes that are cardioverted 
within 24-48 hours should be considered paroxysmal.a 
Persistent AF AF that lasts longer than 7 days, including episodes that are terminated 
by cardioversion, either with drugs or by direct current cardioversion, 
after 7 days or more.  
Long-standing persistent 
AF 
Continuous AF lasting for ≥ 1 year when it is decided to adopt a rhythm 
control strategy. 
Permanent AF AF is accepted by the patient (and physician). Hence, rhythm control 
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interventions are, by definition, not pursued in patients with permanent 
AF. Should a rhythm control strategy be adopted, the arrhythmia would 
be re-classified as ‘long-standing persistent AF’. 
AF = atrial fibrillation. 623 
aThe distinction between paroxysmal and persistent AF is often not made correctly without access to long-term 624 
monitoring.163 Hence, this classification alone is often insufficient to select specific therapies. If both persistent 625 
and paroxysmal episodes are present, the predominant pattern should guide the classification. 626 
 627 
6.2. Atrial fibrillation types reflecting different causes of the arrhythmia  628 
The risk of developing AF is increased in a variety of physiological and disease states, and the historic term 629 
‘lone AF’ is probably misleading and should be avoided.166 Although the pattern of AF may be the same, the 630 
mechanisms underpinning AF vary substantially between patients167 (Table 6). This suggests that stratifying AF 631 
patients by underlying drivers of AF could inform management, for example, considering cardiac and systemic 632 
comorbidity (e.g. diabetes and obesity168), lifestyle factors (e.g. activity level, smoking, alcohol intake169, 170), 633 
markers of cardiac structural remodelling (e.g. fibrosis171-173 or electrocardiographic parameters of AF 634 
complexity174), or genetic background. Table 6 provides such a taxonomy, informed by expert consensus,76, 120, 635 
175 but without much evidence to underpin its clinical use.176 Systematic research defining the major drivers of 636 
AF is clearly needed to better define different types of AF.176 637 
 638 
Table 6 Clinical types of AF (modified from the report on the 4th AFNET/EHRA consensus conference76)a 639 
AF type Clinical presentation Possible pathophysiology 
AF secondary 
to structural 
heart disease 
AF in patients with LV systolic or diastolic 
dysfunction, long-standing hypertension with 
LVH, and/or other structural heart diseases. 
The onset of AF in these patients is a common 
cause of hospitalization and a predictor of poor 
outcome 
Increased atrial pressure and atrial 
structural remodelling, together with 
activation of the sympathetic and renin–
angiotensin system 
Focal AF Patients with repetitive atrial runs and frequent, 
short episodes of paroxysmal AF. Often highly 
symptomatic, younger patients with 
distinguishable atrial waves (coarse AF), atrial 
ectopy, and/or atrial tachycardia deteriorating 
in AF 
Localized triggers, in most cases 
originating from the pulmonary veins, 
initiate AF. AF due to one or a few 
reentrant drivers is also considered to be 
part of this type of AF 
Polygenic AF AF in carriers of common gene variants that 
have been associated with early onset AF 
Currently under study. The presence of 
some gene variants may also influence 
treatment outcomes 
Postoperative 
AF 
New onset of AF (usually self-terminating) 
after major (typically cardiac) surgery in 
patients who were in sinus rhythm before 
surgery and had no history of AF 
Acute factors: inflammation, atrial 
oxidative stress, high sympathetic tone, 
electrolyte changes, and volume overload, 
possibly interacting with a pre-existing 
substrate 
AF in patients 
with mitral 
stenosis or 
prosthetic 
heart valves  
AF in patients with mitral stenosis, after mitral 
valve surgery and in some cases other valvular 
disease 
Left atrial pressure (stenosis) and volume 
(regurgitation) load are the main drivers of 
atrial enlargement and structural atrial 
remodelling in these patients 
AF in athletes Usually paroxysmal, related to duration and 
intensity of training 
Increased vagal tone and atrial volume 
Monogenic AF AF in patients with inherited cardiomyopathies, 
including channelopathies 
The arrhythmogenic mechanisms 
responsible for sudden death are likely to 
contribute to the occurrence of AF in these 
patients 
AF = atrial fibrillation; LV = left ventricular; LVH = left ventricular hypertrophy. 640 
aIt is recognized that these types of AF will overlap in clinical practice, and that their impact for management 641 
needs to be evaluated systematically. 642 
 643 
6.3. Symptom burden in atrial fibrillation 644 
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Patients with AF have significantly poorer quality of life than healthy controls, experiencing a variety of 645 
symptoms including lethargy, palpitations, dyspnoea, chest tightness, sleeping difficulties, and psychosocial 646 
distress.32, 177-180 Improved quality of life has been noted with both pharmacological and interventional 647 
therapies,181-185 but there are limited data to compare the benefit of different treatments.32, 186 Assessment of 648 
quality of life is further constrained by a lack of cross-validation of the several AF-specific quality-of-life 649 
tools.187-191 With regard to symptom assessment, the European Heart Rhythm Association (EHRA) suggested 650 
the EHRA symptom scale (Table 7) to describe symptom severity in AF patients.192 A similar scale (the 651 
Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale) is used in Canada.193 The EHRA scale 652 
has been used and validated.194-199 A modification was proposed in 2014, subdividing EHRA class 2 into mild 653 
(2a) or moderate (2b) impact.199 As symptoms in class 2b (‘troubling’ symptoms) identified patients with a 654 
health utility benefit of rhythm control in that study, this modification may provide a threshold for potential 655 
treatment decisions, but this remains to be tested. While some AF patients had no or minimal symptoms (25–656 
40%), many (15–30%) reported severe or disabling symptoms.194, 196 The EHRA scale should be used to guide 657 
symptom-orientated treatment decisions and for longitudinal patient profiling.  658 
  659 
Table 7 Modified EHRA symptom scale (modified from Wynn et al199) 660 
Modified EHRA 
score 
Symptoms Description 
1 None AF does not cause any symptoms 
2a Mild Normal daily activity not affected by symptoms related to AFa 
2b Moderate Normal daily activity not affecteda 
3 Severe Normal daily activity affected 
4 Disabling Normal daily activity discontinued 
AF = atrial fibrillation; EHRA = European Heart Rhythm Association. 661 
aEHRA class 2a and 2b can be differentiated by evaluating whether patients are functionally affected by their 662 
AF symptoms. AF-related symptoms are most commonly fatigue/tiredness and exertional shortness of breath, or 663 
less frequently palpitations and chest pain.42, 194, 200-202   664 
 665 
Recommendation on use of the modified EHRA symptom scale 666 
Recommendation Class a Level b Refs c 
Use of the modified EHRA symptom scale is recommended in 
clinical practice and research studies to quantify AF-related 
symptoms 
I C 192, 199 
AF = atrial fibrillation; EHRA = European Heart Rhythm Association.  667 
aClass of recommendation. 668 
bLevel of evidence. 669 
cReference(s) supporting recommendations. 670 
 671 
7 Detection and management of risk factors and concomitant 672 
cardiovascular diseases 673 
Many cardiovascular diseases and concomitant conditions increase the risk of developing AF (Table 8), 674 
recurrent AF, and AF-associated complications. Identification of such conditions, their prevention and treatment 675 
is an important leverage to prevent AF and its disease burden. Knowledge of these factors and their management 676 
is hence important for optimal management of AF patients.203, 204  677 
 678 
Table 8 Cardiovascular and other conditions independently associated with AF  679 
Characteristic/comorbidity Association with AF 
Genetic predisposition (based on multiple common gene 
variants associated with AF)64 
HR range 0.4–3.2 
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Older age19 
50–59 years 
60–69 years 
70–79 years 
80–89 years 
HR: 
1.00 (reference) 
4.98 (95% CI 3.49–7.10) 
7.35 (95% CI 5.28–10.2) 
9.33 (95% CI 6.68–13.0) 
Hypertension (treated) vs. none19 HR 1.32 (95% CI 1.08–1.60)  
Heart failure vs. none19 HR 1.43 (95% CI 0.85–2.40)  
Valvular heart disease vs. none205 RR 2.42 (95% CI 1.62–3.60) 
Myocardial infarction vs. none19 HR 1.46 (95% CI 1.07–1.98) 
Thyroid dysfunction206, 207 
hypothyroidism 
subclinical hyperthyroidism  
overt hyperthyroidism 
(reference: euthyroid) 
HR 1.23 (95% CI 0.77-1.97) 
RR 1.31 (95% CI 1.19–1.44) 
RR 1.42 (95% CI 1.22–1.63) 
Obesity19, 208 
none (BMI < 25 kg/m²) 
overweight (BMI 25–30 kg/m²) 
obese (BMI ≥ 31 kg/m²) 
HR: 
1.00 (reference) 
1.13 (95% CI 0.87–1.46) 
1.37 (95% CI 1.05–1.78) 
Diabetes mellitus vs. none19 HR 1.25 (95% CI 0.98–1.60)  
Chronic obstructive pulmonary disease209 
FEV1  
≥ 80% 
60–80% 
< 60% 
RR:  
 
1.00 (reference) 
1.28 (95% CI 0.79–2.06) 
2.53 (95% CI 1.45–4.42) 
Obstructive sleep apnoea vs. none210 HR 2.18 (95% CI 1.34–3.54) 
Chronic kidney disease211 
none 
stage 1 or 2  
stage 3  
stage 4 or 5 
OR: 
1.00 (reference) 
2.67 (95% CI 2.04–3.48) 
1.68 (95% CI 1.26–2.24)  
3.52 (95% CI 1.73–7.15) 
Smoking212 
never 
former 
current 
HR: 
1.00 (reference) 
1.32 (95% CI 1.10–1.57)  
2.05 (95% CI 1.71–2.47) 
Alcohol consumption213 
None 
1–6 drinks/week 
7–14 drinks/week 
15–21 drinks/week 
> 21 drinks/week 
RR: 
1.00 (reference) 
1.01 (95% CI 0.94–1.09)  
1.07 (95% CI 0.98–1.17) 
1.14 (95% CI 1.01–1.28)  
1.39 (95% CI 1.22–1.58)  
Habitual vigorous exercise214 
Non-exercisers 
< 1 day/week 
1−2 days/week 
3−4 days/week 
5−7 days/week 
RR: 
1.00 (reference) 
0.90 (95% CI 0.68−1.20) 
1.09 (95% CI 0.95−1.26) 
1.04 (95% CI 0.91−1.19) 
1.20 (95% CI 1.02−1.41) 
AF = atrial fibrillation; BMI = body mass index; CI = confidence interval; FEV1 = forced expiratory volume in 680 
1 second; HR = hazard ratio; OR = odds ratio; RR = risk ratio 681 
 682 
7.1. Heart failure 683 
Heart failure and AF coincide in many patients.215-217 They are linked by similar risk factors and share a 684 
common pathophysiology.218 Heart failure and AF can cause and exacerbate each other through mechanisms 685 
such as structural cardiac remodelling, activation of neurohormonal mechanisms, and rate-related impairment of 686 
left ventricular (LV) function. Patients with AF and concomitant heart failure, both with preserved ejection 687 
fraction (LV ejection fraction [LVEF] ≥ 50%) and reduced ejection fraction (LVEF < 40%),219, 220 suffer from a 688 
worse prognosis, including increased mortality.16, 221 The recent ESC Guidelines on heart failure222 have also 689 
introduced a new category of heart failure with mid-range ejection fraction (HFmrEF; LVEF 40–49%), although 690 
data on AF patients in this group are currently limited. Prevention of adverse outcomes and maintenance of a 691 
good quality of life are the aims of management in all patients with AF and concomitant heart failure, regardless 692 
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of LVEF.223 The general approach to AF management does not differ between heart failure patients and others, 693 
but a few considerations are worthwhile to consider. Of note, the only therapy with proven prognostic value in 694 
these patients is anticoagulation, and appropriate OAC should be prescribed in all patients at risk of stroke (see 695 
Chapter 8).  696 
 697 
7.1.1. Patients with atrial fibrillation and heart failure with reduced ejection 698 
fraction 699 
In addition to OAC, standard heart-failure therapy should be used in patients with heart failure with reduced 700 
ejection fraction (HFrEF), as detailed in the ESC Guidelines.222 This includes angiotensin-converting enzyme 701 
(ACE) inhibitors or angiotensin receptor blockers (ARBs), mineralocorticoid antagonists, defibrillators and 702 
cardiac resynchronization therapy,218 in addition to combined angiotensin receptor neprilysin inhibition (ARNI) 703 
in patients able to tolerate an ACE inhibitor or ARB with ongoing symptoms.224  704 
 Rate control of AF is discussed in detail in Chapter 9. In brief, only beta-blockers and digoxin are 705 
suitable in HFrEF because of the negative inotropic potential of verapamil and diltiazem. Beta-blockers are 706 
usually the first-line option in patients with clinically stable HFrEF, although a meta-analysis using individual 707 
patient data from randomized controlled trials (RCTs) found no reduction in mortality from beta-blockers versus 708 
placebo in those with AF at baseline (HR 0.97, 95% CI 0.83–1.14).23 Digoxin is commonly prescribed in 709 
clinical practice but no head-to-head RCTs in AF patients have been performed. In a meta-analysis of 710 
observational studies, digoxin had a neutral effect on mortality in patients with AF and concomitant heart failure 711 
(adjusted observational studies HR 0.90, 95% CI 0.70–1.16; propensity-matched observational studies RR 1.08, 712 
95% CI 0.93–1.26).225 Initial and combination rate-control therapy for AF in HFrEF should therefore take 713 
account of individual patient characteristics and symptoms; beta-blocker initiation should be delayed in patients 714 
with acute decompensated heart failure, and digoxin has more adverse effects in patients with renal impairment 715 
(see Chapter 9).  716 
 Patients with AF and HFrEF who present with severe symptoms may require rhythm control therapy in 717 
addition to rate control therapy. For patients who develop HFrEF as a result of rapid AF (tachycardiomyopathy), 718 
a rhythm control strategy is preferred, based on several relatively small patient cohorts and trials reporting 719 
improved LV function after restoration of sinus rhythm.185, 226-228 The diagnosis of tachycardiomyopathy can be 720 
challenging, and at times requires restoration of sinus rhythm.229 Catheter ablation may be a useful method to 721 
restore LV function and quality of life in AF patients with HFrEF,185, 226-228 but further data are needed. Figure 4 722 
summarizes the approach to patients with AF and heart failure.  723 
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 724 
Figure 4 Initial management of newly diagnosed with AF and heart failure. Adapted from Kotecha and 725 
Piccini.218 726 
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; ARNI = 727 
angiotensin receptor neprilysin inhibition; bpm = beats per minute; HF = heart failure. 728 
aIn patients with heart failure and reduced ejection fraction; also consider combined ARNI in patients able to 729 
tolerate an ACE inhibitor or ARB with ongoing symptoms.  730 
 731 
7.1.2. Atrial fibrillation patients with heart failure with preserved ejection fraction  732 
The diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with AF is problematic 733 
because of the difficulty in separating symptoms that are due to HF from those due to AF. Although diagnostic 734 
differentiation can be achieved by cardioversion and clinical reassessment, this option is often not appropriate in 735 
this group, particularly as a specific therapy that improves prognosis in HFpEF is currently lacking. 736 
Echocardiography can support detection of HFpEF in patients with symptomatic AF by providing evidence of 737 
relevant structural heart disease (e.g. LV hypertrophy [LVH]) and/or measurement of diastolic dysfunction. 738 
Reduced early diastolic myocardial velocity e’ by tissue Doppler reflects impaired LV relaxation, while the ratio 739 
of E/e’ has demonstrated a significant correlation with invasive measurement of LV filling pressures.230-234 740 
Natriuretic peptide levels are part of the diagnostic assessment of HFpEF,222 although natriuretic peptide levels 741 
are elevated in AF patients and the optimum diagnostic cut-off is still unknown.235 The management of patients 742 
with AF and concomitant HFpEF should focus on control of fluid balance and concomitant conditions such as 743 
hypertension and ischaemia.  744 
 745 
7.1.3. Atrial fibrillation patients with heart failure with mid-range ejection 746 
fraction 747 
HFmrEF is a recently defined entity, describing patients with symptoms and signs of heart failure, LVEF 40–748 
49%, elevated levels of natriuretic peptides, and either LV hypertrophy, left atrial (LA) enlargement, or 749 
evidence of diastolic dysfunction.222 However, diagnosis is more difficult in patients with AF, as natriuretic 750 
peptides are elevated in AF and LA dilatation is common, regardless of concomitant heart failure. LVEF is also 751 
variable and difficult to assess in AF patients because of AF-induced reduction in systolic LV function and 752 
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variable cardiac cycle length. Further study of this group is required before particular treatment strategies in AF 753 
patients with HFmrEF can be recommended. 754 
 755 
7.1.4. Prevention of atrial fibrillation in heart failure 756 
Retrospective analyses from large randomized trials have reported a lower incidence of new-onset AF in 757 
patients treated with ACE inhibitors/ARBs compared with placebo.236-238 The reduced incidence of AF with 758 
ACE inhibitors/ARBs is less evident in patients with HFpEF239 and is lost in patients without heart failure.240-242 759 
Neprilysin inhibition does not seem to add to this effect.224 Beta-blocker therapy was associated with a 33% 760 
reduction in the adjusted odds of incident AF in HFrEF patients pretreated with ACE inhibitors/ARBs, 761 
reinforcing the importance of beta-blocker therapy in HFrEF patients in sinus rhythm.23 Eplerenone, a 762 
mineralocorticoid receptor antagonist, also reduced the risk of new-onset AF in patients with LVEF ≤ 35%, 763 
New York Heart Association (NYHA) Class II, and pretreatment with ACE inhibitors/ARBs and beta-764 
blockers.243 765 
 766 
7.2. Hypertension 767 
7.2.1. Treatment of hypertension to prevent incident atrial fibrillation 768 
Inhibition of the renin–angiotensin–aldosterone system can prevent structural remodelling and recurrent AF.236, 769 
244 A recent analysis of the Danish healthcare database with long-term monitoring of the effect of different 770 
antihypertensive agents on the occurrence of overt AF suggests a beneficial effect of ACE inhibitors or 771 
ARBs.245 Secondary analyses of ACE inhibitors or ARBs in patients with heart failure or LVH show a lower 772 
incidence of new-onset AF.238, 246  773 
 774 
7.2.2. Blood pressure control in patients with atrial fibrillation 775 
Hypertension is a stroke risk factor in AF, and uncontrolled high blood pressure enhances the risk of stroke and 776 
bleeding events and may lead to recurrent AF. Good blood-pressure control should therefore form an integral 777 
part of the management of AF patients.247 In patients with established AF, but without LV dysfunction or heart 778 
failure, ARBs do not prevent recurrent AF better than placebo.240, 241 ACE inhibitors or ARBs may reduce 779 
recurrent AF after cardioversion when coadministered with antiarrhythmic drug therapy compared with an 780 
antiarrhythmic drug alone.248, 249 Meta-analyses driven by these studies suggested a lower risk of recurrent 781 
AF,236-238, 250 but at least one controlled trial failed to demonstrate benefit.240, 251  782 
 783 
7.3. Valvular heart disease 784 
Valvular heart disease is independently associated with incident AF.252 Approximately 30% of patients with AF 785 
have some form of valvular heart disease, often detected only by echocardiography.201, 253-255 AF worsens 786 
prognosis in patients with severe valvular heart disease,256 including those undergoing surgery or transcatheter 787 
interventions for aortic or mitral valve disease.257-262 Valvular heart disease can be associated with an increased 788 
thromboembolic risk, which probably also adds to the stroke risk in AF patients.263 Similar to heart failure, 789 
valvular disease and AF interact and sustain each other through volume and pressure overload, 790 
tachycardiomyopathy, and neurohumoral factors.264-270 When valve dysfunction is severe, AF can be regarded as 791 
a marker for progressive disease, thus favouring valve repair or replacement.271  792 
 Traditionally, patients with AF have been dichotomized into ‘valvular’ and ‘non-valvular’ AF.272 793 
Although slightly different definitions have been used, valvular AF mainly refers to AF patients that have either 794 
rheumatic valvular disease (predominantly mitral stenosis) or mechanical heart valves. In fact, while AF implies 795 
an incremental risk for thromboembolism in patients with mitral valve stenosis,263, 273, 274 there is no clear 796 
evidence that other valvular diseases, including mitral regurgitation or aortic valve disease, need to be 797 
considered when choosing an anticoagulant or indeed to estimate stroke risk.275 We have therefore decided to 798 
replace the historic term ‘non-valvular’ AF with reference to the specific underlying conditions. 799 
 800 
Recommendations for patients with valvular heart disease and AF 801 
Recommendations Class a Level b Refs c 
Early mitral valve surgery should be considered in severe mitral 
regurgitation, preserved LV function, and new-onset AF, even in 
the absence of symptoms, particularly when valve repair is 
feasible 
 
IIa 
 
C 
276 
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Mitral valvotomy should be considered for asymptomatic patients 
with severe mitral stenosis and suitable valve anatomy who have 
new-onset AF 
IIa C  
AF = atrial fibrillation; LV = left ventricular. 802 
aClass of recommendation. 803 
bLevel of evidence. 804 
cReference(s) supporting recommendations. 805 
 806 
 807 
7.4. Diabetes mellitus 808 
Diabetes and AF frequently coexist because of associations with other risk factors.277-283 Diabetes is a risk factor 809 
for stroke and other complications in AF.284 In patients with AF, a longer duration of diabetes appears to confer 810 
a higher risk of thromboembolism, albeit without greater risk of OAC-related bleeding.285 Unfortunately, 811 
intensive glycaemic control does not affect the rate of new-onset AF,284 while treatment with metformin seems 812 
to be associated with a decreased long-term risk of AF in diabetic patients286 and may even lower long-term 813 
stroke risk.13 Diabetic retinopathy, a measure of disease severity, does not increase the risk of ocular bleeding in 814 
anticoagulated patients.287  815 
 816 
7.5. Obesity and weight loss 817 
7.5.1. Obesity as a risk factor 818 
Obesity increases the risk for AF (risk ratio 1.5–1.8),288-291 with a progressive increase according to body mass 819 
index.288, 290-292 Obese patients may have more LV diastolic dysfunction, increased sympathetic activity and 820 
inflammation, and increased fatty infiltration of the atria.293-295 Obesity may also be a risk factor for ischaemic 821 
stroke, thromboembolism, and death in AF patients.292 822 
  823 
7.5.2. Weight reduction in obese patients with atrial fibrillation  824 
Intensive weight-reduction management in addition to management of other cardiovascular risk factors (in the 825 
range of 10–15 kg weight loss achieved) led to fewer AF recurrences and symptoms compared with an approach 826 
based on general advice in obese patients with AF.203, 204, 296 Improved cardiorespiratory fitness can further 827 
decrease AF burden in obese patients with AF.297 Although the findings in these studies have to be confirmed, 828 
they underpin the positive effect of weight reduction in obese patients.  829 
 830 
7.5.3. Catheter ablation in obese patients 831 
Obesity may increase the rate of AF recurrence after catheter ablation,298-301 with obstructive sleep apnoea as an 832 
important potential confounder. Obesity has also been linked to a higher radiation dose and complication rate 833 
during AF ablation.302, 303 Notably, the symptomatic improvement after catheter ablation of AF in obese patients 834 
seems comparable to the improvement in normal-weight patients.298 In view of the potential to reduce AF 835 
episodes by weight reduction (see Section 6.5.2.), AF ablation should be offered to obese patients in conjunction 836 
with lifestyle modifications that lead to weight reduction. 837 
 838 
Recommendation for obese patients with AF 839 
 840 
AF = atrial fibrillation. 841 
 842 
a Class of recommendation 843 
b Level of evidence 844 
c Reference(s) supporting recommendation(s) 845 
 846 
7.6. Chronic obstructive pulmonary disease, sleep apnoea, and other respiratory 847 
diseases 848 
Recommendation Class a Level b Refsc 
In obese patients with AF, weight loss together with management of 
other risk factors should be considered to reduce AF burden and 
symptoms 
IIa B 204, 288, 296 
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AF has been associated with obstructive sleep apnoea.304, 305 Multiple pathophysiological mechanisms can 849 
contribute to AF in obstructive sleep apnoea, including autonomic dysfunction, hypoxia, hypercapnia, and 850 
inflammation.96, 304-307 Obstructive sleep apnoea exaggerates intrathoracic pressure changes, which in itself and 851 
via vagal activation can provoke shortening of the atrial action potential and induce AF. Risk factor reduction 852 
and continuous positive airway pressure ventilation can reduce AF recurrence.308-312 It seems reasonable to 853 
consider obstructive sleep apnoea screening in AF patients with risk factors. Obstructive sleep apnoea treatment 854 
should be optimized to improve AF treatment results in appropriate patients. Servo-controlled pressure support 855 
therapy should not be used in HFrEF patients with predominantly central sleep apnoea (of which 25% had 856 
concomitant AF).313  857 
 Patients with chronic obstructive pulmonary disease often suffer from atrial tachycardias, which need 858 
to be differentiated from AF by ECG. Agents used to relieve bronchospasm, notably theophyllines and beta-859 
adrenergic agonists, may precipitate AF and make control of the ventricular response rate difficult. Non-860 
selective beta-blockers, sotalol, propafenone, and adenosine should be used with caution in patients with 861 
significant bronchospasm, while they can safely be used in patients with chronic obstructive pulmonary disease. 862 
Beta-1 selective blockers (e.g. bisoprolol, metoprolol, and nebivolol), diltiazem, and verapamil are often 863 
tolerated and effective (see Chapter 9).  864 
 865 
Recommendations for patients with AF and respiratory diseases 866 
Recommendations Class a Level b Refs c 
Correction of hypoxaemia and acidosis should be considered as initial 
management for patients who develop AF during an acute pulmonary 
illness or exacerbation of chronic pulmonary disease 
IIa C  
Interrogation for clinical signs of obstructive sleep apnoea in all AF 
patients should be considered IIa B 
304, 305, 314, 
315 
Obstructive sleep apnoea treatment should be optimized to reduce AF 
recurrences and improve AF treatment results IIa B 
307-311 
AF = atrial fibrillation. 867 
aClass of recommendation. 868 
bLevel of evidence. 869 
cReference(s) supporting recommendations. 870 
 871 
7.7. Chronic kidney disease 872 
AF is present in 15–20% of patients with CKD.316 The definition of CKD in most AF trials is relatively strict. 873 
Although an estimated creatinine clearance (CrCl) rate of < 60 mL/min is indicative of CKD, a number of trials 874 
in AF patients have used CrCl < 50 mL/min to adapt NOAC dosage, usually estimated using the Cockroft–Gault 875 
formula. CrCl in AF patients can deteriorate over time.317 The management of OAC in patients with CKD is 876 
discussed in Section 8.2.4.  877 
 878 
Recommendations for patients with kidney disease and AF 879 
 880 
AF = atrial fibrillation. 881 
aClass of recommendation. 882 
bLevel of evidence. 883 
cReference(s) supporting recommendations. 884 
Recommendations Class a Level b Refs c 
The assessment of kidney function by serum creatinine or 
creatinine clearance is recommended in all AF patients to 
detect kidney disease and to support correct dosing of AF 
therapy 
I A 316, 318-321 
All AF patients treated with oral anticoagulation should be 
considered for at least yearly renal function evaluation to 
detect kidney disease 
IIa B  
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 885 
8 Integrated management of patients with atrial fibrillation 886 
Most patients access the healthcare system initially through pharmacists, community health workers, or primary 887 
care physicians. As AF is often asymptomatic, these healthcare professionals are important stakeholders to 888 
enable adequate detection of AF and to ensure consistent management. The initial assessment should be 889 
performed at the point of first contact with the healthcare system, and is feasible in most healthcare settings 890 
(when an ECG is available). We propose to consider five domains in the initial assessment of patients presenting 891 
with newly diagnosed AF (Figure 5). These domains are: 892 
1. Haemodynamic instability or limiting, severe symptoms 893 
2. Presence of precipitating factors (e.g. thyrotoxicosis, sepsis, or postoperative AF) and 894 
underlying cardiovascular conditions 895 
3. Stroke risk and need for anticoagulation 896 
4. Heart rate and need for rate control 897 
5. Symptom assessment and decision for rhythm control 898 
 899 
Figure 5 Acute and chronic management of AF patients, desired cardiovascular outcomes, and patient benefits. 900 
Adapted from the report on the 4th AFNET/EHRA consensus conference.76 901 
AF = atrial fibrillation; AFNET = German Competence NETwork on Atrial Fibrillation; EHRA = European 902 
Heart Rhythm Association. 903 
 904 
An integrated, structured approach to AF care, as applied successfully to other domains of medicine,322-324 will 905 
facilitate consistent, guideline-adherent AF management for all patients325 (Figure 6), with the potential to 906 
improve outcomes.42, 326, 327 Such approaches are consistent with the Innovative Care for Chronic Conditions 907 
Framework proposal put forward by the World Health Organization.328 Review by an AF service, or at least 908 
referral to a cardiologist, will usually be required after the initial assessment to fully evaluate the effect of AF on 909 
cardiovascular health.329 There may also be reasons for early or urgent referral (Table 9). Integrated care of all 910 
patients with newly diagnosed AF should help to overcome the current shortcomings of AF management, such 911 
as underuse of anticoagulation, access to rate and rhythm control therapy, and inconsistent approaches to 912 
cardiovascular risk reduction. Integrated AF care requires the cooperation of primary care physicians, 913 
cardiologists, cardiac surgeons, AF specialists, stroke specialists, allied health practitioners and patients, 914 
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encompassing lifestyle interventions, treatment of underlying cardiovascular diseases and AF-specific therapy 915 
(Figure 7). 916 
 917 
Figure 6 Achieving optimal management of AF patients. 918 
AF = atrial fibrillation. 919 
aOn-site or through institutionalized cooperation. 920 
bSafety outcomes should be collected in published and monitored central databases. 921 
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 922 
Figure 7 Fundamentals of integrated care in AF patients. 923 
AF = atrial fibrillation; LAA = left atrial appendage. 924 
 925 
Table 9 Clinical signs calling for urgent involvement of a specialized AF service.a  926 
Haemodynamic instability 
Uncontrollable rate 
Symptomatic bradycardia not amenable to reduced dosing of rate control agents 
Severe angina or worsening left ventricular function 
Transient ischemic attack or stroke 
AF = atrial fibrillation 927 
aAnticoagulation should be initiated early in all suitable patients and will not routinely require specialist input.  928 
 929 
8.1. Evidence supporting integrated atrial fibrillation care 930 
Several structured approaches to AF care have been developed. Some evidence underpins their use, while more 931 
research is needed into the best way of delivering integrated AF care. Integrated AF management in an RCT 932 
increased the use of evidence-base care and reduced by approximately one-third the composite outcome of 933 
cardiovascular hospitalization and cardiovascular death over a mean follow-up of 22 months (14.3% vs. 20.8%, 934 
HR 0.65; 95% CI 0.45–0.93; P = 0.017) compared with usual care in a large tertiary care centre.330 Integrated 935 
AF management appeared cost-effective in that study.331 However, an Australian RCT showed only a marginal 936 
effect on unplanned admissions and death using integrated AF care limited to the initial care period, possibly 937 
emphasizing the need for sustained integration of AF care.332 Two observational studies of integrated AF care 938 
found fewer hospitalizations,333, 334 one study showed fewer cases of stroke,333 and a further non-randomized 939 
study identified a trend for a lower rate of the composite outcome of death, cardiovascular hospitalization, and 940 
AF-related emergency visits.335 More research is needed, and integrated AF care is likely to require different 941 
designs in different healthcare settings. 942 
 943 
8.2. Components of integrated atrial fibrillation care 944 
8.2.1. Patient involvement 945 
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Patients should have a central role in the care process. As treatment of AF requires patients to change their 946 
lifestyles and adhere to chronic therapy, at times without an immediately tangible benefit, they need to 947 
understand their responsibilities in the care process. Physicians and healthcare professionals are responsible for 948 
providing access to evidence-based therapy, but adherence to therapy is ultimately the responsibility of 949 
informed and autonomous patients, best described as ‘shared accountability’.336 Hence, information and 950 
education of patients and often of their partners and relatives is indispensable to encourage a self-management 951 
role and to empower patients to participate in shared decision-making,326, 328 and to support their understanding 952 
of the disease and the suggested treatments.337 953 
 954 
8.2.2. Multidisciplinary atrial fibrillation teams 955 
Delegation of tasks from specialists to general physicians and from physicians to allied health professionals is a 956 
fundamental concept of integrated care models. A multidisciplinary AF team approach includes an efficient mix 957 
of interpersonal and communication skills, education and expertise in AF management, as well as the use of 958 
dedicated technology. This approach underlines the importance of redesigning daily practice in a way that 959 
encourages non-specialists and allied professionals to have an important role in educating patients and 960 
coordinating care, while the specialist remains medically responsible. Cultural and regional differences will 961 
determine the composition of AF teams. 962 
 963 
8.2.3. Role of non-specialists 964 
AF patients often initially present to general practitioners or pharmacists. Some physicians in primary care have 965 
extensive expertise in stroke prevention and initial management of AF patients. Others may seek training to 966 
acquire such knowledge. Other components of AF management (e.g. assessment of concomitant cardiovascular 967 
conditions, antiarrhythmic drug therapy, or interventional treatment) often require specialist input. Integrated 968 
AF care structures should support treatment initiation by non-specialists where appropriate, and provide ready 969 
access to specialist knowledge to optimize AF care.  970 
 971 
8.2.4. Technology use to support atrial fibrillation care 972 
Technology, such as decision support software, has the potential to enhance the implementation of evidence-973 
based care and improve outcomes, when used to enhance expert advice.338 Electronic tools can also ensure 974 
coherent communication within the AF team. With a view to support the wider use of such technology, this 975 
Task Force is providing tools free of charge, in the form of smartphone apps, to AF healthcare professionals and 976 
to AF patients. 977 
 978 
Recommendations for an integrated approach to care 979 
Recommendations Class a Level b Refs c 
An integrated approach with structured organization of care and follow-
up should be considered in all patients with AF, aiming to improve 
guideline adherence and reduce hospitalization and mortality 
IIa B 330-332 
Placing patients in a central role in the decision-making should be 
considered in order to tailor management to patient preferences and 
improve adherence to chronic therapy 
IIa C 330, 332, 334 
AF = atrial fibrillation 980 
aClass of recommendation. 981 
bLevel of evidence. 982 
cReference(s) supporting recommendations. 983 
 984 
8.3. Diagnostic workup of atrial fibrillation patients 985 
AF is often found in patients with other, at times undiagnosed, cardiovascular conditions. Thus, all AF patients 986 
will benefit from a comprehensive cardiovascular assessment.339  987 
 988 
8.3.1.  Recommended evaluation in all atrial fibrillation patients 989 
A complete medical history should be taken and all patients should undergo clinical evaluation that includes 990 
thorough assessment for concomitant conditions, establishing the AF pattern, estimation of stroke risk and AF-991 
related symptoms, and assessment of arrhythmia-related complications such as thromboembolism or LV 992 
dysfunction. A 12-lead ECG is recommended to establish a suspected diagnosis of AF, to determine rate in AF, 993 
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and to screen for conduction defects, ischaemia, and signs of structural heart disease. Initial blood tests should 994 
evaluate thyroid and kidney function as well as serum electrolytes and full blood count. Transthoracic 995 
echocardiography is recommended in all AF patients to guide treatment decisions. Transthoracic 996 
echocardiography should be used to identify structural disease (e.g. valvular disease) and assess LV size and 997 
function (systolic and diastolic), atrial size, and right heart function.339, 340 Although biomarkers such as 998 
natriuretic peptides are elevated in AF patients, there is insufficient data to suggest that blood-based parameters 999 
are independent markers for AF.341-343 1000 
 1001 
8.3.2. Additional investigations in selected patients with atrial fibrillation 1002 
Ambulatory ECG monitoring in AF patients can assess the adequacy of rate control, relate symptoms with AF 1003 
recurrences, and detect focal induction of bouts of paroxysmal AF. Transoesophageal echocardiography (TOE) 1004 
is useful to further assess valvular heart disease and to exclude intracardiac thrombi, especially in the LAA, to 1005 
facilitate early cardioversion or catheter ablation.344 Patients with symptoms or signs of myocardial ischaemia 1006 
should undergo coronary angiography or stress testing as appropriate. In patients with AF and signs of cerebral 1007 
ischaemia or stroke, computed tomography (CT) or magnetic resonance imaging (MRI) of the brain is 1008 
recommended to detect stroke and support decisions regarding acute management and long-term 1009 
anticoagulation. Delayed-enhancement MRI of the left atrium using gadolinium contrast,345-347 T1 mapping 1010 
using cardiac MRI,347 and intracardiac echo348 may help to guide treatment decisions in AF, but require external 1011 
validation in multicentre studies.  1012 
 1013 
8.4. Structured follow-up 1014 
Most AF patients need regular follow-up to ensure continued optimal management. Follow-up may be 1015 
undertaken in primary care, by specially trained nurses, by cardiologists, or by AF specialists.325, 330 A specialist 1016 
should coordinate care and follow-up. Follow-up should ensure implementation of the management plan, 1017 
continued engagement of the patient, and therapy adaptation where needed.  1018 
 1019 
Recommendations for diagnostic workup of AF patients 1020 
AF = atrial fibrillation; ECG = electrocardiogram. 1021 
aClass of recommendation. 1022 
bLevel of evidence. 1023 
cReference(s) supporting recommendations. 1024 
 1025 
8.5. Defining goals of atrial fibrillation management 1026 
AF management comprises therapies with prognostic impact (anticoagulation and treatment of cardiovascular 1027 
conditions) and therapies predominantly providing symptomatic benefit (rate control, rhythm control, Table 10). 1028 
Therapies with prognostic benefit need careful explanation to patients when their benefits are not directly felt. 1029 
Rhythm control therapy can be successful if symptoms are controlled, even when AF recurs. Explaining the 1030 
expected benefits to each patient at the start of AF management will prevent unfounded expectations and has the 1031 
potential to optimize quality of life.  1032 
 1033 
Table 10 Goal-based follow-up 1034 
Category Intervention Follow-up aspects Performance indicator 
(examples) 
Recommendations Class a Level b Refs c 
ECG documentation is required to establish the diagnosis of AF I B 349 
A full cardiovascular evaluation, including an accurate history, 
careful clinical examination, and assessment of concomitant 
conditions, is recommended in all AF patients 
I C  
Transthoracic echocardiography is recommended in all AF 
patients to guide management 
I C 339 
Long-term ECG monitoring should be considered in selected 
patients to assess the adequacy of rate control in symptomatic 
patients and to relate symptoms with AF episodes 
IIa C  
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Prognostic  Comorbidity control 
(relevant examples 
given) 
Obesity Weight loss 
Arterial hypertension Blood pressure control 
Heart failure Heart failure therapy 
Coronary artery disease 
 
Statin and antiplatelet therapy  
Revascularization 
Diabetes Glycaemic control 
Valvular Heart Disease Valve repair or replacement 
Prognostic  Anticoagulation Indication (risk profile; timing, 
e.g. post-cardioversion); 
Adherence (NOAC or VKA) 
and INR (if VKA); 
NOAC dosing (co-
medications, age, weight, renal 
function) 
Stroke  
Bleeding 
Mortality 
Mainly symptomatic 
Partly prognostic  
Rate control Symptoms 
Average resting heart rate 
< 110 bpm 
 
EHRA score 
Heart failure status  
LV function 
Exercise capacity 
Hospitalization 
Therapy complications 
Symptomatic at present Rhythm control Symptoms vs. side-effects 
Exclusion of proarrhythmia 
(PR; QRS; QTc interval) 
Relevant for 
implementation of and 
adherence to therapy 
Patient education and 
self-care capabilities 
Knowledge (about disease; 
about treatment; about 
management goals) 
Capabilities (what to do if…) 
Adherence to therapy 
Directed evaluation, preferably 
based on systematic checklists 
Relevant for chronic 
care management 
Caregiver 
involvement 
Who? (spouse; GP; home 
nurse; pharmacist) 
Clearly spelling out 
participation roles 
Knowledge and capabilities 
Directed evaluation of task 
performance (e.g. via patient 
card) 
Dispensed medication 
GP log of follow-up visits 
bpm = beats per minute; EHRA = European Heart Rhythm Association; GP = general practitioner; INR = 1035 
international normalized ratio; LV = left ventricular; NOAC = non-vitamin K antagonist oral anticoagulant; 1036 
VKA = vitamin K antagonist. 1037 
 1038 
9 Stroke prevention therapy in atrial fibrillation patients 1039 
OAC therapy can prevent the majority of ischaemic strokes in AF patients and can prolong life.38, 39, 42, 194, 201, 329, 1040 
350-352 It is superior to no treatment or aspirin in patients with different profiles for stroke risk.353, 354 The net 1041 
clinical benefit is almost universal, with the exception of patients at very low stroke risk, and OAC should 1042 
therefore be used in most patients with AF (Figure 8). Despite this evidence, underuse or premature termination 1043 
of OAC therapy is still common. Bleeding events, both severe and nuisance bleeds, a perceived ‘high risk of 1044 
bleeding’ on anticoagulation, and the efforts required to monitor and dose-adjust VKA therapy are among the 1045 
most common reasons for withholding or ending OAC.352, 355-359 However, the considerable stroke risk without 1046 
OAC often exceeds the bleeding risk on OAC, even in the elderly, in patients with cognitive dysfunction, or in 1047 
patients with frequent falls or frailty.360, 361 The bleeding risk on aspirin is not different to the bleeding risk on 1048 
VKA362 or NOAC therapy,354, 363 while VKA and NOACs, but not aspirin, effectively prevent strokes in AF 1049 
patients.38, 354, 362, 363  1050 
 1051 
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 1052 
Figure 8 Stroke prevention in AF. 1053 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1054 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); LAA = left atrial appendage; 1055 
NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; VKA = vitamin K 1056 
antagonist.  1057 
aCongestive heart failure, hypertension, age ≥75 years (2 points), diabetes, prior stroke/TIA/embolus (2 points), 1058 
vascular disease, age 65–74, female sex. 1059 
bIncludes women without other stroke risk factors.  1060 
cIIaB for women with only one additional stroke risk factor,  1061 
dIB for patients with mechanical heart valves or mitral stenosis 1062 
 1063 
9.1. Prediction of stroke and bleeding risk  1064 
9.1.1. Clinical risk scores for stroke and systemic embolism 1065 
Simple, clinically applicable stroke risk-stratification schemes in AF patients were developed in the late 1990s 1066 
in small cohort studies and have later been refined and validated in larger populations.364-368 The introduction of 1067 
the CHA2DS2-VASc score (Table 11) has clearly simplified the initial decision for OAC in AF patients. Since 1068 
its first incorporation in the ESC guidelines in 2010,369 it has been widely used.370 We recommend estimating 1069 
stroke risk in AF patients based on the CHA2DS2-VASc score.368 In general, patients without clinical stroke risk 1070 
factors do not need antithrombotic therapy, while patients with stroke risk factors (i.e. CHA2DS2-VASc score of 1071 
1 or more for men, and 2 or more for women) are likely to benefit from OAC.  1072 
 1073 
Table 11 Clinical risk factors for stroke, transient ischemic attack, and systemic embolism in the 1074 
CHA2DS2-VASc score. 1075 
CHA2DS2-VASc risk factor Points 
Congestive heart failure  
Signs/symptoms of heart failure or objective evidence of reduced left-ventricular ejection 
fraction 
+1  
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Hypertension  
Resting blood pressure > 140/90 mmHg on at least two occasions or current antihypertensive 
treatment 
+1  
Age 75 years or older  +2  
Diabetes mellitus  
Fasting glucose > 125 mg/dL or treatment with oral hypoglycaemic agent and/or insulin 
+1  
Previous stroke, transient ischemic attack, or thromboembolism  +2  
Vascular disease  
Previous myocardial infarction, peripheral artery disease, or aortic plaque 
+1  
Age 65 to 74 years  +1  
Sex category (female)  +1  
CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), 1076 
Vascular disease, Age 65–74, and Sex (female). 1077 
 1078 
Other, less established risk factors for stroke include unstable international normalized ratio (INR) and low time 1079 
in therapeutic range (TTR) in patients treated with VKAs; previous bleed or anaemia; alcohol excess and other 1080 
markers for decreased therapy adherence; CKD; elevated high-sensitivity troponin T; and elevated N-terminal 1081 
pro-B-type natriuretic peptide. 1082 
 1083 
9.1.2. Anticoagulation in patients with a CHA2DS2-VASc score of 1 in men and 2 1084 
in women 1085 
Controlled trials studying OAC in AF patients have been enriched for patients at high risk of stroke,38, 39, 42, 194, 1086 
201, 329, 351, 352 and hence there is strong evidence that patients with a CHA2DS2-VASc risk score of 2 or more in 1087 
men, and 3 or more in women benefit from OAC. Fortunately, we now have a growing evidence-base regarding 1088 
stroke risk in patients with one clinical risk factor (i.e. CHA2DS2-VASc score of 1 for men, and 2 for women), 1089 
although this relies largely on observed stroke rates in patients not receiving OAC. In many of these patients, 1090 
anticoagulation seems to provide a clinical benefit.371-375 The rates of stroke and thromboembolism vary 1091 
considerably in patients with CHA2DS2-VASc scores of 1 or 2 due to differences in outcomes, populations, and 1092 
anticoagulation status (Web Addenda Table 1).371, 376, 377, 1041 OAC should be considered for men with a 1093 
CHA2DS2-VASc score of 1 and women with a score of 2, balancing the expected stroke reduction, bleeding 1094 
risk, and patient preference. Importantly, age (65 years and older) conveys a relatively high and continuously 1095 
increasing stroke risk that also potentiates other risk factors (such as heart failure and sex). Hence, an 1096 
individualized weighing of risk, as well as patient preferences, should inform the decision to anticoagulate 1097 
patients with only one CHA2DS2-VASc risk factor, apart from female sex. Female sex does not appear to 1098 
increase stroke risk in the absence of other stroke risk factors (Web Addenda Table 1).378, 379 1099 
 Measurement of cardiac troponin (high-sensitivity troponin T or I) and N-terminal pro-B-type 1100 
natriuretic peptide may provide additional prognostic information in selected AF patients.380-382 Biomarker-1101 
based risk scores may in the future prove helpful to better stratify patients (e.g. those at a truly low risk of 1102 
stroke).75, 382  1103 
 1104 
9.1.3. Clinical risk scores for bleeding 1105 
Several bleeding risk scores have been developed, mainly in patients on VKAs. These include HAS-BLED 1106 
(hypertension, abnormal renal/liver function [1 point each], stroke, bleeding history or predisposition, labile 1107 
INR, elderly [>65 years], drugs/alcohol concomitantly [1 point each]), ORBIT (Outcomes Registry for Better 1108 
Informed Treatment of Atrial Fibrillation), and more recently, the ABC (age, biomarkers, clinical history) 1109 
bleeding score, which also makes use of selected biomarkers.383-385 Stroke and bleeding risk factors overlap 1110 
(compare Table 11 and Table 12). For example, older age is one of the most important predictors of both 1111 
ischaemic stroke and bleeding in AF patients.386, 387 A high bleeding risk score should generally not result in 1112 
withholding OAC. Rather, bleeding risk factors should be identified and treatable factors corrected (see Section 1113 
8.5). Table 12 provides details of modifiable bleeding risk factors.  1114 
 1115 
Table 12 Modifiable and non-modifiable risk factors for bleeding in anticoagulated patients based on 1116 
bleeding risk scores. 1117 
Modifiable bleeding risk factors 
Hypertension (especially when systolic blood pressure is > 160 mmHg)a,b,c 
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Labile INR (in patients on vitamin K antagonists) or time in therapeutic range < 60%a 
Medication predisposing to bleeding, such as antiplatelet drugs and non-steroidal anti-inflammatory drugsa,d 
Excess alcohol (≥ 8 drinks/week)a,b 
Potentially modifiable bleeding risk factors 
Anaemiab,c,d 
Impaired renal functiona,b,c,d 
Impaired liver functiona,b 
Reduced platelet count or functionb 
Non-modifiable bleeding risk factors 
Agee (> 65 years)a (≥ 75 years)b,c,d 
History of major bleedinga,b,c,d 
Previous strokea,b 
Dialysis-dependent CKD or renal transplanta,c 
Cirrhotic liver diseasea 
Malignancyb 
Genetic factorsb 
Biomarker-based bleeding risk factors 
High-sensitivity troponin Te 
Growth differentiation factor-15e 
Serum creatinine/estimated CrCLe 
ABC = age, biomarkers, clinical history; ATRIA = AnTicoagulation and Risk factors In Atrial fibrillation; CKD 1118 
= chronic kidney disease; CrCl = creatinine clearance; HAS-BLED = hypertension, abnormal renal/liver 1119 
function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (>65 years), drugs/alcohol 1120 
concomitantly (1 point each); INR = international normalized ratio; ORBIT = Outcomes Registry for Better 1121 
Informed Treatment of Atrial Fibrillation; TTR = time in therapeutic range; VKA = vitamin K antagonist. 1122 
aDerived from the HAS-BLED score.384 1123 
bDerived from the HEMORR2HAGES score.383 1124 
cDerived from the ATRIA score.385 1125 
dDerived from the ORBIT score.388 1126 
eDerived from the ABC bleeding score.387 1127 
 1128 
 Recommendations for prediction of stroke and bleeding risk  1129 
Recommendations Class a Level b Refs c 
The CHA2DS2-VASc score is recommended for stroke risk 
prediction in patients with AF 
I A 368, 371, 
386 
Bleeding risk scores should be considered in AF patients on oral 
anticoagulation to identify modifiable factors for major bleeding 
IIa B 384, 386, 
387, 389-392 
Biomarkers such as high-sensitivity troponin and N-terminal pro-
B-type natriuretic peptide may be considered to further refine 
stroke and bleeding risk in AF patients 
IIb B 380-382, 
387, 393 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1130 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); OAC = oral anticoagulation. 1131 
aClass of recommendation. 1132 
bLevel of evidence. 1133 
cReference(s) supporting recommendations. 1134 
 1135 
9.2. Stroke prevention 1136 
9.2.1. Vitamin K antagonists 1137 
Warfarin and other VKAs were the first anticoagulants used in AF patients. VKA therapy reduces risk of stroke 1138 
by two-thirds and mortality by one-quarter compared with control (aspirin or no therapy).38 VKAs have been 1139 
used in many patients throughout the world with good outcomes,394-396 and this is reflected in the warfarin arms 1140 
of the NOAC trials (see Section 8.2.2.). The use of VKAs is limited by the narrow therapeutic interval, 1141 
necessitating frequent monitoring and dose adjustments, but VKAs, when delivered with adequate TTR, are 1142 
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effective for stroke prevention in AF patients. Clinical parameters can help to identify patients who are likely to 1143 
achieve a decent TTR on VKA therapy.397 These have been summarized in the SAMe-TT2R2 score. Patients who 1144 
fare well on this score, when treated with a VKA, have on average a higher TTR than patients who do not fare 1145 
well on the score.398, 399 VKAs are currently the only treatment with established safety in AF patients with 1146 
rheumatic mitral valve disease and/or a mechanical heart valve prosthesis.400  1147 
 1148 
9.2.2. Non-vitamin K antagonist oral anticoagulants 1149 
NOACs, including the direct thrombin inhibitor dabigatran and the factor Xa inhibitors apixaban, edoxaban, and 1150 
rivaroxaban, are suitable alternatives to VKAs for stroke prevention in AF (Table 13). Their use in clinical 1151 
practice is increasing rapidly.401 All NOACs have a predictable effect (onset and offset) without need for regular 1152 
anticoagulation monitoring. The phase III trials have been conducted with carefully selected doses of the 1153 
NOACs, including clear rules for dose reduction that should be followed in clinical practice (Table 13). 1154 
 1155 
Apixaban 1156 
In the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 1157 
Fibrillation) trial,319 apixaban reduced stroke or systemic embolism by 21% compared with warfarin, combined 1158 
with a 31% reduction in major bleeding and an 11% reduction in all-cause mortality (all statistically significant). 1159 
Rates of haemorrhagic stroke and intracranial haemorrhage, but not of ischaemic stroke, were lower on 1160 
apixaban. Rates of gastrointestinal bleeding were similar between the two treatment arms.402  1161 
 Apixaban is the only NOAC that has been compared with aspirin in AF patients: apixaban significantly 1162 
reduced stroke or systemic embolism by 55% compared with aspirin, with no significant difference in rates of 1163 
major bleeding or intracranial haemorrhage.354, 403  1164 
 1165 
Dabigatran 1166 
In the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study,318, 404 dabigatran 150 mg 1167 
twice daily reduced stroke and systemic embolism by 35% compared with warfarin without a significant 1168 
difference in major bleeding events. Dabigatran 110 mg twice daily was non-inferior to warfarin for prevention 1169 
of stroke and systemic embolism, with 20% fewer major bleeding events. Both dabigatran doses significantly 1170 
reduced haemorrhagic stroke and intracranial haemorrhage. Dabigatran 150 mg twice daily significantly 1171 
reduced ischaemic stroke by 24% and vascular mortality by 12%, while gastrointestinal bleeding was 1172 
significantly increased by 50%. There was a non-significant numerical increase in the rate of myocardial 1173 
infarction with both dabigatran doses,318, 404 which has not been replicated in large post-authorization 1174 
analyses.396 These data have also replicated the benefit of dabigatran over VKAs found in the RE-LY trial in 1175 
patients enriched for the higher dabigatran dose (150 mg twice daily).396  1176 
  1177 
Edoxaban 1178 
In the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–1179 
Thrombolysis in Myocardial Infarction 48) trial,321 edoxaban 60 mg once daily and edoxaban 30 mg once daily 1180 
(with dose reductions in certain patients according to Table 13), were compared with adjusted-dose warfarin.405 1181 
Edoxaban 60 mg once daily was non-inferior to warfarin (primary outcome, HR 0.87; 97.5% CI 0.73–1.04; P = 1182 
0.08). In an on-treatment analysis, edoxaban 60 mg once daily significantly reduced stroke or systemic 1183 
embolism by 21% and significantly reduced major bleeding events by 20% compared with warfarin, while 1184 
edoxaban 30 mg once daily was non-inferior to warfarin for prevention of stroke and systemic embolism but 1185 
significantly reduced major bleeding events by 53%. Cardiovascular death was reduced in patients randomized 1186 
to edoxaban 60 mg once daily or edoxaban 30 mg once daily compared with warfarin. Only the higher dose 1187 
regimen has been approved for stroke prevention in AF. 1188 
 1189 
Rivaroxaban 1190 
In the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 1191 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial,320 patients were 1192 
randomized to rivaroxaban 20 mg once daily or VKA, with a dose adjustment to 15 mg daily for those with 1193 
estimated CrCl 30–49 mL/min by the Cockroft–Gault formula. Rivaroxaban was non-inferior to warfarin for the 1194 
prevention of stroke and systemic embolism in the intent-to-treat analysis, while the per-protocol on-treatment 1195 
analysis achieved statistical superiority with a 21% reduction in stroke or systemic embolism compared with 1196 
warfarin. Rivaroxaban did not reduce the rates of mortality, ischaemic stroke, or major bleeding events 1197 
compared to VKA. There was an increase in gastrointestinal bleeding events, but a significant reduction in 1198 
haemorrhagic stroke and intracranial haemorrhage with rivaroxaban compared with warfarin. Comparable event 1199 
rates have been reported in post-authorization analyses, which are part of the post-approval risk-management 1200 
process.406, 4071201 
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Table 13 NOACs compared with warfarin in controlled trials 1202 
  Dabigatran (RE-LY) 
Rivaroxaban 
(ROCKET-AF) 
Apixaban 
(ARISTOTLE) 
Edoxaban 
(ENGAGE AF-TIMI 48) 
Mechanism Oral direct thrombin inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor Oral direct factor Xa inhibitor 
Bioavailability, % 6 66 fasting, 80–100 with food 50 62 
Time to peak levels, h 3 2–4 3 1–2 
Half-life, h 12–17 5–13 9–14 10–14 
Excretion 80% renal 66% liver, 33% renal 27% renal 50% renal 
Dose 150 mg or 110 mg twice daily 20 mg once daily 5 mg twice daily 60 mg or 30 mg once daily 
Dose reduction in selected 
patients   
Rivaroxaban 15 mg once daily if 
CrCl 30–49 mL/min 
Apixaban 2.5 mg twice daily if at least 
2 of age ≥ 80 years, body weight ≤ 60 
kg or serum creatinine level ≥ 1.5 
mg/dL (133 µmol/L) 
Edoxaban 60 mg reduced to 30 mg once 
daily, and edoxaban 30 mg reduced to 15 mg 
once daily, if any of the following: CrCl 30–
50 mL/min, body weight ≤ 60 kg, 
concomitant use of verapamil or quinidine or 
dronedarone 
Study design Randomized, open-label Randomized, double-blind Randomized, double-blind Randomized, double-blind 
Number of patients 18,113 14,264 18,201 21,105 
Follow-up period, years 2 1.9 1.8 2.8 
Randomized groups 
Dose-adjusted warfarin vs. blinded 
doses of dabigatran (150 mg twice 
daily or 110 mg twice daily) 
Dose-adjusted warfarin vs. 
rivaroxaban 20 mg once daily 
Dose-adjusted warfarin vs. apixaban 5 
mg twice daily 
Dose-adjusted warfarin vs. edoxaban (60 mg 
once daily or 30 mg once daily)  
Age, years Mean ± SD 71.5 ± 8.7  Median 73; IQR 65–78 Median 70; IQR 63–76 Median 72; IQR 64–78 
Men, % 63.6 60.3 64.5 61.9 
CHADS2 score (mean) 2.1 3.5 2.1 2.8 
  1203 
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 Outcomes Warfarin Dabigatran 150 
Dabigatran 
110 Warfarin Rivaroxaban Warfarin Apixaban Warfarin Edoxaban 60 Edoxaban 30 
 
n = 6022 n = 6076 n = 6015 n = 7133 n = 7131 n = 9081 n = 9120 n = 7036 n = 7035 n = 7034 
Event 
rate, 
%/year 
Event rate, 
%/year (RR 
vs. warfarin)  
Event rate, 
%/year (RR 
vs. 
warfarin)  
Event rate, 
%/year 
Event rate, %/year 
(HR vs. warfarin)  
Event rate, 
%/year 
Event rate, %/year (HR 
vs. warfarin)  
Event rate, 
%/year 
Event rate, 
%/year (HR vs. 
warfarin)  
Event rate, 
%/year (HR 
vs. warfarin)  
Stroke/systemic embolism 1.72 
1.12 (0.65, 
0.52–0.81; 
P for non-
inferiority and 
superiority 
< 0.001) 
1.54 (0.89, 
0.73–1.09; 
P for non-
inferiority 
< 0.001) 
2.42 
2.12 (0.88, 0.75–1.03; 
P for non-inferiority 
< 0.001, P for 
superiority = 0.12) 
1.60 
1.27 (0.79, 0.66–0.95; 
P < 0.001 for non-
inferiority, 
P = 0.01 for superiority) 
1.80 
1.57 (0.87, 0.73–
1.04; 
P < 0.001 for 
non-inferiority, P 
= 0.08 for 
superiority) 
2.04 (1.13, 
0.96–1.34; 
P = 0.005 for 
non-
inferiority, P 
= 0.10 for 
superiority) 
Ischaemic stroke 1.22 
0.93 (0.76, 
0.59–0.97; 
P = 0.03) 
1.34 (1.10, 
0.88–1.37; 
P = 0.42) 
1.42 1.34 (0.94; 0.75–1.17; P = 0.581) 1.05 
0.97 (0.92, 0.74–1.13; 
P = 0.42) 1.25 
1.25 (1.00, 0.83–
1.19; 
P = 0.97) 
1.77 (1.41, 
1.19–1.67; 
P < 0.001) 
Haemorrhagic stroke 0.38 
0.10 (0.26, 
0.14–0.49; 
P < 0.001) 
0.12 (0.31, 
0.17–0.56; 
P < 0.001) 
0.44 0.26 (0.59; 0.37–0.93; P = 0.024) 0.47 
0.24 (0.51, 0.35–0.75; 
P < 0.001) 0.47 
0.26 (0.54, 0.38–
0.77; 
P < 0.001) 
0.16 (0.33, 
0.22–0.50; 
P < 0.001) 
Major bleeding 3.61 
3.40 (0.94, 
0.82–1.08; 
P = 0.41) 
2.92 (0.80, 
0.70–0.93; 
P = 0.003) 
3.45 3.60 (1.04; 0.90-2.30; P = 0.58) 3.09 
2.13 (0.69, 0.60–0.80; 
P < 0.001) 3.43 
2.75 (0.80, 0.71–
0.91; P < 0.001) 
1.61 (0.47, 
0.41–0.55; P 
< 0.001) 
Intracranial bleeding 0.77 
0.32 (0.42, 
0.29–0.61; 
P < 0.001) 
0.23 (0.29 
0.19–0.45; 
P < 0.001) 
0.74 0.49 (0.67; 0.47–0.93; P = 0.02) 0.80 
0.33 (0.42, 0.30–0.58; 
P < 0.001) 0.85 
0.39 (0.47, 0.34–
0.63; P < 0.001)  
0.26 (0.30, 
0.21–0.43; P 
< 0.001) 
Gastrointestinal major 
bleeding 1.09 
1.60 (1.48, 
1.19–1.86; 
P < 0.001) 
1.13 (1.04, 
0.82–1.33; 
P = 0.74) 
1.24 2.00 (1.61; 1.30-1.99; P < 0.001) 0.86 
0.76 (0.89, 0.70–1.15; 
P = 0.37) 1.23 
1.51 (1.23, 1.02–
1.50; P = 0.03) 
0.82 (0.67, 
0.53–0.83; P 
< 0.001) 
Myocardial infarction 0.64 
0.81 (1.27, 
0.94-1.71; 
P = 0.12) 
0.82 (1.29, 
0.96-1.75; 
P = 0.09) 
1.12 0.91 (0.81; 0.63–1.06; P = 0.12) 0.61 
0.53 (0.88, 0.66–1.17; 
P = 0.37) 0.75 
0.70 (0.94, 0.74–
1.19; P = 0.60) 
0.89 (1.19, 
0.95–1.49; P 
= 0.13) 
Death from any cause 4.13 
3.64 (0.88, 
0.77–1.00; 
P = 0.051) 
3.75 (0.91, 
0.80–1.03; 
P = 0.13) 
2.21 1.87 (0.85; 0.70–1.02; P = 0.07) 3.94 
3.52 (0.89, 0.80–0.99; 
P = 0.047) 4.35 
3.99 (0.92, 0.83–
1.01; P = 0.08) 
3.80 (0.87, 
0.79–0.96; P 
= 0.006) 
AF = atrial fibrillation; CHADS2 = Cardiac failure, Hypertension, Age, Diabetes, Stroke (Doubled); CrCl = creatinine clearance; HR = hazard ratio; IQR = interquartile range (25th to 1204 
75th quartiles); RR = risk ratio; SD = standard deviation.  1205 
RRs and HRs compared to warfarin therapy are presented with 95% confidence intervals and P-values.1206 
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 1207 
9.2.3. Non-vitamin K antagonist oral anticoagulants or vitamin K antagonists 1208 
Both VKAs and NOACs are effective for the prevention of stroke in AF. A meta-analysis39 based on the high-1209 
dose treatment groups of the pivotal studies of warfarin versus NOACs included 42,411 patients receiving a 1210 
NOAC and 29,272 receiving warfarin. NOACs in these dosages significantly reduced stroke or systemic 1211 
embolic events by 19% compared with warfarin (RR 0.81; 95% CI 0.73–0.91; P < 0.0001), mainly driven by a 1212 
reduction in haemorrhagic stroke (RR 0.49; 95% CI 0.38–0.64; P < 0.0001). Mortality was 10% lower in 1213 
patients randomized to NOAC therapy (RR 0.90; 95% CI 0.85–0.95; P = 0.0003) and intracranial haemorrhage 1214 
was halved (RR 0.48; 95% CI 0.39–0.59; P < 0.0001), while gastrointestinal bleeding events were more 1215 
frequent (RR 1.25; 95% CI 1.01–1.55; P = 0.04).39 The stroke reduction with NOACs was consistent in all 1216 
evaluated subgroups, while there was a suggestion of greater relative reduction in bleeding with NOACs at 1217 
centres with poor INR control (interaction P = 0.022). Notably, the substantial reduction in intracranial 1218 
haemorrhage by NOACs compared with warfarin seems unrelated to poor or good INR control.408, 409  1219 
 1220 
9.2.4. Oral anticoagulation in atrial fibrillation patients with chronic kidney 1221 
disease 1222 
CKD is associated with stroke and bleeding in large data sets.410, 411 Anticoagulation can be safely used in AF 1223 
patients with moderate or moderate-to-severe CKD (glomerular filtration rate [GFR] ≥ 15 mL/min): the SPAF 1224 
(Stroke Prevention in Atrial Fibrillation) III trial randomized 805/1936 participants with stage 3 CKD (estimated 1225 
GFR < 59 mL/min/1.73 m2), and reported good outcomes on warfarin (INR 2–3).412 This finding is supported by 1226 
a large Swedish database, in which stroke risk was lower in CKD patients with AF treated with warfarin 1227 
(adjusted HR 0.76; 95% CI 0.72–0.80),413 while bleeding was also slightly increased, especially during therapy 1228 
initiation.414 In a meta-analysis of the major NOAC trials, patients with mild or moderate CKD suffered fewer 1229 
strokes, systemic emboli, or major bleeding events on NOACs than on warfarin.415 Kidney function should be 1230 
regularly monitored in AF patients on OAC to allow dose adaptation for those on NOACs (Table 14) and to 1231 
refine risk estimation.416  1232 
 1233 
Table 14 Inclusion criteria, dose adjustments, and outcomes in patients with chronic kidney disease in the 1234 
four major randomized trials comparing NOACs with warfarin in patients with AF. Adapted from Hart 1235 
et al.316 1236 
 Dabigatran  
(RE-LY)318, 425 
Rivaroxaban  
(ROCKET-AF) 
320, 426 
Apixaban  
(ARISTOTLE)319, 427 
Edoxaban  
(ENGAGE AF-
TIMI 48)321 
Renal clearance 80% 35% 25% 50% 
Number of 
patients 
18,113 14,264 18,201 21,105 
Dose 150 mg or 110 
mg twice daily 
20 mg once daily 5 mg twice daily 60 mg or 30 mg 
once daily 
Exclusion criteria 
for CKD 
CrCl < 30 
mL/min 
CrCl < 30 
mL/min 
Serum creatinine > 
2.5 mg/dL or CrCl < 
25 mL/min 
CrCl < 30 mL/min 
Dose adjustment 
with CKD 
None 15 mg once daily 
if CrCl < 30–49 
mL/min 
2.5 mg twice daily if 
serum creatinine ≥ 
1.5 mg/dL plus age ≥ 
80 years or weight ≤ 
60 kg 
30 mg or 15 mg 
once daily if CrCl 
< 50 mL/min 
Per cent of 
patients with CKD 
20% with CrCl 
30–49 mL/min 
21% with CrCl 
30–49 mL/min 
15% with CrCl 30–50 
mL/dL 
19% with CrCl < 
50 mL/min 
Reduction of 
stroke and 
systemic 
embolism 
No interaction 
with CKD status 
No interaction 
with CKD status 
No interaction with 
CKD status 
NA 
Reduction of 
major 
haemorrhages 
compared with 
warfarin 
Reduction in 
major 
haemorrhage 
with dabigatran 
was greater in 
patients with 
Major 
haemorrhage 
similar 
Reduction in major 
haemorrhage with 
apixaban 
NA 
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estimated GFR 
> 80 mL/min 
with either dose 
AF = atrial fibrillation; CKD = chronic kidney disease; CrCl = creatinine clearance; GFR = glomerular filtration 1237 
rate; NA = not available; NOAC = non-vitamin K antagonist oral anticoagulant. 1238 
 1239 
9.2.5. Oral anticoagulation in atrial fibrillation patients on dialysis 1240 
Approximately one in eight dialysis patient suffers from AF, with an incidence rate of 2.7/100 patient-years.417 1241 
AF is associated with increased mortality in patients on dialysis.417 There are no randomized trials assessing 1242 
OAC in haemodialysis patients,418 and no controlled trials of NOACs in patients with severe CKD (CrCl < 25–1243 
30 mL/min).318-321 Warfarin use was associated either with a neutral or increased risk of stroke in database 1244 
analyses of patients on dialysis,419-421 including a population-based analysis in Canada (adjusted HR for stroke 1245 
1.14; 95% CI 0.78–1.67, adjusted HR for bleeding 1.44; 95% CI 1.13–1.85).422 In contrast, data from Denmark 1246 
suggest a benefit of OAC in patients on renal replacement therapy.423 Hence, controlled studies of 1247 
anticoagulants (both VKAs and NOACs) in AF patients on dialysis are needed.424  1248 
 1249 
9.2.6. Patients with atrial fibrillation requiring kidney transplantation 1250 
There are no randomized trials assessing OAC in patients after kidney transplantation. The prescription of 1251 
NOAC therapy should be guided by the estimated GFR of the transplanted kidney. Potential pharmacokinetic 1252 
interactions of OAC with immunosuppressive agents should be considered. 1253 
 1254 
 1255 
9.2.7. Antiplatelet therapy as an alternative to oral anticoagulants 1256 
The evidence supporting antiplatelet monotherapy for stroke prevention in AF is very limited.38, 428-430 VKA 1257 
therapy prevents stroke, non-central nervous system embolus, myocardial infarction, and vascular death better 1258 
than single or dual antiplatelet therapy with aspirin and clopidogrel (annual risk of 5.6% for aspirin and 1259 
clopidogrel vs. 3.9% with VKA therapy).431 Even greater benefits were seen in VKA-treated patients with a high 1260 
TTR.432 Antiplatelet therapy increases bleeding risk, especially dual antiplatelet therapy (2.0% vs. 1.3% with 1261 
antiplatelet monotherapy; P < 0.001),433 with bleeding rates that are similar to those on OAC.354, 362, 431, 434 Thus, 1262 
antiplatelet therapy cannot be recommended for stroke prevention in AF patients. 1263 
 1264 
Recommendations for stroke prevention in patients with AF 1265 
Recommendations Class a Level b Refs c 
Oral anticoagulation therapy to prevent thromboembolism is 
recommended for all male AF patients with a CHA2DS2-VASc 
score of 2 or more 
I A 38, 318-321, 354, 
404 
Oral anticoagulation therapy to prevent thromboembolism is 
recommended in all female AF patients with a CHA2DS2-
VASc score of 3 or more 
I 
 
A 38, 318-321, 354, 
404 
Oral anticoagulation therapy to prevent thromboembolism 
should be considered in male AF patients with a CHA2DS2-
VASc score of 1, considering individual characteristics and 
patient preferences 
IIa B 371, 375-377 
Oral anticoagulation therapy to prevent thromboembolism 
should be considered in female AF patients with a CHA2DS2-
VASc score of 2, considering individual characteristics and 
patient preferences 
IIa B 371, 376, 377 
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is 
recommended for stroke prevention in AF patients with 
moderate-to-severe mitral stenosis or mechanical heart 
valves 
I B 274, 435-440 
When oral anticoagulation is initiated in a patient with AF 
who is eligible for a NOAC (apixaban, dabigatran, edoxaban, 
or rivaroxaban), a NOAC is recommended in preference to a 
Vitamin K antagonist 
I A 39, 318-321, 404 
When patients are treated with a vitamin K antagonist, time I A 
395, 432, 441-444 
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AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 1266 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); INR = international normalized 1267 
ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; TTR = time in 1268 
therapeutic range; VKA = vitamin K antagonist. 1269 
aClass of recommendation. 1270 
bLevel of evidence. 1271 
cReference(s) supporting recommendations. 1272 
 1273 
9.3. Left atrial appendage occlusion and exclusion 1274 
9.3.1. Left atrial appendage occlusion devices 1275 
Interventional LAA occlusion,446-449 and limited experience with percutaneous LAA ligation, has mainly been 1276 
reported in observational studies and registries. Only one device (Watchman®) has been compared with VKA 1277 
therapy in randomized trials (PROTECT AF [Watchman Left Atrial Appendage System for Embolic Protection 1278 
in Patients With AF trial], see Web Addenda Table 2; and PREVAIL [Prospective Randomized Evaluation of 1279 
the Watchman LAA Closure Device In Patients with AF Versus Long Term Warfarin Therapy trial]).449-451 In 1280 
these data sets, LAA occlusion was non-inferior to VKA treatment for the prevention of stroke in AF patients 1281 
with moderate stroke risk, with a possibility of lower bleeding rates in the patients who continued follow-up.452, 1282 
453 These data were confirmed in a patient-level meta-analysis of the two trials and their associated registries.453 1283 
LAA occlusion may also reduce stroke risk in patients with contraindications to OAC.454, 455 The implantation 1284 
procedure can cause serious complications,446, 456-458 with high event rates reported in analyses from insurance 1285 
databases and systematic reviews, possibly identifying a certain degree of reporting bias.446, 456 A large recent 1286 
European registry reported a high rate of implantation success (98%), with an acceptable procedure-related 1287 
complication rate of 4% at 30 days.459 Most patients who historically would be considered unsuitable for OAC 1288 
therapy seem to do relatively well on contemporarily managed OAC.396, 407, 460 Adequately powered controlled 1289 
trials are urgently needed to inform the best use of these devices, including LAA occluders in patients who are 1290 
truly unsuitable for OAC or in patients who suffer a stroke on OAC, randomized comparisons of LAA occluders 1291 
with NOACs, and assessment of the minimal antiplatelet therapy acceptable after LAA occlusion. 1292 
 1293 
9.3.2. Surgical left atrial appendage occlusion or exclusion 1294 
Surgical LAA occlusion or exclusion concomitant to cardiac surgery has been performed for many decades and 1295 
with various techniques. Multiple observational studies indicate the feasibility and safety of surgical LAA 1296 
occlusion/exclusion, but only limited controlled trial data are available.461-464 Residual LAA flow or incomplete 1297 
LAA exclusion can increase stroke risk.465 In most studies, LAA occlusion/exclusion was performed during 1298 
other open heart surgery, and more recently in combination with surgical ablation of AF463 or as a stand-alone 1299 
thoracoscopic procedure. One randomized trial evaluating the role of concomitant AF surgery and LAA 1300 
occlusion reported in 2015, without a clear benefit of LAA exclusion for stroke prevention in the subgroup 1301 
undergoing AF surgery.466 A large randomized trial is currently underway.467  1302 
 1303 
Recommendations for occlusion or exclusion of the LAA 1304 
in therapeutic range (TTR) should be kept as high as 
possible and closely monitored 
AF patients already on treatment with a vitamin K antagonist 
may be considered for NOAC treatment if TTR is not well 
controlled despite good adherence, or if patient preference 
without contraindication (e.g. prosthetic valve) 
IIb A 39, 318, 319, 404, 
408 
Combinations of oral anticoagulants and platelet inhibitors 
increase bleeding risk and should be avoided in AF patients 
without another indication for platelet inhibition 
III (harm) B 429, 445 
In male or female AF patients without additional stroke risk 
factors, anticoagulant or antiplatelet therapy is not 
recommended for stroke prevention 
III (harm) B 368, 371, 376, 377 
Antiplatelet monotherapy is not recommended for stroke 
prevention in AF patients, regardless of stroke risk 
III (harm) A 38, 429, 430 
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) 
are not recommended in patients with mechanical heart 
valves (Level of evidence B) or moderate-to-severe mitral 
stenosis (Level of evidence C) 
III (harm) B/C 318-321, 400, 404 
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Recommendations Class a Level b Refs c 
After surgical occlusion or exclusion of the LAA, it is recommended to 
continue anticoagulation in at-risk patients with AF for stroke 
prevention 
I B 461, 462 
LAA occlusion may be considered for stroke prevention in patients 
with AF and contraindications for long-term anticoagulant treatment 
(e.g. those with a previous life-threatening bleed without a reversible 
cause) 
IIb B 449, 453, 454 
Surgical occlusion or exclusion of the LAA may be considered for 
stroke prevention in patients with AF undergoing cardiac surgery 
IIb B 463 
Surgical occlusion or exclusion of the LAA may be considered for 
stroke prevention in patients undergoing thoracoscopic ablation surgery 
IIb B 468 
AF = atrial fibrillation; LAA = left atrial appendage. 1305 
aClass of recommendation. 1306 
bLevel of evidence. 1307 
cReference(s) supporting recommendations. 1308 
 1309 
9.4. Secondary stroke prevention 1310 
The most important risk factors for stroke in patients with AF are advanced age and previous cardioembolic 1311 
stroke or TIA,382 emphasizing the need for OAC in these patients. The highest risk of recurrent stroke is in the 1312 
early phase after a first stroke or TIA.469, 470 1313 
 1314 
9.4.1. Treatment of acute ischaemic stroke 1315 
Systemic thrombolysis with recombinant tissue plasminogen activator (rtPA)  is an effective and approved 1316 
medical treatment for acute ischaemic stroke in patients presenting within 4.5 hours of symptom onset.471 1317 
Systemic thrombolysis is contraindicated in patients on therapeutic OAC.472, 473 Recombinant tissue 1318 
plasminogen activator can be given in patients treated with a VKA if the INR is below 1.7,474 or in dabigatran-1319 
treated patients with a normal activated partial thromboplastin time and last intake of drug > 48 hours previously 1320 
(based on expert consensus).472 Whether specific NOAC antidotes475 could be used followed by systemic 1321 
thrombolysis needs to be investigated. Thrombectomy can be performed in anticoagulated patients with distal 1322 
occlusion of the internal carotid artery or middle cerebral artery in a 6-hour window.476 1323 
 1324 
9.4.2. Initiation of anticoagulation after transient ischaemic attack or ischaemic 1325 
stroke 1326 
Data on the optimal use of anticoagulants (heparin, low-molecular-weight heparin, heparinoid, VKA, NOAC) in 1327 
the first days after a stroke are scarce. Parenteral anticoagulants seem to be associated with a non-significant 1328 
reduction in recurrent ischaemic stroke when administered 7 to 14 days after the acute stroke (odds ratio [OR] 1329 
0.68; 95% CI 0.44–1.06), with a significant increase in symptomatic intracranial bleeding (OR 2.89; 95% CI 1330 
1.19–7.01), and a similar rate of death or disability at final follow-up.477 It seems likely that the bleeding risk on 1331 
parenteral anticoagulation exceeds the stroke prevention benefit in the first days after a large stroke, whereas 1332 
patients with a TIA or a small stroke may benefit from early (immediate) initiation or continuation of 1333 
anticoagulation. Therefore, we propose to initiate anticoagulation in AF patients between 1 and 12 days after an 1334 
ischaemic stroke, depending on its severity (Figure 9).478 We suggest repeat brain imaging to determine the 1335 
optimal initiation of anticoagulation in patients with a large stroke at risk for haemorrhagic transformation. 1336 
Long-term OAC with a VKA363, 479-481 or NOAC482 conveys benefits in AF patients who survived a stroke. 1337 
NOACs seem to convey slightly better outcomes, mainly driven by fewer intracranial haemorrhages and 1338 
haemorrhagic strokes (OR 0.44, 95% CI 0.32–0.62).482 Detailed data for edoxaban have not yet been 1339 
published.321 If a patient suffers a stroke or TIA whilst taking an anticoagulant, switching to another 1340 
anticoagulant should be considered. 1341 
 1342 
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Figure 9 Initiation or continuation of anticoagulation in AF patients after a stroke or TIA. This approach is 1343 
based on consensus rather than prospective data. 1344 
  1345 
AF = atrial fibrillation; CT = computed tomography; MRI = magnetic resonance imaging; NIHSS = National 1346 
Institutes of Health stroke severity scale (available at http://www.strokecenter.org/wp-1347 
content/uploads/2011/08/NIH_Stroke_Scale.pdf); OAC = oral anticoagulation; TIA = transient ischaemic 1348 
attack. 1349 
 1350 
9.4.3. Initiation of anticoagulation after intracranial haemorrhage 1351 
No prospective studies have investigated the benefit or risk of the initiation of OAC after intracranial 1352 
haemorrhage,483 and patients with a history of intracranial bleeding were excluded from the randomized trials 1353 
comparing NOACs with VKAs. The available evidence indicates that anticoagulation in patients with AF can be 1354 
reinitiated after 4–8 weeks, especially when the cause of bleeding or the relevant risk factor (e.g. uncontrolled 1355 
hypertension) has been treated, and that such treatment leads to fewer recurrent (ischaemic) strokes and lower 1356 
mortality.460, 484 If anticoagulation is resumed, it seems reasonable to consider anticoagulants with a low 1357 
bleeding risk.39 Figure 10 depicts a consensus opinion on the initiation or resumption of OAC after an 1358 
intracranial haemorrhage. We recommend a multidisciplinary decision with input from stroke 1359 
physicians/neurologists, cardiologists, neuroradiologists, and neurosurgeons.  1360 
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 1361 
Figure 10 Initiation or resumption of anticoagulation in AF patients after an intracranial bleed. This approach is 1362 
based on consensus and retrospective data. In all patients, evaluation by a multidisciplinary panel is required 1363 
before treatment (stroke physician/neurologist, cardiologist, neuroradiologist, and neurosurgeon).  1364 
AF = atrial fibrillation; LAA = left atrial appendage; NOAC = non-vitamin K antagonist oral anticoagulant; 1365 
OAC = oral anticoagulation; PCI = percutaneous coronary intervention; VKA = vitamin K antagonist. 1366 
 1367 
Recommendations for secondary stroke prevention 1368 
Recommendations Class a Level b Refs c 
Anticoagulation with heparin or low-molecular-weight heparin 
immediately after ischaemic stroke is not recommended in AF 
patients 
III (harm) A 477 
In patients who suffer a transient ischemic attack or stroke while 
on anticoagulation, adherence to therapy should be assessed and 
optimized 
IIa C  
In patients who suffer a moderate-to-severe ischaemic stroke 
while on anticoagulation, anticoagulation should be interrupted for 
3–12 days based on a multidisciplinary assessment of acute 
stroke and bleeding risk 
IIa C  
In AF patients who suffer a stroke, aspirin should be considered 
for prevention of secondary stroke until the initiation or resumption 
of oral anticoagulation. 
IIa B 485 
Systemic thrombolysis with a recombinant tissue plasminogen 
activator is not recommended if the INR is above 1.7 (or, for 
patients on dabigatran, if activated partial thromboplastin time is 
outside the normal range) 
III (harm) C 472, 474 
NOACs are recommended in preference to VKAs or aspirin in AF 
patients with a previous stroke 
I B 363, 482 
After TIA or stroke, combination therapy of OAC and an III (harm) B 486 
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 1369 
 1370 
AF = atrial fibrillation; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral 1371 
anticoagulant; OAC = oral anticoagulation; TIA = transient ischaemic attack; VKA = vitamin K antagonist. 1372 
aClass of recommendation. 1373 
bLevel of evidence. 1374 
cReference(s) supporting recommendations. 1375 
 1376 
9.5. Strategies to minimize bleeding on anticoagulant therapy 1377 
In a meta-analysis of 47 studies, the overall incidence of major bleeding with VKAs was 2.1 (range 0.9–3.4) per 1378 
100 patient-years in controlled trials and 2.0 (range 0.2–7.6) per 100 patient-years for observational data sets.488 1379 
Minimizing treatable bleeding risk factors (see Table 12) seems paramount to reduce the bleeding rate on 1380 
anticoagulants.  1381 
 1382 
9.5.1. Uncontrolled hypertension 1383 
Uncontrolled blood pressure increases the risk of bleeding on OAC.53 Hence, keeping systolic blood pressure 1384 
well controlled is of particular relevance in anticoagulated patients with AF. Treatment according to current 1385 
guidelines is recommended in patients with known hypertension.489 1386 
 1387 
9.5.2. Previous bleeding event 1388 
History of bleeding events and the presence of anaemia are important parts of the assessment of all patients 1389 
receiving OAC. The majority of bleeding events are gastrointestinal. Compared with warfarin, the risk of 1390 
gastrointestinal bleeds was increased for dabigatran 150 mg twice daily,396, 490 rivaroxaban 20 mg once daily,491 1391 
and edoxaban 60 mg once daily.321 The risk of gastrointestinal bleeds was comparable to warfarin on dabigatran 1392 
110 mg twice daily490 and on apixaban 5 mg twice daily319 Recent observational analyses do not replicate these 1393 
findings, suggesting a smaller effect.396, 492, 493 In patients in whom the source of bleeding has been identified and 1394 
corrected, OAC can be reinitiated. This also appears true for patients who have had an intracranial haemorrhage, 1395 
once modifiable bleeding risk factors (e.g. uncontrolled hypertension) have been corrected.460, 484  1396 
 1397 
9.5.3. Labile international normalized ratio and adequate non-vitamin K 1398 
antagonist oral anticoagulant dosing  1399 
TTR on VKA therapy is an important predictor of major haemorrhage.432, 441, 494 Therefore we recommend 1400 
targeting the INR between 2.0 and 3.0 in patients on VKAs, maintaining a high TTR (e.g. ≥ 70%494), and to 1401 
consider switching to a NOAC when a high TTR cannot be sustained.444 NOAC dosing should follow the dose-1402 
reduction criteria evaluated in the clinical trials, considering renal function, age, and weight. Patient information 1403 
and empowerment, best delivered through integrated AF management, seem paramount to achieve this goal.  1404 
 1405 
9.5.4. Alcohol abuse 1406 
Alcohol excess is a risk factor for bleeding in anticoagulated patients,384 mediated by poor adherence, liver 1407 
disease, variceal bleeding, and risk of major trauma. Severe alcohol abuse and binge drinking habits should be 1408 
corrected in patients eligible for OAC.  1409 
 1410 
9.5.5. Falls and dementia 1411 
Falls and dementia are associated with increased mortality in AF patients,495 without evidence that these 1412 
conditions markedly increase the risk of intracranial haemorrhage.495, 496 Hence, anticoagulation should only be 1413 
withheld from patients with severe uncontrolled falls (e.g. epilepsy or advanced multisystem atrophy with 1414 
backwards falls), or in selected patients with dementia where compliance and adherence cannot be ensured by a 1415 
caregiver. 1416 
 1417 
9.5.6. Genetic testing 1418 
antiplatelet is not recommended 
After intracranial haemorrhage, oral anticoagulation in patients 
with AF may be reinitiated after 4–8 weeks provided the cause of 
bleeding or the relevant risk factor has been treated or controlled 
IIb B 483, 484, 487 
Page 47 of 148 ESC AF Guidelines 
 
In addition to food and drug interactions, multiple genetic variations affect the metabolism of VKAs.497 The 1419 
systematic use of genetic information for adjustment of VKA dosage has been evaluated in several controlled 1420 
clinical studies.498-500 Genetic testing has little effect on TTR or bleeding risk on warfarin, and is not 1421 
recommended for clinical use at present.501 1422 
 1423 
9.5.7. Bridging periods off oral anticoagulation 1424 
Most cardiovascular interventions (e.g. percutaneous coronary intervention or pacemaker implantation) can be 1425 
performed safely on continued OAC. When interruption of OAC is required, bridging does not seem to be 1426 
beneficial, except in patients with mechanical heart valves. In a randomized trial of 1884 patients with AF, 1427 
interruption of anticoagulation was non-inferior to heparin administration for the outcome of arterial 1428 
thromboembolism (incidence of 0.4% and 0.3%, respectively) and resulted in a lower risk of major bleeding 1429 
(1.3% and 3.2%, respectively).502 A short interruption or continued OAC should be considered in patients at 1430 
highest risk of stroke. 1431 
 1432 
9.6. Management of bleeding events in anticoagulated patients with atrial fibrillation 1433 
9.6.1. Management of minor, moderate, and severe bleeding 1434 
General assessment of an anticoagulated patient with AF experiencing a bleeding event should include 1435 
assessment of bleeding site, onset, and severity of the bleeding, the time-point of last intake of OAC and other 1436 
antithrombotic drugs, and other factors influencing bleeding risk such as CKD, alcohol abuse, and concurrent 1437 
medications. Laboratory tests should include haemoglobin, haematocrit, platelet count, renal function, and for 1438 
VKA patients, prothrombin time, activated partial thromboplastin time, and INR. Coagulation tests do not 1439 
provide much information in patients on NOACs, except for activated partial thromboplastin time in the case of 1440 
dabigatran. More specific coagulation tests do exist, including diluted thrombin time (HEMOCLOT) for 1441 
dabigatran and calibrated quantitative anti-factor Xa assays for factor Xa inhibitors.503 However, these tests are 1442 
not always readily available and are often unnecessary for bleeding management.504 1443 
 We propose a simple scheme to manage bleeding events in patients on OAC (Figure 11). Minor 1444 
bleeding events should be treated with supportive measures such as mechanical compression or minor surgery to 1445 
achieve haemostasis. In patients receiving VKAs, the next dose of VKA can be postponed. NOACs have a short 1446 
plasma half-life of approximately 12 hours and improved haemostasis is expected within 12–24 hours after a 1447 
delayed or omitted dose. Treatment of moderate bleeding events may require blood transfusions and fluid 1448 
replacement. Specific diagnostic and treatment interventions directed against the cause of the bleeding (e.g. 1449 
gastroscopy) should be performed promptly. If the intake of NOAC was recent (< 2–4 h), charcoal 1450 
administration and/or gastric lavage will reduce further exposure. Dialysis clears dabigatran but is not effective 1451 
for the other NOACs.  1452 
 Immediate reversal of the antithrombotic effect is indicated in severe or life-threatening bleeding 1453 
events. An agreed, the institutional procedure for the management of life-threatening bleeds should be 1454 
documented and accessible at all times to ensure adequate initial management. For VKAs, administration of 1455 
fresh frozen plasma restores coagulation more rapidly than vitamin K, and prothrombin complex concentrates 1456 
achieve even faster blood coagulation.505 Registry data suggest that the combination of plasma and prothrombin 1457 
complex concentrates is associated with the lowest case fatality following intracranial haemorrhage on VKA 1458 
treatment with an INR ≥ 1.3.506 In a multicentre randomized trial of 188 patients, four-factor prothrombin 1459 
complex concentrates achieved more rapid INR reversal and effective haemostasis than plasma in patients 1460 
undergoing urgent surgical or invasive procedures.507 Administration of prothrombin complex concentrates may 1461 
also be considered for severe bleeding on NOAC treatment if specific antidotes are not available.  1462 
 Several antidotes to NOACs are under development. Idarucizumab (approved in 2015 by the US Food 1463 
and Drug Administration and the European Medicines Agency) is a clinically available humanized antibody 1464 
fragment that binds dabigatran and rapidly and dose-dependently reverses the effects without over-correction or 1465 
thrombin generation.475 Andexanet alpha, a modified recombinant human factor Xa that lacks enzymatic 1466 
activity, reverses the anticoagulant activity of apixaban and rivaroxaban in healthy probands within minutes 1467 
after administration and for the duration of infusion, with a transient increase in markers of coagulation activity 1468 
of uncertain clinical relevance.508 Another agent under development is ciraparantag (PER977), an antidote 1469 
targeted to reverse both direct thrombin and factor Xa inhibitors as well as the indirect inhibitor enoxaparin.509 1470 
The clinical usefulness of these specific antidotes needs further evaluation. 1471 
 1472 
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Figure 11 Management of active bleeding in patients receiving anticoagulation.1473 
 1474 
INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; 1475 
PCC = prothrombin complex concentrates; FFP = four-factor prothrombin complex concentrates; VKA = 1476 
vitamin K antagonist. 1477 
 1478 
9.6.2. Oral anticoagulation in atrial fibrillation patients at risk of or having a 1479 
bleeding event 1480 
While anticoagulation therapy should be paused to control active bleeding, absolute contraindications to long-1481 
term OAC after a bleeding episode are rare. When nuisance bleeds are the reason to stop OAC, a change from 1482 
one anticoagulant to another seems reasonable. Many causes or triggers of major bleeding events can be treated 1483 
and/or eliminated, including uncontrolled hypertension, gastrointestinal ulcers, and intracranial aneurysms. 1484 
Reinitiation of anticoagulation after a bleeding event is often clinically justified.460, 510 Difficult decisions, 1485 
including the discontinuation and recommencement of OAC, should be taken by a multidisciplinary team, 1486 
balancing estimated risk of recurrent stroke and bleeding, and considering the bleeding risk of different stroke 1487 
prevention therapies. LAA exclusion or occlusion might be an alternative in selected patients.  1488 
 1489 
Recommendations for management of bleeding 1490 
Recommendations  Class a Level b Refs c 
Blood pressure control in anticoagulated patients with 
hypertension should be considered to reduce the risk of 
bleeding 
IIa B 511 
When dabigatran is used, a reduced dose of dabigatran 
(110 mg twice daily) may be considered in patients > 75 
years to reduce the risk of bleeding 
IIb B 490 
In patients at high risk of gastrointestinal bleeding, a 
VKA or another NOAC should be preferred over 
dabigatran 150 mg twice daily, rivaroxaban 20 mg once 
daily, or edoxaban 60 mg once daily 
IIa B 321, 396, 402, 
405, 490, 492, 
493, 512 
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AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation; 1491 
VKA = vitamin K antagonist 1492 
aClass of recommendation. 1493 
bLevel of evidence. 1494 
cReference(s) supporting recommendations. 1495 
 1496 
9.7. Combination therapy with oral anticoagulants and antiplatelets  1497 
Approximately 15% of AF patients in contemporary trials513 and registries514-516 have a history of myocardial 1498 
infarction. Between 5% and 15% of AF patients will require stenting at some point in their lives. This scenario 1499 
requires careful consideration of antithrombotic therapy, balancing bleeding risk, stroke risk, and risk of acute 1500 
coronary syndromes (ACS).516 Co-prescription of OAC with antiplatelet therapy, in particular triple therapy, 1501 
increases the absolute risk of major haemorrhage.445, 517, 518 A recent meta-analysis involving 30,866 patients 1502 
with a recent ACS evaluated the effects of adding NOAC therapy to single (4135 patients) or dual (26,731 1503 
patients) antiplatelet therapy.519 The addition of a NOAC increased the bleeding risk by 79–134%, while 1504 
reducing recurrent ischaemic events only marginally in patients without AF. OAC monotherapy, and not 1505 
combination therapy with antiplatelets, is recommended in AF patients with stable CAD but without an ACS 1506 
and/or coronary intervention in the previous 12 months. In patients treated for ACS and in those receiving a 1507 
coronary stent, short-term triple combination therapy of OAC, clopidogrel, and aspirin seems warranted (Figure 1508 
12).  1509 
Advice and treatment to avoid alcohol excess should be 
considered in all AF patients considered for OAC 
IIa C  
Genetic testing before the initiation of VKA therapy is not 
recommended. 
III (no benefit) B 497 
Reinitiation of OAC after a bleeding event should be 
considered in all eligible patients by a multidisciplinary 
AF team, considering different anticoagulants and 
stroke-prevention interventions, improved management 
of factors that contributed to bleeding, and stroke risk 
IIa B 460 
In AF patients with severe active bleeding events, it is 
recommended to interrupt OAC therapy until the 
underlying cause is resolved 
I C  
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 1510 
Figure 12 Antithrombotic therapy after an ACS in AF patients requiring anticoagulation. 1511 
ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K 1512 
antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention. 1513 
aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients, especially those not 1514 
receiving a stent or patients at a longer time from the index event.  1515 
bOAC plus single antiplatelet.  1516 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high 1517 
risk of coronary events. 1518 
 1519 
 1520 
9.7.1. Antithrombotic therapy after acute coronary syndromes and percutaneous 1521 
coronary intervention in patients requiring oral anticoagulation 1522 
The optimal combination antithrombotic therapy or duration of combination therapy for AF patients undergoing 1523 
percutaneous coronary intervention is not known, but the continued bleeding risk suggests a short duration. 1524 
Expert consensus,520 reviewed and reconsidered by this Task Force, suggests the following principles: AF 1525 
patients at risk for stroke, patients with mechanical valves, and patients with recent or recurrent deep vein 1526 
thrombosis or pulmonary embolism should continue OAC during and after stenting. In general, a short period of 1527 
triple therapy (OAC, aspirin, clopidogrel) is recommended, followed by a period of dual therapy (OAC plus a 1528 
single antiplatelet) (Figure 13). When a NOAC is used, the consensus recommendation is that the lowest dose 1529 
effective for stroke prevention in AF should be considered. Dose reduction beyond the dosing regimens tested in 1530 
the phase III trials is not currently recommended, and awaits assessment in ongoing controlled trials. The 1531 
combination of aspirin, clopidogrel, and low-dose rivaroxaban (2.5 mg twice daily) is not recommended for 1532 
stroke prevention in AF.521 1533 
 The use of prasugrel or ticagrelor as part of triple therapy should be avoided unless there is a clear need 1534 
for these agents (e.g. stent thrombosis on aspirin plus clopidogrel), given the lack of evidence and the greater 1535 
risk of major bleeding compared with clopidogrel.522, 523 Ongoing trials will inform about such combination 1536 
therapies in the future. 1537 
 The omission of aspirin while maintaining clopidogrel and OAC has been evaluated in the WOEST 1538 
(What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary 1539 
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StenTing) trial, in which 573 anticoagulated patients undergoing percutaneous coronary intervention (70% with 1540 
AF) were randomized to either dual therapy with OAC and clopidogrel (75 mg once daily) or to triple therapy 1541 
with OAC, clopidogrel, and aspirin.524 Bleeding was lower in the dual versus triple therapy arm, driven by fewer 1542 
minor bleeding events. The rates of myocardial infarction, stroke, target vessel revascularization, and stent 1543 
thrombosis did not differ (albeit with low event numbers), but all-cause mortality was lower in the dual therapy 1544 
group at 1 year (2.5% vs. triple 6.4%). Although the trial was too small to assess ischaemic outcomes, dual 1545 
therapy with OAC and clopidogrel may emerge in the future as an alternative to triple therapy in patients with 1546 
AF and ACS and/or coronary intervention.525  1547 
 1548 
Figure 13 Antithrombotic therapy after percutaneous intervention in AF patients requiring anticoagulation. 1549 
ACS = acute coronary syndrome; AF = atrial fibrillation; OAC = oral anticoagulation (using vitamin K 1550 
antagonists or non-vitamin K antagonist oral anticoagulants); PCI = percutaneous coronary intervention. 1551 
aDual therapy with OAC and aspirin or clopidogrel may be considered in selected patients.  1552 
bOAC plus single antiplatelet.  1553 
cDual therapy with OAC and an antiplatelet agent (aspirin or clopidogrel) may be considered in patients at high 1554 
risk of coronary events. 1555 
 1556 
Recommendations for combination therapy with oral anticoagulants and antiplatelets 1557 
 1558 
Recommendations Class a Level b Refs c 
After elective coronary stenting for stable coronary artery disease in 
AF patients at risk of stroke, combination triple therapy with aspirin, 
clopidogrel and an oral anticoagulant should be considered for 1 month 
to prevent recurrent coronary and cerebral ischaemic events 
IIa B 522, 524 
After an ACS with stent implantation in AF patients at risk of stroke, 
combination triple therapy with aspirin, clopidogrel, and an oral 
anticoagulant should be considered for 1–6 months to prevent recurrent 
coronary and cerebral ischaemic events 
IIa C 520 
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After an ACS without stent implantation in AF patients at risk of 
stroke, dual therapy with an oral anticoagulant and aspirin or 
clopidogrel should be considered for up to 12 months to prevent 
recurrent coronary and cerebral ischaemic events 
IIa C  
The duration of combination antithrombotic therapy, especially triple 
therapy, should be kept to a limited period, balancing the estimated risk 
of recurrent coronary events and bleeding 
IIa B 520 
Dual therapy with any oral anticoagulant plus clopidogrel 75 mg/day 
may be considered as an alternative to initial triple therapy with aspirin 
in selected patients. 
IIb C 524, 525 
ACS = acute coronary syndromes; AF = atrial fibrillation 1559 
aClass of recommendation. 1560 
bLevel of evidence. 1561 
cReference(s) supporting recommendations. 1562 
 1563 
10 Rate control therapy in AF 1564 
Rate control is an integral part of the management of AF patients, and is often sufficient to improve AF-related 1565 
symptoms. Compared with stroke prevention and rhythm control, very little robust evidence exists to inform the 1566 
best type and intensity of rate control treatment, with the majority of data derived from short-term crossover 1567 
trials and observational studies.41, 526-528 Pharmacological rate control can be achieved for acute or long-term rate 1568 
control with beta-blockers, digoxin, the calcium channel blockers diltiazem and verapamil, or combination 1569 
therapy (Table 15). A number of antiarrhythmic drugs also have rate-limiting properties (amiodarone, 1570 
dronedarone, sotalol, and to some extent propafenone), but they should only be used in patients needing rhythm 1571 
control therapy (see Chapter 10). 1572 
 1573 
10.1. Acute rate control 1574 
In the setting of acute new-onset AF, patients are often in need of heart rate control. Physicians should evaluate 1575 
underlying causes of elevated heart rate, such as infection, endocrine imbalance, anaemia, and pulmonary 1576 
embolism. For acute rate control, beta-blockers and diltiazem/verapamil are preferred over digoxin because of 1577 
their rapid onset of action and effectiveness at high sympathetic tone.528-532 The choice of drug (Table 15) and 1578 
target heart rate will depend on patient characteristics, symptoms, LVEF and haemodynamics, but a lenient 1579 
initial approach to heart rate seems acceptable. Combination therapy may be required (Figure 14). In patients 1580 
with evidence of HFrEF, beta-blockers, digitalis (digoxin or digitoxin), or their combination should be used,218, 1581 
533 as diltiazem and verapamil can have negative inotropic effects in patients with LVEF < 40%.222, 534, 535 In 1582 
critically ill patients and those with severely impaired LV systolic function, intravenous amiodarone can be used 1583 
where excess heart rate is leading to haemodynamic instability.536-538 Urgent cardioversion should be considered 1584 
in unstable patients (see Chapter 10.2). 1585 
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 1586 
Figure 14 Acute heart rate control of AF.  1587 
See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.  1588 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction. 1589 
 1590 
10.2. Long-term pharmacological rate control  1591 
10.2.1. Beta-blockers 1592 
Beta-adrenoreceptor blocker monotherapy is often the first-line rate-controlling agent,539 largely based on 1593 
observations of better acute heart rate control than digoxin. Interestingly, the prognostic benefit of beta-blockers 1594 
seen in HFrEF patients with sinus rhythm is lost in those with AF. In an individual patient-level meta-analysis 1595 
of RCTs, beta-blockers did not reduce all-cause mortality compared to placebo in those with AF at baseline (HR 1596 
0.97; 95% CI 0.83–1.14; P = 0.73), whereas there was a clear benefit in patients with sinus rhythm (HR 0.73; 1597 
95% CI 0.67–0.80; P < 0.001).23 The study, which included 3066 participants with HFrEF and AF, showed 1598 
consistency across all subgroups and outcomes, with no heterogeneity between the 10 RCTs included (I2 = 0%). 1599 
Despite this lack of prognostic benefit in HFrEF, this Task Force still considers beta-blockers as a useful first-1600 
line rate control agent across all AF patients, based on the potential for symptomatic and cardiac function 1601 
improvement as a result of rate control, the lack of harm from published studies, and the good tolerability profile 1602 
across all ages in sinus rhythm and in AF.23, 540 1603 
 1604 
10.2.2. Non-dihydropyridine calcium channel blockers 1605 
Verapamil or diltiazem provides reasonable rate control in AF patients.541 They should be avoided in patients 1606 
with HFrEF because of their negative inotropic effects.222, 534, 535 Verapamil or diltiazem can improve 1607 
arrhythmia-related symptoms,526 in comparison with beta-blockers, which reduced exercise capacity and 1608 
increased B-type natriuretic peptide in one small trial of low-risk patients with preserved LVEF.542  1609 
 1610 
10.2.3. Digitalis 1611 
Cardiac glycosides such as digoxin and digitoxin have been in use for over two centuries, although prescriptions 1612 
have been declining steadily over the past 15 years.543 In the randomized Digitalis Investigation Group (DIG) 1613 
trial, digoxin had no effect on mortality compared to placebo in HFrEF patients in sinus rhythm (RR 0.99; 95% 1614 
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CI 0.91–1.07), but reduced hospital admissions (RR 0.72; 95% CI 0.66–0.79).544, 545 There have been no head-1615 
to-head RCTs of digoxin in AF patients.546 Observational studies have associated digoxin use with excess 1616 
mortality in AF patients,547-549 but this association is likely due to selection and prescription biases rather than 1617 
harm caused by digoxin,550-553 particularly as digoxin is commonly prescribed to sicker patients.225 In a 1618 
crossover mechanistic trial of 47 patients with HFrEF and AF, there were no differences in heart rate, blood 1619 
pressure, walking distance, or LVEF between carvedilol and digoxin, although beta-blockers did result in higher 1620 
B-type natriuretic peptide levels, combination carvedilol/digoxin improved LVEF, and digoxin withdrawal 1621 
reduced LVEF.554 Comparisons with other rate control therapies are based on small, short-duration studies that 1622 
identify no or marginal differences in exercise capacity, quality of life, or LVEF compared to digoxin.526, 554-558 1623 
Lower doses of digoxin (≤ 250 µg once daily), corresponding to serum digoxin levels of 0.5–0.9 ng/mL, may be 1624 
associated with better prognosis.225 1625 
 1626 
10.2.4. Amiodarone 1627 
Amiodarone can be useful for rate control as a last resort. The wide array of extracardiac adverse effects 1628 
associated with amiodarone renders it a reserve agent in patients whose heart rate cannot be controlled with 1629 
combination therapy (e.g. beta-blocker or verapamil/diltiazem combined with digoxin). 1630 
  1631 
In summary, there is equipoise for the use of different rate control agents in AF. The choice of beta-blocker, 1632 
diltiazem/verapamil, digoxin, or combination therapy should be made on an individual basis, after consideration 1633 
of patient characteristics and patient preference. All available therapies have the potential for adverse effects and 1634 
patients should initially be treated with a low dose and uptitrated to achieve symptom improvement. In practice, 1635 
achieving a heart rate < 110 bpm will often require combination therapy (Figure 15). The benefit of different 1636 
rate control strategies on symptoms, quality of life, and other intermediate outcomes is under investigation.559  1637 
 1638 
Figure 15 Long-term heart rate control of AF.  1639 
See Table 15 for medication dosage. Digitoxin is a suitable alternative to digoxin, where available.  1640 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction. 1641 
 1642 
10.3. Heart rate targets in atrial fibrillation 1643 
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The optimal heart rate target in AF patients is unclear. The RACE (Rate Control Efficacy in Permanent Atrial 1644 
Fibrillation) II study randomized 614 patients with permanent AF to either a target heart rate < 80 bpm at rest 1645 
and < 110 bpm during moderate exercise, or to a lenient heart rate target of < 110 bpm. There was no difference 1646 
in a composite of clinical events (14.9% in the strict rate control group, 12.9% in the lenient group),560 NYHA 1647 
class, or hospitalizations.560, 561 Similar results were found in a pooled analysis of the AFFIRM (Atrial 1648 
Fibrillation Follow-up Investigation of Rhythm Management) and RACE trials (1091 participants), albeit with 1649 
smaller heart rate differences and without randomization.562 It is worthwhile to note that many ‘adequately rate-1650 
controlled’ patients (resting heart rate 60–100 bpm) are severely symptomatic, calling for additional 1651 
management.194 Nonetheless, lenient rate control is an acceptable initial approach, regardless of heart failure 1652 
status, unless symptoms call for stricter rate control.  1653 
 1654 
10.4. Atrioventricular node ablation and pacing  1655 
Ablation of the atrioventricular node/His bundle and implantation of a VVI pacemaker can control ventricular 1656 
rate when medications fail to control rate and symptoms. It is a relatively simple procedure with a low 1657 
complication rate and low long-term mortality risk,563, 564 especially when the pacemaker is implanted a few 1658 
weeks before the AV nodal ablation and the initial pacing rate after ablation is set at 70–90 bpm.565, 566 The 1659 
procedure does not worsen LV function567 and may even improve LVEF in selected patients.568-570 In some 1660 
patients in heart failure treated with biventricular pacing (cardiac resynchronization therapy), AF can 1661 
terminate,571 although such a ‘rhythm control’ effect of cardiac resynchronization therapy is likely to be small 1662 
and clearly needs confirmation.572 AV nodal ablation renders patients pacemaker-dependent for the rest of their 1663 
lives, limiting AV nodal ablation and pacing to patients whose symptoms cannot be managed by rate controlling 1664 
medication or by reasonable rhythm control interventions. The choice of pacing therapy (right ventricular or 1665 
biventricular pacing with or without an implantable defibrillator) will depend on individual patient 1666 
characteristics, including LVEF.573, 574  1667 
 1668 
Recommendations for rate control 1669 
Recommendations Class a Level b Refs c 
Beta-blocker, digoxin, diltiazem, or verapamil are recommended 
to control heart rate in AF patients with LVEF ≥ 40% I B 
225, 526, 
528, 531, 
532, 541, 
555, 575  
Beta-blocker and/or digoxin are recommended to control heart 
rate in AF patients with LVEF < 40%  I B 
23, 225, 526, 
533, 554, 
575, 576 
Combination therapy comprising different rate controlling agents 
should be considered if a single agent does not achieve the 
necessary heart rate target 
IIa C 23, 554, 577 
In cases of haemodynamic instability or severe depression in 
LVEF, amiodarone may be considered for acute control of heart 
rate 
Ilb B 536-538 
In patients with permanent AF (i.e. where no attempt to restore 
sinus rhythm is planned), antiarrhythmic drugs should not 
routinely be used for rate control 
III (harm) A 41, 578, 579 
A resting heart rate of < 110 bpm (i.e. lenient rate control) should 
be considered as the initial heart rate target for rate control 
therapy 
IIa B 560 
Rhythm rather than rate control strategies should be considered 
as the preferred management in pre-excited AF and AF during 
pregnancy 
IIa C  
Atrioventricular node ablation should be considered to control 
heart rate in patients unresponsive or intolerant to intensive rate 
and rhythm control therapy, accepting that these patients will 
become pacemaker dependent 
IIa B 
184, 564, 
569 
AF = atrial fibrillation; bpm = beats per minute; LVEF = left ventricular ejection fraction.  1670 
Digitoxin is a suitable alternative to digoxin, where available. In patients with heart failure with reduced ejection 1671 
fraction (LVEF < 40%), recommended beta-blockers are bisoprolol, carvedilol, long-acting metoprolol, and 1672 
nebivolol. 1673 
a Class of recommendation. 1674 
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b Level of evidence. 1675 
c Reference(s) supporting recommendations. 1676 
 1677 
Table 15 Rate control therapy in AF 1678 
Therapy Acute 
intravenous 
rate control 
Long-term oral 
rate control 
Side-effect profile Comments 
Beta-blockersa 
 Bisoprolol Not available 1.25–20 mg once 
daily or split 
Most common 
reported adverse 
symptoms are 
lethargy, headache, 
peripheral oedema, 
upper respiratory tract 
symptoms, 
gastrointestinal upset, 
and dizziness. 
Adverse effects 
include bradycardia, 
atrioventricular block, 
and hypotension 
Bronchospasm is 
rare – in cases of 
asthma, recommend 
beta-1 selective 
agents (avoid 
carvedilol). 
Contraindicated in 
acute cardiac failure 
and a history of 
severe 
bronchospasm 
 
 Carvedilol Not available 3.125–50 mg 
twice daily 
 Metoprolol 2.5–10 mg 
intravenous 
bolus (repeated 
as required) 
100–200 mg total 
daily dose 
(according to 
preparation) 
Nebivolol N/A 2.5–10 mg once 
daily or split 
Esmolol 0.5 mg 
intravenous 
bolus over 1 
min; then 0.05–
0.25 mcg/kg/min 
 
Calcium-channel blockers 
 Diltiazem 15–25 mg 
intravenous 
bolus (repeated 
as required) 
60 mg three 
times daily up to 
360 mg total daily 
dose (120–360 
mg once daily 
modified release) 
Most common 
reported adverse 
symptoms are 
dizziness, malaise, 
lethargy, headache, 
hot flushes, 
gastrointestinal upset, 
and oedema. Adverse 
effects include 
bradycardia, 
atrioventricular block, 
and hypotension 
(prolonged 
hypotension possible 
with verapamil) 
Use with caution in 
combination with 
beta-blockers. 
Reduce dose with 
hepatic impairment 
and start with smaller 
dose in renal 
impairment. 
Contraindicated in LV 
failure with 
pulmonary 
congestion or LVEF 
< 40% 
 Verapamil 2.5–10 mg 
intravenous 
bolus (repeated 
as required) 
40–120 mg three 
times daily (120–
480 mg once 
daily modified 
release) 
Cardiac glycosides 
 Digoxin 0.5 mg 
intravenous 
bolus (0.75–1.5 
mg over 24 h in 
divided doses) 
0.0625–0.25 mg 
daily dose 
Most common 
reported adverse 
symptoms are 
gastrointestinal upset, 
dizziness, blurred 
vision, headache, and 
rash. In toxic states 
(serum levels > 2 
ng/mL), digoxin is 
proarrhythmic and 
can aggravate heart 
failure, particularly 
with coexistent 
hypokalaemia 
High plasma levels 
associated with 
increased risk of 
death. Check renal 
function before 
starting and adapt 
dose in patients with 
CKD. 
Contraindicated in 
accessory 
conducting 
pathways, ventricular 
tachycardia, and 
hypertrophic 
cardiomyopathy with 
outflow tract 
obstruction 
 Digitoxin  
  
0.4–0.6 mg 
intravenous 
bolus 
0.05–0.3 mg 
daily dose 
Specific indications 
 Amiodarone 300 mg 200 mg daily Hypotension, Suggested as 
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intravenously 
diluted in 250 
mL 5% dextrose 
over 30–60 min 
(preferably via 
central venous 
cannula)b 
bradycardia, nausea, 
QT prolongation, 
pulmonary toxicity, 
skin discolouration, 
thyroid dysfunction, 
corneal deposits, and 
cutaneous reaction 
with extravasation 
adjunctive therapy in 
patients where heart 
rate control cannot 
be achieved using 
combination therapy 
AF = atrial fibrillation; CKD = chronic kidney disease; LV = left ventricular; LVEF = left ventricular ejection 1679 
fraction.  1680 
aA number of other beta-blockers are also available, but are not recommended as specific rate control therapy in 1681 
AF. These include atenolol (25–100 mg once daily with a short biological half-life), propranolol (non-selective, 1682 
1 mg over 1 min and repeat up to 3 mg at 2-min intervals [acute] or 10–40 mg three times daily [long-term]), or 1683 
labetalol (non-selective, 1–2 mg/min [acute]). 1684 
bIf ongoing requirement for amiodarone, follow with 900 mg intravenous over 24 hours diluted in 500–1000 mL 1685 
via a central venous cannula. 1686 
 1687 
11 Rhythm control therapy in atrial fibrillation 1688 
Restoring and maintaining sinus rhythm is an integral part of AF management. Antiarrhythmic drugs 1689 
approximately double the rate of sinus rhythm compared with placebo.580-584 Catheter ablation or combination 1690 
therapy is often effective when antiarrhythmic drugs fail.226, 585-587 Although many clinicians believe that 1691 
maintaining sinus rhythm can improve outcomes in AF patients,588 all trials that have compared rhythm control 1692 
to rate control (with appropriate anticoagulation) therapy have resulted in neutral outcomes.41, 578, 579, 582, 589-593 1693 
Whether modern rhythm control management involving catheter ablation, combination therapy, and early 1694 
therapy leads to a reduction in major cardiovascular events (e.g. stroke and cardiovascular death) is currently 1695 
under investigation (e.g. in the EAST [Early treatment of Atrial fibrillation for Stroke prevention Trial] – 1696 
AFNET 440 and CABANA [Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation Trial]594 1697 
trials). For now, rhythm control therapy is indicated to improve symptoms in AF patients who remain 1698 
symptomatic on adequate rate control therapy. 1699 
 1700 
11.1. Acute restoration of sinus rhythm 1701 
11.1.1. Antiarrhythmic drugs for acute restoration of sinus rhythm 1702 
(‘pharmacological cardioversion’) 1703 
Antiarrhythmic drug can restore sinus rhythm in patients with AF (pharmacological cardioversion) as 1704 
shown in small controlled trials, meta-analyses,41, 584, 595, 596 and in a few larger controlled trials.597-605 1705 
Outside of Europe, dofetilide is available and can convert recent-onset AF.606 Pharmacological cardioversion 1706 
restores sinus rhythm in approximately 50% of patients with recent-onset AF (Table 16).607-609 In the short term, 1707 
electrical cardioversion restores sinus rhythm quicker and more effectively than pharmacological cardioversion 1708 
and is associated with shorter hospitalization.609-613 Pharmacological cardioversion, conversely, does not require 1709 
sedation or fasting (Figure 16).  1710 
 Flecainide and propafenone are effective for pharmacological cardioversion,595, 602-605, 614, 615 but their 1711 
use is restricted largely to patients without structural heart disease. Ibutilide is an alternative where available, 1712 
but carries a risk of torsades de pointes.615 Vernakalant602-605 can be given to patients with mild heart failure 1713 
(NYHA Class I or II), including those with ischaemic heart disease, provided they do not present with 1714 
hypotension or severe aortic stenosis.616-618 Amiodarone can be used in patients with heart failure and in patients 1715 
with ischaemic heart disease (although patients with severe heart failure were excluded in most of the AF 1716 
cardioversion trials).596 Amiodarone also slows heart rate by 10–12 bpm after 8–12 hours when given 1717 
intravenously.596 Both amiodarone and flecainide appear more effective than sotalol in restoring sinus 1718 
rhythm.600, 601, 619 1719 
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 1720 
Figure 16 Rhythm control management of acute AF. 1721 
AF = atrial fibrillation; HFmrEF = heart failure with mid-range ejection fraction; HFrEF = heart failure with 1722 
reduced ejection fraction. 1723 
aIbutilide should not be used in patients with long QT interval. 1724 
 1725 
11.1.2. ‘Pill in the pocket’ cardioversion performed by patients 1726 
In selected patients with infrequent symptomatic episodes of paroxysmal AF, a single bolus of oral flecainide 1727 
(200–300 mg) or propafenone (450–600 mg) can be self-administered by the patient at home (‘pill in the pocket’ 1728 
therapy) to restore sinus rhythm, after safety has been established in the hospital setting.620 This approach seems 1729 
marginally less effective than hospital-based cardioversion,621 but is practical and provides control and 1730 
reassurance to selected patients.  1731 
 1732 
Table 16 Antiarrhythmic drugs for pharmacological cardioversion 1733 
Drug Route First dose Follow-up 
dose 
Risks Referenc
es 
Flecainide Oral 
 
200–300 mg 
 
 
 
 
N/A 
Avoid in patients with IHD and/or 
significant structural heart disease. 
Hypotension, atrial flutter with 1:1 
conduction, QT prolongation 
595, 598 
IV 1.5–2 mg/kg 
over 10 min 
Amiodarone IVa 5–7 mg/kg over 
1–2 h 
50 mg/h to a 
maximum 
of 1.0 g 
over 24 h 
Phlebitis, hypotension, 
bradycardia/AV block. Will slow 
ventricular rate. 
Delayed conversion to sinus rhythm 
(8–12 h) 
596-601  
Propafenone IV 
 
1.5–2 mg/kg 
over 10 min 
 
 Avoid in patients with IHD and/or 
significant structural heart disease. 
Hypotension, atrial flutter with 1:1 
622-625 
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Oral 450–600 mg conduction, QRS prolongation (mild) 
Ibutilideb IV 1 mg over 10 
min 
1 mg over 
10 min after 
waiting for 
10 min 
Avoid in patients with QT 
prolongation, hypokalemia, severe 
LVH, or low ejection fraction. 
QT prolongation, polymorphic 
ventricular tachycardia/torsades de 
pointes (3–4% of patients). Will slow 
ventricular rate 
614, 615 
Vernakalant IV 3 mg/kg over 10 
min 
2 mg/kg 
over 10 min 
after 
waiting for 
15 min 
Avoid in patients with systolic blood 
pressure < 100 mmHg, recent (< 30 
days) ACS, NYHA Class III and IV 
heart failure, QT interval 
prolongation (uncorrected QT > 440 
ms), and severe aortic stenosis. 
Hypotension, non-sustained 
ventricular arrhythmias, QT and 
QRS prolongation 
602-605, 618 
ACS = acute coronary syndromes; IHD = ischaemic heart disease; IV = intravenous; LVH = left ventricular 1734 
hypertrophy; NYHA = New York Heart Association. 1735 
aUse a large peripheral vessel and change to oral amiodarone within 24 h of IV (central line) administration.  1736 
bIbutilide is only available in selected European countries. 1737 
 1738 
11.1.3. Electrical cardioversion 1739 
Synchronized direct current electrical cardioversion quickly and effectively converts AF to sinus rhythm and is 1740 
the method of choice in severely haemodynamically compromised patients with new-onset AF (Figure 16).626-1741 
628 Electrical cardioversion can be performed safely in sedated patients treated with intravenous midazolam 1742 
and/or propofol. Continuous monitoring of blood pressure and oximetry during the procedure is important.629 1743 
Skin burns may occasionally be observed. Intravenous atropine or isoproterenol or temporary transcutaneous 1744 
pacing should be available to mitigate post-cardioversion bradycardia. Biphasic defibrillators are more effective 1745 
than monophasic waveforms, and have become industry standard.626, 628 Anterior–posterior electrode positions 1746 
generate a stronger shock field in the left atrium than anterolaterally positioned electrodes, and restore sinus 1747 
rhythm more effectively. 626, 627, 630  1748 
 Pretreatment with amiodarone (requiring a few weeks of therapy),631, 632 sotalol,631 ibutilide,633 or 1749 
vernakalant634 can improve efficacy of electrical cardioversion, and similar effects are likely for flecainide584 1750 
and propafenone.635 Beta-blockers,636 verapamil, diltiazem,637-639 and digoxin640, 641 do not reliably terminate AF 1751 
or facilitate electrical cardioversion. When antiarrhythmic drug therapy is planned to maintain sinus rhythm 1752 
after cardioversion, it seems prudent to start therapy 1–3 days before cardioversion (amiodarone: a few weeks) 1753 
to promote pharmacological conversion and to achieve effective drug levels.584, 601 1754 
 1755 
11.1.4. Anticoagulation in patients undergoing cardioversion  1756 
Cardioversion carries an inherent risk of stroke in non-anticoagulated patients,642 which is reduced substantially 1757 
by the administration of anticoagulation.643 Immediate initiation of anticoagulation is important in all patients 1758 
scheduled for cardioversion.644-646 Patients who have been in AF for longer than 48 hours should start OAC at 1759 
least 3 weeks before cardioversion and continue it for 4 weeks afterwards (in patients without a need for long-1760 
term anticoagulation), and continue it indefinitely in patients at risk of stroke. This practice has never been 1761 
evaluated in controlled trials, but seemed safe in a large observational data set from Finland.647 When early 1762 
cardioversion is desired, TOE can exclude the majority of left atrial thrombi, allowing immediate 1763 
cardioversion.648, 649 Ongoing studies will inform about the safety and efficacy of newly initiated anticoagulation 1764 
using NOACs in patients scheduled for electrical cardioversion. 1765 
 1766 
11.2. Long-term antiarrhythmic drug therapy 1767 
The aim of antiarrhythmic drug therapy is improvement in AF-related symptoms.41, 580 Hence, the decision to 1768 
initiate long-term antiarrhythmic drug therapy needs to balance symptom burden, possible adverse drug 1769 
reactions, and patient preferences. The principles of antiarrhythmic drug therapy outlined in the 2010 ESC AF 1770 
guidelines369 are still relevant and should be observed: 1771 
1. Treatment is aimed at reducing AF-related symptoms; 1772 
2. Efficacy of antiarrhythmic drugs to maintain sinus rhythm is modest; 1773 
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3. Clinically successful antiarrhythmic drug therapy may reduce rather than eliminate the recurrence of 1774 
AF; 1775 
4. If one antiarrhythmic drug ‘fails’, a clinically acceptable response may be achieved with another agent; 1776 
5. Drug-induced proarrhythmia or extra-cardiac side-effects are frequent; 1777 
6. Safety rather than efficacy considerations should primarily guide the choice of antiarrhythmic drug. 1778 
 1779 
Antiarrhythmic drug therapy approximately doubles sinus rhythm maintenance compared with no therapy.580 1780 
There is no appreciable effect on mortality or cardiovascular complications, but rhythm control therapy can 1781 
slightly increase the risk of hospitalizations (often for AF).41, 578, 579, 582, 589-593 To reduce the risk of side-1782 
effects,201, 580 a shorter duration of antiarrhythmic drug therapy seems desirable. As an example, short-term 1783 
treatment (4 weeks) with flecainide for 4 weeks after cardioversion of AF was well-tolerated and prevented 1784 
most (80%) AF recurrences when compared with long-term treatment.584 Short-term antiarrhythmic drug 1785 
therapy is also used to avoid early AF recurrences after catheter ablation650 and may be reasonable in patients 1786 
deemed at increased risk of antiarrhythmic drug side-effects or in those with a low perceived risk of recurrent 1787 
AF.  1788 
 In addition to antiarrhythmic drug therapy and catheter ablation (see Section 10.3), management of 1789 
concomitant cardiovascular conditions can reduce symptom burden in AF and facilitate maintenance of sinus 1790 
rhythm.203, 204, 296, 312 This includes weight reduction, blood pressure control, heart failure treatment, increasing 1791 
cardiorespiratory fitness, and other measures (see Chapter 6). 1792 
 1793 
11.2.1. Selection of antiarrhythmic drugs for long-term therapy: Safety first!  1794 
Usually, the safety of antiarrhythmic drug therapy determines the initial choice of antiarrhythmic drugs (Figure 1795 
17). The following major antiarrhythmic drugs are available to prevent AF: 1796 
 1797 
Amiodarone is an effective multichannel blocker, reduces ventricular rate, and is safe in patients with heart 1798 
failure.582, 651 Torsades de pointes proarrhythmia can occur, and QT interval and TU waves should be monitored 1799 
on therapy (see Table 17).652 Amiodarone often causes extracardiac side-effects, especially on long-term 1800 
therapy,653, 654 rendering it a second-line treatment in patients who are suitable for other antiarrhythmic drugs. 1801 
Amiodarone appears less suitable to episodic short-term therapy (unless after catheter ablation),655 probably 1802 
because of its long biological half-life. 1803 
 1804 
Dronedarone maintains sinus rhythm, reduces ventricular rate, and prevents cardiovascular hospitalizations 1805 
(mostly due to AF) and cardiovascular death in patients with paroxysmal or persistent AF or flutter who had at 1806 
least one relevant cardiovascular comorbidity.583, 588, 656 Dronedarone increases mortality in patients with 1807 
recently decompensated heart failure (with or without AF)657 and in patients with permanent AF in whom sinus 1808 
rhythm is not restored.658 Dronedarone moderately increases serum creatinine, reflecting a reduction in 1809 
creatinine excretion rather than a decline in kidney function.659  1810 
 1811 
Flecainide and propafenone are effective in preventing recurrent AF.581, 584, 620 They should only be used in 1812 
patients without significant ischaemic heart disease or heart failure to avoid the risk of life-threatening 1813 
ventricular arrhythmias.660 High ventricular rates resulting from the conversion of AF into atrial flutter with 1:1 1814 
conduction by flecainide or propafenone can be prevented by preadministering a beta-blocker, verapamil, or 1815 
diltiazem. 1816 
 1817 
Quinidine and disopyramide have been associated with an increase in all-cause mortality (OR 2.39; 95% CI 1818 
1.03–5.59; number needed to harm 109; 95% CI 34–4985) at 1-year follow-up,580, 661 likely due to ventricular 1819 
arrhythmias (torsades de pointes).580, 661 Although this proarrhythmic effect is more common at higher doses, 1820 
they are less commonly used for rhythm control in AF. Disopyramide may be useful in ‘vagally mediated’ AF 1821 
(e.g. AF occurring in athletes and/or during sleep76), and has been shown to reduce LV outflow gradient and 1822 
improve symptoms in patients with hypertrophic cardiomyopathy.662-664  1823 
 1824 
Sotalol has a relevant risk of torsades de pointes (1% in the Prevention of Atrial Fibrillation After Cardioversion 1825 
[PAFAC] trial118). Its d-enantiomer is associated with an increased mortality compared to placebo in patients 1826 
with LV dysfunction post-myocardial infarction,665 probably due to ventricular arrhythmias (OR 2.47; 95% CI 1827 
1.2–5.05; number needed to harm 166; 95% CI 61–1159).580, 665 On the other hand, d,l sotalol has been used in 1828 
AF patients without safety signals in two controlled trials.581, 601  1829 
 1830 
Dofetilide is another potassium channel blocker that is mainly available outside of Europe. Dofetilide restores 1831 
and maintains sinus rhythm in heart failure patients666 and occasionally in patients refractory to other 1832 
antiarrhythmic drugs.667 1833 
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 1834 
Overall, it seems prudent to limit the use of quinidine, disopyramide, dofetilide, and sotalol to specific 1835 
situations. Similarly, combinations of QT-prolonging antiarrhythmic drugs should generally be avoided (Table 1836 
17). 1837 
 1838 
Figure 17 Initiation of rhythm control therapy in symptomatic patients. 1839 
AF = atrial fibrillation; HF = heart failure; LVH = left ventricular hypertrophy; 1840 
aSotalol requires careful evaluation of proarrhythmic risk. 1841 
bCatheter ablation should isolate pulmonary veins and can be performed using radiofrequency or cryoballoon 1842 
catheters.  1843 
cCatheter ablation as a first-line therapy is usually reserved for heart failure patients with tachycardiomyopathy. 1844 
dAmiodarone is a second-choice therapy in many patients because of its extracardiac side-effects. 1845 
 1846 
11.2.2. Twelve-lead electrocardiogram as a tool to identify patients at risk of 1847 
proarrhythmia 1848 
Identifying patients at risk of proarrhythmia can help to mitigate the proarrhythmic risk of antiarrhythmic 1849 
drugs.668 In addition to the clinical characteristics mentioned above, monitoring PR, QT, and QRS durations 1850 
during initiation of antiarrhythmic drug therapy can identify patients at higher risk of drug-induced 1851 
proarrhythmia on longer-term treatment.669-671 In addition, the presence of ‘abnormal TU waves’ is a sign of 1852 
imminent torsades de pointes.652 Periodic ECG analysis for proarrhythmia signs has been used successfully in 1853 
recent antiarrhythmic drug trials.118, 584, 672 Specifically, ECG monitoring was used systematically on days 1–3 in 1854 
patients receiving flecainide, propafenone, or sotalol to identify those at risk of proarrhythmia.118, 584, 601 Based 1855 
on this evaluated practice, we suggest to record an ECG in all patients before initiation of antiarrhythmic drugs. 1856 
Scheduled ECGs during the initiation period seem reasonable (Table 17).  1857 
 1858 
Table 17 Oral antiarrhythmic drugs used for maintaining sinus rhythm after cardioversion.  1859 
Page 62 of 148 ESC AF Guidelines 
 
Drug Dose Main contraindications and 
precautions 
Warning signs 
warranting 
discontinuation 
Atrioventricu
lar nodal 
slowing 
Suggested 
ECG 
monitoring 
during 
initiation 
Amiodarone 600 mg in 
divided 
doses for 4 
weeks, 400 
mg for 4 
weeks, then 
200 mg 
once daily 
Caution when using concomitant 
therapy with QT-prolonging drugs 
and in patients with sinoatrial node 
or atrioventricular node and 
conduction disease.  
The dose of VKAs and of digitalis 
should be reduced. Increased risk of 
myopathy with statins. 
Caution in patients with pre-
existing liver disease 
QT 
prolongation > 
500 ms 
10–12 bpm in 
AF 
Baseline, 1 
week, 4 
weeks 
Dronedarone 400 mg 
twice daily 
Contraindicated in NYHA class III 
or IV or unstable heart failure, 
during concomitant therapy with 
QT-prolonging drugs, or powerful 
CYP3A4 inhibitors (e.g. verapamil, 
diltiazem, azole antifungal agents), 
and when CrCl < 30 mg/mL. 
The dose of digitalis, beta-blockers, 
and of some statins should be 
reduced.  
Elevations in serum creatinine of 
0.1–0.2 mg/dL are common and do 
not reflect a decline in renal 
function. 
Caution in patients with pre-
existing liver disease 
QT 
prolongation > 
500 ms 
10–12 bpm in 
AF 
Baseline, 1 
week, 4 
weeks 
Flecainide 
 
100–150 mg 
twice daily 
 
Contraindicated if CrCl < 50 
mg/mL, liver disease, IHD, or 
reduced LVEF. 
Caution in the presence of sinoatrial 
node or atrioventricular node or 
conduction system disease. 
CYP2D6 inhibitors (e.g. fluoxetine, 
tricyclic) increase plasma 
concentration 
QRS duration 
increases > 25% 
above baseline 
None Baseline, 
day 1, day 
2–3 
Flecainide slow 
release 
200 mg 
once daily 
Propafenone 
 
150–300 mg 
three times 
daily 
 
Contraindicated in IHD or reduced 
LV ejection fraction. 
Caution in the presence of sinoatrial 
node or atrioventricular node and 
conduction system disease, renal or 
liver impairment, and asthma. 
Increases concentration of digitalis 
and warfarin 
QRS duration 
increase > 25% 
above baseline 
Slight Baseline, 
day 1, day 
2–3 
Propafenone 
SR 
225–425 mg 
twice daily 
d,l sotalol 80–160 mg 
twice daily 
Contraindicated in the presence of 
significant LV hypertrophy, systolic 
heart failure, asthma, pre-existing 
QT prolongation, hypokalaemia, 
CrCl < 50 mg/mL.  
Moderate renal dysfunction requires 
careful adaptation of dose 
QT interval 
> 500 ms, QT 
prolongation by 
> 60 ms upon 
therapy 
initiation 
Similar to 
high-dose 
blockers 
Baseline, 
day 1, day 
2–3 
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AF = atrial fibrillation; bpm = beats per minute; CrCl = creatinine clearance; ECG = electrocardiogram; IHD = 1860 
ischaemic heart disease; LV = left ventricular; LVEF = left ventricular ejection fraction; NYHA = New York 1861 
Heart Association; VKA = vitamin K antagonist. 1862 
 1863 
11.2.3. New antiarrhythmic drugs 1864 
Several compounds that inhibit the ultrarapid potassium current (IKur) and other inhibitors of atypical ion 1865 
channels are in clinical development.673-675 They are not available for clinical use at present. The antianginal 1866 
compound ranolazine inhibits potassium and sodium currents and increases glucose metabolism at the expense 1867 
of free fatty acid metabolism, thereby enhancing efficient use of oxygen.676, 677 Ranolazine was safe in patients 1868 
with non–ST-segment elevation myocardial infarction and unstable angina evaluated in the MERLIN 1869 
(Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome) 1870 
trial.678 In a post-hoc analysis of continuous ECG recordings obtained during the first 7 days after 1871 
randomization, patients assigned to ranolazine had a trend towards fewer episodes of AF than those on placebo 1872 
(75 [2.4%] vs. 55 [1.7%] patients; P = 0.08).679 In the HARMONY (A Study to Evaluate the Effect of 1873 
Ranolazine and Dronedarone When Given Alone and in Combination in Patients With Paroxysmal Atrial 1874 
Fibrillation) trial, the highest tested dose of a combination of ranolazine (750 mg twice daily) and dronedarone 1875 
(225 mg twice daily) slightly reduced AF burden in 134 subjects with paroxysmal AF and dual-chamber 1876 
pacemakers.680 Small, open-label studies suggest that ranolazine might enhance the antiarrhythmic effect of 1877 
amiodarone for cardioversion,681-683 whereas the results from a controlled trial of ranolazine and the ranolazine–1878 
dronedarone combination to prevent AHRE in pacemaker patients were ambiguous.684 At present, there is 1879 
insufficient evidence to recommend ranolazine as an antiarrhythmic drug, alone or in combination with other 1880 
antiarrhythmic drugs. Of note, the ‘funny channel blocker’ ivabradine, which is used for angina and heart 1881 
failure, increases the risk of AF.685 1882 
 1883 
11.2.4. Antiarrhythmic effects of non-antiarrhythmic drugs 1884 
ACE inhibitors or ARBs appear to prevent new-onset AF in patients with LV dysfunction and in hypertensive 1885 
patients with LV hypertrophy.219, 236, 237, 239, 246, 250, 686 Neprilysin inhibition needs to be studied further, but does 1886 
not seem to enhance this effect.224 A Danish cohort study also suggested that initial treatment of uncomplicated 1887 
hypertension with ACE inhibitors or ARBs reduces incident AF compared with other hypertensive agents.245 1888 
ARB therapy did not reduce the AF burden in patients with AF without structural heart disease.241 Thus, ACE 1889 
inhibitors or ARBs are unlikely to have a relevant direct antiarrhythmic effect. However, it might be justified to 1890 
consider adding ACE inhibitors or ARB therapy to antiarrhythmic drugs to reduce AF recurrences after 1891 
cardioversion.248, 249, 687  1892 
 Compared with placebo, beta-blockers are associated with a reduced risk of new-onset AF in patients 1893 
with reduced ejection fraction and sinus rhythm.23 Beta-blockers have also been reported to reduce symptomatic 1894 
AF recurrences,580, 636, 688 but this finding may be driven by the beneficial effect of rate control, which will 1895 
render AF more often asymptomatic. 1896 
 Perioperative statin therapy appeared to reduce the risk of postoperative AF in a number of small 1897 
RCTs689, 690; however, an adequately powered placebo-controlled trial has shown no effect of perioperative 1898 
rosuvastatin therapy on postoperative AF.691 Statin treatment does not prevent AF in other settings.692, 693 1899 
Similarly, polyunsaturated fatty acids failed to show convincing benefit.241, 694-698 The role of aldosterone 1900 
antagonists in the management of AF has not been extensively investigated in humans; although preliminary 1901 
evidence from trials of eplerenone is encouraging for primary prevention,243 at present there is no robust 1902 
evidence to make any recommendation for the use of aldosterone antagonists for secondary prevention of AF.699-1903 
701 1904 
 1905 
Recommendations for rhythm control therapy 1906 
Recommendations Class a Level b Refs d  
General recommendations 
Management of cardiovascular risk factors and avoidance of AF 
triggers should be pursued in patients on rhythm control therapy to 
facilitate maintenance of sinus rhythm 
IIa B 203, 204, 
296, 312 
Rhythm control therapy is indicated for symptom improvement in 
patients with AF 
I B 120, 586, 
601 
With the exception of AF associated with haemodynamic instability, 
the choice between electrical and pharmacological cardioversion 
IIa C  
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should be guided by patient and physician preferences 
Cardioversion of AF 
Electrical cardioversion of AF is recommended in patients with acute 
haemodynamic instability to acutely restore cardiac output 
I B 612, 702-
704 
Cardioversion of AF (either electrical or pharmacological) is 
recommended in symptomatic patients with persistent or long-
standing persistent AF as part of rhythm control therapy 
I B 584, 601, 
627, 628, 
648, 705 
Pretreatment with amiodarone, flecainide, ibutilide, or propafenone 
should be considered to enhance success of electrical cardioversion 
and prevent recurrent AF 
IIa B 248, 584, 
633 
In patients with no history of ischaemic or structural heart disease, 
flecainide, propafenone, or vernakalant are recommended for 
pharmacological cardioversion of new-onset AF 
I A 602-605, 
614, 618, 
622, 706, 
707 
In patients with no history of ischaemic or structural heart disease, 
ibutilide should be considered for pharmacological conversion of AF 
IIa B  
In selected patients with recent-onset AF and no significant structural 
or ischaemic heart disease, a single oral dose of flecainide or 
propafenone (the ‘pill in the pocket’ approach) should be considered 
for patient-led cardioversion, following safety assessment 
IIa B 620, 621 
In patients with ischaemic and/or structural heart disease, 
amiodarone is recommended for cardioversion of AF 
I A 597-601 
Vernakalant may be considered as an alternative to amiodarone for 
pharmacological conversion of AF in patients without hypotension, 
severe heart failure, or severe structural heart disease (especially 
aortic stenosis) 
IIb B 602-605, 
616, 618 
Stroke prevention in patients designated for cardioversion of AF 
Anticoagulation with heparin or a NOAC should be initiated as soon 
as possible before every cardioversion of AF or atrial flutter 
IIa B 708, 709 
For cardioversion of AF/atrial flutter, effective anticoagulation is 
recommended for a minimum of 3 weeks before cardioversion 
I B 648, 708 
Transoesophageal echocardiography (TOE) is recommended to 
exclude cardiac thrombus, as an alternative to preprocedural 
anticoagulation when early cardioversion is planned 
I B 648, 708 
Early cardioversion can be performed without TOE in patients with a 
definite duration of AF < 48 hours 
IIa B 648 
In patients at risk for stroke (e.g. presence of CHA2DS2-VASc 
factors), anticoagulant therapy should be continued long-term after 
cardioversion according to the long-term anticoagulation 
recommendations, irrespective of the method of cardioversion or the 
apparent maintenance of sinus rhythm. In patients without stroke risk 
factors, anticoagulation is recommended for 4 weeks after 
cardioversion 
I B 353, 710 
In patients where thrombus is identified on TOE, effective 
anticoagulation is recommended for at least 3 weeks 
I C  
A repeat TOE to ensure thrombus resolution should be considered 
before cardioversion 
IIa C  
Antiarrhythmic drugs for the long-term maintenance of sinus rhythm/prevention of recurrent 
AF 
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The choice of antiarrhythmic drug needs to be carefully evaluated, taking 
into account the presence of comorbidities, cardiovascular risk and 
potential for serious proarrhythmia, extracardiac toxic effects, patient 
preferences, and symptom burden 
I A 41, 580 
Dronedarone, flecainide, propafenone, or sotalol are recommended for 
prevention of recurrent symptomatic AF in patients with normal left 
ventricular function and without pathological left ventricular hypertrophy.  
I A 581, 583, 
584, 588, 
601 
Dronedarone is recommended for prevention of recurrent symptomatic 
AF in patients with stable coronary artery disease, and without heart 
failure 
I A 583, 588 
Amiodarone is recommended for prevention of recurrent symptomatic AF 
in patients with heart failure 
I B 596-598 
Amiodarone is more effective in preventing AF recurrences than other 
antiarrhythmic drugs but extracardiac toxic effects are common and 
increase with time. For this reason, other antiarrhythmic drugs should be 
considered first 
IIa C 596-598 
Patients on antiarrhythmic drug therapy should be periodically evaluated 
to confirm their eligibility for treatment 
 
IIa 
 
C 
 
583, 588, 
657, 658, 
660  
ECG recording during the initiation of antiarrhythmic drug therapy should 
be considered to monitor heart rate, detect QRS and QT interval 
prolongation, and the occurrence of atrioventricular block 
 
IIa 
 
B 
 
584 582, 
583, 588, 
601 
Antiarrhythmic drug therapy is not recommended in patients with 
prolonged QT interval (> 0.5 s) or with significant sinoatrial node disease 
or atrioventricular node dysfunction who do not have a functioning 
permanent pacemaker 
 
III 
(harm) 
 
C 
 
Adding atrial-based bradycardia pacing to drug treatment that induces or 
exacerbates sinus node dysfunction should be considered to allow 
continuation of antiarrhythmic drug therapy in patients in whom AF 
ablation is declined or not indicated 
IIa B 711, 712 
Continuation of antiarrhythmic drug therapy beyond the blanking period 
after AF ablation should be considered to maintain sinus rhythm when 
recurrences seem likely 
IIa B 713 
Antiarrhythmic effects of non-antiarrhythmic drugs 
ACE inhibitors, ARBs, and beta-blockers should be considered for 
prevention of new-onset AF in patients with heart failure and reduced 
ejection fraction 
IIa A 23, 219, 236, 
237, 239, 
250, 714 
ACE inhibitors and ARBs should be considered for prevention of new-
onset AF in patients with hypertension, particularly with LV hypertrophy 
IIa B 238, 246, 
686, 714 
Pretreatment with ACE inhibitors or ARBs may be considered in patients 
with recurrent AF undergoing electrical cardioversion and receiving 
antiarrhythmic drug therapy 
IIb B 236, 237, 
248, 249 
ARBs or ACE inhibitors are not recommended for the secondary 
prevention of paroxysmal AF in patients with little or no underlying heart 
disease. 
III (no 
benefit) 
B 241, 697 
ACE = angiotensin-converting enzyme; AF = atrial fibrillation; ARB = angiotensin receptor blocker; CHA2DS2-1907 
VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled), Vascular 1908 
disease, Age 65–74, and Sex (female); ECG = electrocardiogram; NOAC = non-vitamin K antagonist oral 1909 
anticoagulant; TOE = transoesophageal echocardiography. 1910 
aClass of recommendation. 1911 
bLevel of evidence. 1912 
cReference(s) supporting recommendations. 1913 
 1914 
11.3. Catheter ablation 1915 
Page 66 of 148 ESC AF Guidelines 
 
Since the initial description of triggers in the pulmonary veins that initiate paroxysmal AF,108 catheter ablation 1916 
of AF has developed from a specialized, experimental procedure into a common treatment to prevent recurrent 1917 
AF.587, 715 This is primarily achieved through isolation of the pulmonary veins, probably requiring complete 1918 
isolation for full effectiveness,716 and additional ablation in the posterior left atrial wall. AF ablation, when 1919 
performed in experienced centres by adequately trained teams, is more effective than antiarrhythmic drug 1920 
therapy in maintaining sinus rhythm, and the complication rate, though not negligible, is similar to the 1921 
complication rate for antiarrhythmic drugs.585, 717, 1042 1922 
 1923 
11.3.1. Indications 1924 
Catheter ablation of AF is effective in restoring and maintaining sinus rhythm in patients with symptomatic 1925 
paroxysmal, persistent, and probably long-standing persistent AF – in general as second-line treatment after 1926 
failure of or intolerance to antiarrhythmic drug therapy. In such patients, catheter ablation is more effective than 1927 
antiarrhythmic drug therapy.185, 586, 713, 717-720 As first-line treatment for paroxysmal AF, randomized trials 1928 
showed only modestly improved rhythm outcome with catheter ablation compared to antiarrhythmic drug 1929 
therapy.585, 721-723 Complication rates were similar, but ablation was performed in expert centres, justifying 1930 
catheter ablation as first-line therapy in selected patients with paroxysmal AF who ask for interventional 1931 
therapy. Fewer data are available reporting the effectiveness and safety of catheter ablation in patients with 1932 
persistent or long-standing persistent AF, but all point to lower recurrence rates after catheter ablation compared 1933 
to antiarrhythmic drug therapy with or without cardioversion.185, 717, 723-726, 1039 In patients who experience 1934 
symptomatic recurrences of AF despite antiarrhythmic drug therapy, all RCTs showed better sinus rhythm 1935 
maintenance with catheter ablation than on antiarrhythmic drugs.586, 713, 727, 728 There is no current indication for 1936 
catheter ablation to prevent cardiovascular outcomes (or desired withdrawal of anticoagulation), or to reduce 1937 
hospitalization.40, 594 1938 
 1939 
11.3.2. Techniques and technologies 1940 
Complete pulmonary vein isolation (PVI) on an atrial level is the best documented target for catheter 1941 
ablation,716, 729-731 achievable by point-by-point radiofrequency ablation, linear lesions encircling the pulmonary 1942 
veins, or cryoballoon ablation, with similar outcomes.732-734 Complete isolation of the pulmonary veins has 1943 
better rhythm outcomes than incomplete isolation.716 PVI was initially tested in patients with paroxysmal AF, 1944 
but appears to be non-inferior to more extensive ablation in persistent AF as well.729, 735 More extensive 1945 
ablations have been used in patients with persistent AF, but there are insufficient data to guide the use of these at 1946 
present.117, 718, 719, 735-737 Extended ablation procedures (beyond PVI) consistently require longer procedures and 1947 
more ionizing radiation, potentially creating risk for patients. Left atrial macro-reentrant tachycardia is relatively 1948 
uncommon after PVI (≈ 5%). It also seems even less common after cryoballoon ablation,734 but may occur in up 1949 
to 25% of patients after left atrial substrate modification ablation, often due to incomplete ablation lines. Thus, 1950 
for patients with persistent AF, ablation of complex fractionated electrograms, ablation of rotors, or routine 1951 
deployment of linear lesions or other additional ablations does not seem justified in the first procedure.735, 738, 739 1952 
However, additional ablation on top of complete PVI716 may be considered in patients with recurrent AF after 1953 
the initial ablation procedure.719, 740, 741 In patients with documented right atrial isthmus-dependent flutter 1954 
undergoing AF ablation, right atrial isthmus ablation is recommended. Adenosine testing to identify patients in 1955 
need of additional ablation remains controversial after evaluation in several reports.739, 742-744 Ablation of so-1956 
called ‘rotors’ guided by body surface mapping or endocardial mapping is under evaluation and cannot be 1957 
recommended for routine clinical use at present.  1958 
 1959 
11.3.3. Outcome and complications 1960 
The rhythm outcome after catheter ablation of AF is difficult to predict in individual patients.173, 227, 713, 728 Most 1961 
patients require more than one procedure to achieve symptom control.713, 726, 728 In general, better rhythm 1962 
outcome and lower procedure-related complications can be expected in younger patients with a short history of 1963 
AF and frequent, short AF episodes in the absence of significant structural heart disease.745 Catheter ablation is 1964 
more effective than antiarrhythmic drug therapy in maintaining sinus rhythm (Web Addenda Figure 2).746, 1039  1965 
Sinus rhythm without severely symptomatic recurrences of AF is found in up to 70% of patients with 1966 
paroxysmal AF, and around 50% in persistent AF.713, 728, 735, 1042 Very late recurrence of AF after years of sinus 1967 
rhythm is not uncommon and may reflect disease progression, with important implications for continuation of 1968 
AF therapies.728 Multiple variables have been identified as risk factors for recurrence after catheter ablation of 1969 
AF, but their predictive power is weak. The decision for catheter ablation thus should be based on a shared 1970 
decision-making process747 (see Chapter 7), following thorough explanation of the potential benefits and risks, 1971 
and of the alternatives such as antiarrhythmic drug or acceptance of current symptoms without rhythm control 1972 
therapy.175  1973 
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Complications of catheter ablation for AF 1974 
There is a clear need to systematically capture complications in clinical practice to improve the quality of AF 1975 
ablation procedures.175 The median length of hospital stay in AF patients undergoing their first ablation as part 1976 
of the EURObservational Research Programme (EORP) was 3 days (interquartile range 2–4 days), based on 1977 
data from 1391 patients from hospitals performing at least 50 ablations per year. Five to seven per cent of 1978 
patients will suffer severe complications after catheter ablation of AF, and 2–3% will experience life-threatening 1979 
but usually manageable complications.727, 748-750 Intraprocedural death has been reported, but is rare (< 0.2%).751 1980 
The most important severe complications are stroke/TIA (< 1%), cardiac tamponade (1–2%), pulmonary vein 1981 
stenosis, and severe oesophageal injury leading to atrio-oesophageal fistula weeks after ablation (Table 18). 1982 
‘Silent strokes’ (i.e. white matter lesions detectable by brain MRI), have been observed in around 10% of 1983 
patients treated with radiofrequency and cryoballoon ablation.752 The clinical relevance of this observation is 1984 
unclear.749 Post-procedure complications include stroke, with the highest risk within the first week,753 late 1985 
pericardial tamponade several days after catheter ablation,751 and oesophageal fistulas, which usually become 1986 
apparent 7–30 days after ablation. Timely detection of atrio-oesophageal fistulas can be life-saving and should 1987 
be based on the typical triad of infection without a clear focus, retrosternal pain, and stroke or TIA.748 1988 
 1989 
Table 18 Complications related to catheter ablation of AF 1990 
Complication severity Complication type Rate727, 748, 750, 754-759 
Life-threatening complications 
Periprocedural death < 0.2% 
Oesophageal injury (perforation/fistula)a < 0.5% 
Periprocedural stroke (including TIA/air 
embolism) < 1% 
Cardiac tamponade 1–2% 
Severe complications 
Pulmonary vein stenosis < 1% 
Persistent phrenic nerve palsy 1–2% 
Vascular complications 2–4% 
Other severe complications ≈ 1% 
Other moderate or minor 
complications  1–2% 
Unknown significance Asymptomatic cerebral embolism (silent stroke)b 5–20% 
 Radiation exposure  
AF = atrial fibrillation; TIA = transient ischaemic attack. 1991 
aOesophageal fistula should be suspected in patients presenting with the triad of unspecific signs of infection, 1992 
chest pain, and stroke or TIA in the first weeks after an ablation procedure. It requires immediate therapy. 1993 
b< 10% for cryoablation or radiofrequency ablation, > 20% for phased radiofrequency ablation 1994 
 1995 
11.3.4. Anticoagulation – before, during, and after ablation 1996 
Patients anticoagulated with VKAs should continue therapy during ablation (with an INR of 2–3).760 1997 
Anticoagulation with NOACs is an alternative to warfarin.478, 761-765 There is no safety signal from observational 1998 
cohorts treated with uninterrupted NOAC therapy undergoing catheter ablation in experienced centres.761, 763, 766, 1999 
767 The first controlled trial, enrolling around 200 patients, has recently been published,768 as well as several 2000 
observational data sets.761, 769, 770 Ongoing studies compare uninterrupted VKA with NOAC therapy in AF 2001 
patients undergoing ablation (e.g. AXAFA – AFNET 5 [Apixaban During Atrial Fibrillation Catheter Ablation: 2002 
Comparison to Vitamin K Antagonist Therapy – Anticoagulation using the direct factor Xa inhibitor apixaban 2003 
during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy; NCT02227550] and 2004 
RE-CIRCUIT [Randomized Evaluation of dabigatran etexilate Compared to warfarin in pulmonaRy vein 2005 
Page 68 of 148 ESC AF Guidelines 
 
ablation: assessment of different peri-proCedUral anticoagulation sTrategies; NCT02348723]). During ablation, 2006 
heparin should be given to maintain an activated clotting time > 300 seconds. Anticoagulation should be 2007 
maintained for at least 8 weeks after ablation for all patients. The true incidence of thromboembolic events after 2008 
catheter ablation has never been systematically studied and the expected stroke risk has been adopted from non-2009 
ablation AF cohorts. Although observational studies suggest a relatively low stroke rate in the first few years 2010 
after catheter ablation of AF,737, 771-776 the long-term risk of recurrent AF and the safety profile of 2011 
anticoagulation in ablated patients need to be considered. In the absence of controlled trial data, OAC after 2012 
catheter ablation should follow general anticoagulation recommendations, regardless of the presumed rhythm 2013 
outcome. 2014 
 2015 
11.3.5. Ablation of atrial fibrillation in heart failure patients 2016 
Catheter ablation, compared with amiodarone therapy, significantly reduces recurrent AF in AF patients with 2017 
HFrEF.777 Selected patients with HFrEF and AF can achieve recovery of LV systolic function after catheter 2018 
ablation (probably reflecting tachycardiomyopathy). Several smaller trials suggest improved LV function after 2019 
catheter ablation in HFrEF patients185, 226-228, 778, 779 and reduced hospitalizations,720, 777 especially in patients 2020 
without a previous myocardial infarction.780 Larger trials are warranted to confirm these findings. Catheter 2021 
ablation can be demanding in these patients. Thus, indications for catheter ablation in HFrEF patients should be 2022 
carefully balanced, and the procedures performed in experienced centres.  2023 
 2024 
11.3.6. Follow-up after catheter ablation 2025 
Patients and physicians involved in the follow-up after catheter ablation should know the signs and symptoms of 2026 
late complications to allow swift referral for treatment. Patient should also be aware that symptomatic and 2027 
asymptomatic AF recurrences are frequent after catheter ablation.119, 781, 782 In line with the primary goal of 2028 
rhythm control therapy, asymptomatic episodes should generally not trigger further rhythm control therapy. 2029 
Patients should be seen at least once by a rhythm specialist in the first 12 months after ablation. Further rhythm 2030 
control options should be considered in patients with symptomatic recurrences, including discussion in a Heart 2031 
Team (Figure 17). 2032 
 2033 
11.4. Atrial fibrillation surgery 2034 
11.4.1. Concomitant atrial fibrillation surgery 2035 
The Cox maze procedure was first performed 30 years ago as a ‘cut-and-sew’ technique, including isolation of 2036 
the posterior left atrium, a connection to the posterior mitral annulus, a cavotricuspid connection, a cavocaval 2037 
connection, and exclusion of the LAA (Figure 18).783 Thereby, the Cox maze procedure creates an electrical 2038 
labyrinth (maze) of passages through which the sinoatrial node impulse finds a route to the atrioventricular node 2039 
while preventing fibrillatory conduction. The Cox maze procedure and other, often simpler, forms of AF surgery 2040 
have mainly been used in patients undergoing other open heart surgical procedures.461, 466, 784-798 In a systematic 2041 
review commissioned for these guidelines, concomitant AF surgery resulted in greater freedom from AF, atrial 2042 
flutter, and atrial tachycardia (RR 1.94, 95% CI 1.51–2.49; n = 554 from seven RCTs) (Web Addenda Figure 2043 
3).1040 Patients undergoing the Cox maze procedure required pacemaker implantation more often (RR 1.69, 95% 2044 
CI 1.12–2.54; n = 1631 from 17 RCTs), without a detectable difference in other outcomes or complications. 2045 
These findings are underpinned by an analysis of Society of Thoracic Surgeons database comprising 67,389 2046 
patients in AF: mortality or major morbidity was not affected by concomitant AF surgery (adjusted OR 1.00; 2047 
95% CI 0.83–1.20), but pacemaker implantation was more frequent (adjusted OR 1.26; 95% CI 1.07–1.49).799 2048 
Predictors of AF recurrence after surgery include left atrial dilatation, older age, > 10-year history of AF, and 2049 
non-paroxysmal AF.800-804 Regarding AF type, surgical PVI seems effective in paroxysmal AF.805 Biatrial lesion 2050 
patterns may be more effective in persistent and long-standing persistent AF.797, 803, 806 The suggested 2051 
management of patients with AF-related symptoms undergoing cardiac surgery is displayed in Figure 19, with 2052 
an important contribution of the AF Heart Team to advise and inform patient choice. 2053 
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 2054 
Figure 18 A. Surgical lesion sets for the biatrial Cox maze procedure. Left and middle panel: right atrial lesions. 2055 
Right panel: left atrial lesions.  2056 
B: Left atrial lesions in a thoracoscopic minimally invasive surgical procedure (dashed lines), including left 2057 
appendage exclusion (double line). 2058 
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 2059 
Figure 19 Surgical rhythm control in patients undergoing cardiac surgery. 2060 
AF = atrial fibrillation; CABG = coronary artery bypass graft; LAA = left atrial appendage; PVI = pulmonary 2061 
vein isolation. 2062 
aAF surgery may be PVI in paroxysmal AF and biatrial maze in persistent or long-standing persistent AF.  2063 
bOral anticoagulation should be continued in patients at risk of stroke irrespective of AF surgery or LAA 2064 
exclusion. 2065 
 2066 
 2067 
11.4.2. Stand-alone rhythm control surgery  2068 
Current technology (e.g. bipolar radiofrequency or cryothermy) renders the procedure easier and more 2069 
reproducible and feasible via a mini-thoracotomy.786, 807, 808 Thoracoscopic PVI with bipolar radiofrequency 2070 
prevents recurrence of paroxysmal AF (69–91% freedom from arrhythmias at 1 year, see Figure 18B for lesion 2071 
set),468, 809, 810 and seems effective in patients refractory to catheter ablation.811 The average length of hospital 2072 
stay for thoracoscopic ablation varies from 3.6 to 6.0 days.468, 812, 813 The FAST (Atrial Fibrillation Catheter 2073 
Ablation vs Surgical Ablation Treatment) trial,468 and another smaller trial,814 suggested that thoracoscopic AF 2074 
surgery could be more effective than catheter ablation for the maintenance of sinus rhythm,468, 814 while also 2075 
causing more complications (Table 19).815 To improve results,468, 816-818 more extensive lesion sets have been 2076 
performed, connecting lines between the PVI encircling and towards the mitral annulus.812, 819-822 To improve the 2077 
generation of transmural lesions,716 endo-epicardial ablation strategies have recently been proposed.812, 823-825 2078 
Although preliminary experience with hybrid simultaneous ablation shows promise, procedural time and rates of 2079 
bleeding complications are higher.812, 823  2080 
 2081 
Table 19 Complications of thoracoscopic AF surgery 2082 
Complication Rate468, 815, 822, 826 
Conversion to sternotomy 0–1.6% 
Pacemaker implantation 0–3.3% 
Drainage for pneumothorax 0–3.3% 
Pericardial tamponade 0–6.0% 
Transient ischaemic attack a 0–3.0% 
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AF = atrial fibrillation. 2083 
aThe rate of asymptomatic cerebral embolism is unknown 2084 
 2085 
11.5. Choice of rhythm control following treatment failure 2086 
There is insufficient evidence on which to base clear recommendations on how to treat patients with recurrent 2087 
AF after catheter ablation. Early recurrences of AF or atrial tachycardias after ablation (occurring within 8 2088 
weeks) may be treated with cardioversion. Many of the published series of patients undergoing AF ablation 2089 
included those who failed antiarrhythmic drug therapy. Thus, considering ablation therapy in patients who have 2090 
symptomatic recurrences on antiarrhythmic drug therapy is often reasonable. Alternatively, trialling another 2091 
antiarrhythmic drug can be considered. Combining antiarrhythmic drug with ablation (‘hybrid therapy’, see 2092 
Section 11) should be considered based on the different and possibly synergistic effects of these drugs with AF 2093 
ablation, possibly benefitting patients in whom either treatment alone was previously ineffective. Rate control 2094 
without rhythm control, surgical ablation, or repeat catheter ablation should be considered as well as third-line 2095 
options (Figure 20). Patient preferences and local access to therapy are important considerations to inform the 2096 
therapy choice in patients who are in need of further rhythm control therapy after an initial therapy failure.  2097 
 2098 
Figure 20 Choice of rhythm control approaches following treatment failure. 2099 
AAD = antiarrhythmic drug; AF = atrial fibrillation; PVI = pulmonary vein isolation. 2100 
a catheter ablation should target PVI. Class I level B for paroxysmal AF and Class IIa level B for persistent AF.  2101 
b AF surgery may be PVI (e.g. in paroxysmal AF) or maze surgery (e.g. in therapy-refractory or long-standing 2102 
persistent AF).  2103 
c Hybrid therapy involves combination of antiarrhythmic drugs, catheter ablation, and/or AF surgery. 2104 
 2105 
11.6. The atrial fibrillation Heart Team 2106 
In view of the complexity of the different treatment options in patients with failed rhythm control therapy but 2107 
who still require or demand further rhythm control therapy, this Task Force proposes that decisions involving 2108 
AF surgery or extensive AF ablation should be based on advice from an AF Heart Team. This will also apply to 2109 
reversal to a rate control strategy in patients with severe (EHRA III or IV) AF symptoms. An AF Heart Team 2110 
should consist of a cardiologist with expertise in antiarrhythmic drug therapy, an interventional 2111 
electrophysiologist, and a cardiac surgeon with expertise in appropriate patient selection, techniques, and 2112 
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technologies for interventional or surgical AF ablation. Such AF Heart Teams – and a collaborative 2113 
infrastructure supporting a continued interaction between physicians delivering continued care, AF 2114 
cardiologists, interventional electrophysiologists, and AF surgeons – should be established to provide optimal 2115 
advice and ultimately to improve rhythm outcomes for patients in need of advanced and complex rhythm control 2116 
interventions.  2117 
 2118 
Recommendations for catheter ablation of AF and AF surgery 2119 
Minimally invasive surgery with epicardial pulmonary vein 
isolation should be considered in patients with symptomatic AF 
when catheter ablation has failed. Decisions on such patients 
should be supported by an AF Heart Team 
IIa B 468 812, 819, 
823 
Maze surgery, possibly via a minimally invasive approach, 
performed by an adequately trained operator in an experienced 
centre, should be considered by an AF Heart Team as a 
treatment option for patients with symptomatic refractory 
persistent AF or post-ablation AF to improve symptoms 
IIa C 808, 832 
Recommendations Class a Level b Refs c 
Catheter ablation of symptomatic paroxysmal AF is 
recommended to improve AF symptoms in patients who have 
symptomatic recurrences of AF on antiarrhythmic drug therapy 
(amiodarone, dronedarone, flecainide, propafenone, sotalol) and 
who prefer further rhythm control therapy, when performed by an 
electrophysiologist who has received appropriate training and is 
performing the procedure in an experienced centre 
I A 585-587, 713, 
727 
Ablation of common atrial flutter should be considered to prevent 
recurrent flutter as part of an AF-ablation procedure if previously 
documented or occurring during the AF ablation 
IIa B 827 
Catheter ablation of AF should be considered as first-line therapy 
to prevent recurrent AF and to improve symptoms in selected 
patients with symptomatic paroxysmal AF as an alternative to 
antiarrhythmic drug therapy, considering patient choice, benefit, 
and risk 
IIa B 585 
All patients should receive oral anticoagulation for stroke 
prevention for at least 8 weeks after catheter (IIaB) or surgical 
(IIaC) ablation. 
IIa B/C 727 
Anticoagulation for stroke prevention should be continued 
indefinitely after apparently successful catheter or surgical 
ablation of AF in patients at high risk of stroke 
IIa C  
When catheter ablation of AF is planned, continuation of oral 
anticoagulation with VKA (IIaB) or NOAC (IIaC) should be 
considered during the procedure, maintaining effective 
anticoagulation 
IIa B/C 760, 768 
Catheter ablation should target complete isolation of the 
pulmonary veins using radiofrequency ablation or cryothermy 
balloon catheters 
IIa B 585, 715, 716, 
734, 735 
AF ablation should be considered in symptomatic patients with AF 
and heart failure with reduced ejection fraction to improve 
symptoms and cardiac function when tachycardiomyopathy is 
suspected 
IIa C 185, 226-228, 
720, 777-779, 
828 
AF ablation should be considered as a strategy to avoid 
pacemaker implantation in patients with AF-related bradycardia 
IIa C 829, 830 
Catheter or surgical ablation should be considered in patients with 
symptomatic persistent or long-standing persistent AF refractory 
to antiarrhythmic drug therapy to improve symptoms, considering 
patient choice, benefit and risk, supported by an AF Heart Team 
IIa C 468, 735, 777, 
831, 832, 
1040 
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Maze surgery, preferably biatrial, should be considered in 
patients undergoing cardiac surgery to improve symptoms 
attributable to AF, balancing the added risk of the procedure and 
the benefit of rhythm control therapy 
IIa A 461, 466, 
790, 791, 
796, 797 
Concomitant biatrial maze or pulmonary vein isolation surgery 
may be considered in asymptomatic AF patients undergoing 
cardiac surgery 
IIb C 796, 797, 833 
AF = atrial fibrillation; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.  2120 
aClass of recommendation. 2121 
bLevel of evidence. 2122 
cReference(s) supporting recommendations. 2123 
 2124 
12 Hybrid rhythm control therapy 2125 
AF has many different drivers, which are only partially targeted by antiarrhythmic drug or catheter ablation.96 2126 
Hence, combination or ‘hybrid’ rhythm control therapy seems reasonable, although there is little evidence 2127 
supporting its use. 2128 
 2129 
12.1. Combining antiarrhythmic drugs and catheter ablation 2130 
Antiarrhythmic drug therapy is commonly given for 8–12 weeks after ablation to reduce early recurrences of AF 2131 
after catheter ablation, supported by a recent controlled trial where amiodarone halved early AF recurrences 2132 
compared with placebo.650 Prospective studies have not been done, but a meta-analysis of the available (weak) 2133 
evidence suggests slightly better prevention of recurrent AF in patients treated with antiarrhythmic drugs after 2134 
catheter ablation.713 Many patients are treated with antiarrhythmic drug therapy after catheter ablation (most 2135 
often amiodarone or flecainide),587 and this seems a reasonable option in patients with recurrent AF after 2136 
ablation. It seems common sense to consider antiarrhythmic drug therapy in patients who are in need of further 2137 
rhythm control therapy after catheter ablation, but controlled trials to confirm this are desirable. 2138 
 Combining cavotricuspid isthmus ablation and antiarrhythmic drugs may lead to improved rhythm 2139 
control without the need for left atrial ablation in patients who develop ‘drug-induced atrial flutter’ on therapy 2140 
with flecainide, propafenone, or amiodarone,834-836 although recurrent AF is a concern in the long term.837, 838  2141 
 2142 
12.2. Combining antiarrhythmic drugs and pacemakers 2143 
In selected patients with sick sinus syndrome and fast ventricular response during AF paroxysms requiring rate 2144 
control therapy, the addition of a pacemaker not only optimizes rate control but may also help to control 2145 
rhythm.711, 712 Moreover, when antiarrhythmic drug treatment leads to sinus node dysfunction and bradycardia, 2146 
pacing may permit uptitration of the antiarrhythmic drug dose. Such strategies have never been prospectively 2147 
investigated and the existing populations studied are highly selected.839, 840 Some patients with AF-induced 2148 
bradycardia may benefit from catheter ablation of AF, obviating the need for antiarrhythmic drugs and 2149 
pacemaker implantation.829, 830 2150 
 2151 
13 Specific situations 2152 
13.1. Frail and ‘elderly’ patients 2153 
Many AF patients present at an older age (e.g. > 75 or > 80 years). There are no studies suggesting that 2154 
cardiovascular risk reduction is less effective in these ‘elderly’ AF patients than in younger patients. Rather, age 2155 
is one of the strongest predictors/risk factors for ischaemic stroke in AF (Table 11).382 Good data are available to 2156 
support the use of anticoagulants in older patients from BAFTA (Birmingham Atrial Fibrillation Treatment of 2157 
the Aged Study),362 the NOAC trials,39 and from analyses in elderly Americans (Medicare).396 Elderly AF 2158 
patients are at higher risk of stroke and thus are more likely to benefit from OAC than younger patients,841 and 2159 
yet OAC is still underutilized in the elderly.220, 842 Although the evidence base is smaller for other treatment 2160 
options in AF, the available data support the use of available rate and rhythm control interventions, including 2161 
pacemakers and catheter ablation, without justification to discriminate by age group. Individual patients at older 2162 
age may present with multiple comorbidities including dementia, a tendency to falls, CKD, anaemia, 2163 
hypertension, diabetes, and cognitive dysfunction. Such conditions may limit quality of life more than AF-2164 
related symptoms. Impairment of renal and hepatic function and multiple simultaneous medications make drug 2165 
interactions and adverse drug reactions more likely. Integrated AF management and careful adaptation of drug 2166 
dosing seem reasonable to reduce complications of AF therapy in such patients.843 2167 
 2168 
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13.2. Inherited cardiomyopathies, channelopathies, and accessory pathways 2169 
Several inherited cardiac conditions are associated with early-onset AF (Table 20). Treatment of the underlying 2170 
cardiac condition is an important contribution to AF management in these young patients (see also ESC 2171 
guidelines on the sudden cardiac death844 and hypertrophic cardiomyopathy845).  2172 
 2173 
Table 20 Inherited cardiomyopathies, channelopathies, and pathways associated with AF 2174 
 2175 
Syndrome Gene Functional alteration AF 
prevalence 
References 
Long QT syndrome KCNQ1 
KCNH2 
SCN5A 
ANK2 
others 
IKs  
IKr  
INa  
INa,K  
Various effects 
5–10% 846-850 
Brugada syndrome SCN5A 
GPDIL 
SCN1B 
CACNA1C 
CACNB2b 
others 
INa  
INa  
INa  
ICa  
ICa  
others 
10–20% 851-855 
Short QT syndrome KCNH2 
KCNQ1 
KCNJ2 
CACNA1C 
CACNB2b 
 
IKr  
IKs  
IK1  
ICa  
ICa  
 
Up to 70% 853, 856-858 
Catecholaminergic 
ventricular tachycardia 
RYR2 
CASQ2 
Abnormal Ca2+ release from 
sarcoplasmic reticulum 
Variable but 
significant 
859-861 
 
Hypertrophic 
cardiomyopathy 
Sarcomeric 
genes 
 5–15% 862-864 
Wolff–Parkinson–White 
syndrome 
PRKAG  Variable 865 
Holt–Oram syndrome TBX5  Variable 866 
Arrhythmogenic right 
ventricular 
cardiomyopathy 
Several 
desmosomal 
genes, 
unknown gene 
loci 
 
 >40% in 
patients with 
VTs 
867, 868 
AF = atrial fibrillation. 2176 
 2177 
13.2.1. Wolff–Parkinson–White syndrome 2178 
Patients with pre-excitation and AF are at risk of rapid conduction across the accessory pathway, resulting in a 2179 
fast ventricular rate, possibly ventricular fibrillation, and sudden death. In AF patients with evidence of an 2180 
antegrade accessory pathway, catheter ablation of the pathway is recommended.869, 870 This procedure is safe and 2181 
effective and may be considered as a prophylactic treatment strategy.871, 872 In AF patients surviving a sudden 2182 
death event with evidence of an accessory pathway, urgent catheter ablation of the pathway is recommended.869 2183 
A documented short pre-excited RR interval (< 250 ms) during spontaneous or induced AF is one of the risk 2184 
markers for sudden death in Wolff–Parkinson–White syndrome (WPW) syndrome, in addition to a history of 2185 
symptomatic tachycardia, the presence of multiple accessory pathways, and Ebstein’s anomaly. Intravenous 2186 
procainamide, propafenone, or ajmaline can be used to acutely slow ventricular rate,873, 874 whereas digoxin, 2187 
verapamil, and diltiazem are contraindicated.875 Intravenous amiodarone should be used with caution, as there 2188 
are case reports of accelerated ventricular rhythms and ventricular fibrillation in patients with pre-excited AF 2189 
receiving intravenous amiodarone infusion.876  2190 
 2191 
13.2.2. Hypertrophic cardiomyopathy  2192 
AF is the most common arrhythmia in patients with hypertrophic cardiomyopathy, affecting approximately one-2193 
quarter of this population.877 Observational data highlight a high stroke risk in hypertrophic cardiomyopathy 2194 
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patients with AF, confirming the need for OAC.878 While there is more experience with VKAs, there are no data 2195 
to suggest that NOACs cannot be used in these patients.845 Studies of rate or rhythm control medications in 2196 
patients with hypertrophic cardiomyopathy are relatively scarce. Beta-blockers and diltiazem or verapamil seem 2197 
reasonable treatment options for rate control in these patients. In the absence of signiﬁcant LV outflow tract 2198 
obstruction, digoxin can be used alone or in combination with beta-blockers.845 Amiodarone seems a safe 2199 
antiarrhythmic drug in AF patients with hypertrophic cardiomyopathy,879 and expert opinion suggests that 2200 
disopyramide may be beneficial in those with outflow tract obstruction. AF ablation is effective to suppress 2201 
symptomatic AF recurrences.880-884 Surgical treatment of AF may be appropriate in patients with hypertrophic 2202 
cardiomyopathy undergoing surgery (e.g. for LV outflow tract obstruction or mitral valve surgery), but 2203 
experience is limited.  2204 
 2205 
13.2.3. Channelopathies and arrhythmogenic right ventricular cardiomyopathy  2206 
Many channelopathies and inherited cardiomyopathies are associated with AF. AF prevalence ranges from 5% 2207 
to 20% in patients with long QT syndrome or Brugada syndrome, and is up to 70% in short QT syndrome 2208 
(Table 20).853, 856-858 Penetrance of disease phenotype including AF is variable.61, 852, 885, 886 Both shortening as 2209 
well as prolongation of the atrial action potential have been demonstrated as likely mechanisms underlying AF 2210 
in these diseases. It seems reasonable to consider antiarrhythmic drugs that reverse the suspected channel defect 2211 
in AF patients with inherited cardiomyopathies (e.g. a sodium channel blocker in LQT3852 and quinidine in 2212 
Brugada syndrome887). More importantly, new-onset AF in young, otherwise healthy individuals should trigger 2213 
a careful search for such inherited conditions, including clinical history, family history, ECG phenotype, and 2214 
echocardiography and/or other cardiac imaging. 2215 
 Monogenic defects only account for 3–5% of all patients with AF, even in younger populations.846, 848, 2216 
888-890 Furthermore, there is no clear link between detected mutations and specific outcomes or therapeutic needs. 2217 
For these reasons, genetic testing is not recommended in the general AF population.77 Other guidelines have 2218 
described the indications for genetic testing in patients with inherited arrhythmogenic diseases.844, 891  2219 
 2220 
Recommendations for inherited cardiomyopathies 2221 
 2222 
Recommendations  Class a Level b Refs c 
WPW syndrome    
Catheter ablation of the accessory pathway in WPW patients with AF 
and rapid conduction over the accessory pathway is recommended to 
prevent sudden cardiac death 
I B 892-894 
Catheter ablation of the accessory pathway is recommended without 
delay in WPW patients who survive sudden cardiac death I C 
869 
Asymptomatic patients with overt pre-excitation and AF should be 
considered for accessory pathway ablation after careful counselling IIa B 
872, 895 
Hypertrophic cardiomyopathy    
Lifelong oral anticoagulation to prevent stroke is recommended in 
hypertrophic cardiomyopathy patients who develop AF I B 
878 
Restoration of sinus rhythm by electrical or pharmacological 
cardioversion to improve symptoms is recommended in hypertrophic 
cardiomyopathy patients with symptomatic new-onset AF 
I B 845 
In haemodynamically stable hypertrophic cardiomyopathy patients 
with AF, ventricular rate control using beta-blockers and 
diltiazem/verapamil is recommended 
I C 845 
Treatment of LV outflow tract obstruction should be considered in 
AF patients with hypertrophic cardiomyopathy to improve symptoms IIa B 
896 
Amiodarone should be considered to achieve rhythm control and 
maintain sinus rhythm in hypertrophic cardiomyopathy patients IIa C 
845, 897 
Inherited cardiomyopathies and channelopathies     
Targeted genetic testing should be considered in patients with AF and 
a suspicion of inherited cardiomyopathies or channelopathies based 
on clinical history, family history, or electrocardiographic phenotype 
IIa A 852 
AF = atrial fibrillation; LV = left ventricular; WPW = Wolff–Parkinson–White syndrome. 2223 
aClass of recommendation. 2224 
bLevel of evidence. 2225 
cReference(s) supporting recommendations. 2226 
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 2227 
13.3. Sports and atrial fibrillation 2228 
Physical activity improves cardiovascular health, which translates into a lower risk of AF.898 Therefore, physical 2229 
activity is a cornerstone of preventing AF. Intensive sports practice, especially endurance sports (> 1500 h of 2230 
endurance sports practice),899 increases the risk of AF later in life,900-902 probably mediated by altered autonomic 2231 
tone, volume load during exercise, atrial hypertrophy, and dilatation.903, 904 This results in a U-shaped 2232 
relationship of physical activity and incident AF.214, 898, 902, 905, 906 Detraining can reduce AF in models904 and 2233 
reduces ventricular arrhythmias in athletes,907 but the role of detraining for AF in human athletes is unknown. 2234 
The management of athletes with AF is similar to general AF management, but requires a few special 2235 
considerations. Clinical risk factors will determine the need for anticoagulation. Sports with direct bodily 2236 
contact or prone to trauma should be avoided in patients on OAC. Beta-blockers are not well tolerated and at 2237 
times prohibited, and digoxin, verapamil, and diltiazem are often not potent enough to slow heart rate during 2238 
exertional AF. Catheter ablation for AF probably has similar outcomes in athletes as in non-athletes,908, 909 but 2239 
further data are needed. Pill-in-the-pocket therapy has been used as well.620 After ingestion of flecainide or 2240 
propafenone as pill-in-the-pocket, patients should refrain from sports as long as AF persists and until two half-2241 
lives of the antiarrhythmic drug have elapsed. Prophylactic ablation of the flutter circuit may be considered in 2242 
athletes treated with sodium channel blockers.910 2243 
 2244 
Recommendations for physical activity in patients with AF 2245 
Recommendations Class a Level b Refsc 
Moderate regular physical activity is recommended to prevent AF, while 
athletes should be counselled that long-lasting, more intense sports 
participation can promote AF 
I A 
214, 898, 900-
902, 905, 906 
AF ablation should be considered to prevent recurrent AF in athletes IIa B 908, 909 
The ventricular rate while exercising with AF should be evaluated in 
every athlete (by symptoms and/or by monitoring), and titrated rate 
control should be instituted 
IIa C  
After ingestion of pill-in-the-pocket Class I antiarrhythmic drugs, 
patients should refrain from sports as long as AF persists and until two 
half-lives of the antiarrhythmic drug have elapsed 
IIa C 620 
AF = atrial fibrillation. 2246 
aClass of recommendation. 2247 
bLevel of evidence. 2248 
cReference(s) supporting recommendations. 2249 
 2250 
13.4. Pregnancy 2251 
AF in pregnant women is rare and is usually associated with pre-existing heart disease. AF is associated with 2252 
increased complications for the mother and foetus.911, 912 Better treatment of congenital heart diseases will 2253 
probably increase the incidence of AF during pregnancy in the future.913 Pregnant women with AF should be 2254 
managed as high-risk pregnancies in close collaboration with cardiologists, obstetricians, and neonatologists. 2255 
 2256 
13.4.1. Rate control 2257 
Owing to a lack of specific data, beta-blockers, verapamil, diltiazem, and digoxin all carry a US Food and Drug 2258 
Administration pregnancy safety category of C (benefits may outweigh risk), except for atenolol (category D: 2259 
positive evidence of risk). Their use should be at the lowest dose and for the shortest time required. None of the 2260 
agents are teratogenic, but they readily cross the placenta.914 Beta-blockers are commonly used in clinical 2261 
practice (e.g. for management of gestational hypertension and pre-eclampsia), but may be associated with 2262 
intrauterine growth retardation,915 and hence growth scans after 20 weeks gestation are recommended. Digoxin 2263 
is considered safe for maternal and foetal arrhythmias.916 There are insufficient data to comment on verapamil or 2264 
diltiazem, hence rate control using beta-blockers and/or digoxin is recommended.917 With regards to 2265 
breastfeeding, all rate control agents are present in breast milk, although levels of beta-blockers, digoxin, and 2266 
verapamil are too low to be considered harmful. Diltiazem will be present at high levels and should be 2267 
considered second-line treatment.918  2268 
 2269 
13.4.2. Rhythm control 2270 
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Rhythm control therapy in pregnant patients with AF has only been reported in case studies. Amiodarone is 2271 
associated with severe adverse foetal side-effects and should only be considered for emergency situations.919 2272 
Flecainide and sotalol can both be used for conversion of foetal arrhythmias without major adverse effects,920 2273 
and thus are likely to be safe to treat maternal symptomatic AF. Electrical cardioversion can be effective for 2274 
restoration of sinus rhythm when tachyarrhythmia is causing haemodynamic instability, with low rates of 2275 
adverse outcomes for both mother and foetus.921 However, in view of the risk of foetal distress, electrical 2276 
cardioversion should only be carried out where facilities are available for foetal monitoring and emergency 2277 
caesarean section. As with other emergencies during pregnancy, patients should receive 100% oxygen, 2278 
intravenous access should be established early, and the mother should be positioned in the left lateral position to 2279 
improve venous return.922 2280 
 2281 
13.4.3. Anticoagulation 2282 
VKAs should be avoided in the first trimester because of teratogenic effects, and in the 2–4 weeks preceding 2283 
delivery to avoid foetal bleeding. Low-molecular-weight heparins are a safe substitute, as they do not cross the 2284 
placenta.923 In the third trimester, frequent laboratory checks for adequate anticoagulation (e.g. every 10–14 2285 
days) and corresponding dose adjustments are advised, given that in some women high doses of both VKA and 2286 
heparin may be needed to maintain adequate anticoagulation. Pregnant patients with AF and mechanical 2287 
prosthetic valves who elect to stop VKA treatment in consultation with their specialist team between 6 and 12 2288 
weeks of gestation, should receive continuous, dose-adjusted unfractionated heparin or dose-adjusted 2289 
subcutaneous low-molecular-weight heparin. As only limited data are available about teratogenesis for NOACs, 2290 
these drugs should be avoided during pregnancy. 2291 
 2292 
Recommendations during pregnancy 2293 
Recommendations Class a Level b Refs c 
Electrical cardioversion can be performed safely at all stages of 
pregnancy, and is recommended in patients who are 
haemodynamically unstable due to AF, and whenever the risk of 
ongoing AF is considered high, for the mother or the foetus 
I C  
Anticoagulation is recommended in pregnant patients with AF at risk 
of stroke. To minimize teratogenic risk and intrauterine bleeding, 
dose-adjusted heparins are recommended during the first trimester 
of pregnancy and in the 2–4 weeks before delivery. Vitamin K 
antagonists or heparin can be used in the remaining parts of the 
pregnancy 
I  B 923 
NOACs should be avoided in pregnancy and in women planning a 
pregnancy 
III 
(harm) C 
 
NOAC =  non-vitamin K antagonist oral anticoagulants  2294 
aClass of recommendation. 2295 
bLevel of evidence. 2296 
cReference(s) supporting recommendations. 2297 
 2298 
13.5. Postoperative atrial fibrillation 2299 
AF is common after cardiac surgery (occurring in 15–45% of patients),924-926 and is associated with increased 2300 
length of hospital stay and higher rates of complications and mortality.927 Postoperative AF is also not 2301 
uncommon after other major surgery, especially in elderly patients. The treatment of postoperative AF is mainly 2302 
based on studies of patients undergoing cardiac surgery, with much less evidence in the non-cardiac surgery 2303 
setting.  2304 
 2305 
13.5.1. Prevention of postoperative atrial fibrillation 2306 
Beta-blockers reduce postoperative AF and supraventricular tachycardias, albeit with high heterogeneity and 2307 
moderate risk of bias in a systematic review of published studies (the most commonly studied drug was 2308 
propranolol, with AF in 16.3% of the treatment group vs. 31.7% in the control group).925 In the majority of these 2309 
studies, beta-blockers were administered postoperatively, a regimen supported in a recent meta-analysis.928 2310 
Amiodarone reduced the incidence of postoperative AF compared to a beta-blocker regimen in several meta-2311 
analyses, also reducing hospital stay.925, 929-931  2312 
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 Despite initial reports from meta-analyses,689, 932, 933 preoperative treatment with statins did not prevent 2313 
postoperative AF in a prospective controlled trial.934 Other therapies have also been studied in small, hypothesis-2314 
generating trials, but have not demonstrated clear beneficial effects. These include magnesium,925, 935, 936 n-3 2315 
polyunsaturated fatty acids,937-945 colchicine,946 corticosteroids,947, 948 and posterior pericardectomy.949 2316 
Postoperative overdrive biatrial pacing has not gained widespread use despite some suggestion of prophylactic 2317 
effects.925, 950 2318 
 2319 
13.5.2. Anticoagulation 2320 
Postoperative AF is associated with an increased early stroke risk, increased morbidity, and 30-day mortality.927, 2321 
951, 952 In the long term, patients with an episode of postoperative AF have a twofold increase in cardiovascular 2322 
mortality and a substantially increased risk of future AF and ischaemic stroke compared with patients that 2323 
remain in sinus rhythm after surgery.952-958 OAC at discharge has been associated with a reduced long-term 2324 
mortality in patients with postoperative AF,959 without evidence from controlled trials. Good quality data are 2325 
needed to determine whether long-term anticoagulation can prevent strokes in patients with postoperative AF at 2326 
high stroke risk,368, 386 and to assess whether short episodes of postoperative AF (e.g. < 48 h) carry a similar risk 2327 
as longer episodes.960 The indication and timing of OAC in postoperative AF patients should take into 2328 
consideration the risk of postoperative bleeding.  2329 
 2330 
13.5.3. Rhythm control therapy in postoperative atrial fibrillation 2331 
In haemodynamically unstable patients, cardioversion and consideration of antiarrhythmic drugs is 2332 
recommended. Amiodarone or vernakalant have been efficient in converting postoperative AF to sinus 2333 
rhythm.603, 950, 961 A recent medium-sized trial randomizing patients with postoperative AF to either rhythm 2334 
control therapy with amiodarone or to rate control did not find a difference in hospital admissions during a 60-2335 
day follow-up,962 underpinning that the aim of rhythm control therapy should be to improve AF-related 2336 
symptoms in postoperative AF. In asymptomatic patients and in those with acceptable symptoms, rate control or 2337 
deferred cardioversion preceded by anticoagulation is a reasonable approach.  2338 
 2339 
Recommendations for preventing postoperative AF 2340 
Recommendations Class a Level b Refs c 
Perioperative oral beta-blocker therapy is recommended for the 
prevention of postoperative AF after cardiac surgery I B 
925, 928 
Restoration of sinus rhythm by electrical cardioversion or 
antiarrhythmic drugs is recommended in postoperative AF with 
haemodynamic instability 
I C  
Long-term anticoagulation should be considered in patients 
with AF after cardiac surgery at risk for stroke, considering 
individual stroke and bleeding risk 
IIa B 368, 386 
Antiarrhythmic drugs should be considered for recurrent or 
symptomatic postoperative AF after cardiac surgery in an 
attempt to restore sinus rhythm 
IIa C  
Perioperative amiodarone should be considered for 
prophylactic therapy to prevent AF after cardiac surgery IIa  A 
925 
Intravenous vernakalant may be considered for cardioversion 
of postoperative AF in patients without severe heart failure, 
hypotension, or severe structural heart disease (especially 
aortic stenosis) 
IIb B 603 
Asymptomatic postoperative AF should initially be managed 
with rate control and anticoagulation IIa B 
962 
AF = atrial fibrillation. 2341 
aClass of recommendation. 2342 
bLevel of evidence. 2343 
cReference(s) supporting recommendations. 2344 
 2345 
13.6. Atrial arrhythmias in grown-up patients with congenital heart disease 2346 
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Atrial arrhythmias (AF, atrial flutter, atrial tachycardias) often occur late after surgical repair of congenital heart 2347 
defects, occurring in 15–40% of grown-up patients with congenital heart disease (GUCH). They are associated 2348 
with heart failure, syncope, thromboembolic events, and sudden death.963-967 The pathophysiological substrate is 2349 
complex, associated with hypertrophy, fibrosis, hypoxaemia, chronic haemodynamic overload, and surgical 2350 
scars and patches. Additionally, related primary anomalies in the conduction pathways can lead to reentrant 2351 
atrial and ventricular tachycardia, heart block, and sinus node dysfunction.963 Macro-reentrant atrial tachycardia 2352 
or atypical atrial flutter may be seen after nearly any surgical procedure involving atriotomy or atrial patches.  2353 
 2354 
13.6.1. General management of atrial arrhythmias in grown-up patients with 2355 
congenital heart disease 2356 
The conventional stroke risk factors should be used to inform decisions on long-term anticoagulation in GUCH 2357 
patients with AF. In addition, anticoagulation should be considered in GUCH patients with atrial arrhythmias 2358 
when they present with intracardial repair, cyanosis, Fontan palliation, or systemic right ventricle, in addition to 2359 
those with conventional stroke risk factors.968 Beta-blockers, verapamil, diltiazem, and digitalis can be used. 2360 
Care should be taken to avoid bradycardia and hypotension. 2361 
 Sodium channel blockers suppress approximately half of atrial arrhythmias in Fontan patients.969 2362 
Amiodarone is more effective, but long-term treatment with an antiarrhythmic drugs carries a high risk of 2363 
extracardiac side-effects in this relatively young population. Intracardiac thrombi are common in GUCH 2364 
patients undergoing cardioversion for AF, but also in patients with atrial tachycardias or atrial flutter.970 2365 
Therefore, both a TOE and anticoagulation for a few weeks before the planned cardioversion should be 2366 
considered.964 Radiofrequency ablation may be a good option for symptomatic GUCH patients with atrial 2367 
arrhythmias, especially in those with atrial flutter and other macro-reentrant tachycardias. Interventions should 2368 
be performed in adequately qualified centres by specialized teams.  2369 
 2370 
13.6.2. Atrial tachyarrhythmias and atrial septal defects 2371 
Atrial flutter and fibrillation occur in 14–22% of adults with unoperated atrial septal defects, especially in older 2372 
patients,971 and can lead to heart failure.972 Early repair can reduce but not eliminate the risk of AF.973 Biatrial 2373 
volume overload,974 pulmonary hypertension,975 and possibly the arrhythmogenic effect of atrial patches can 2374 
contribute to these arrhythmias.976 Anticoagulation should be decided based on stroke risk factors. In patients 2375 
with a history of paroxysmal or persistent AF, AF surgery could be considered at the time of surgical closure, or 2376 
catheter ablation in patients undergoing interventional atrial septal defect closure. Catheter ablation of late atrial 2377 
arrhythmias has shown to be effective in 46 consecutive patients after surgical atrial septal defect.977 2378 
 2379 
13.6.3. Atrial tachyarrhythmias after Fontan operation 2380 
Atrial arrhythmias occur in up to 40% of patients with a Fontan circulation, and can manifest as atrial flutter, 2381 
primary atrial tachycardia, AF, and accelerated junctional rhythm or junctional tachycardia978 with or without 2382 
sinoatrial node dysfunction.979 Patients with atriopulmonary anastomoses (possibly due to higher atrial volume 2383 
and pressure load) and those with early postoperative atrial arrhythmias are more likely to develop long-term 2384 
atrial arrhythmias.980 Atrial arrhythmias can also be the first manifestation of obstruction of the atriopulmonary 2385 
anastomosis, a complication that must be identified. Right atrial thrombus formation is common in Fontan 2386 
patients with atrial arrhythmias and requires oral anticoagulation.981 Operative conversion to total 2387 
cavopulmonary artery connection with concomitant arrhythmia surgery can in some patients improve heart 2388 
failure symptoms and reduce recurrent arrhythmias,969, 982 with low recurrence rates of clinically apparent atrial 2389 
arrhythmias in the first few years after repeat surgery.983-985 Catheter ablation of atrial arrhythmia in Fontan 2390 
patients has been successful in selected patients.986 2391 
 2392 
13.6.4. Atrial tachyarrhythmias after tetralogy of Fallot correction  2393 
Approximately one-third of patients after repair of tetralogy of Fallot develop atrial arrhythmias, including intra-2394 
atrial reentrant tachycardia, focal atrial tachycardia, and AF.987 Circuits involving the cavotricuspid isthmus and 2395 
areas of presumed surgical right atrial scaring have been described as responsible for atrial arrhythmias.  2396 
 2397 
Recommendations in patients with GUCH 2398 
Recommendations Class a Level b Refs c 
Atrial septal defect closure should be considered before 
the fourth decade of life to diminish the chance of atrial 
flutter and fibrillation 
IIa C 971, 972, 974 
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In patients who need surgical closure of an atrial septal 
defect and who have a history of symptomatic atrial 
arrhythmia, atrial ablation should be considered at the 
time of surgical closure 
IIa C 204, 988, 989 
Cox maze surgery should be considered in patients with 
symptomatic AF and an indication for corrective repair of 
congenital heart defects. All such surgery should be done 
in experienced centres 
IIa C 988, 990 
Oral anticoagualtion should be considered in all adult 
patients with intracardiac repair, cyanosis, Fontan 
palliation, or systemic right ventricle and a history of AF, 
atrial flutter, or intra-atrial reentrant tachycardia. In all 
other congenital heart disease patients with AF, 
anticoagulation should be considered if the CHA2DS2-
VASC score is ≥ 1 
IIa C  968 
Catheter ablation of atrial arrhythmias associated with 
congenital heart defects may be considered when 
performed in experienced centres 
IIb C 991 
In patients with congenital heart disease, 
transoesophageal echocardiography may be considered 
together with 3-week anticoagulation therapy before 
cardioversion 
IIb C 964, 970, 988, 990 
AF = atrial fibrillation; CHA2DS2-VASc = Congestive Heart failure, hypertension, Age ≥75 (doubled), 2399 
Diabetes, Stroke (doubled), Vascular disease, Age 65–74, and Sex (female); GUCH = grown-up patients with 2400 
congenital heart disease; OAC = oral anticoagulation; TOE = transoesophageal echocardiography. 2401 
aClass of recommendation.  2402 
bLevel of evidence. 2403 
cReference(s) supporting recommendations. 2404 
 2405 
13.7. Management of atrial flutter 2406 
The goals for the management of atrial flutter are similar to those for AF.992 Based on the available evidence, the 2407 
stroke risk in patients with atrial flutter is not much different from that in AF.827 Furthermore, many patients 2408 
diagnosed with atrial flutter develop AF.993-995 Thus, anticoagulation should be used in patients with atrial flutter 2409 
similar to that in patients with AF. Rate control in atrial flutter is achieved with the same medications as in AF, 2410 
but is often more difficult to achieve. Flecainide, propafenone, dofetilide, and intravenous ibutilide are useful for 2411 
cardioversion of atrial flutter. They should be combined with a rate-controlling agent to avoid 1:1 conduction of 2412 
slowing flutter waves to the ventricles. Ibutilide is more effective for conversion of atrial flutter than AF, 2413 
whereas vernakalant is less effective in converting typical atrial flutter.996, 997 Electrical cardioversion of atrial 2414 
flutter can be performed using lower energies (50–100 J) than for AF.998, 999 Atrial overdrive pacing through 2415 
pacemaker leads or endocardial or transesophageal catheters can convert atrial flutter to sinus rhythm.1000, 1001 2416 
Anticoagulation and transoesophageal echocardiography around cardioversion or overdrive pacing should be 2417 
used similar to that in AF.  2418 
 Ablation of the cavotricuspid isthmus for isthmus-dependent right atrial flutter (either the common 2419 
counter-clockwise atrial flutter or the less-common clockwise atrial flutter) restores and maintains sinus rhythm 2420 
with a success rate of 90–95%.1002 It may also reduce AF recurrences in selected patients,1003, 1004 and help to 2421 
prevent hospitalizations.1004, 1005 Isthmus ablation is comparably safe and more effective than antiarrhythmic 2422 
drug therapy, and is recommended for recurrent atrial flutter.585-587, 713 Catheter ablation of left atrial macro-2423 
reentrant tachycardia is more complex, with lower success rates and higher recurrence rates.1006, 1007  2424 
 2425 
Recommendations for management of atrial flutter 2426 
Recommendations Class a Level b Refs c 
For patients with atrial flutter, antithrombotic therapy is recommended 
according to the same risk profile used for AF 
I B 827 
Overdrive atrial pacing of atrial flutter should be considered as an 
alternative to electrical cardioversion, depending on local availability and 
experience 
IIa B 1000, 1001 
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Management of typical atrial flutter with ablation of the cavotricuspid 
isthmus is recommended for patients failing antiarrhythmic drug therapy or 
as first-line treatment considering patient preference 
I B 158 
If atrial flutter has been documented before AF ablation, ablation of the 
cavotricuspid isthmus should be considered as part of the AF ablation 
procedure 
IIa C  
AF = atrial fibrillation. 2427 
aClass of recommendation. 2428 
bLevel of evidence. 2429 
cReference(s) supporting recommendations. 2430 
 2431 
14 Patient involvement, education and self-management 2432 
A fundamental aspect of a structured AF management programme is the focus on patient-centred care.  2433 
 2434 
14.1. Patient-centred care 2435 
Autonomous, informed patients are better placed to adhere to long-term therapy, and it is very likely that long-2436 
term management of chronic conditions such as AF will benefit from informed patients involved in the disease 2437 
management who are aware of their own responsibilities.328 Shared decision-making747 and patient-centred 2438 
organization of care can help to ensure adherence to management and empower patients, and respect individual 2439 
patient preferences, needs, and values (see Chapter 7.2).326, 1008, 1009 Patients in an active role tend to have better 2440 
health outcomes and care experiences, and engagement itself can be considered as an intermediate outcome, 2441 
particularly where related to improved clinical outcomes.1010 2442 
 2443 
14.2. Integrated patient education  2444 
Education is a prerequisite for informed, involved patients and patient-centred care. However, lack of AF-2445 
related knowledge in patients is common, even in those who have received verbal and written information,32, 1011, 2446 
1012 indicating the need to further develop structured patient education. Several patient-information tools have 2447 
been developed, largely focusing on oral anticoagulation.1013-1016 Understanding patients’ perceptions and 2448 
attitudes towards AF and its management can improve AF management and related outcomes.1017 This includes 2449 
tailored patient education focusing on the disease, symptom recognition, therapy, modifiable risk factors for AF, 2450 
and self-management activities.1018, 1019  2451 
 2452 
14.3. Self-management and shared decision-making  2453 
Self-management is primarily focused on tasks to manage the condition, such as adhering to a therapeutic 2454 
regimen or modifying behaviour (e.g. resulting in smoking cessation or weight loss).1020 It requires 2455 
understanding of the treatment modalities and goals.350 Within a multidisciplinary team, allied health 2456 
professionals can guide this interactive process in which communication, trust, and reciprocal respect foster 2457 
patient engagement.1021 Shared decision-making should be considered as a routine part of the decision-making 2458 
process,747 supported by decision aids where applicable.1022 Models of care that integrate education, 2459 
engagement, and shared decision making are now available,1023 and may be of particular value in the 2460 
management of AF. 2461 
 2462 
Recommendations for patient involvement, education, and self-management 2463 
Recommendations Class a Level b Refs c 
Tailored patient education is recommended in all phases of AF 
management to support patients’ perception of AF and to 
improve management 
I C 
1014, 1017 
Patient involvement in the care process should be considered to 
encourage self-management and responsibility for lifestyle 
changes 
IIa C 
328, 1010 
Shared decision-making should be considered to ensure that 
care is based on the best available evidence and fits the needs, 
values, and preferences of the patient 
IIa C 
747 
AF = atrial fibrillation. 2464 
aClass of recommendation. 2465 
bLevel of evidence. 2466 
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cReference(s) supporting recommendations. 2467 
 2468 
15 Gaps in evidence 2469 
There are some areas of AF management that are supported by excellent evidence from multiple, adequately 2470 
powered randomized trials (e.g. oral anticoagulation. Other areas, such as rhythm control therapy, integrated AF 2471 
management, and lifestyle modifications are clearly developing the required evidence, while areas such as rate 2472 
control are in dire need of better studies to underpin future guidelines. Here we identify areas in need of further 2473 
research.  2474 
 2475 
15.1. Major health modifiers causing atrial fibrillation 2476 
Atrial fibrillation has different causes in different patients. More research is needed into the major causes (and 2477 
electrophysiological mechanisms) of AF in different patient groups.176, 1024 Such research should consider the 2478 
major comorbidities associated with AF, and characterize the response to AF therapy in patients with different, 2479 
pathophysiologically distinct types of AF.  2480 
 2481 
15.2. How much atrial fibrillation constitutes a mandate for therapy? 2482 
Technological advances allow screening for an irregular pulse using patient-operated ECG devices, 2483 
smartphones, and a variety of other technologies. These may be very useful to detect silent, undiagnosed AF.157 2484 
Adequately powered studies evaluating the diagnostic accuracy of such technologies, the diagnostic yield in 2485 
different populations, the shortest duration of atrial arrhythmias conveying a stroke risk, and ideally the effect of 2486 
ECG screening on outcomes are needed. 2487 
 2488 
15.3. Atrial high-rate episodes and need for anticoagulation 2489 
All of the information on the benefit of OAC has been in patients with AF diagnosed by ECG. Technological 2490 
advances allow ready detection of AHRE in patients with implanted devices and an atrial lead. Such patients are 2491 
at increased stroke risk, but it is unclear whether they benefit from OAC. Controlled trials evaluating OAC in 2492 
AHRE patients are ongoing and will provide evidence on the best antithrombotic therapy in these patients. 2493 
 2494 
15.4. Stroke risk in specific populations 2495 
Several specific AF groups should be studied to better characterize their risk for AF, stroke, and other AF-2496 
related complications (e.g. patients with one stroke risk factor, and non-Caucasian patients). Confounding 2497 
factors (e.g. different therapy of concomitant cardiovascular diseases) may help to explain the variability in the 2498 
reported rates of incident AF, prevalent AF, and AF complications. This also applies to the effect of gender in 2499 
AF patients.47 2500 
 2501 
15.5. Anticoagulation in patients with severe chronic kidney disease 2502 
The use of NOACs has not been tested in patients with creatinine clearance < 30 mL/min, and there is very little 2503 
evidence on the effects of OAC in patients on haemodialysis or on other forms of renal-replacement therapy. 2504 
Studies evaluating OAC in patients with severe chronic kidney disease are needed to inform the best 2505 
management in this patient group at high risk for stroke and bleeding.  2506 
 2507 
15.6. Left atrial appendage occlusion for stroke prevention 2508 
The most common justification for LAA occlusion devices in clinical practice is a perceived high bleeding risk 2509 
and, less often, contraindications for OAC.459 Unfortunately, LAA occluders have not been tested in such 2510 
populations. Furthermore, LAA occluders have not been compared with NOAC therapy in patients at risk for 2511 
bleeding, or with thoracoscopic LAA clipping. There is a clear need to conduct adequately designed and 2512 
powered trials to define the clinical role of LAA occluders compared with NOAC therapy in patients with 2513 
relative or absolute contraindications for anticoagulation, and/or in those suffering from an ischaemic stroke on 2514 
anticoagulant therapy. 2515 
 2516 
15.7. Anticoagulation in atrial fibrillation patients after a bleeding or stroke event 2517 
At least 2% of anticoagulated patients with AF will experience a serious bleeding event per year. Observational 2518 
data suggest that OAC can be reinitiated even after an intracerebral bleeding event.460, 484 Controlled studies 2519 
evaluating different anticoagulation and stroke prevention interventions are urgently needed to provide evidence 2520 
on the best management of patients who have suffered a bleeding event that would usually lead to withholding 2521 
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OAC. Some studies (e.g. APACHE II1025) are ongoing, but adequately powered trials are needed. Similarly, 2522 
prospectively collected data are needed on the efficacy and bleeding risk following (re-)initiation of OAC after 2523 
stroke or intracranial bleeding.  2524 
 2525 
15.8. Anticoagulation and optimal timing of non-acute cardioversion 2526 
Based on retrospective data, previous recommendations on the safe time-window in which a cardioversion can 2527 
be performed in new-onset AF used ≤ 48 hours as the ‘gold standard’ for non-protected cardioversion. However, 2528 
new evidence has emerged that initiating precardioversion anticoagulation in patients with AF episodes of < 24 2529 
hours or even < 12 hours would provide even better safety.642, 647, 1026-1028 Further research is needed to establish 2530 
a clear safety margin in this clinical situation.  2531 
 2532 
15.9. Competing causes of stroke or transient ischaemic attack in atrial fibrillation 2533 
patients 2534 
Prospective RCTs have demonstrated the superiority of carotid endarterectomy compared to stenting in patients 2535 
with symptomatic high-degree stenosis of the internal carotid artery.1029 As endartectomy minimizes the need 2536 
for combination therapy with OAC and antiplatelets,1030 this approach has appeal in patients with AF to reduce 2537 
bleeding risk. However, few of these studies included patients with AF. In a large observational study, the 2538 
composite of in-hospital mortality, post-procedural stroke, and cardiac complications was higher in AF patients 2539 
undergoing carotid stenting (457/7668; 6.0%) compared with endarterectomy (4438/51320; 8.6%; P < 2540 
0.0001).1031 Despite adjustment for baseline risk, this may just reflect the type of patients referred for each 2541 
procedure, and further randomized studies are needed to confirm the optimal treatment strategy in AF patients 2542 
with carotid disease.  2543 
 2544 
15.10. Anticoagulation in patients with biological heart valves (including transcatheter 2545 
aortic valve implantation) and non-rheumatic valve disease 2546 
The optimal antithrombotic therapy in the first months after biological valve replacement (including after 2547 
catheter-based valve replacement) is not known. VKAs remain the mainstay during the initial postoperative 2548 
period; NOACs probably deliver the same protection. In patients without AF, many centres use platelet 2549 
inhibitors only. NOACs appear to be equally effective as VKAs in patients with moderate aortic stenosis, based 2550 
on a subanalysis from the ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared 2551 
with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) trial1032 as well 2552 
as the Loire Valley AF project.1033 Further data would be helpful to confirm these observations.1034 The safety 2553 
and efficacy of NOACs in patients with rheumatic mitral valve disease has not been evaluated and should be 2554 
studied. 2555 
 2556 
15.11. Anticoagulation after ‘successful’ catheter ablation 2557 
In view of the long-term recurrence rates of AF, this Task Force recommends to continue OAC in AF patients 2558 
after ‘successful’ catheter ablation. Nonetheless, observational data suggest that the stroke risk may be lower 2559 
after catheter ablation of AF compared with other AF patients. The ongoing EAST (Early treatment of Atrial 2560 
fibrillation for Stroke prevention Trial) trial will inform in a more general way whether rhythm control therapy 2561 
can reduce stroke rates in anticoagulated AF patients. If confirmed, there may be a place for a controlled trial 2562 
evaluating the termination of OAC therapy at an interval after ‘successful’ catheter ablation.  2563 
 2564 
15.12. Comparison of rate control agents 2565 
Although the use of rate control therapy is very common in AF patients, robust data comparing rate control 2566 
therapies are scant, with the majority of studies being small uncontrolled trials over short periods of follow-up. 2567 
Some studies are funded (e.g. RATE-AF [Rate Control Therapy Evaluation in Permanent Atrial Fibrillation]559) 2568 
and will investigate the potential benefits of different rate controlling agents, characteristics, or biomarkers that 2569 
can help to personalize the use of rate control, and the adverse-event profile of specific drugs in defined groups 2570 
of patients (e.g. AF with HFrEF). 2571 
 2572 
15.13. Catheter ablation in persistent and long-standing persistent AF 2573 
While a few recent randomized studies support the use of catheter or surgical ablation in patients with persistent 2574 
AF and long-standing persistent AF, there is a clear need for more data evaluating this intervention in 2575 
adequately powered randomized trials.  2576 
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 2577 
15.14. Optimal technique for repeat catheter ablation 2578 
PVI emerges as the most important target for catheter ablation of AF. Although a plethora of different additional 2579 
ablation techniques have been published, their added value is questionable in patients undergoing a first catheter 2580 
ablation, including those with persistent AF.735 Many patients are in need of multiple catheter-ablation 2581 
procedures, and such interventions often follow local or operator-specific protocols without clear evidence to 2582 
support the choice of ablation target or intervention. There is a clear clinical need to define the best approach in 2583 
patients who are in need of a second ablation procedure. 2584 
 2585 
15.15. Combination therapy for maintenance of sinus rhythm  2586 
In the follow-up after initially successful catheter ablation, even when done in experienced centres, many 2587 
patients will experience symptomatic recurrences of AF. These patients are often managed with antiarrhythmic 2588 
drugs. There is a surprising paucity of data evaluating different rhythm control interventions in patients with 2589 
recurrent AF after catheter ablation. Such studies seem reasonable and feasible. 2590 
 2591 
15.16. Can rhythm control therapy convey a prognostic benefit in atrial fibrillation 2592 
patients? 2593 
The progress in rhythm control therapy (catheter ablation, new antiarrhythmic drugs) and observational long-2594 
term analyses suggest that rhythm control therapy may have a prognostic benefit. Ongoing trials such as 2595 
CABANA and EAST – AFNET 4 will provide initial answers to this important question, but more data are 2596 
needed, in addition to trials of surgical ablation techniques.  2597 
 2598 
15.17. Thoracoscopic ‘stand-alone’ atrial fibrillation surgery 2599 
Minimally invasive epicardial ablation surgery for the treatment of stand-alone AF was reported a decade 2600 
ago.1035 The procedure has since evolved towards a totally thoracoscopic procedure,1036 and lesion sets were 2601 
extended to a complete left atrial maze.822 With such rapid development and the coexistence of different 2602 
techniques and lesion sets, scientific evidence on long-term results is still limited. Randomized trials using a 2603 
standardized procedure are urgently needed to clearly define the benefits and risks of thoracoscopic AF ablation, 2604 
and to further support decisions of the AF Heart Team. 2605 
  2606 
15.18. Surgical exclusion of the left atrial appendage 2607 
Exclusion of the LAA has been performed by cardiothoracic surgeons for decades, but prospective randomized 2608 
studies comparing the rate of ischaemic stroke with or without left appendage exclusion are presently lacking. 2609 
The LAAOS (Left Atrial Appendage Occlusion Study) III is currently randomizing cardiac surgery patients with 2610 
AF to undergo concomitant occlusion or no occlusion of the appendage.467 More data are also needed to confirm 2611 
the safety and efficacy of thoracoscopic exclusion, following early positive observational data.1037 2612 
  2613 
15.19. Concomitant atrial fibrillation surgery 2614 
Adequately powered randomized trials are needed, employing systematic follow-up, uniform lesion sets and 2615 
energy sources to evaluate the benefits and risks of concomitant AF surgery in symptomatic AF patients. An 2616 
RCT on non-uniform lesion sets with long-term follow-up is due to publish shortly.1038 These will assist the AF 2617 
Heart Team to decide on optimal therapy for individual patients, including the full repertoire of medical and 2618 
surgical options for the treatment of AF. 2619 
2620 
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16 To do and not to do messages from the Guidelines 2621 
 2622 
Recommendations for diagnosis and screening of AF Class Level 
ECG documentation is required to establish the diagnosis of AF I B 
Opportunistic screening for AF is recommended by pulse taking or ECG rhythm 
strip in patients > 65 years of age I B 
In patients with TIA or ischaemic stroke, screening for AF is recommended by 
short-term ECG recording followed by continuous ECG monitoring for at least 
72 hours 
I B 
It is recommended to interrogate pacemakers and ICDs on a regular basis for 
atrial high rate episodes (AHRE). Patients with AHRE should undergo further 
ECG monitoring to document AF before initiating AF therapy 
I B 
Recommendations for general management of AF Class Level 
Tailored patient education is recommended in all phases of AF management to 
support patients’ perception of AF and to improve management I C 
A full cardiovascular evaluation, including an accurate history, careful clinical 
examination, and assessment of concomitant conditions, is recommended in all 
AF patients 
I C 
Use of the modified EHRA symptom scale is recommended in clinical practice 
and research studies to quantify AF-related symptoms I C 
Transthoracic echocardiography is recommended in all AF patients to guide 
management I C 
The assessment of kidney function by serum creatinine or creatinine clearance is 
recommended in all AF patients to detect kidney disease and to support correct 
dosing of AF therapy 
I A 
Recommendations for stroke prevention in AF Class Level 
The CHA2DS2-VASc score is recommended for stroke risk prediction in patients 
with AF I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended for 
all male AF patients with a CHA2DS2-VASc score of 2 or more 
I A 
Oral anticoagulation therapy to prevent thromboembolism is recommended in all 
female AF patients with a CHA2DS2-VASc score of 3 or more 
I 
 A 
When oral anticoagulation is initiated in a patient with AF who is eligible for a 
non vitamin-K-antagonist oral anticoagulant (NOAC, apixaban, dabigatran, 
edoxaban, or rivaroxaban), a NOAC is recommended in preference to a Vitamin 
K antagonist 
I A 
Vitamin K antagonist therapy (INR 2.0–3.0 or higher) is recommended for stroke 
prevention in AF patients with moderate-to-severe mitral stenosis or mechanical 
heart valves 
I B 
NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) are not recommended 
in patients with mechanical heart valves (Level of evidence B) or moderate-to-
severe mitral stenosis (Level of evidence C) 
III (harm) B/C 
When patients are treated with a vitamin K antagonist, time in therapeutic range 
(TTR) should be kept as high as possible and closely monitored I A 
Combinations of oral anticoagulants and platelet inhibitors increase bleeding risk 
and should be avoided in AF patients without another indication for platelet III (harm) B 
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inhibition 
In male or female AF patients without additional stroke risk factors, 
anticoagulant or antiplatelet therapy is not recommended for stroke prevention III (harm) B 
Antiplatelet monotherapy is not recommended for stroke prevention in AF 
patients, regardless of stroke risk III (harm) A 
After surgical occlusion or exclusion of the left atrial appendage, it is 
recommended to continue anticoagulation in at-risk patients with AF for stroke 
prevention 
I B 
Genetic testing before the initiation of vitamin K antagonist therapy is not 
recommended. 
III (no 
benefit) B 
In AF patients with severe active bleeding events, it is recommended to interrupt 
oral anticoagulation therapy until the underlying cause is resolved I C 
NOACs should be avoided in pregnancy and in women planning a pregnancy III (harm) C 
For patients with atrial flutter, antithrombotic therapy is recommended according 
to the same risk profile used for AF I B 
Management of typical atrial flutter with ablation of the cavotricuspid isthmus is 
recommended for patients failing antiarrhythmic drug therapy or as first-line 
treatment considering patient preference 
I B 
Lifelong oral anticoagulation to prevent stroke is recommended in hypertrophic 
cardiomyopathy patients who develop AF I B 
Anticoagulation with heparin or low-molecular-weight heparin immediately after 
ischaemic stroke is not recommended in AF patients III (harm) A 
Systemic thrombolysis with a recombinant tissue plasminogen activator is not 
recommended if the INR is above 1.7 (or, for patients on dabigatran, if activated 
partial thromboplastin time is outside the normal range) 
III (harm) C 
After TIA or stroke, combination therapy of OAC and an antiplatelet is not 
recommended III (harm) B 
Recommendations for rate control of AF Class Level 
Beta-blocker, digoxin, diltiazem, or verapamil is recommended to control heart 
rate in AF patients with LVEF ≥ 40% I B 
Beta-blocker and/or digoxin is recommended to control heart rate in AF patients 
with LVEF < 40%  I B 
In patients with permanent AF (i.e. where no attempt to restore sinus rhythm is 
planned), antiarrhythmic drugs should not routinely be used for rate control III (harm) A 
Recommendations for rhythm control of AF Class Level  
Rhythm control therapy is indicated for symptom improvement in patients with 
AF I B 
Cardioversion of AF (either electrical or pharmacological) is recommended in 
symptomatic patients with persistent or long-standing persistent AF as part of 
rhythm control therapy 
I B 
In patients with no history of ischaemic or structural heart disease, flecainide, 
propafenone, or vernakalant is recommended for pharmacological cardioversion 
of new-onset AF 
I A 
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In patients with ischaemic and/or structural heart disease, amiodarone is 
recommended for cardioversion of AF I A 
For cardioversion of AF/atrial flutter, effective anticoagulation is recommended 
for a minimum of 3 weeks before cardioversion I B 
Transoesophageal echocardiography (TOE) is recommended to exclude cardiac 
thrombus, as an alternative to preprocedural anticoagulation when early 
cardioversion is planned 
I B 
The choice of antiarrhythmic drug needs to be carefully evaluated, taking into 
account the presence of comorbidities, cardiovascular risk and potential for 
serious proarrhythmia, extracardiac toxic effects, patient preferences, and 
symptom burden 
I A 
Dronedarone, flecainide, propafenone, or sotalol is recommended for prevention 
of recurrent symptomatic AF in patients with normal left ventricular function and 
without pathological left ventricular hypertrophy.  
I A 
Dronedarone is recommended for prevention of recurrent symptomatic AF in 
patients with stable coronary artery disease, and without heart failure I A 
Amiodarone is recommended for prevention of recurrent symptomatic AF in 
patients with heart failure I B 
Antiarrhythmic drug therapy is not recommended in patients with prolonged QT 
interval (> 0.5 s) or with significant sinoatrial node disease or atrioventricular 
node dysfunction who do not have a functioning permanent pacemaker 
 
III (harm) 
 
C 
Catheter ablation of symptomatic paroxysmal AF is recommended to improve 
AF symptoms in patients who have symptomatic recurrences of AF on 
antiarrhythmic drug therapy (amiodarone, dronedarone, flecainide, propafenone, 
sotalol) and who prefer further rhythm control therapy, when performed by an 
electrophysiologist who has received appropriate training and is performing the 
procedure in an experienced centre 
I A 
ARBs or ACE inhibitors are not recommended for the secondary prevention of 
paroxysmal AF in patients with little or no underlying heart disease. 
III (no 
benefit) B 
Moderate regular physical activity is recommended to prevent AF, while athletes 
should be counselled that long-lasting, more intense sports participation can 
promote AF 
I A 
 2623 
 2624 
  2625 
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17 A short summary of the management of AF patients 2626 
 2627 
Here, we provide 17 simple rules to guide diagnosis and management of AF patients according to the 2016 2628 
ESC/EACTS/ESO Guidelines for the management of atrial fibrillation 2629 
 2630 
1. Use ECG screening in at risk populations for atrial fibrillation, especially stroke survivors and the 2631 
Elderly. 2632 
2. Document AF by ECG before starting treatment. 2633 
3. Evaluate all AF patients by clinical evaluation, ECG, and echocardiogram for underlying 2634 
cardiovascular conditions such as hypertension, heart failure, valvular heart disease, and others. 2635 
4. Provide tailored information and education to AF patients to empower them to support AF 2636 
management. 2637 
5. Propose life style changes to all suitable AF patients to make their management more effective. 2638 
6. Treat underlying cardiovascular conditions adequately, e.g. valve repair or replacement in AF patients 2639 
with significant valvular heart disease, treatment of heart failure, or management of hypertension, 2640 
among others. 2641 
7. Use oral anticoagulation in all AF patients unless they are at low risk for stroke based on the 2642 
CHA2DS2VASc score or have true contraindications for anticoagulant therapy. 2643 
8. Anticoagulate patients with atrial flutter similar to atrial fibrillation. Offer isthmus ablation to 2644 
symptomatic flutter patients. 2645 
9. Reduce all modifiable bleeding risk factors in all AF patients on oral anticoagulation, e.g. by treating 2646 
hypertension, minimising the duration and intensity of concomitant antiplatelet and NSAID therapy , 2647 
treating anaemia and eliminating causes for blood loss, maintaining stable INR values in patients on 2648 
vitamin K antagonists, and moderating alcohol intake 2649 
10. Check ventricular rate in all AF patients and use rate control medications to achieve lenient rate 2650 
control. 2651 
11. Evaluate AF-related symptoms in all AF patients using the modified EHRA score. Whenever patients 2652 
have AF-related symptoms, aim to improve symptoms by adjustment of rate control therapy and by 2653 
offering antiarrhythmic drugs, cardioversion, or catheter or surgical ablation. 2654 
12. Select antiarrhythmic drugs based on their safety profile and consider catheter or surgical ablation 2655 
when antiarrhythmic drugs fail. 2656 
13. Do not offer routine genetic testing in AF patients unless there is a suspicion for an inherited cardiac 2657 
condition. 2658 
14. Do not use antiplatelet therapy for stroke prevention in AF. 2659 
15. Do not permanently discontinue oral anticoagulation in AF patients at increased risk of stroke unless 2660 
such a decision is taken by a multidisciplinary team. 2661 
16. Do neither use rhythm control therapy in asymptomatic AF patients, nor in patients with permanent 2662 
AF. 2663 
17. Do not perform cardioversion or catheter ablation without anticoagulation unless an atrial thrombus has 2664 
been ruled out by transesophageal echocardiogram. 2665 
 2666 
  2667 
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 2668 
18 Web Addenda 2669 
All Web figures and Web tables are available in the Web addenda, available at European Heart Journal online 2670 
and also via the ESC Website (www.escardio.org/guidelines). 2671 
 2672 
19 Appendix 2673 
ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Victor Aboyans 2674 
(France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Lina Badimon (Spain), Gonzalo Barón-2675 
Esquivias (Spain), Helmut Baumgartner (Germany), Jeroen J. Bax (The Netherlands), Héctor Bueno (Spain), 2676 
Scipione Carerj (Italy), Veronica Dean (France), Çetin Erol (Turkey), Donna Fitzsimons (UK), Oliver 2677 
Gaemperli (Switzerland), Paulus Kirchhof (UK/Germany), Philippe Kolh (Belgium), Patrizio Lancellotti 2678 
(Belgium), Gregory Y. H. Lip (UK), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr 2679 
Ponikowski (Poland), Marco Roffi (Switzerland), Adam Torbicki (Poland), António Vaz Carneiro (Portugal), 2680 
Stephan Windecker (Switzerland). 2681 
 2682 
ESC National Cardiac Societies actively involved in the review process of the 2016 ESC Guidelines for the 2683 
management of atrial fibrillation developed in collaboration with EACTS  2684 
 2685 
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Cardiac Society, Boško Skorić; Cyprus: Cyprus Society of Cardiology, Loizos Antoniades; Czech Republic: 2691 
Czech Society of Cardiology, Milos Taborsky; Denmark: Danish Society of Cardiology, Steen Pehrson; 2692 
Egypt: Egyptian Society of Cardiology, Said Khaled; Estonia: Estonian Society of Cardiology, Priit Kampus; 2693 
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Society of Cardiology, David O. Arnar; Ireland: Irish Cardiac Society, David Keane; Israel: Israel Heart 2698 
Society, Roy Beinart; Italy: Italian Federation of Cardiology, Francesco Romeo; Kazakhstan: Association of 2699 
Cardiologists of Kazakhstan, Kulzida Koshumbayeva; Kosovo: Kosovo Society of Cardiology, Gani Bajraktari; 2700 
Kyrgyzstan: Kyrgyz Society of Cardiology, Aibek Mirrakhimov, Latvia: Latvian Society of Cardiology, 2701 
Oskars Kalejs; Lebanon: Lebanese Society of Cardiology, Samer Nasr; Lithuania: Lithuanian Society of 2702 
Cardiology, Germanas Marinskis; Luxembourg: Luxembourg Society of Cardiology, Carlo Dimmer; Malta: 2703 
Maltese Cardiac Society, Mark Sammut; Moldova: Moldavian Society of Cardiology, Aurel Grosu; Morocco: 2704 
Moroccan Society of Cardiology, Salima Abdelali; The Netherlands: Netherlands Society of Cardiology, 2705 
Martin E. W. Hemels; Norway: Norwegian Society of Cardiology, Ole-Gunnar Anfinsen; Poland: Polish 2706 
Cardiac Society, Beata Średniawa; Portugal: Portuguese Society of Cardiology, Pedro Adragao; Romania: 2707 
Romanian Society of Cardiology, Gheorghe-Andrei Dan; Russian Federation: Russian Society of Cardiology, 2708 
Evgeny N. Mikhaylov; San Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology 2709 
Society of Serbia, Tatjana Potpara; Slovakia: Slovak Society of Cardiology, Peter Hlivak Slovenia: Slovenian 2710 
Society of Cardiology, Igor Zupan; Spain: Spanish Society of Cardiology, Angel Arenal; Sweden: Swedish 2711 
Society of Cardiology, Frieder Braunschweig; Switzerland: Swiss Society of Cardiology, Dipen Shah; Tunisia: 2712 
Tunisian Society of Cardiology and Cardio-Vascular Surgery, Ag Sana Ouali; Turkey: Turkish Society of 2713 
Cardiology, Mesut Demir; Ukraine: Ukrainian Association of Cardiology, Oleg Sychov; United Kingdom: 2714 
British Cardiovascular Society, Ed Duncan. 2715 
 2716 
  2717 
Page 90 of 148 ESC AF Guidelines 
 
 2718 
20 References 2719 
 2720 
 2721 
1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim 2722 
YH, McAnulty JH, Jr., Zheng ZJ, Forouzanfar MH, Naghavi M, Mensah GA, Ezzati M, Murray CJ. 2723 
Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2724 
2014;129:837-847. 2725 
2. Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future 2726 
incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol 2727 
2013;112:1142-1147. 2728 
3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, Stijnen T, Lip 2729 
GY, Witteman JC. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur 2730 
Heart J 2006;27:949-953. 2731 
4. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, D'Agostino RB, Massaro 2732 
JM, Beiser A, Wolf PA, Benjamin EJ. Lifetime risk for development of atrial fibrillation: the 2733 
Framingham Heart Study. Circulation 2004;110:1042-1046. 2734 
5. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of 2735 
diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke 2736 
prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2737 
2001;285:2370-2375. 2738 
6. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, Witteman JC, Stricker BH, 2739 
Heeringa J. Projections on the number of individuals with atrial fibrillation in the European Union, from 2740 
2000 to 2060. Eur Heart J 2013;34:2746-2751. 2741 
7. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: 2742 
European perspective. Clin Epidemiol 2014;6:213-220. 2743 
8. Bjorck S, Palaszewski B, Friberg L, Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin 2744 
therapy revisited: a population-based study. Stroke 2013;44:3103-3108. 2745 
9. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of 2746 
the prevalence, incidence, management and outcome of a large contemporary cohort of patients with 2747 
incident non-valvular atrial fibrillation. J Am Heart Assoc 2015;4:e001486. 2748 
10. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial 2749 
fibrillation. Circulation 2012;126:e143-146. 2750 
11. Ball J, Carrington MJ, McMurray JJ, Stewart S. Atrial fibrillation: profile and burden of an 2751 
evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807-1824. 2752 
12. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and 2753 
predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-2754 
9N. 2755 
13. Nguyen TN, Hilmer SN, Cumming RG. Review of epidemiology and management of atrial 2756 
fibrillation in developing countries. Int J Cardiol 2013;167:2412-2420. 2757 
14. Oldgren J, Healey JS, Ezekowitz M, Commerford P, Avezum A, Pais P, Zhu J, Jansky P, 2758 
Sigamani A, Morillo CA, Liu L, Damasceno A, Grinvalds A, Nakamya J, Reilly PA, Keltai K, Van 2759 
Gelder IC, Yusufali AH, Watanabe E, Wallentin L, Connolly SJ, Yusuf S, RE-LY Atrial Fibrillation 2760 
Registry Investigators. Variations in cause and management of atrial fibrillation in a prospective 2761 
registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation 2762 
Registry. Circulation 2014;129:1568-1576. 2763 
15. Chiang CE, Naditch-Brule L, Murin J, Goethals M, Inoue H, O'Neill J, Silva-Cardoso J, 2764 
Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. Distribution and 2765 
risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight 2766 
from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ 2767 
Arrhythm Electrophysiol 2012;5:632-639. 2768 
16. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, D'Agostino RB, Murabito JM, 2769 
Kannel WB, Benjamin EJ. Temporal relations of atrial fibrillation and congestive heart failure and their 2770 
joint influence on mortality: the Framingham Heart Study. Circulation 2003;107:2920-2925. 2771 
17. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, Smith CJ. Detection of atrial 2772 
fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. 2773 
Stroke 2014;45:520-526. 2774 
18. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs 2775 
V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators. Cryptogenic stroke 2776 
and underlying atrial fibrillation. N Engl J Med 2014;370:2478-2486. 2777 
Page 91 of 148 ESC AF Guidelines 
 
19. Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD, Newton-Cheh C, Lubitz 2778 
SA, Magnani JW, Ellinor PT, Seshadri S, Wolf PA, Vasan RS, Benjamin EJ, Levy D. 50 year trends in 2779 
atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a 2780 
cohort study. Lancet 2015;386:154-162. 2781 
20. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial 2782 
fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98:946-952. 2783 
21. Stewart S, Hart CL, Hole DJ, McMurray JJ. A population-based study of the long-term risks 2784 
associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2785 
2002;113:359-364. 2786 
22. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci 2787 
D. All-cause mortality in 272,186 patients hospitalized with incident atrial fibrillation 1995-2008: a 2788 
Swedish nationwide long-term case-control study. Eur Heart J 2013;34:1061-1067. 2789 
23. Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, Lip GY, Coats AJ, 2790 
Andersson B, Kirchhof P, von Lueder TG, Wedel H, Rosano G, Shibata MC, Rigby A, Flather MD, 2791 
Beta-Blockers in Heart Failure Collaborative Group. Efficacy of beta blockers in patients with heart 2792 
failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. 2793 
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the 2794 
Framingham Study. Stroke 1991;22:983-988. 2795 
25. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial 2796 
fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 2797 
1995;98:476-484. 2798 
26. Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A. Comparison of 2799 
cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. Int J Stroke 2800 
2012;7:276-281. 2801 
27. Grond M, Jauss M, Hamann G, Stark E, Veltkamp R, Nabavi D, Horn M, Weimar C, 2802 
Kohrmann M, Wachter R, Rosin L, Kirchhof P. Improved detection of silent atrial fibrillation using 72-2803 
hour Holter ECG in patients with ischemic stroke: a prospective multicenter cohort study. Stroke 2804 
2013;44:3357-3364. 2805 
28. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A. Atrial 2806 
fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 1997;28:316-321. 2807 
29. Knecht S, Oelschlager C, Duning T, Lohmann H, Albers J, Stehling C, Heindel W, Breithardt 2808 
G, Berger K, Ringelstein EB, Kirchhof P, Wersching H. Atrial fibrillation in stroke-free patients is 2809 
associated with memory impairment and hippocampal atrophy. Eur Heart J 2008;29:2125-2132. 2810 
30. Ball J, Carrington MJ, Stewart S, SAFETY investigators. Mild cognitive impairment in high-risk 2811 
patients with chronic atrial fibrillation: a forgotten component of clinical management? Heart 2812 
2013;99:542-547. 2813 
31. Marzona I, O'Donnell M, Teo K, Gao P, Anderson C, Bosch J, Yusuf S. Increased risk of 2814 
cognitive and functional decline in patients with atrial fibrillation: results of the ONTARGET and 2815 
TRANSCEND studies. CMAJ 2012;184:E329-336. 2816 
32. Thrall G, Lane D, Carroll D, Lip GY. Quality of life in patients with atrial fibrillation: a 2817 
systematic review. Am J Med 2006;119:448 e441-419. 2818 
33. von Eisenhart Rothe A, Hutt F, Baumert J, Breithardt G, Goette A, Kirchhof P, Ladwig KH. 2819 
Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation 2820 
patients: a longitudinal analysis - data from the German Competence Network on Atrial Fibrillation. 2821 
Europace 2015;17:1354-1362. 2822 
34. Steinberg BA, Kim S, Fonarow GC, Thomas L, Ansell J, Kowey PR, Mahaffey KW, Gersh BJ, 2823 
Hylek E, Naccarelli G, Go AS, Reiffel J, Chang P, Peterson ED, Piccini JP. Drivers of hospitalization 2824 
for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of 2825 
Atrial Fibrillation (ORBIT-AF). Am Heart J 2014;167:735-742 e732. 2826 
35. Kirchhof P, Schmalowsky J, Pittrow D, Rosin L, Kirch W, Wegscheider K, Meinertz T. 2827 
Management of patients wtih atrial fibrillation by primary care physicians in Germany: 1-year results of 2828 
the ATRIUM registry. Clin Cardiol 2014;37:277-284. 2829 
36. Stewart S, Murphy N, Walker A, McGuire A, McMurray JJV. Cost of an emerging epidemic: 2830 
an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292. 2831 
37. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total incremental 2832 
health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual 2833 
Outcomes 2011;4:313-320. 2834 
38. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in 2835 
patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-867. 2836 
Page 92 of 148 ESC AF Guidelines 
 
39. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm 2837 
AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and 2838 
safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of 2839 
randomised trials. Lancet 2014;383:955-962. 2840 
40. Kirchhof P, Breithardt G, Camm AJ, Crijns HJ, Kuck KH, Vardas P, Wegscheider K. Improving 2841 
outcomes in patients with atrial fibrillation: rationale and design of the Early treatment of Atrial 2842 
fibrillation for Stroke prevention Trial. Am Heart J 2013;166:442-448. 2843 
41. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, 2844 
Povsic TJ, Raju SS, Shah B, Kosinski AS, McBroom AJ, Sanders GD. Rate- and rhythm-control 2845 
therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 2014;160:760-773. 2846 
42. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, 2847 
Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G. Prognosis and treatment of atrial 2848 
fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research 2849 
Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2850 
2014;35:3365-3376. 2851 
43. Marijon E, Le Heuzey JY, Connolly S, Yang S, Pogue J, Brueckmann M, Eikelboom J, 2852 
Themeles E, Ezekowitz M, Wallentin L, Yusuf S, RE-LY Investigators. Causes of death and 2853 
influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized 2854 
evaluation of long-term anticoagulant therapy study. Circulation 2013;128:2192-2201. 2855 
44. Senoo K, Lip GY, Lane DA, Buller HR, Kotecha D. Residual risk of stroke and death in 2856 
anticoagulated patients according to the type of atrial fibrillation: AMADEUS Trial. Stroke 2857 
2015;46:2523-2528. 2858 
45. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, Thacker EL, Judd 2859 
S, Howard VJ, Howard G, Herrington DM, Cushman M. Atrial fibrillation and the risk of myocardial 2860 
infarction. JAMA Intern Med 2014;174:107-114. 2861 
46. Emdin CA, Wong CX, Hsiao AJ, Altman DG, Peters SA, Woodward M, Odutayo AA. Atrial 2862 
fibrillation as risk factor for cardiovascular disease and death in women compared with men: 2863 
systematic review and meta-analysis of cohort studies. BMJ 2016;532:h7013. 2864 
47. Ko D, Rahman F, Schnabel RB, Yin X, Benjamin EJ, Christophersen IE. Atrial fibrillation in 2865 
women: epidemiology, pathophysiology, presentation, and prognosis. Nat Rev Cardiol 2016:[Epub 2866 
ahead of print]. 2867 
48. Andersson T, Magnuson A, Bryngelsson IL, Frobert O, Henriksson KM, Edvardsson N, Poci 2868 
D. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients 2869 
hospitalized with incident atrial fibrillation without concomitant diseases: A nationwide cohort study of 2870 
9519 patients. Int J Cardiol 2014;177:91-99. 2871 
49. Fang MC, Singer DE, Chang Y, Hylek EM, Henault LE, Jensvold NG, Go AS. Gender 2872 
differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the 2873 
AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005;112:1687-1691. 2874 
50. Pancholy SB, Sharma PS, Pancholy DS, Patel TM, Callans DJ, Marchlinski FE. Meta-analysis 2875 
of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial 2876 
fibrillation treated with oral anticoagulants. Am J Cardiol 2014;113:485-490. 2877 
51. Potpara TS, Marinkovic JM, Polovina MM, Stankovic GR, Seferovic PM, Ostojic MC, Lip GY. 2878 
Gender-related differences in presentation, treatment and long-term outcome in patients with first-2879 
diagnosed atrial fibrillation and structurally normal heart: the Belgrade atrial fibrillation study. Int J 2880 
Cardiol 2012;161:39-44. 2881 
52. Ball J, Carrington MJ, Wood KA, Stewart S, SAFETY Investigators. Women versus men with 2882 
chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT 2883 
studY (SAFETY). PLoS One 2013;8:e65795. 2884 
53. Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients 2885 
with atrial fibrillation: a systematic review. Qjm 2007;100:599-607. 2886 
54. Roten L, Rimoldi SF, Schwick N, Sakata T, Heimgartner C, Fuhrer J, Delacretaz E, Tanner H. 2887 
Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing 2888 
Clin Electrophysiol 2009;32:622-626. 2889 
55. Forleo GB, Tondo C, De Luca L, Dello Russo A, Casella M, De Sanctis V, Clementi F, 2890 
Fagundes RL, Leo R, Romeo F, Mantica M. Gender-related differences in catheter ablation of atrial 2891 
fibrillation. Europace 2007;9:613-620. 2892 
56. Henry L, Hunt S, Holmes SD, Martin LM, Ad N. Are there gender differences in outcomes 2893 
after the Cox-Maze procedure for atrial fibrillation? Innovations (Phila) 2013;8:190-198. 2894 
57. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: 2895 
Ten years later. Gend Med 2010;7:206-217. 2896 
Page 93 of 148 ESC AF Guidelines 
 
58. Fox CS, Parise H, D'Agostino RB, Sr., Lloyd-Jones DM, Vasan RS, Wang TJ, Levy D, Wolf 2897 
PA, Benjamin EJ. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 2898 
2004;291:2851-2855. 2899 
59. Oyen N, Ranthe MF, Carstensen L, Boyd HA, Olesen MS, Olesen SP, Wohlfahrt J, Melbye M. 2900 
Familial aggregation of lone atrial fibrillation in young persons. J Am Coll Cardiol 2012;60:917-921. 2901 
60. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, Arking DE, Muller-2902 
Nurasyid M, Krijthe BP, Lubitz SA, Bis JC, Chung MK, Dorr M, Ozaki K, Roberts JD, Smith JG, 2903 
Pfeufer A, Sinner MF, Lohman K, Ding J, Smith NL, Smith JD, Rienstra M, Rice KM, Van Wagoner 2904 
DR, Magnani JW, Wakili R, Clauss S, Rotter JI, Steinbeck G, Launer LJ, Davies RW, Borkovich M, 2905 
Harris TB, Lin H, Volker U, Volzke H, Milan DJ, Hofman A, Boerwinkle E, Chen LY, Soliman EZ, 2906 
Voight BF, Li G, Chakravarti A, Kubo M, Tedrow UB, Rose LM, Ridker PM, Conen D, Tsunoda T, 2907 
Furukawa T, Sotoodehnia N, Xu S, Kamatani N, Levy D, Nakamura Y, Parvez B, Mahida S, Furie KL, 2908 
Rosand J, Muhammad R, Psaty BM, Meitinger T, Perz S, Wichmann HE, Witteman JC, Kao WH, 2909 
Kathiresan S, Roden DM, Uitterlinden AG, Rivadeneira F, McKnight B, Sjogren M, Newman AB, Liu 2910 
Y, Gollob MH, Melander O, Tanaka T, Stricker BH, Felix SB, Alonso A, Darbar D, Barnard J, 2911 
Chasman DI, Heckbert SR, Benjamin EJ, Gudnason V, Kaab S. Meta-analysis identifies six new 2912 
susceptibility loci for atrial fibrillation. Nat Genet 2012;44:670-675. 2913 
61. Olesen MS, Nielsen MW, Haunso S, Svendsen JH. Atrial fibrillation: the role of common and 2914 
rare genetic variants. Eur J Hum Genet 2014;22:297-306. 2915 
62. Sinner MF, Tucker NR, Lunetta KL, Ozaki K, Smith JG, Trompet S, Bis JC, Lin H, Chung MK, 2916 
Nielsen JB, Lubitz SA, Krijthe BP, Magnani JW, Ye J, Gollob MH, Tsunoda T, Muller-Nurasyid M, 2917 
Lichtner P, Peters A, Dolmatova E, Kubo M, Smith JD, Psaty BM, Smith NL, Jukema JW, Chasman 2918 
DI, Albert CM, Ebana Y, Furukawa T, Macfarlane PW, Harris TB, Darbar D, Dorr M, Holst AG, 2919 
Svendsen JH, Hofman A, Uitterlinden AG, Gudnason V, Isobe M, Malik R, Dichgans M, Rosand J, 2920 
Van Wagoner DR, METASTROKE Consortium, AFGen Consortium, Benjamin EJ, Milan DJ, Melander 2921 
O, Heckbert SR, Ford I, Liu Y, Barnard J, Olesen MS, Stricker BH, Tanaka T, Kaab S, Ellinor PT. 2922 
Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial 2923 
fibrillation. Circulation 2014;130:1225-1235. 2924 
63. Gudbjartsson DF, Arnar DO, Helgadottir A, Gretarsdottir S, Holm H, Sigurdsson A, 2925 
Jonasdottir A, Baker A, Thorleifsson G, Kristjansson K, Palsson A, Blondal T, Sulem P, Backman VM, 2926 
Hardarson GA, Palsdottir E, Helgason A, Sigurjonsdottir R, Sverrisson JT, Kostulas K, Ng MC, Baum 2927 
L, So WY, Wong KS, Chan JC, Furie KL, Greenberg SM, Sale M, Kelly P, MacRae CA, Smith EE, 2928 
Rosand J, Hillert J, Ma RC, Ellinor PT, Thorgeirsson G, Gulcher JR, Kong A, Thorsteinsdottir U, 2929 
Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 2007;448:353-2930 
357. 2931 
64. Lubitz SA, Lunetta KL, Lin H, Arking DE, Trompet S, Li G, Krijthe BP, Chasman DI, Barnard J, 2932 
Kleber ME, Dorr M, Ozaki K, Smith AV, Muller-Nurasyid M, Walter S, Agarwal SK, Bis JC, Brody JA, 2933 
Chen LY, Everett BM, Ford I, Franco OH, Harris TB, Hofman A, Kaab S, Mahida S, Kathiresan S, 2934 
Kubo M, Launer LJ, Macfarlane PW, Magnani JW, McKnight B, McManus DD, Peters A, Psaty BM, 2935 
Rose LM, Rotter JI, Silbernagel G, Smith JD, Sotoodehnia N, Stott DJ, Taylor KD, Tomaschitz A, 2936 
Tsunoda T, Uitterlinden AG, Van Wagoner DR, Volker U, Volzke H, Murabito JM, Sinner MF, 2937 
Gudnason V, Felix SB, Marz W, Chung M, Albert CM, Stricker BH, Tanaka T, Heckbert SR, Jukema 2938 
JW, Alonso A, Benjamin EJ, Ellinor PT. Novel genetic markers associate with atrial fibrillation risk in 2939 
Europeans and Japanese. J Am Coll Cardiol 2014;63:1200-1210. 2940 
65. Lemmens R, Buysschaert I, Geelen V, Fernandez-Cadenas I, Montaner J, Schmidt H, 2941 
Schmidt R, Attia J, Maguire J, Levi C, Jood K, Blomstrand C, Jern C, Wnuk M, Slowik A, Lambrechts 2942 
D, Thijs V, International Stroke Genetics Consortium. The association of the 4q25 susceptibility 2943 
variant for atrial fibrillation with stroke is limited to stroke of cardioembolic etiology. Stroke 2944 
2010;41:1850-1857. 2945 
66. Tada H, Shiffman D, Smith JG, Sjogren M, Lubitz SA, Ellinor PT, Louie JZ, Catanese JJ, 2946 
Engstrom G, Devlin JJ, Kathiresan S, Melander O. Twelve-single nucleotide polymorphism genetic 2947 
risk score identifies individuals at increased risk for future atrial fibrillation and stroke. Stroke 2948 
2014;45:2856-2862. 2949 
67. Wang J, Klysik E, Sood S, Johnson RL, Wehrens XH, Martin JF. Pitx2 prevents susceptibility 2950 
to atrial arrhythmias by inhibiting left-sided pacemaker specification. Proc Natl Acad Sci U S A 2951 
2010;107:9753-9758. 2952 
68. Franco D, Chinchilla A, Daimi H, Dominguez JN, Aranega A. Modulation of conductive 2953 
elements by Pitx2 and their impact on atrial arrhythmogenesis. Cardiovasc Res 2011;91:223-231. 2954 
69. Kirchhof P, Kahr PC, Kaese S, Piccini I, Vokshi I, Scheld HH, Rotering H, Fortmueller L, 2955 
Laakmann S, Verheule S, Schotten U, Fabritz L, Brown NA. PITX2c is expressed in the adult left 2956 
Page 94 of 148 ESC AF Guidelines 
 
atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in 2957 
gene expression. Circ Cardiovasc Genet 2011;4:123-133. 2958 
70. Wang J, Bai Y, Li N, Ye W, Zhang M, Greene SB, Tao Y, Chen Y, Wehrens XH, Martin JF. 2959 
Pitx2-microRNA pathway that delimits sinoatrial node development and inhibits predisposition to atrial 2960 
fibrillation. Proc Natl Acad Sci U S A 2014. 2961 
71. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and 2962 
atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2010;55:747-753. 2963 
72. Parvez B, Shoemaker MB, Muhammad R, Richardson R, Jiang L, Blair MA, Roden DM, 2964 
Darbar D. Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after 2965 
successful cardioversion. Heart Rhythm 2013;10:849-855. 2966 
73. Benjamin Shoemaker M, Muhammad R, Parvez B, White BW, Streur M, Song Y, Stubblefield 2967 
T, Kucera G, Blair M, Rytlewski J, Parvathaneni S, Nagarakanti R, Saavedra P, Ellis CR, Patrick 2968 
Whalen S, Roden DM, Darbar RD. Common atrial fibrillation risk alleles at 4q25 predict recurrence 2969 
after catheter-based atrial fibrillation ablation. Heart Rhythm 2013;10:394-400. 2970 
74. Parvez B, Vaglio J, Rowan S, Muhammad R, Kucera G, Stubblefield T, Carter S, Roden D, 2971 
Darbar D. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single 2972 
nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:539-545. 2973 
75. Kirchhof P, Sipido KR, Cowie MR, Eschenhagen T, Fox KA, Katus H, Schroeder S, Schunkert 2974 
H, Priori S, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine. The 2975 
continuum of personalized cardiovascular medicine: a position paper of the European Society of 2976 
Cardiology. Eur Heart J 2014;35:3250-3257. 2977 
76. Kirchhof P, Breithardt G, Aliot E, Al Khatib S, Apostolakis S, Auricchio A, Bailleul C, Bax J, 2978 
Benninger G, Blomstrom-Lundqvist C, Boersma L, Boriani G, Brandes A, Brown H, Brueckmann M, 2979 
Calkins H, Casadei B, Clemens A, Crijns H, Derwand R, Dobrev D, Ezekowitz M, Fetsch T, Gerth A, 2980 
Gillis A, Gulizia M, Hack G, Haegeli L, Hatem S, Georg Hausler K, Heidbuchel H, Hernandez-Brichis 2981 
J, Jais P, Kappenberger L, Kautzner J, Kim S, Kuck KH, Lane D, Leute A, Lewalter T, Meyer R, Mont 2982 
L, Moses G, Mueller M, Munzel F, Nabauer M, Nielsen JC, Oeff M, Oto A, Pieske B, Pisters R, 2983 
Potpara T, Rasmussen L, Ravens U, Reiffel J, Richard-Lordereau I, Schafer H, Schotten U, Stegink 2984 
W, Stein K, Steinbeck G, Szumowski L, Tavazzi L, Themistoclakis S, Thomitzek K, Van Gelder IC, 2985 
von Stritzky B, Vincent A, Werring D, Willems S, Lip GY, Camm AJ. Personalized management of 2986 
atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart 2987 
Rhythm Association consensus conference. Europace 2013;15:1540-1556. 2988 
77. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, 2989 
Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, 2990 
Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP, Heart Rhythm Society, European 2991 
Heart Rhythm Association. HRS/EHRA expert consensus statement on the state of genetic testing for 2992 
the channelopathies and cardiomyopathies: this document was developed as a partnership between 2993 
the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2994 
2011;13:1077-1109. 2995 
78. Anne W, Willems R, Roskams T, Sergeant P, Herijgers P, Holemans P, Ector H, Heidbuchel 2996 
H. Matrix metalloproteinases and atrial remodeling in patients with mitral valve disease and atrial 2997 
fibrillation. Cardiovasc Res 2005;67:655-666. 2998 
79. Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of human atrial fibrillation. 2999 
Biomed Pharmacother 2010;64:177-183. 3000 
80. Nguyen BL, Fishbein MC, Chen LS, Chen PS, Masroor S. Histopathological substrate for 3001 
chronic atrial fibrillation in humans. Heart Rhythm 2009;6:454-460. 3002 
81. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of 3003 
atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96:1180-1184. 3004 
82. Venteclef N, Guglielmi V, Balse E, Gaborit B, Cotillard A, Atassi F, Amour J, Leprince P, 3005 
Dutour A, Clement K, Hatem SN. Human epicardial adipose tissue induces fibrosis of the atrial 3006 
myocardium through the secretion of adipo-fibrokines. Eur Heart J 2013. 3007 
83. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A. 3008 
Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation 3009 
2002;106:2091-2097. 3010 
84. Schotten U, Ausma J, Stellbrink C, Sabatschus I, Vogel M, Frechen D, Schoendube F, 3011 
Hanrath P, Allessie MA. Cellular mechanisms of depressed atrial contractility in patients with chronic 3012 
atrial fibrillation. Circulation 2001;103:691-698. 3013 
85. Allessie MA, de Groot NM, Houben RP, Schotten U, Boersma E, Smeets JL, Crijns HJ. 3014 
Electropathological substrate of long-standing persistent atrial fibrillation in patients with structural 3015 
heart disease: longitudinal dissociation. Circ Arrhythm Electrophysiol 2010;3:606-615. 3016 
Page 95 of 148 ESC AF Guidelines 
 
86. Spach MS, Josephson ME. Initiating reentry: the role of nonuniform anisotropy in small 3017 
circuits. J Cardiovasc Electrophysiol 1994;5:182-209. 3018 
87. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation 3019 
substrate during development and reversal of heart failure in dogs. Circulation 2002;105:2672-2678. 3020 
88. Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH, Leong DP, Brooks AG, 3021 
Young GD, Kistler PM, Kalman JM, Worthley MI, Sanders P. Effect of atrial fibrillation on atrial 3022 
thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 2013;61:852-860. 3023 
89. Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a 3024 
clinical review. Eur Heart J 2013;34:1475-1480. 3025 
90. Xu J, Cui G, Esmailian F, Plunkett M, Marelli D, Ardehali A, Odim J, Laks H, Sen L. Atrial 3026 
extracellular matrix remodeling and the maintenance of atrial fibrillation. Circulation 2004;109:363-3027 
368. 3028 
91. Gramley F, Lorenzen J, Plisiene J, Rakauskas M, Benetis R, Schmid M, Autschbach R, 3029 
Knackstedt C, Schimpf T, Mischke K, Gressner A, Hanrath P, Kelm M, Schauerte P. Decreased 3030 
plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote 3031 
increased metalloproteinase activity with increasing duration of human atrial fibrillation. J Cardiovasc 3032 
Electrophysiol 2007;18:1076-1082. 3033 
92. Hatem SN, Sanders P. Epicardial adipose tissue and atrial fibrillation. Cardiovasc Res 3034 
2014;102:205-213. 3035 
93. Leone O, Boriani G, Chiappini B, Pacini D, Cenacchi G, Martin Suarez S, Rapezzi C, Bacchi 3036 
Reggiani ML, Marinelli G. Amyloid deposition as a cause of atrial remodelling in persistent valvular 3037 
atrial fibrillation. Eur Heart J 2004;25:1237-1241. 3038 
94. Dobrev D, Friedrich A, Voigt N, Jost N, Wettwer E, Christ T, Knaut M, Ravens U. The G 3039 
protein-gated potassium current I(K,ACh) is constitutively active in patients with chronic atrial 3040 
fibrillation. Circulation 2005;112:3697-3706. 3041 
95. Van Wagoner DR, Pond AL, Lamorgese M, Rossie SS, McCarthy PM, Nerbonne JM. Atrial L-3042 
type Ca2+ currents and human atrial fibrillation. Circ Res 1999;85:428-436. 3043 
96. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial 3044 
fibrillation: a translational appraisal. Physiol Rev 2011;91:265-325. 3045 
97. Voigt N, Heijman J, Wang Q, Chiang DY, Li N, Karck M, Wehrens XH, Nattel S, Dobrev D. 3046 
Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial 3047 
fibrillation. Circulation 2014;129:145-156. 3048 
98. Voigt N, Li N, Wang Q, Wang W, Trafford AW, Abu-Taha I, Sun Q, Wieland T, Ravens U, 3049 
Nattel S, Wehrens XH, Dobrev D. Enhanced sarcoplasmic reticulum Ca2+ leak and increased Na+-3050 
Ca2+ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial 3051 
fibrillation. Circulation 2012;125:2059-2070. 3052 
99. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, 3053 
De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat 3054 
atria. J Am Coll Cardiol 2001;38:883-891. 3055 
100. Aime-Sempe C, Folliguet T, Rucker-Martin C, Krajewska M, Krajewska S, Heimburger M, 3056 
Aubier M, Mercadier JJ, Reed JC, Hatem SN. Myocardial cell death in fibrillating and dilated human 3057 
right atria. J Am Coll Cardiol 1999;34:1577-1586. 3058 
101. Spach MS, Heidlage JF, Barr RC, Dolber PC. Cell size and communication: role in structural 3059 
and electrical development and remodeling of the heart. Heart Rhythm 2004;1:500-515. 3060 
102. Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated 3061 
atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol 3062 
2008;51:2053-2057. 3063 
103. Barretto AC, Mady C, Nussbacher A, Ianni BM, Oliveira SA, Jatene A, Ramires JA. Atrial 3064 
fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol 1998;67:19-25. 3065 
104. Levy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin 3066 
Electrophysiol 1997;20:2670-2674. 3067 
105. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous system in 3068 
atrial fibrillation: pathophysiology and therapy. Circ Res 2014;114:1500-1515. 3069 
106. Christ T, Rozmaritsa N, Engel A, Berk E, Knaut M, Metzner K, Canteras M, Ravens U, 3070 
Kaumann A. Arrhythmias, elicited by catecholamines and serotonin, vanish in human chronic atrial 3071 
fibrillation. Proc Natl Acad Sci U S A 2014;111:11193-11198. 3072 
107. Greiser M, Kerfant BG, Williams GS, Voigt N, Harks E, Dibb KM, Giese A, Meszaros J, 3073 
Verheule S, Ravens U, Allessie MA, Gammie JS, van der Velden J, Lederer WJ, Dobrev D, Schotten 3074 
U. Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes. J Clin Invest 3075 
2014;124:4759-4772. 3076 
Page 96 of 148 ESC AF Guidelines 
 
108. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le 3077 
Mouroux A, Le Metayer P, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats 3078 
originating in the pulmonary veins. N Engl J Med 1998;339:659-666. 3079 
109. Patterson E, Jackman WM, Beckman KJ, Lazzara R, Lockwood D, Scherlag BJ, Wu R, Po S. 3080 
Spontaneous pulmonary vein firing in man: relationship to tachycardia-pause early 3081 
afterdepolarizations and triggered arrhythmia in canine pulmonary veins in vitro. J Cardiovasc 3082 
Electrophysiol 2007;18:1067-1075. 3083 
110. Atienza F, Almendral J, Moreno J, Vaidyanathan R, Talkachou A, Kalifa J, Arenal A, 3084 
Villacastin JP, Torrecilla EG, Sanchez A, Ploutz-Snyder R, Jalife J, Berenfeld O. Activation of inward 3085 
rectifier potassium channels accelerates atrial fibrillation in humans: evidence for a reentrant 3086 
mechanism. Circulation 2006;114:2434-2442. 3087 
111. Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J. Stable microreentrant sources as a 3088 
mechanism of atrial fibrillation in the isolated sheep heart. Circulation 2000;101:194-199. 3089 
112. Sahadevan J, Ryu K, Peltz L, Khrestian CM, Stewart RW, Markowitz AH, Waldo AL. 3090 
Epicardial mapping of chronic atrial fibrillation in patients: preliminary observations. Circulation 3091 
2004;110:3293-3299. 3092 
113. Sanders P, Nalliah CJ, Dubois R, Takahashi Y, Hocini M, Rotter M, Rostock T, Sacher F, Hsu 3093 
LF, Jonsson A, O'Neill MD, Jais P, Haissaguerre M. Frequency mapping of the pulmonary veins in 3094 
paroxysmal versus permanent atrial fibrillation. J Cardiovasc Electrophysiol 2006;17:965-972. 3095 
114. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal 3096 
discharge. Am Heart J 1959;58:59-70. 3097 
115. Cox JL, Canavan TE, Schuessler RB, Cain ME, Lindsay BD, Stone C, Smith PK, Corr PB, 3098 
Boineau JP. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping 3099 
and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. J Thorac 3100 
Cardiovasc Surg 1991;101:406-426. 3101 
116. Narayan SM, Krummen DE, Shivkumar K, Clopton P, Rappel WJ, Miller JM. Treatment of 3102 
atrial fibrillation by the ablation of localized sources: CONFIRM (Conventional Ablation for Atrial 3103 
Fibrillation With or Without Focal Impulse and Rotor Modulation) trial. J Am Coll Cardiol 2012;60:628-3104 
636. 3105 
117. Haissaguerre M, Hocini M, Denis A, Shah AJ, Komatsu Y, Yamashita S, Daly M, Amraoui S, 3106 
Zellerhoff S, Picat MQ, Quotb A, Jesel L, Lim H, Ploux S, Bordachar P, Attuel G, Meillet V, Ritter P, 3107 
Derval N, Sacher F, Bernus O, Cochet H, Jais P, Dubois R. Driver domains in persistent atrial 3108 
fibrillation. Circulation 2014;130:530-538. 3109 
118. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, 3110 
Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. 3111 
Eur Heart J 2004;25:1385-1394. 3112 
119. Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H. 3113 
Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of 3114 
asymptomatic arrhythmia recurrence. Circulation 2005;112:307-313. 3115 
120. Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, Cappato R, Cosio F, Crijns 3116 
H, Diener HC, Goette A, Israel CW, Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, 3117 
Steinbeck G, Vardas P, Waldo A, Wegscheider K, Willems S, Breithardt G. Early and comprehensive 3118 
management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA 3119 
consensus conference 'research perspectives in AF'. Eur Heart J 2009;30:2969-2977c. 3120 
121. Xiong Q, Proietti M, Senoo K, Lip GY. Asymptomatic versus symptomatic atrial fibrillation: A 3121 
systematic review of age/gender differences and cardiovascular outcomes. Int J Cardiol 3122 
2015;191:172-177. 3123 
122. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, 3124 
quality of life, and management. J Interv Card Electrophysiol 2000;4:369-382. 3125 
123. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the 3126 
Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010;31:967-975. 3127 
124. Vanassche T, Lauw MN, Eikelboom JW, Healey JS, Hart RG, Alings M, Avezum A, Diaz R, 3128 
Hohnloser SH, Lewis BS, Shestakovska O, Wang J, Connolly SJ. Risk of ischaemic stroke according 3129 
to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. 3130 
Eur Heart J 2015;36:281-287a. 3131 
125. Steinberg BA, Hellkamp AS, Lokhnygina Y, Patel MR, Breithardt G, Hankey GJ, Becker RC, 3132 
Singer DE, Halperin JL, Hacke W, Nessel CC, Berkowitz SD, Mahaffey KW, Fox KA, Califf RM, 3133 
Piccini JP. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: 3134 
results from the ROCKET-AF Trial. Eur Heart J 2015;36:288-296. 3135 
Page 97 of 148 ESC AF Guidelines 
 
126. Fitzmaurice DA, Hobbs FD, Jowett S, Mant J, Murray ET, Holder R, Raftery JP, Bryan S, 3136 
Davies M, Lip GY, Allan TF. Screening versus routine practice in detection of atrial fibrillation in 3137 
patients aged 65 or over: cluster randomised controlled trial. BMJ 2007;335:383. 3138 
127. Rizos T, Guntner J, Jenetzky E, Marquardt L, Reichardt C, Becker R, Reinhardt R, Hepp T, 3139 
Kirchhof P, Aleynichenko E, Ringleb P, Hacke W, Veltkamp R. Continuous stroke unit 3140 
electrocardiographic monitoring versus 24-hour Holter electrocardiography for detection of 3141 
paroxysmal atrial fibrillation after stroke. Stroke 2012;43:2689-2694. 3142 
128. Gladstone DJ, Spring M, Dorian P, Panzov V, Thorpe KE, Hall J, Vaid H, O'Donnell M, 3143 
Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A, Hachinski V, Coutts SB, Sahlas DJ, Teal P, Yip 3144 
S, Spence JD, Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, 3145 
Boyle K, Aviv R, Kapral MK, Mamdani M, EMBRACE Investigators and Coordinators. Atrial fibrillation 3146 
in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-2477. 3147 
129. Friberg L, Engdahl J, Frykman V, Svennberg E, Levin LA, Rosenqvist M. Population 3148 
screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). 3149 
Europace 2013;15:135-140. 3150 
130. Davis RC, Hobbs FD, Kenkre JE, Roalfe AK, Iles R, Lip GY, Davies MK. Prevalence of atrial 3151 
fibrillation in the general population and in high-risk groups: the ECHOES study. Europace 3152 
2012;14:1553-1559. 3153 
131. Hobbs FD, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, Raftery J, Davies M, Lip G. 3154 
A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total 3155 
population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 3156 
and over. The SAFE study. Health Technol Assess 2005;9:iii-iv, ix-x, 1-74. 3157 
132. Aronsson M, Svennberg E, Rosenqvist M, Engdahl J, Al-Khalili F, Friberg L, Frykman-Kull V, 3158 
Levin LA. Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG 3159 
recording. Europace 2015;17:1023-1029. 3160 
133. Levin LA, Husberg M, Sobocinski PD, Kull VF, Friberg L, Rosenqvist M, Davidson T. A cost-3161 
effectiveness analysis of screening for silent atrial fibrillation after ischaemic stroke. Europace 3162 
2015;17:207-214. 3163 
134. Lowres N, Neubeck L, Redfern J, Freedman SB. Screening to identify unknown atrial 3164 
fibrillation. A systematic review. Thromb Haemost 2013;110:213-222. 3165 
135. Engdahl J, Andersson L, Mirskaya M, Rosenqvist M. Stepwise screening of atrial fibrillation in 3166 
a 75-year-old population: implications for stroke prevention. Circulation 2013;127:930-937. 3167 
136. Kaleschke G, Hoffmann B, Drewitz I, Steinbeck G, Naebauer M, Goette A, Breithardt G, 3168 
Kirchhof P. Prospective, multicentre validation of a simple, patient-operated electrocardiographic 3169 
system for the detection of arrhythmias and electrocardiographic changes. Europace 2009;11:1362-3170 
1368. 3171 
137. Tieleman RG, Plantinga Y, Rinkes D, Bartels GL, Posma JL, Cator R, Hofman C, Houben RP. 3172 
Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. Europace 3173 
2014;16:1291-1295. 3174 
138. Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, Fought AJ, Topol EJ. 3175 
Comparison of 24-hour Holter monitoring with 14-day novel adhesive patch electrocardiographic 3176 
monitoring. Am J Med 2014;127:95 e11-97. 3177 
139. Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, Bennett AA, Briffa T, 3178 
Bauman A, Martinez C, Wallenhorst C, Lau JK, Brieger DB, Sy RW, Freedman SB. Feasibility and 3179 
cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone 3180 
ECG in pharmacies. The SEARCH-AF study. Thromb Haemost 2014;111:1167-1176. 3181 
140. Quinn FR, Gladstone D. Screening for undiagnosed atrial fibrillation in the community. Curr 3182 
Opin Cardiol 2014;29:28-35. 3183 
141. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, Lau CP, Fain E, 3184 
Yang S, Bailleul C, Morillo CA, Carlson M, Themeles E, Kaufman ES, Hohnloser SH, ASSERT 3185 
Investigators. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012;366:120-129. 3186 
142. Hindricks G, Pokushalov E, Urban L, Taborsky M, Kuck KH, Lebedev D, Rieger G, 3187 
Purerfellner H. Performance of a new leadless implantable cardiac monitor in detecting and 3188 
quantifying atrial fibrillation - results of the XPECT trial. Circ Arrhythm Electrophysiol 2010;3:141-147. 3189 
143. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van Gelder IC, 3190 
Hohnloser SH, Carlson M, Fain E, Nakamya J, Mairesse GH, Halytska M, Deng WQ, Israel CW, 3191 
Healey JS, ASSERT Investigators. Temporal relationship between subclinical atrial fibrillation and 3192 
embolic events. Circulation 2014;129:2094-2099. 3193 
144. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M, Gasparini M, Lewalter T, 3194 
Camm JA, Singer DE. Device-detected atrial fibrillation and risk for stroke: an analysis of >10,000 3195 
Page 98 of 148 ESC AF Guidelines 
 
patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation 3196 
information from implanted devices). Eur Heart J 2014;35:508-516. 3197 
145. Santini M, Gasparini M, Landolina M, Lunati M, Proclemer A, Padeletti L, Catanzariti D, Molon 3198 
G, Botto GL, La Rocca L, Grammatico A, Boriani G. Device-detected atrial tachyarrhythmias predict 3199 
adverse outcome in real-world patients with implantable biventricular defibrillators. J Am Coll Cardiol 3200 
2011;57:167-172. 3201 
146. Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD. Temporal 3202 
relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored 3203 
device data: a subgroup analysis of TRENDS. Heart Rhythm 2011;8:1416-1423. 3204 
147. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C, Qi D, Ziegler 3205 
PD. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics 3206 
and stroke risk: the TRENDS study. Circ Arrhythm Electrophysiol 2009;2:474-480. 3207 
148. Lamas G. How much atrial fibrillation is too much atrial fibrillation? N Engl J Med 3208 
2012;366:178-180. 3209 
149. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, 3210 
Boriani G, Brandes A, Ezekowitz M, Diener H, Haegeli L, Heidbuchel H, Lane D, Mont L, Willems S, 3211 
Dorian P, Aunes-Jansson M, Blomstrom-Lundqvist C, Borentain M, Breitenstein S, Brueckmann M, 3212 
Cater N, Clemens A, Dobrev D, Dubner S, Edvardsson NG, Friberg L, Goette A, Gulizia M, Hatala R, 3213 
Horwood J, Szumowski L, Kappenberger L, Kautzner J, Leute A, Lobban T, Meyer R, Millerhagen J, 3214 
Morgan J, Muenzel F, Nabauer M, Baertels C, Oeff M, Paar D, Polifka J, Ravens U, Rosin L, Stegink 3215 
W, Steinbeck G, Vardas P, Vincent A, Walter M, Breithardt G, Camm AJ. Comprehensive risk 3216 
reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from 3217 
the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus 3218 
conference. Europace 2012;14:8-27. 3219 
150. Kirchhof P, Lip GY, Van Gelder IC, Bax J, Hylek E, Kaab S, Schotten U, Wegscheider K, 3220 
Boriani G, Ezekowitz M, Diener H, Heidbuchel H, Lane D, Mont L, Willems S, Dorian P, Vardas P, 3221 
Breithardt G, Camm AJ. Comprehensive risk reduction in patients with atrial fibrillation: Emerging 3222 
diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET/EHRA 3223 
consensus conference. Thromb Haemost 2011;106:1012-1019. 3224 
151. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of 3225 
atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. 3226 
Lancet Neurol 2015;14:377-387. 3227 
152. Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, Diener HC, Di 3228 
Lazzaro V, Rymer MM, Hogge L, Rogers TB, Ziegler PD, Assar MD. Predictors for atrial fibrillation 3229 
detection after cryptogenic stroke: Results from CRYSTAL AF. Neurology 2016;86:261-269. 3230 
153. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, 3rd. 3231 
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. 3232 
TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41. 3233 
154. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, Sacco RL, Connolly 3234 
SJ, Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: 3235 
the case for a new clinical construct. Lancet Neurol 2014;13:429-438. 3236 
155. Mant J, Fitzmaurice DA, Hobbs FD, Jowett S, Murray ET, Holder R, Davies M, Lip GY. 3237 
Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and 3238 
interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly 3239 
(SAFE) trial. BMJ 2007;335:380. 3240 
156. Israel CW, Gronefeld G, Ehrlich JR, Li YG, Hohnloser SH. Long-term risk of recurrent atrial 3241 
fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J 3242 
Am Coll Cardiol 2004;43:47-52. 3243 
157. Svennberg E, Engdahl J, Al-Khalili F, Friberg L, Frykman V, Rosenqvist M. Mass Screening 3244 
for Untreated Atrial Fibrillation: The STROKESTOP Study. Circulation 2015;131:2176-2184. 3245 
158. Bun SS, Latcu DG, Marchlinski F, Saoudi N. Atrial flutter: more than just one of a kind. Eur 3246 
Heart J 2015;36:2356-2363. 3247 
159. Granada J, Uribe W, Chyou PH, Maassen K, Vierkant R, Smith PN, Hayes J, Eaker E, 3248 
Vidaillet H. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 3249 
2000;36:2242-2246. 3250 
160. Halligan SC, Gersh BJ, Brown RD, Jr., Rosales AG, Munger TM, Shen WK, Hammill SC, 3251 
Friedman PA. The natural history of lone atrial flutter. Ann Intern Med 2004;140:265-268. 3252 
161. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, Packer DL, Hammill 3253 
SC, Shen WK, Gersh BJ. Long-term progression and outcomes with aging in patients with lone atrial 3254 
fibrillation: a 30-year follow-up study. Circulation 2007;115:3050-3056. 3255 
Page 99 of 148 ESC AF Guidelines 
 
162. Gillis AM, Rose MS. Temporal patterns of paroxysmal atrial fibrillation following DDDR 3256 
pacemaker implantation. Am J Cardiol 2000;85:1445-1450. 3257 
163. Charitos EI, Purerfellner H, Glotzer TV, Ziegler PD. Clinical classifications of atrial fibrillation 3258 
poorly reflect its temporal persistence: insights from 1,195 patients continuously monitored with 3259 
implantable devices. J Am Coll Cardiol 2014;63:2840-2848. 3260 
164. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Pattern of 3261 
atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 3262 
2013;167:2682-2687. 3263 
165. Lee G, Sanders P, Kalman JM. Catheter ablation of atrial arrhythmias: state of the art. Lancet 3264 
2012;380:1509-1519. 3265 
166. Wyse DG, Van Gelder IC, Ellinor PT, Go AS, Kalman JM, Narayan SM, Nattel S, Schotten U, 3266 
Rienstra M. Lone atrial fibrillation: does it exist? J Am Coll Cardiol 2014;63:1715-1723. 3267 
167. Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial 3268 
fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res 3269 
2014;114:1453-1468. 3270 
168. Chao TF, Suenari K, Chang SL, Lin YJ, Lo LW, Hu YF, Tuan TC, Tai CT, Tsao HM, Li CH, 3271 
Ueng KC, Wu TJ, Chen SA. Atrial substrate properties and outcome of catheter ablation in patients 3272 
with paroxysmal atrial fibrillation associated with diabetes mellitus or impaired fasting glucose. Am J 3273 
Cardiol 2010;106:1615-1620. 3274 
169. Albertsen IE, Rasmussen LH, Lane DA, Overvad TF, Skjoth F, Overvad K, Lip GY, Larsen 3275 
TB. The impact of smoking on thromboembolism and mortality in patients with incident atrial 3276 
fibrillation: insights from the Danish Diet, Cancer, and Health study. Chest 2014;145:559-566. 3277 
170. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Albertsen IE, Lane DA, Lip GY, Larsen 3278 
TB. Alcohol intake and prognosis of atrial fibrillation. Heart 2013;99:1093-1099. 3279 
171. Daccarett M, Badger TJ, Akoum N, Burgon NS, Mahnkopf C, Vergara G, Kholmovski E, 3280 
McGann CJ, Parker D, Brachmann J, Macleod RS, Marrouche NF. Association of left atrial fibrosis 3281 
detected by delayed-enhancement magnetic resonance imaging and the risk of stroke in patients with 3282 
atrial fibrillation. J Am Coll Cardiol 2011;57:831-838. 3283 
172. Neilan TG, Shah RV, Abbasi SA, Farhad H, Groarke JD, Dodson JA, Coelho-Filho O, 3284 
McMullan CJ, Heydari B, Michaud GF, John RM, van der Geest R, Steigner ML, Blankstein R, 3285 
Jerosch-Herold M, Kwong RY. The incidence, pattern, and prognostic value of left ventricular 3286 
myocardial scar by late gadolinium enhancement in patients with atrial fibrillation. J Am Coll Cardiol 3287 
2013;62:2205-2214. 3288 
173. Marrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, Kholmovski E, Burgon 3289 
N, Hu N, Mont L, Deneke T, Duytschaever M, Neumann T, Mansour M, Mahnkopf C, Herweg B, 3290 
Daoud E, Wissner E, Bansmann P, Brachmann J. Association of atrial tissue fibrosis identified by 3291 
delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA 3292 
2014;311:498-506. 3293 
174. Bonizzi P, Zeemering S, Karel JM, Di Marco LY, Uldry L, Van Zaen J, Vesin JM, Schotten U. 3294 
Systematic comparison of non-invasive measures for the assessment of atrial fibrillation complexity: a 3295 
step forward towards standardization of atrial fibrillation electrogram analysis. Europace 2014. 3296 
175. Kirchhof P, Breithardt G, Bax J, Benninger G, Blomstrom-Lundqvist C, Boriani G, Brandes A, 3297 
Brown H, Brueckmann M, Calkins H, Calvert M, Christoffels V, Crijns H, Dobrev D, Ellinor P, Fabritz 3298 
L, Fetsch T, Freedman SB, Gerth A, Goette A, Guasch E, Hack G, Haegeli L, Hatem S, Haeusler KG, 3299 
Heidbuchel H, Heinrich-Nols J, Hidden-Lucet F, Hindricks G, Juul-Moller S, Kaab S, Kappenberger L, 3300 
Kespohl S, Kotecha D, Lane DA, Leute A, Lewalter T, Meyer R, Mont L, Munzel F, Nabauer M, 3301 
Nielsen JC, Oeff M, Oldgren J, Oto A, Piccini JP, Pilmeyer A, Potpara T, Ravens U, Reinecke H, 3302 
Rostock T, Rustige J, Savelieva I, Schnabel R, Schotten U, Schwichtenberg L, Sinner MF, Steinbeck 3303 
G, Stoll M, Tavazzi L, Themistoclakis S, Tse HF, Van Gelder IC, Vardas PE, Varpula T, Vincent A, 3304 
Werring D, Willems S, Ziegler A, Lip GY, Camm AJ. A roadmap to improve the quality of atrial 3305 
fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm 3306 
Association consensus conference. Europace 2016;18:37-50. 3307 
176. Fabritz L, Guasch E, Antoniades C, Bardinet I, Benninger G, Betts TR, Brand E, Breithardt G, 3308 
Bucklar-Suchankova G, Camm AJ, Cartlidge D, Casadei B, Chua WW, Crijns HJ, Deeks J, Hatem S, 3309 
Hidden-Lucet F, Kaab S, Maniadakis N, Martin S, Mont L, Reinecke H, Sinner MF, Schotten U, 3310 
Southwood T, Stoll M, Vardas P, Wakili R, West A, Ziegler A, Kirchhof P. Expert consensus 3311 
document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin 3312 
personalized prevention and treatment. Nat Rev Cardiol 2016;13:230-237. 3313 
Page 100 of 148 ESC AF Guidelines 
 
177. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, Akhtar M, Luderitz 3314 
B. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: 3315 
implications for the assessment of investigational therapy. J Am Coll Cardiol 2000;36:1303-1309. 3316 
178. Sears SF, Serber ER, Alvarez LG, Schwartzman DS, Hoyt RH, Ujhelyi MR. Understanding 3317 
atrial symptom reports: objective versus subjective predictors. Pacing Clin Electrophysiol 3318 
2005;28:801-807. 3319 
179. Peinado R, Arribas F, Ormaetxe JM, Badia X. Variation in quality of life with type of atrial 3320 
fibrillation. Rev Esp Cardiol 2010;63:1402-1409. 3321 
180. Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I, 3322 
Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, Silva-Cardoso J, Zharinov O, Brette S, Neill 3323 
JO, RealiseAF investigators. Symptoms, functional status and quality of life in patients with controlled 3324 
and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. Heart 3325 
2012;98:195-201. 3326 
181. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH, Pharmacological Intervention in Atrial 3327 
Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on quality of life in patients 3328 
with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J 3329 
2003;24:1430-1436. 3330 
182. Pepine CJ. Effects of pharmacologic therapy on health-related quality of life in elderly patients 3331 
with atrial fibrillation: a systematic review of randomized and nonrandomized trials. Clin Med Insights 3332 
Cardiol 2013;7:1-20. 3333 
183. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG, Kingma JH, 3334 
Crijns HJ, Van Gelder IC, RACE Study Group. Effect of rate or rhythm control on quality of life in 3335 
persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) 3336 
Study. J Am Coll Cardiol 2004;43:241-247. 3337 
184. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D, Kanagaratnam L, 3338 
Heddle W, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian intervention randomized control 3339 
of rate in atrial fibrillation trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697-1702. 3340 
185. Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, Rahman-Haley SL, McDonagh TA, 3341 
Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate 3342 
control in the management of persistent atrial fibrillation in heart failure. J Am Coll Cardiol 3343 
2013;61:1894-1903. 3344 
186. Rienstra M, Lubitz SA, Mahida S, Magnani JW, Fontes JD, Sinner MF, Van Gelder IC, Ellinor 3345 
PT, Benjamin EJ. Symptoms and functional status of patients with atrial fibrillation: state of the art and 3346 
future research opportunities. Circulation 2012;125:2933-2943. 3347 
187. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramirez P, Badia X. Validation of the AF-3348 
QoL, a disease-specific quality of life questionnaire for patients with atrial fibrillation. Europace 3349 
2010;12:364-370. 3350 
188. Spertus J, Dorian P, Bubien R, Lewis S, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer 3351 
AP, Bhandari A, Burk C. Development and validation of the Atrial Fibrillation Effect on QualiTy-of-Life 3352 
(AFEQT) Questionnaire in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2011;4:15-25. 3353 
189. Dorian P, Burk C, Mullin CM, Bubien R, Godejohn D, Reynolds MR, Lakkireddy DR, Wimmer 3354 
AP, Bhandari A, Spertus J. Interpreting changes in quality of life in atrial fibrillation: How much change 3355 
is meaningful? Am Heart J 2013;166:381-387.e388. 3356 
190. Ware JE, Jr., Gandek B. Overview of the SF-36 Health Survey and the International Quality of 3357 
Life Assessment (IQOLA) Project. J Clin Epidemiol 1998;51:903-912. 3358 
191. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. 3359 
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 3360 
Res 2011;20:1727-1736. 3361 
192. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, 3362 
Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck 3363 
G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: 3364 
executive summary. Eur Heart J 2007;28:2803-2817. 3365 
193. Dorian P, Cvitkovic SS, Kerr CR, Crystal E, Gillis AM, Guerra PG, Mitchell LB, Roy D, Skanes 3366 
AC, Wyse DG. A novel, simple scale for assessing the symptom severity of atrial fibrillation at the 3367 
bedside: the CCS-SAF scale. Can J Cardiol 2006;22:383-386. 3368 
194. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, 3369 
Zamorano JL. Management of atrial fibrillation in seven European countries after the publication of the 3370 
2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic 3371 
events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6-14. 3372 
Page 101 of 148 ESC AF Guidelines 
 
195. Lip GY, Laroche C, Popescu MI, Rasmussen LH, Vitali-Serdoz L, Dan GA, Kalarus Z, Crijns 3373 
HJ, Oliveira MM, Tavazzi L, Maggioni AP, Boriani G. Improved outcomes with European Society of 3374 
Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a 3375 
report from the EORP-AF General Pilot Registry. Europace 2015;17:1777-1786. 3376 
196. Freeman JV, Simon DN, Go AS, Spertus J, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, 3377 
Mahaffey KW, Thomas LE, Chang P, Peterson ED, Piccini JP, Outcomes Registry for Better Informed 3378 
Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients. Association Between Atrial 3379 
Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for 3380 
Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circ Cardiovasc Qual Outcomes 3381 
2015;8:393-402. 3382 
197. Boriani G, Laroche C, Diemberger I, Fantecchi E, Popescu MI, Rasmussen LH, Sinagra G, 3383 
Petrescu L, Tavazzi L, Maggioni AP, Lip GY. Asymptomatic atrial fibrillation: clinical correlates, 3384 
management, and outcomes in the EORP-AF Pilot General Registry. Am J Med 2015;128:509-518 3385 
e502. 3386 
198. Szymanski FM, Filipiak KJ, Karpinski G, Platek AE, Opolski G. Occurrence of poor sleep 3387 
quality in atrial fibrillation patients according to the EHRA score. Acta Cardiol 2014;69:291-296. 3388 
199. Wynn GJ, Todd DM, Webber M, Bonnett L, McShane J, Kirchhof P, Gupta D. The European 3389 
Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement 3390 
through a simple modification. Europace 2014;16:965-972. 3391 
200. Meinertz T, Kirch W, Rosin L, Pittrow D, Willich SN, Kirchhof P, ATRIUM investigators. 3392 
Management of atrial fibrillation by primary care physicians in Germany: baseline results of the 3393 
ATRIUM registry. Clin Res Cardiol 2011;100:897-905. 3394 
201. Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, Goette A, Lewalter T, 3395 
Ravens U, Meinertz T, Breithardt G, Steinbeck G. The Registry of the German Competence NETwork 3396 
on Atrial Fibrillation: Patient characteristics and initial management. Europace 2009;11:423-434. 3397 
202. von Eisenhart Rothe AF, Goette A, Kirchhof P, Breithardt G, Limbourg T, Calvert M, Baumert 3398 
J, Ladwig KH. Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional 3399 
comparison of patients enroled in two large clinical trials. Europace 2014;16:812-819. 3400 
203. Pathak RK, Middeldorp ME, Lau DH, Mehta AB, Mahajan R, Twomey D, Alasady M, Hanley 3401 
L, Antic NA, McEvoy RD, Kalman JM, Abhayaratna WP, Sanders P. Aggressive risk factor reduction 3402 
study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J 3403 
Am Coll Cardiol 2014;64:2222-2231. 3404 
204. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, Lorimer MF, Lau 3405 
DH, Antic NA, Brooks AG, Abhayaratna WP, Kalman JM, Sanders P. Effect of weight reduction and 3406 
cardiometabolic risk factor management on symptom burden and severity in patients with atrial 3407 
fibrillation: a randomized clinical trial. JAMA 2013;310:2050-2060. 3408 
205. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, 3409 
Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 3410 
1997;96:2455-2461. 3411 
206. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen 3412 
PR, Pedersen OD, Torp-Pedersen C, Gislason GH. The spectrum of thyroid disease and risk of new 3413 
onset atrial fibrillation: a large population cohort study. BMJ 2012;345:e7895. 3414 
207. Kim EJ, Lyass A, Wang N, Massaro JM, Fox CS, Benjamin EJ, Magnani JW. Relation of 3415 
hypothyroidism and incident atrial fibrillation (from the Framingham Heart Study). Am Heart J 3416 
2014;167:123-126. 3417 
208. Vermond RA, Geelhoed B, Verweij N, Tieleman RG, Van der Harst P, Hillege HL, Van Gilst 3418 
WH, Van Gelder IC, Rienstra M. Incidence of atrial fibrillation and relationship with cardiovascular 3419 
events, heart failure, and mortality: A community-based study from the netherlands. J Am Coll Cardiol 3420 
2015;66:1000-1007. 3421 
209. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial 3422 
fibrillation in the Copenhagen City Heart Study. Eur Respir J 2003;21:1012-1016. 3423 
210. Gami AS, Hodge DO, Herges RM, Olson EJ, Nykodym J, Kara T, Somers VK. Obstructive 3424 
sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol 2007;49:565-571. 3425 
211. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, Warnock DG, Muntner 3426 
P. Association of chronic kidney disease with atrial fibrillation among adults in the United States: 3427 
REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm 3428 
Electrophysiol 2011;4:26-32. 3429 
212. Chamberlain AM, Agarwal SK, Folsom AR, Duval S, Soliman EZ, Ambrose M, Eberly LE, 3430 
Alonso A. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in 3431 
Communities (ARIC) study. Heart Rhythm 2011;8:1160-1166. 3432 
Page 102 of 148 ESC AF Guidelines 
 
213. Larsson SC, Drca N, Wolk A. Alcohol consumption and risk of atrial fibrillation: a prospective 3433 
study and dose-response meta-analysis. J Am Coll Cardiol 2014;64:281-289. 3434 
214. Aizer A, Gaziano JM, Cook NR, Manson JE, Buring JE, Albert CM. Relation of vigorous 3435 
exercise to risk of atrial fibrillation. Am J Cardiol 2009;103:1572-1577. 3436 
215. Guha K, McDonagh T. Heart failure epidemiology: European perspective. Curr Cardiol Rev 3437 
2013;9:123-127. 3438 
216. Braunschweig F, Cowie MR, Auricchio A. What are the costs of heart failure? Europace 3439 
2011;13 Suppl 2:ii13-17. 3440 
217. Wodchis WP, Bhatia RS, Leblanc K, Meshkat N, Morra D. A review of the cost of atrial 3441 
fibrillation. Value Health 2012;15:240-248. 3442 
218. Kotecha D, Piccini JP. Atrial fibrillation in heart failure: what should we do? Eur Heart J 3443 
2015;36:3250-3257. 3444 
219. Olsson LG, Swedberg K, Ducharme A, Granger CB, Michelson EL, McMurray JJ, Puu M, 3445 
Yusuf S, Pfeffer MA. Atrial fibrillation and risk of clinical events in chronic heart failure with and without 3446 
left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of 3447 
Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004. 3448 
220. Kotecha D, Chudasama R, Lane DA, Kirchhof P, Lip GY. Atrial fibrillation and heart failure 3449 
due to reduced versus preserved ejection fraction: A systematic review and meta-analysis of death 3450 
and adverse outcomes. Int J Cardiol 2016;203:660-666. 3451 
221. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-3452 
analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur J Heart Fail 3453 
2009;11:676-683. 3454 
222. AUTHORS TO BE ADDED, The Task Force for the diagnosis and teatment of acute and 3455 
chronic heart failure of the European Society of Cardiology (ESC). 2016 ESC Guidelines for the 3456 
diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016. 3457 
223. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, Svendsen JH, Vos MA, 3458 
Anker SD, Coats AJ, Haverkamp W, Manolis AS, Chung MK, Sanders P, Pieske B, Gorenek B, Lane 3459 
D, Boriani G, Linde C, Hindricks G, Tsutsui H, Homma S, Brownstein S, Nielsen JC, Lainscak M, 3460 
Crespo-Leiro M, Piepoli M, Seferovic P, Savelieva I. European Heart Rhythm Association/Heart 3461 
Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart 3462 
Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2016;18:12-36. 3463 
224. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, 3464 
Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-3465 
neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. 3466 
225. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GY, Steeds RP, Townend J, Kotecha 3467 
D. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled 3468 
trial data. BMJ 2015;351:h4451. 3469 
226. Anselmino M, Matta M, D'Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, Pappone C, 3470 
Neumann T, Noelker G, Fiala M, Bertaglia E, Frontera A, Duncan E, Nalliah C, Jais P, Weerasooriya 3471 
R, Kalman JM, Gaita F. Catheter ablation of atrial fibrillation in patients with left ventricular systolic 3472 
dysfunction: a systematic review and meta-analysis. Circ Arrhythm Electrophysiol 2014;7:1011-1018. 3473 
227. Ganesan AN, Nandal S, Luker J, Pathak RK, Mahajan R, Twomey D, Lau DH, Sanders P. 3474 
Catheter ablation of atrial fibrillation in patients with concomitant left ventricular impairment: a 3475 
systematic review of efficacy and effect on ejection fraction. Heart Lung Circ 2015;24:270-280. 3476 
228. Khan MN, Jais P, Cummings J, Di Biase L, Sanders P, Martin DO, Kautzner J, Hao S, 3477 
Themistoclakis S, Fanelli R, Potenza D, Massaro R, Wazni O, Schweikert R, Saliba W, Wang P, Al-3478 
Ahmad A, Beheiry S, Santarelli P, Starling RC, Dello Russo A, Pelargonio G, Brachmann J, Schibgilla 3479 
V, Bonso A, Casella M, Raviele A, Haissaguerre M, Natale A, PABA-CHF Investigators. Pulmonary-3480 
vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med 2008;359:1778-1785. 3481 
229. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, 3482 
mechanisms, clinical features and management. Int J Cardiol 2014;172:40-46. 3483 
230. Kusunose K, Yamada H, Nishio S, Tomita N, Niki T, Yamaguchi K, Koshiba K, Yagi S, 3484 
Taketani Y, Iwase T, Soeki T, Wakatsuki T, Akaike M, Sata M. Clinical utility of single-beat E/e' 3485 
obtained by simultaneous recording of flow and tissue Doppler velocities in atrial fibrillation with 3486 
preserved systolic function. JACC Cardiovasc Imaging 2009;2:1147-1156. 3487 
231. Li C, Zhang J, Zhou C, Huang L, Tang H, Rao L. Will simultaneous measurement of E/e' 3488 
index facilitate the non-invasive assessment of left ventricular filling pressure in patients with non-3489 
valvular atrial fibrillation? Eur J Echocardiogr 2010;11:296-301. 3490 
Page 103 of 148 ESC AF Guidelines 
 
232. Senechal M, O'Connor K, Deblois J, Magne J, Dumesnil JG, Pibarot P, Bergeron S, Poirier P. 3491 
A simple Doppler echocardiography method to evaluate pulmonary capillary wedge pressure in 3492 
patients with atrial fibrillation. Echocardiography 2008;25:57-63. 3493 
233. Sohn DW, Song JM, Zo JH, Chai IH, Kim HS, Chun HG, Kim HC. Mitral annulus velocity in 3494 
the evaluation of left ventricular diastolic function in atrial fibrillation. J Am Soc Echocardiogr 3495 
1999;12:927-931. 3496 
234. Wada Y, Murata K, Tanaka T, Nose Y, Kihara C, Uchida K, Okuda S, Susa T, Kishida Y, 3497 
Matsuzaki M. Simultaneous Doppler tracing of transmitral inflow and mitral annular velocity as an 3498 
estimate of elevated left ventricular filling pressure in patients with atrial fibrillation. Circ J 3499 
2012;76:675-681. 3500 
235. Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, 3501 
O'Connor CM, Lam CS. Patient selection in heart failure with preserved ejection fraction clinical trials. 3502 
J Am Coll Cardiol 2015;65:1668-1682. 3503 
236. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of 3504 
atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 3505 
2010;55:2299-2307. 3506 
237. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. 3507 
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor 3508 
blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-1839. 3509 
238. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the 3510 
renin-angiotensin system: a systematic review and meta-analysis. Am J Ther 2008;15:36-43. 3511 
239. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson 3512 
EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Olofsson B, Puu M, Yusuf S, CHARM 3513 
Investigators. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by 3514 
candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity 3515 
(CHARM) program. Am Heart J 2006;152:86-92. 3516 
240. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, 3517 
Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial 3518 
fibrillation. N Engl J Med 2009;360:1606-1617. 3519 
241. Goette A, Schon N, Kirchhof P, Breithardt G, Fetsch T, Hausler KG, Klein HU, Steinbeck G, 3520 
Wegscheider K, Meinertz T. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. 3521 
Circ Arrhythm Electrophysiol 2012;5:43-51. 3522 
242. Active I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, 3523 
Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. N 3524 
Engl J Med 2011;364:928-938. 3525 
243. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B. 3526 
Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF 3527 
(Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll 3528 
Cardiol 2012;59:1598-1603. 3529 
244. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel 3530 
U. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme 3531 
in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-1677. 3532 
245. Marott SC, Nielsen SF, Benn M, Nordestgaard BG. Antihypertensive treatment and risk of 3533 
atrial fibrillation: a nationwide study. Eur Heart J 2014;35:1205-1214. 3534 
246. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, 3535 
Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces 3536 
new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For 3537 
End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-719. 3538 
247. Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, Lip GY, Narkiewicz K, 3539 
Parati G, Redon J, Schmieder R, Tsioufis C, Mancia G. Hypertension and atrial fibrillation: diagnostic 3540 
approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias 3541 
and Thrombosis' of the European Society of Hypertension. J Hypertens 2012;30:239-252. 3542 
248. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano 3543 
JM, Cabeza P, Moro C. Use of irbesartan to maintain sinus rhythm in patients with long-lasting 3544 
persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331-336. 3545 
249. Ueng K-C, Tsai T-P, Yu W-C, Tsai C-F, Lin M-C, Chan K-C, Chen C-Y, Wu D-J, Lin C-S, 3546 
Chen S-A. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-3547 
standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 3548 
2003;24:2090-2098. 3549 
Page 104 of 148 ESC AF Guidelines 
 
250. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of renin-angiotensin 3550 
system prevents new-onset atrial fibrillation. Am Heart J 2006;152:217-222. 3551 
251. Tveit A, Seljeflot I, Grundvold I, Abdelnoor M, Smith P, Arnesen H. Effect of candesartan and 3552 
various inflammatory markers on maintenance of sinus rhythm after electrical cardioversion for atrial 3553 
fibrillation. Am J Cardiol 2007;99:1544-1548. 3554 
252. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of 3555 
atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236-241. 3556 
253. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger 3557 
MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B, Lancellotti P, Pierard L, Price S, Schafers 3558 
HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, 3559 
Zembala M, Joint Task Force on the Management of Valvular Heart Disease of the European Society 3560 
of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS). Guidelines on the 3561 
management of valvular heart disease (version 2012). Eur Heart J 2012;33:2451-2496. 3562 
254. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 3rd, Guyton RA, O'Gara PT, 3563 
Ruiz CE, Skubas NJ, Sorajja P, Sundt TM, 3rd, Thomas JD. 2014 AHA/ACC guideline for the 3564 
management of patients with valvular heart disease: executive summary: a report of the American 3565 
College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll 3566 
Cardiol 2014;63:2438-2488. 3567 
255. Nieuwlaat R, Capucci A, Camm AJ, Olsson SB, Andresen D, Davies DW, Cobbe S, Breithardt 3568 
G, Le Heuzey JY, Prins MH, Levy S, Crijns HJ. Atrial fibrillation management: a prospective survey in 3569 
ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2005;26:2422-2434. 3570 
256. Moretti M, Fabris E, Morosin M, Merlo M, Barbati G, Pinamonti B, Gatti G, Pappalardo A, 3571 
Sinagra G. Prognostic significance of atrial fibrillation and severity of symptoms of heart failure in 3572 
patients with low gradient aortic stenosis and preserved left ventricular ejection fraction. Am J Cardiol 3573 
2014;114:1722-1728. 3574 
257. Ngaage DL, Schaff HV, Mullany CJ, Barnes S, Dearani JA, Daly RC, Orszulak TA, Sundt TM, 3575 
3rd. Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation 3576 
justified? Ann Thorac Surg 2007;84:434-442; discussion 442-433. 3577 
258. Ngaage DL, Schaff HV, Barnes SA, Sundt TM, 3rd, Mullany CJ, Dearani JA, Daly RC, 3578 
Orszulak TA. Prognostic implications of preoperative atrial fibrillation in patients undergoing aortic 3579 
valve replacement: is there an argument for concomitant arrhythmia surgery? Ann Thorac Surg 3580 
2006;82:1392-1399. 3581 
259. Eguchi K, Ohtaki E, Matsumura T, Tanaka K, Tohbaru T, Iguchi N, Misu K, Asano R, 3582 
Nagayama M, Sumiyoshi T, Kasegawa H, Hosoda S. Pre-operative atrial fibrillation as the key 3583 
determinant of outcome of mitral valve repair for degenerative mitral regurgitation. Eur Heart J 3584 
2005;26:1866-1872. 3585 
260. Lim E, Barlow CW, Hosseinpour AR, Wisbey C, Wilson K, Pidgeon W, Charman S, Barlow 3586 
JB, Wells FC. Influence of atrial fibrillation on outcome following mitral valve repair. Circulation 3587 
2001;104:I59-63. 3588 
261. Maan A, Heist EK, Passeri J, Inglessis I, Baker J, Ptaszek L, Vlahakes G, Ruskin JN, 3589 
Palacios I, Sundt T, Mansour M. Impact of atrial fibrillation on outcomes in patients who underwent 3590 
transcatheter aortic valve replacement. Am J Cardiol 2015;115:220-226. 3591 
262. Barbash IM, Minha S, Ben-Dor I, Dvir D, Torguson R, Aly M, Bond E, Satler LF, Pichard AD, 3592 
Waksman R. Predictors and clinical implications of atrial fibrillation in patients with severe aortic 3593 
stenosis undergoing transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2015;85:468-3594 
477. 3595 
263. Halperin JL, Hart RG. Atrial fibrillation and stroke: new ideas, persisting dilemmas. Stroke 3596 
1988;19:937-941. 3597 
264. Messika-Zeitoun D, Bellamy M, Avierinos JF, Breen J, Eusemann C, Rossi A, Behrenbeck T, 3598 
Scott C, Tajik JA, Enriquez-Sarano M. Left atrial remodelling in mitral regurgitation--methodologic 3599 
approach, physiological determinants, and outcome implications: a prospective quantitative Doppler-3600 
echocardiographic and electron beam-computed tomographic study. Eur Heart J 2007;28:1773-1781. 3601 
265. Calvo N, Bisbal F, Guiu E, Ramos P, Nadal M, Tolosana JM, Arbelo E, Berruezo A, Sitges M, 3602 
Brugada J, Mont L. Impact of atrial fibrillation-induced tachycardiomyopathy in patients undergoing 3603 
pulmonary vein isolation. Int J Cardiol 2013;168:4093-4097. 3604 
266. Edner M, Caidahl K, Bergfeldt L, Darpo B, Edvardsson N, Rosenqvist M. Prospective study of 3605 
left ventricular function after radiofrequency ablation of atrioventricular junction in patients with atrial 3606 
fibrillation. Br Heart J 1995;74:261-267. 3607 
Page 105 of 148 ESC AF Guidelines 
 
267. Gertz ZM, Raina A, Saghy L, Zado ES, Callans DJ, Marchlinski FE, Keane MG, Silvestry FE. 3608 
Evidence of atrial functional mitral regurgitation due to atrial fibrillation: reversal with arrhythmia 3609 
control. J Am Coll Cardiol 2011;58:1474-1481. 3610 
268. Kihara T, Gillinov AM, Takasaki K, Fukuda S, Song JM, Shiota M, Shiota T. Mitral 3611 
regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: an 3612 
echocardiographic study. Echocardiography 2009;26:885-889. 3613 
269. Zhou X, Otsuji Y, Yoshifuku S, Yuasa T, Zhang H, Takasaki K, Matsukida K, Kisanuki A, 3614 
Minagoe S, Tei C. Impact of atrial fibrillation on tricuspid and mitral annular dilatation and valvular 3615 
regurgitation. Circ J 2002;66:913-916. 3616 
270. Ring L, Dutka DP, Wells FC, Fynn SP, Shapiro LM, Rana BS. Mechanisms of atrial mitral 3617 
regurgitation: insights using 3D transoesophageal echo. Eur Heart J Cardiovasc Imaging 3618 
2014;15:500-508. 3619 
271. Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger 3620 
MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, Schafers 3621 
HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO, Windecker S, Zamorano JL, 3622 
Zembala M, ESC Committee for Practice Guidelines (CPG), Joint Task Force on the Management of 3623 
Valvular Heart Disease of the European Society of Cardiology (ESC), European Association for 3624 
Cardio-Thoracic Surgery (EACTS). Guidelines on the management of valvular heart disease (version 3625 
2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of 3626 
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur J 3627 
Cardiothorac Surg 2012;42:S1-44. 3628 
272. Molteni M, Polo Friz H, Primitz L, Marano G, Boracchi P, Cimminiello C. The definition of 3629 
valvular and non-valvular atrial fibrillation: results of a physicians' survey. Europace 2014;16:1720-3630 
1725. 3631 
273. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients 3632 
with atrial fibrillation. Ann Thorac Surg 1996;61:755-759. 3633 
274. Szekely P. Systemic Embolism and Anticoagulant Prophylaxis in Rheumatic Heart Disease. 3634 
Br Med J 1964;1:1209-1212. 3635 
275. De Caterina R, Camm AJ. What is 'valvular' atrial fibrillation? A reappraisal. Eur Heart J 3636 
2014;35:3328-3335. 3637 
276. Goldstone AB, Patrick WL, Cohen JE, Aribeana CN, Popat R, Woo YJ. Early surgical 3638 
intervention or watchful waiting for the management of asymptomatic mitral regurgitation: a 3639 
systematic review and meta-analysis. Ann Cardiothorac Surg 2015;4:220-229. 3640 
277. Schoen T, Pradhan AD, Albert CM, Conen D. Type 2 diabetes mellitus and risk of incident 3641 
atrial fibrillation in women. J Am Coll Cardiol 2012;60:1421-1428. 3642 
278. Du X, Ninomiya T, de Galan B, Abadir E, Chalmers J, Pillai A, Woodward M, Cooper M, 3643 
Harrap S, Hamet P, Poulter N, Lip GY, Patel A. Risks of cardiovascular events and effects of routine 3644 
blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the 3645 
ADVANCE study. Eur Heart J 2009;30:1128-1135. 3646 
279. Rizzo MR, Sasso FC, Marfella R, Siniscalchi M, Paolisso P, Carbonara O, Capoluongo MC, 3647 
Lascar N, Pace C, Sardu C, Passavanti B, Barbieri M, Mauro C, Paolisso G. Autonomic dysfunction is 3648 
associated with brief episodes of atrial fibrillation in type 2 diabetes. J Diabetes Complications 3649 
2015;29:88-92. 3650 
280. Olson TM, Terzic A. Human K(ATP) channelopathies: diseases of metabolic homeostasis. 3651 
Pflugers Arch 2010;460:295-306. 3652 
281. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, Bauer JA, Tchou PJ, 3653 
Niebauer MJ, Natale A, Van Wagoner DR. C-reactive protein elevation in patients with atrial 3654 
arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 3655 
2001;104:2886-2891. 3656 
282. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 3657 
2011;11:98-107. 3658 
283. Ziolo MT, Mohler PJ. Defining the role of oxidative stress in atrial fibrillation and diabetes. J 3659 
Cardiovasc Electrophysiol 2015;26:223-225. 3660 
284. Fatemi O, Yuriditsky E, Tsioufis C, Tsachris D, Morgan T, Basile J, Bigger T, Cushman W, 3661 
Goff D, Soliman EZ, Thomas A, Papademetriou V. Impact of intensive glycemic control on the 3662 
incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes 3663 
mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study). Am J Cardiol 3664 
2014;114:1217-1222. 3665 
Page 106 of 148 ESC AF Guidelines 
 
285. Overvad TF, Skjoth F, Lip GY, Lane DA, Albertsen IE, Rasmussen LH, Larsen TB. Duration 3666 
of Diabetes Mellitus and Risk of Thromboembolism and Bleeding in Atrial Fibrillation: Nationwide 3667 
Cohort Study. Stroke 2015;46:2168-2174. 3668 
286. Chang S-H, Wu L-S, Chiou M-J, Liu J-R, Yu K-H, Kuo C-F, Wen M-S, Chen W-J, Yeh Y-H, 3669 
See L-C. Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes 3670 
mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014;13:123. 3671 
287. Lip GY, Clementy N, Pierre B, Boyer M, Fauchier L. The impact of associated diabetic 3672 
retinopathy on stroke and severe bleeding risk in diabetic patients with atrial fibrillation: the Loire 3673 
valley atrial fibrillation project. Chest 2015;147:1103-1110. 3674 
288. Huxley RR, Misialek JR, Agarwal SK, Loehr LR, Soliman EZ, Chen LY, Alonso A. Physical 3675 
activity, obesity, weight change, and risk of atrial fibrillation: the Atherosclerosis Risk in Communities 3676 
study. Circ Arrhythm Electrophysiol 2014;7:620-625. 3677 
289. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJ. Long-term cardiovascular 3678 
consequences of obesity: 20-year follow-up of more than 15 000 middle-aged men and women (the 3679 
Renfrew-Paisley study). Eur Heart J 2006;27:96-106. 3680 
290. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation 3681 
and obesity--results of a meta-analysis. Am Heart J 2008;155:310-315. 3682 
291. Wang TJ, Parise H, Levy D, D'Agostino RB, Sr., Wolf PA, Vasan RS, Benjamin EJ. Obesity 3683 
and the risk of new-onset atrial fibrillation. JAMA 2004;292:2471-2477. 3684 
292. Overvad TF, Rasmussen LH, Skjoth F, Overvad K, Lip GY, Larsen TB. Body mass index and 3685 
adverse events in patients with incident atrial fibrillation. Am J Med 2013;126:640.e649-617. 3686 
293. Karason K, Molgaard H, Wikstrand J, Sjostrom L. Heart rate variability in obesity and the 3687 
effect of weight loss. Am J Cardiol 1999;83:1242-1247. 3688 
294. Russo C, Jin Z, Homma S, Rundek T, Elkind MS, Sacco RL, Di Tullio MR. Effect of obesity 3689 
and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J 3690 
Am Coll Cardiol 2011;57:1368-1374. 3691 
295. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels 3692 
in overweight and obese adults. Jama 1999;282:2131-2135. 3693 
296. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, Twomey D, Elliott 3694 
AD, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Long-Term Effect of Goal-Directed Weight 3695 
Management in an Atrial Fibrillation Cohort: A Long-Term Follow-Up Study (LEGACY). J Am Coll 3696 
Cardiol 2015;65:2159-2169. 3697 
297. Pathak RK, Elliott A, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Hendriks JM, 3698 
Twomey D, Kalman JM, Abhayaratna WP, Lau DH, Sanders P. Impact of CARDIOrespiratory FITness 3699 
on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study. J Am 3700 
Coll Cardiol 2015;66:985-996. 3701 
298. Cha YM, Friedman PA, Asirvatham SJ, Shen WK, Munger TM, Rea RF, Brady PA, Jahangir 3702 
A, Monahan KH, Hodge DO, Meverden RA, Gersh BJ, Hammill SC, Packer DL. Catheter ablation for 3703 
atrial fibrillation in patients with obesity. Circulation 2008;117:2583-2590. 3704 
299. Jongnarangsin K, Chugh A, Good E, Mukerji S, Dey S, Crawford T, Sarrazin JF, Kuhne M, 3705 
Chalfoun N, Wells D, Boonyapisit W, Pelosi F, Jr., Bogun F, Morady F, Oral H. Body mass index, 3706 
obstructive sleep apnea, and outcomes of catheter ablation of atrial fibrillation. J Cardiovasc 3707 
Electrophysiol 2008;19:668-672. 3708 
300. Guijian L, Jinchuan Y, Rongzeng D, Jun Q, Jun W, Wenqing Z. Impact of body mass index on 3709 
atrial fibrillation recurrence: a meta-analysis of observational studies. Pacing Clin Electrophysiol 3710 
2013;36:748-756. 3711 
301. Zhuang J, Lu Y, Tang K, Peng W, Xu Y. Influence of body mass index on recurrence and 3712 
quality of life in atrial fibrillation patients after catheter ablation: a meta-analysis and systematic 3713 
review. Clin Cardiol 2013;36:269-275. 3714 
302. Ector J, Dragusin O, Adriaenssens B, Huybrechts W, Willems R, Ector H, Heidbuchel H. 3715 
Obesity is a major determinant of radiation dose in patients undergoing pulmonary vein isolation for 3716 
atrial fibrillation. J Am Coll Cardiol 2007;50:234-242. 3717 
303. Shoemaker MB, Muhammad R, Farrell M, Parvez B, White BW, Streur M, Stubblefield T, 3718 
Rytlewski J, Parvathaneni S, Nagarakanti R, Roden DM, Saavedra P, Ellis C, Whalen SP, Darbar D. 3719 
Relation of morbid obesity and female gender to risk of procedural complications in patients 3720 
undergoing atrial fibrillation ablation. Am J Cardiol 2013;111:368-373. 3721 
304. Vizzardi E, Sciatti E, Bonadei I, D'Aloia A, Curnis A, Metra M. Obstructive sleep apnoea-3722 
hypopnoea and arrhythmias: new updates. J Cardiovasc Med (Hagerstown) 2014. 3723 
305. Digby GC, Baranchuk A. Sleep apnea and atrial fibrillation; 2012 update. Curr Cardiol Rev 3724 
2012;8:265-272. 3725 
Page 107 of 148 ESC AF Guidelines 
 
306. Lin YK, Lai MS, Chen YC, Cheng CC, Huang JH, Chen SA, Chen YJ, Lin CI. Hypoxia and 3726 
reoxygenation modulate the arrhythmogenic activity of the pulmonary vein and atrium. Clin Sci (Lond) 3727 
2012;122:121-132. 3728 
307. Linz D. Atrial fibrillation in obstructive sleep apnea: atrial arrhythmogenic substrate of a 3729 
different sort. Am J Cardiol 2012;110:1071. 3730 
308. Patel D, Mohanty P, Di Biase L, Shaheen M, Lewis WR, Quan K, Cummings JE, Wang P, Al-3731 
Ahmad A, Venkatraman P, Nashawati E, Lakkireddy D, Schweikert R, Horton R, Sanchez J, 3732 
Gallinghouse J, Hao S, Beheiry S, Cardinal DS, Zagrodzky J, Canby R, Bailey S, Burkhardt JD, 3733 
Natale A. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep 3734 
apnea: the impact of continuous positive airway pressure. Circ Arrhythm Electrophysiol 2010;3:445-3735 
451. 3736 
309. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K, Kramer DB, Zimetbaum PJ, 3737 
Buxton AE, Josephson ME, Anter E. Treatment of obstructive sleep apnea reduces the risk of atrial 3738 
fibrillation recurrence after catheter ablation. J Am Coll Cardiol 2013;62:300-305. 3739 
310. Naruse Y, Tada H, Satoh M, Yanagihara M, Tsuneoka H, Hirata Y, Ito Y, Kuroki K, Machino 3740 
T, Yamasaki H, Igarashi M, Sekiguchi Y, Sato A, Aonuma K. Concomitant obstructive sleep apnea 3741 
increases the recurrence of atrial fibrillation following radiofrequency catheter ablation of atrial 3742 
fibrillation: clinical impact of continuous positive airway pressure therapy. Heart Rhythm 2013;10:331-3743 
337. 3744 
311. Neilan TG, Farhad H, Dodson JA, Shah RV, Abbasi SA, Bakker JP, Michaud GF, van der 3745 
Geest R, Blankstein R, Steigner M, John RM, Jerosch-Herold M, Malhotra A, Kwong RY. Effect of 3746 
sleep apnea and continuous positive airway pressure on cardiac structure and recurrence of atrial 3747 
fibrillation. J Am Heart Assoc 2013;2:e000421. 3748 
312. Li L, Wang ZW, Li J, Ge X, Guo LZ, Wang Y, Guo WH, Jiang CX, Ma CS. Efficacy of catheter 3749 
ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous 3750 
positive airway pressure treatment: a meta-analysis of observational studies. Europace 3751 
2014;16:1309-1314. 3752 
313. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d'Ortho MP, Erdmann E, Levy P, 3753 
Simonds AK, Somers VK, Zannad F, Teschler H. Adaptive Servo-Ventilation for Central Sleep Apnea 3754 
in Systolic Heart Failure. N Engl J Med 2015;373:1095-1105. 3755 
314. Bitter T, Nolker G, Vogt J, Prinz C, Horstkotte D, Oldenburg O. Predictors of recurrence in 3756 
patients undergoing cryoballoon ablation for treatment of atrial fibrillation: the independent role of 3757 
sleep-disordered breathing. J Cardiovasc Electrophysiol 2012;23:18-25. 3758 
315. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep 3759 
apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol 2011;108:47-3760 
51. 3761 
316. Hart RG, Eikelboom JW, Brimble KS, McMurtry MS, Ingram AJ. Stroke prevention in atrial 3762 
fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29:S71-78. 3763 
317. Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, Vicente V, Lip 3764 
GY. Renal impairment in a "real-life" cohort of anticoagulated patients with atrial fibrillation 3765 
(implications for thromboembolism and bleeding). Am J Cardiol 2013;111:1159-1164. 3766 
318. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, 3767 
Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, 3768 
Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in 3769 
patients with atrial fibrillation. N Engl J Med 2009;361:1139-1151. 3770 
319. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, 3771 
Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, 3772 
Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, 3773 
Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, 3774 
ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. 3775 
N Engl J Med 2011;365:981-992. 3776 
320. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, 3777 
Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, 3778 
ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 3779 
2011;365:883-891. 3780 
321. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, 3781 
Ezekowitz MD, Weitz JI, Spinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel 3782 
SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, Investigators EA-T. Edoxaban versus warfarin in 3783 
patients with atrial fibrillation. N Engl J Med 2013;369:2093-2104. 3784 
Page 108 of 148 ESC AF Guidelines 
 
322. Page K, Marwick TH, Lee R, Grenfell R, Abhayaratna WP, Aggarwal A, Briffa TG, Cameron J, 3785 
Davidson PM, Driscoll A, Garton-Smith J, Gascard DJ, Hickey A, Korczyk D, Mitchell JA, Sanders R, 3786 
Spicer D, Stewart S, Wade V. A systematic approach to chronic heart failure care: a consensus 3787 
statement. Med J Aust 2014;201:146-150. 3788 
323. Stock S, Pitcavage JM, Simic D, Altin S, Graf C, Feng W, Graf TR. Chronic care model 3789 
strategies in the United States and Germany deliver patient-centered, high-quality diabetes care. 3790 
Health Aff (Millwood) 2014;33:1540-1548. 3791 
324. Lundstrom H, Siersma V, Nielsen AB, Brodersen J, Reventlow S, Andersen PK, de Fine 3792 
Olivarius N. The effectiveness of structured personal care of type 2 diabetes on recurrent outcomes: a 3793 
19 year follow-up of the study Diabetes Care in General Practice (DCGP). Diabetologia 3794 
2014;57:1119-1123. 3795 
325. Berti D, Hendriks JM, Brandes A, Deaton C, Crijns HJ, Camm AJ, Hindricks G, Moons P, 3796 
Heidbuchel H. A proposal for interdisciplinary, nurse-coordinated atrial fibrillation expert programmes 3797 
as a way to structure daily practice. Eur Heart J 2013;34:2725-2730. 3798 
326. Wagner EH, Austin BT, Von Korff M. Organizing care for patients with chronic illness. Milbank 3799 
Q 1996;74:511-544. 3800 
327. Nieuwlaat R, Olsson SB, Lip GY, Camm AJ, Breithardt G, Capucci A, Meeder JG, Prins MH, 3801 
Levy S, Crijns HJ, Euro Heart Survey Investigators. Guideline-adherent antithrombotic treatment is 3802 
associated with improved outcomes compared with undertreatment in high-risk patients with atrial 3803 
fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 2007;153:1006-1012. 3804 
328. Nuno R, Coleman K, Bengoa R, Sauto R. Integrated care for chronic conditions: the 3805 
contribution of the ICCC Framework. Health Policy 2012;105:55-64. 3806 
329. Kirchhof P, Nabauer M, Gerth A, Limbourg T, Lewalter T, Goette A, Wegscheider K, Treszl A, 3807 
Meinertz T, Oeff M, Ravens U, Breithardt G, Steinbeck G. Impact of the type of centre on 3808 
management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. 3809 
Thromb Haemost 2011;105:1010-1023. 3810 
330. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, 3811 
Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized 3812 
trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. Eur 3813 
Heart J 2012;33:2692-2699. 3814 
331. Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Cost-effectiveness of a specialized 3815 
atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. Europace 2013;15:1128-1135. 3816 
332. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, Abhayaratna WP, Chan 3817 
YK, Esterman A, Thompson DR, Scuffham PA, Carrington MJ. Standard versus atrial fibrillation-3818 
specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: 3819 
pragmatic, multicentre, randomised controlled trial. Lancet 2015;385:775-784. 3820 
333. Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidisciplinary atrial 3821 
fibrillation clinic. Curr Cardiol Rev 2013;9:55-62. 3822 
334. Conti A, Canuti E, Mariannini Y, Viviani G, Poggioni C, Boni V, Pini R, Vanni S, Padeletti L, 3823 
Gensini GF. Clinical management of atrial fibrillation: early interventions, observation, and structured 3824 
follow-up reduce hospitalizations. Am J Emerg Med 2012;30:1962-1969. 3825 
335. Carter L, Gardner M, Magee K, Fearon A, Morgulis I, Doucette S, Sapp JL, Gray C, 3826 
Abdelwahab A, Parkash R. An Integrated Management Approach to Atrial Fibrillation. J Am Heart 3827 
Assoc 2016;5:e002950. 3828 
336. Peterson ED, Ho PM, Barton M, Beam C, Burgess LH, Casey DE, Jr., Drozda JP, Jr., 3829 
Fonarow GC, Goff D, Jr., Grady KL, King DE, King ML, Masoudi FA, Nielsen DR, Stanko S. 3830 
ACC/AHA/AACVPR/AAFP/ANA Concepts for Clinician-Patient Shared Accountability in Performance 3831 
Measures: A Report of the American College of Cardiology/American Heart Association Task Force 3832 
on Performance Measures. Circulation 2014. 3833 
337. Lane DA, Aguinaga L, Blomstrom-Lundqvist C, Boriani G, Dan GA, Hills MT, Hylek EM, 3834 
LaHaye SA, Lip GY, Lobban T, Mandrola J, McCabe PJ, Pedersen SS, Pisters R, Stewart S, Wood K, 3835 
Potpara TS, Gorenek B, Conti JB, Keegan R, Power S, Hendriks J, Ritter P, Calkins H, Violi F, 3836 
Hurwitz J. Cardiac tachyarrhythmias and patient values and preferences for their management: the 3837 
European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm 3838 
Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de 3839 
Estimulacion Cardiaca y Electrofisiologia (SOLEACE). Europace 2015;17:1747-1769. 3840 
338. Hendriks JM, de Wit R, Vrijhoef HJ, Tieleman RG, Crijns HJ. An integrated chronic care 3841 
program for patients with atrial fibrillation: study protocol and methodology for an ongoing prospective 3842 
randomised controlled trial. Int J Nurs Stud 2010;47:1310-1316. 3843 
Page 109 of 148 ESC AF Guidelines 
 
339. Donal E, Lip GY, Galderisi M, Goette A, Shah D, Marwan M, Lederlin M, Mondillo S, 3844 
Edvardsen T, Sitges M, Grapsa J, Garbi M, Senior R, Gimelli A, Potpara TS, Van Gelder IC, Gorenek 3845 
B, Mabo P, Lancellotti P, Kuck KH, Popescu BA, Hindricks G, Habib G, Cosyns B, Delgado V, 3846 
Haugaa KH, Muraru D, Nieman K, Cohen A. EACVI/EHRA Expert Consensus Document on the role 3847 
of multi-modality imaging for the evaluation of patients with atrial fibrillation. Eur Heart J Cardiovasc 3848 
Imaging 2016;17:355-383. 3849 
340. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster 3850 
E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, 3851 
Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by 3852 
echocardiography in adults: an update from the american society of echocardiography and the 3853 
European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-271. 3854 
341. Filion KB, Agarwal SK, Ballantyne CM, Eberg M, Hoogeveen RC, Huxley RR, Loehr LR, 3855 
Nambi V, Soliman EZ, Alonso A. High-sensitivity cardiac troponin T and the risk of incident atrial 3856 
fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Am Heart J 2015;169:31-38  3857 
342. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, 3858 
Tracy RP, Van Wagoner DR, Psaty BM, Lauer MS, Chung MK. Inflammation as a risk factor for atrial 3859 
fibrillation. Circulation 2003;108:3006-3010. 3860 
343. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal 3861 
RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial 3862 
fibrillation: the Cardiovascular Health Study. Circulation 2009;120:1768-1774. 3863 
344. Bartel T, Erbel R, Acute Trial Investigators. Transoesophageal echocardiography for 3864 
immediate and safe cardioversion in patients with atrial fibrillation. Eur Heart J 2001;22:2041-2044. 3865 
345. Mahnkopf C, Mitlacher M, Brachmann J. [Relevance of magnetic resonance imaging for 3866 
catheter ablation of atrial fibrillation]. Herzschrittmacherther Elektrophysiol 2014;25:252-257. 3867 
346. Haemers P, Claus P, Willems R. The use of cardiac magnetic resonance imaging in the 3868 
diagnostic workup and treatment of atrial fibrillation. Cardiol Res Pract 2012;2012:658937. 3869 
347. Ling LH, Kistler PM, Ellims AH, Iles LM, Lee G, Hughes GL, Kalman JM, Kaye DM, Taylor AJ. 3870 
Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and 3871 
systolic dysfunction. J Am Coll Cardiol 2012;60:2402-2408. 3872 
348. Lewalter T, Ibrahim R, Albers B, Camm AJ. An update and current expert opinions on 3873 
percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. Europace 3874 
2013;15:652-656. 3875 
349. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, Goette A, Hindricks G, 3876 
Hohnloser S, Kappenberger L, Kuck KH, Lip GY, Olsson B, Meinertz T, Priori S, Ravens U, Steinbeck 3877 
G, Svernhage E, Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation: 3878 
executive summary: Recommendations from a consensus conference organized by the German Atrial 3879 
Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur 3880 
Heart J 2007;28:2803-2817. 3881 
350. Alonso-Coello P, Montori VM, Sola I, Schunemann HJ, Devereaux P, Charles C, Roura M, 3882 
Diaz MG, Souto JC, Alonso R, Oliver S, Ruiz R, Coll-Vinent B, Diez AI, Gich I, Guyatt G. Values and 3883 
preferences in oral anticoagulation in patients with atrial fibrillation, physicians' and patients' 3884 
perspectives: protocol for a two-phase study. BMC Health Serv Res 2008;8:221. 3885 
351. Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, Blendea D, Nattel S, De 3886 
Bono J, Conroy JM, Hess PL, Guasch E, Halperin JL, Kirchhof P, MD GC, Camm AJ. Contemporary 3887 
management of atrial fibrillation: what can clinical registries tell us about stroke prevention and current 3888 
therapeutic approaches? J Am Heart Assoc 2014;3. 3889 
352. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GY, Lane DA. Dabigatran 3890 
adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J 3891 
Thromb Haemost 2015;13:495-504. 3892 
353. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke 3893 
in patients with atrial fibrillation. Ann Intern Med 2007;147:590-592. 3894 
354. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, 3895 
Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, 3896 
Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo 3897 
A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S, AVERROES Steering 3898 
Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-817. 3899 
355. Frankel DS, Parker SE, Rosenfeld LE, Gorelick PB. HRS/NSA 2014 Survey of Atrial 3900 
Fibrillation and Stroke: Gaps in Knowledge and Perspective, Opportunities for Improvement. Heart 3901 
Rhythm 2015. 3902 
Page 110 of 148 ESC AF Guidelines 
 
356. Le Heuzey JY, Ammentorp B, Darius H, De Caterina R, Schilling RJ, Schmitt J, Zamorano JL, 3903 
Kirchhof P. Differences among western European countries in anticoagulation management of atrial 3904 
fibrillation. Data from the PREFER IN AF registry. Thromb Haemost 2014;111:833-841. 3905 
357. O'Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, Gersh BJ, Fonarow GC, 3906 
Koller CR, Ezekowitz MD, Mahaffey KW, Chang P, Peterson ED, Piccini JP, Singer DE. Physician 3907 
practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the 3908 
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart 3909 
J 2014;167:601-609 e601. 3910 
358. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. Warfarin 3911 
discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 3912 
2010;3:624-631. 3913 
359. Zalesak M, Siu K, Francis K, Yu C, Alvrtsyan H, Rao Y, Walker D, Sander S, Miyasato G, 3914 
Matchar D, Sanchez H. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients 3915 
treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-574. 3916 
360. Donze J, Clair C, Hug B, Rodondi N, Waeber G, Cornuz J, Aujesky D. Risk of falls and major 3917 
bleeds in patients on oral anticoagulation therapy. Am J Med 2012;125:773-778. 3918 
361. Man-Son-Hing M, Nichol G, Lau A, Laupacis A. Choosing antithrombotic therapy for elderly 3919 
patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999;159:677-685. 3920 
362. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E, BAFTA 3921 
investigators, Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke 3922 
prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation 3923 
Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. 3924 
363. Diener HC, Eikelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, O'Donnell M, Hohnloser 3925 
SH, Hankey GJ, Shestakovska O, Yusuf S, AVERROES Steering Committee and Investigators. 3926 
Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic 3927 
attack: a predefined subgroup analysis from AVERROES, a randomised trial. Lancet Neurol 3928 
2012;11:225-231. 3929 
364. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. 3930 
Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke 3931 
Prevention in Atrial Fibrillation III Study. JAMA 1998;279:1273-1277. 3932 
365. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of 3933 
clinical classification schemes for predicting stroke: results from the National Registry of Atrial 3934 
Fibrillation. JAMA 2001;285:2864-2870. 3935 
366. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, 3936 
Koefed BG, Laupacis A. A clinical prediction rule to identify patients with atrial fibrillation and a low 3937 
risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-943. 3938 
367. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, Larson MG, Kannel WB, 3939 
Benjamin EJ. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation 3940 
in the community: the Framingham Heart Study. JAMA 2003;290:1049-1056. 3941 
368. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for 3942 
predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: 3943 
the euro heart survey on atrial fibrillation. Chest 2010;137:263-272. 3944 
369. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, 3945 
Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, 3946 
De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, 3947 
Rutten FH, ESC Committee for Practice Guidelines, European Heart Rhythm Association, European 3948 
Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task 3949 
Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). 3950 
Europace 2010;12:1360-1420. 3951 
370. Kirchhof P, Curtis AB, Skanes AC, Gillis AM, Samuel Wann L, Camm AJ. Atrial fibrillation 3952 
guidelines across the Atlantic: a comparison of the current recommendations of the European Society 3953 
of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, 3954 
the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, 3955 
and the Canadian Cardiovascular Society. Eur Heart J 2013;34:1471-1474. 3956 
371. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff 3957 
O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting 3958 
stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 3959 
2011;342:d124. 3960 
Page 111 of 148 ESC AF Guidelines 
 
372. Chao TF, Liu CJ, Wang KL, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chen TJ, Lip GY, 3961 
Chen SA. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score 3962 
(beyond sex) receive oral anticoagulation? J Am Coll Cardiol 2015;65:635-642. 3963 
373. Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in 3964 
patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am 3965 
Coll Cardiol 2015;65:1385-1394. 3966 
374. Fauchier L, Lecoq C, Clementy N, Bernard A, Angoulvant D, Ivanes F, Babuty D, Lip GY. Oral 3967 
Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional 3968 
Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. Chest 2016;149:960-968. 3969 
375. Joundi RA, Cipriano LE, Sposato LA, Saposnik G, Stroke Outcomes Research Working 3970 
Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: 3971 
Systematic Review and Meta-Analysis. Stroke 2016;47:1364-1367. 3972 
376. Friberg L, Skeppholm M, Terent A. Benefit of anticoagulation unlikely in patients with atrial 3973 
fibrillation and a CHA2DS2-VASc score of 1. J Am Coll Cardiol 2015;65:225-232. 3974 
377. Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or 3975 
one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis 3976 
for warfarin, aspirin, or no therapy. Thromb Haemost 2015;114:826-834. 3977 
378. Mikkelsen AP, Lindhardsen J, Lip GY, Gislason GH, Torp-Pedersen C, Olesen JB. Female 3978 
sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study. J Thromb Haemost 3979 
2012;10:1745-1751. 3980 
379. Wagstaff AJ, Overvad TF, Lip GY, Lane DA. Is female sex a risk factor for stroke and 3981 
thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. Qjm 3982 
2014;107:955-967. 3983 
380. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, Reilly PA, 3984 
Vinereanu D, Siegbahn A, Yusuf S, Wallentin L. Cardiac biomarkers are associated with an increased 3985 
risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term 3986 
Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605-1616. 3987 
381. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, Gersh BJ, 3988 
Hanna M, Hohnloser S, Horowitz J, Huber K, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-3989 
terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights 3990 
from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). 3991 
J Am Coll Cardiol 2013;61:2274-2284. 3992 
382. Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, 3993 
Siegbahn A, Stewart RA, White HD, Granger CB, Wallentin L, ARISTOTLE and STABILITY 3994 
Investigators. The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk 3995 
score for predicting stroke in atrial fibrillation. Eur Heart J 2016:[Epub ahead of print]. 3996 
383. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical 3997 
classification schemes for predicting hemorrhage: results from the National Registry of Atrial 3998 
Fibrillation (NRAF). Am Heart J 2006;151:713-719. 3999 
384. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score 4000 
(HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart 4001 
Survey. Chest 2010;138:1093-1100. 4002 
385. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new 4003 
risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors 4004 
in Atrial Fibrillation) Study. J Am Coll Cardiol 2011;58:395-401. 4005 
386. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke 4006 
and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur 4007 
Heart J 2012;33:1500-1510. 4008 
387. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, 4009 
Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L, ARISTOTLE and RE-4010 
LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk 4011 
score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016:[Epub ahead of 4012 
print]. 4013 
388. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey 4014 
KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a 4015 
simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015;36:3258-3264. 4016 
389. Loewen P, Dahri K. Risk of bleeding with oral anticoagulants: an updated systematic review 4017 
and performance analysis of clinical prediction rules. Ann Hematol 2011;90:1191-1200. 4018 
390. Olesen JB, Lip GY, Hansen PR, Lindhardsen J, Ahlehoff O, Andersson C, Weeke P, Hansen 4019 
ML, Gislason GH, Torp-Pedersen C. Bleeding risk in 'real world' patients with atrial fibrillation: 4020 
Page 112 of 148 ESC AF Guidelines 
 
comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb 4021 
Haemost 2011;9:1460-1467. 4022 
391. Van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification 4023 
schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 4024 
2011;9:39-48. 4025 
392. Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, Vicente V, Lip 4026 
GY. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or 4027 
CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 4028 
2013;62:2199-2204. 4029 
393. Wallentin L, Hijazi Z, Andersson U, Alexander JH, De Caterina R, Hanna M, Horowitz JD, 4030 
Hylek EM, Lopes RD, Asberg S, Granger CB, Siegbahn A, ARISTOTLE Investigators. Growth 4031 
differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients 4032 
with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic 4033 
Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2014;130:1847-1858. 4034 
394. Raunso J, Selmer C, Olesen JB, Charlot MG, Olsen AM, Bretler DM, Nielsen JD, Dominguez 4035 
H, Gadsboll N, Kober L, Gislason GH, Torp-Pedersen C, Hansen ML. Increased short-term risk of 4036 
thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. 4037 
Eur Heart J 2012;33:1886-1892. 4038 
395. Sjogren V, Grzymala-Lubanski B, Renlund H, Friberg L, Lip GY, Svensson PJ, Sjalander A. 4039 
Safety and efficacy of well managed warfarin. A report from the Swedish quality register Auricula. 4040 
Thromb Haemost 2015;113:1370-1377. 4041 
396. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, Levenson M, Sheu TC, 4042 
Mott K, Goulding MR, Houstoun M, MaCurdy TE, Worrall C, Kelman JA. Cardiovascular, bleeding, 4043 
and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular 4044 
atrial fibrillation. Circulation 2015;131:157-164. 4045 
397. Apostolakis S, Sullivan RM, Olshansky B, Lip GY. Factors affecting quality of anticoagulation 4046 
control among patients with atrial fibrillation on warfarin: the SAMe-TT(2)R(2) score. Chest 4047 
2013;144:1555-1563. 4048 
398. Lip GY, Haguenoer K, Saint-Etienne C, Fauchier L. Relationship of the SAMe-TT(2)R(2) 4049 
score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with 4050 
atrial fibrillation. Chest 2014;146:719-726. 4051 
399. Gallego P, Roldan V, Marin F, Galvez J, Valdes M, Vicente V, Lip GY. SAMe-TT2R2 score, 4052 
time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med 4053 
2014;127:1083-1088. 4054 
400. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, 4055 
Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, 4056 
Simoons ML, Van de Werf F, RE-ALIGN Investigators. Dabigatran versus warfarin in patients with 4057 
mechanical heart valves. N Engl J Med 2013;369:1206-1214. 4058 
401. Olesen JB, Sorensen R, Hansen ML, Lamberts M, Weeke P, Mikkelsen AP, Kober L, 4059 
Gislason GH, Torp-Pedersen C, Fosbol EL. Non-vitamin K antagonist oral anticoagulation agents in 4060 
anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. 4061 
Europace 2015;17:187-193. 4062 
402. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, 4063 
Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. Major bleeding in patients with atrial 4064 
fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke 4065 
and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical 4066 
Outcomes. J Am Coll Cardiol 2014;63:2141-2147. 4067 
403. Flaker GC, Eikelboom JW, Shestakovska O, Connolly SJ, Kaatz S, Budaj A, Husted S, Yusuf 4068 
S, Lip GY, Hart RG. Bleeding during treatment with aspirin versus apixaban in patients with atrial 4069 
fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial 4070 
fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) 4071 
trial. Stroke 2012;43:3291-3297. 4072 
404. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L, Randomized Evaluation of Long-4073 
Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 4074 
2010;363:1875-1876. 4075 
405. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, Deenadayalu N, 4076 
Jarolim P, Betcher J, Shi M, Brown K, Patel I, Mercuri M, Antman EM. Association between edoxaban 4077 
dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, 4078 
double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385:2288-2295. 4079 
Page 113 of 148 ESC AF Guidelines 
 
406. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, Michalski F, 4080 
Kohler C, Werth S, Sahin K, Tittl L, Hansel U, Weiss N. Rates, management, and outcome of 4081 
rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014;124:955-962. 4082 
407. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, 4083 
XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated 4084 
with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145-1153. 4085 
408. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, 4086 
Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, RE-LY investigators. Efficacy and 4087 
safety of dabigatran compared with warfarin at different levels of international normalised ratio control 4088 
for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983. 4089 
409. Piccini JP, Hellkamp AS, Lokhnygina Y, Patel MR, Harrell FE, Singer DE, Becker RC, 4090 
Breithardt G, Halperin JL, Hankey GJ, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM, 4091 
ROCKET AF Investigators. Relationship between time in therapeutic range and comparative 4092 
treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. J Am Heart Assoc 4093 
2014;3:e000521. 4094 
410. Olesen JB, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, 4095 
Torp-Pedersen C. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 4096 
2012;367:625-635. 4097 
411. Albertsen IE, Rasmussen LH, Overvad TF, Graungaard T, Larsen TB, Lip GY. Risk of stroke 4098 
or systemic embolism in atrial fibrillation patients treated with warfarin: A systematic review and meta-4099 
analysis. Stroke 2013;44:1329-1336. 4100 
412. Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with 4101 
moderate chronic kidney disease. Clin J Am Soc Nephrol 2011;6:2599-2604. 4102 
413. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial 4103 
fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2014. 4104 
414. Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, Perkovic V, Winkelmayer WC, 4105 
Ma Z, Hemmelgarn BR. The association between kidney function and major bleeding in older adults 4106 
with atrial fibrillation starting warfarin treatment: population based observational study. BMJ 4107 
2015;350:h246. 4108 
415. Del-Carpio Munoz F, Gharacholou SM, Munger TM, Friedman PA, Asirvatham SJ, Packer 4109 
DL, Noseworthy PA. Meta-Analysis of Renal Function on the Safety and Efficacy of Novel Oral 4110 
Anticoagulants for Atrial Fibrillation. Am J Cardiol 2016;117:69-75. 4111 
416. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, 4112 
Camm AJ, Kirchhof P. Updated European Heart Rhythm Association Practical Guide on the use of 4113 
non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 4114 
2015;17:1467-1507. 4115 
417. Zimmerman D, Sood MM, Rigatto C, Holden RM, Hiremath S, Clase CM. Systematic review 4116 
and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. 4117 
Nephrol Dial Transplant 2012;27:3816-3822. 4118 
418. Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial 4119 
fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011;57:1339-4120 
1348. 4121 
419. Wizemann V, Tong L, Satayathum S, Disney A, Akiba T, Fissell RB, Kerr PG, Young EW, 4122 
Robinson BM. Atrial fibrillation in hemodialysis patients: clinical features and associations with 4123 
anticoagulant therapy. Kidney Int 2010;77:1098-1106. 4124 
420. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk 4125 
for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 2009;20:2223-2233. 4126 
421. Winkelmayer WC, Liu J, Setoguchi S, Choudhry NK. Effectiveness and safety of warfarin 4127 
initiation in older hemodialysis patients with incident atrial fibrillation. Clin J Am Soc Nephrol 4128 
2011;6:2662-2668. 4129 
422. Shah M, Avgil Tsadok M, Jackevicius CA, Essebag V, Eisenberg MJ, Rahme E, Humphries 4130 
KH, Tu JV, Behlouli H, Guo H, Pilote L. Warfarin use and the risk for stroke and bleeding in patients 4131 
with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-1203. 4132 
423. Bonde AN, Lip GY, Kamper AL, Hansen PR, Lamberts M, Hommel K, Hansen ML, Gislason 4133 
GH, Torp-Pedersen C, Olesen JB. Net clinical benefit of antithrombotic therapy in patients with atrial 4134 
fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol 4135 
2014;64:2471-2482. 4136 
424. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban 4137 
use in atrial fibrillation patients on hemodialysis. Circulation 2015;131:972-979. 4138 
Page 114 of 148 ESC AF Guidelines 
 
425. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, 4139 
Reilly PA, Siegbahn A, Yusuf S, Wallentin L. Efficacy and safety of dabigatran compared with warfarin 4140 
in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation 4141 
of Long-term Anticoagulation Therapy) trial analysis. Circulation 2014;129:961-970. 4142 
426. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, 4143 
Mahaffey KW, Patel MR, Singer DE, Califf RM. Prevention of stroke and systemic embolism with 4144 
rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal 4145 
impairment. Eur Heart J 2011;32:2387-2394. 4146 
427. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, 4147 
Lopes RD, Lopez-Sendon J, Granger CB, Wallentin L. Efficacy of apixaban when compared with 4148 
warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE 4149 
trial. Eur Heart J 2012;33:2821-2830. 4150 
428. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation 4151 
Study. Final results. Circulation 1991;84:527-539. 4152 
429. Olesen JB, Lip GY, Lindhardsen J, Lane DA, Ahlehoff O, Hansen ML, Raunso J, Tolstrup JS, 4153 
Hansen PR, Gislason GH, Torp-Pedersen C. Risks of thromboembolism and bleeding with 4154 
thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' 4155 
nationwide cohort study. Thromb Haemost 2011;106:739-749. 4156 
430. Sjalander S, Sjalander A, Svensson PJ, Friberg L. Atrial fibrillation patients do not benefit 4157 
from acetylsalicylic acid. Europace 2014;16:631-638. 4158 
431. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, 4159 
Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral 4160 
anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for 4161 
prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-4162 
1912. 4163 
432. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf 4164 
S, ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation 4165 
depends on the quality of international normalized ratio control achieved by centers and countries as 4166 
measured by time in therapeutic range. Circulation 2008;118:2029-2037. 4167 
433. Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S, ACTIVE 4168 
Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 4169 
2009;360:2066-2078. 4170 
434. van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen 4171 
P, Perez-Gomez F, Knottnerus JA, Boode B, Ezekowitz MD, Singer DE. Effect of age on stroke 4172 
prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 4173 
2009;40:1410-1416. 4174 
435. Olesen KH. The natural history of 271 patients with mitral stenosis under medical treatment. 4175 
Br Heart J 1962;24:349-357. 4176 
436. Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix L, NASPEAF 4177 
Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with 4178 
valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 4179 
2004;44:1557-1566. 4180 
437. Rowe JC, Bland EF, Sprague HB, White PD. The course of mitral stenosis without surgery: 4181 
ten- and twenty-year perspectives. Ann Intern Med 1960;52:741-749. 4182 
438. Wilson JK, Greenwood WF. The natural history of mitral stenosis. Can Med Assoc J 4183 
1954;71:323-331. 4184 
439. Cannegieter SC, van der Meer FJ, Briet E, Rosendaal FR. Warfarin and aspirin after heart-4185 
valve replacement. N Engl J Med 1994;330:507-508; author reply 508-509. 4186 
440. Chiang CW, Lo SK, Ko YS, Cheng NJ, Lin PJ, Chang CH. Predictors of systemic embolism in 4187 
patients with mitral stenosis. A prospective study. Ann Intern Med 1998;128:885-889. 4188 
441. Wan Y, Heneghan C, Perera R, Roberts N, Hollowell J, Glasziou P, Bankhead C, Xu Y. 4189 
Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic 4190 
review. Circ Cardiovasc Qual Outcomes 2008;1:84-91. 4191 
442. Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin 4192 
treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR 4193 
control. Thromb Res 2009;124:37-41. 4194 
443. Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality 4195 
associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 4196 
2011;106:968-977. 4197 
Page 115 of 148 ESC AF Guidelines 
 
444. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, 4198 
Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, 4199 
Weitz JI. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position 4200 
paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. 4201 
Thromb Haemost 2013;110:1087-1107. 4202 
445. Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, 4203 
Oldgren J, Eikelboom JW, Reilly PA, Yusuf S. Concomitant use of antiplatelet therapy with dabigatran 4204 
or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. 4205 
Circulation 2013;127:634-640. 4206 
446. Bajaj NS, Parashar A, Agarwal S, Sodhi N, Poddar KL, Garg A, Tuzcu EM, Kapadia SR. 4207 
Percutaneous left atrial appendage occlusion for stroke prophylaxis in nonvalvular atrial fibrillation: a 4208 
systematic review and analysis of observational studies. JACC Cardiovasc Interv 2014;7:296-304. 4209 
447. Lewalter T, Kanagaratnam P, Schmidt B, Rosenqvist M, Nielsen-Kudsk JE, Ibrahim R, Albers 4210 
BA, Camm AJ. Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: 4211 
opportunities and challenges for percutaneous left atrial appendage occlusion. Europace 4212 
2014;16:626-630. 4213 
448. Meier B, Blaauw Y, Khattab AA, Lewalter T, Sievert H, Tondo C, Glikson M. EHRA/EAPCI 4214 
expert consensus statement on catheter-based left atrial appendage occlusion. Europace 4215 
2014;16:1397-1416. 4216 
449. Holmes DR, Jr., Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY. 4217 
Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients 4218 
with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol 4219 
2014;64:1-12. 4220 
450. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P. 4221 
Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in 4222 
patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009;374:534-542. 4223 
451. Reddy VY, Doshi SK, Sievert H, Buchbinder M, Neuzil P, Huber K, Halperin JL, Holmes D. 4224 
Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-4225 
Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection 4226 
in Patients with Atrial Fibrillation) Trial. Circulation 2013;127:720-729. 4227 
452. Reddy VY, Sievert H, Halperin J, Doshi SK, Buchbinder M, Neuzil P, Huber K, Whisenant B, 4228 
Kar S, Swarup V, Gordon N, Holmes D, PROTECT AF Steering Committee and Investigators. 4229 
Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. 4230 
JAMA 2014;312:1988-1998. 4231 
453. Holmes DR, Jr., Doshi SK, Kar S, Price MJ, Sanchez JM, Sievert H, Valderrabano M, Reddy 4232 
VY. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial 4233 
Fibrillation: A Patient-Level Meta-Analysis. J Am Coll Cardiol 2015;65:2614-2623. 4234 
454. Reddy VY, Mobius-Winkler S, Miller MA, Neuzil P, Schuler G, Wiebe J, Sick P, Sievert H. Left 4235 
atrial appendage closure with the Watchman device in patients with a contraindication for oral 4236 
anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage 4237 
Closure Technology). J Am Coll Cardiol 2013;61:2551-2556. 4238 
455. Santoro G, Meucci F, Stolcova M, Rezzaghi M, Mori F, Palmieri C, Paradossi U, Pastormerlo 4239 
LE, Rosso G, Berti S. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial 4240 
fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. 4241 
EuroIntervention 2014. 4242 
456. Badheka AO, Chothani A, Mehta K, Patel NJ, Deshmukh A, Hoosien M, Shah N, Singh V, 4243 
Grover P, Savani GT, Panaich SS, Rathod A, Patel N, Arora S, Bhalara V, Coffey JO, O'Neill W, 4244 
Makkar R, Grines CL, Schreiber T, Di Biase L, Natale A, Viles-Gonzalez JF. Utilization and adverse 4245 
outcomes of percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation in the 4246 
United States: influence of hospital volume. Circ Arrhythm Electrophysiol 2015;8:42-48. 4247 
457. Pison L, Potpara TS, Chen J, Larsen TB, Bongiorni MG, Blomstrom-Lundqvist C. Left atrial 4248 
appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm 4249 
Association Survey. Europace 2015;17:642-646. 4250 
458. Price MJ, Gibson DN, Yakubov SJ, Schultz JC, Di Biase L, Natale A, Burkhardt JD, Pershad 4251 
A, Byrne TJ, Gidney B, Aragon JR, Goldstein J, Moulton K, Patel T, Knight B, Lin AC, Valderrabano 4252 
M. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the 4253 
U.S. transcatheter LAA ligation consortium. J Am Coll Cardiol 2014;64:565-572. 4254 
459. Boersma LV, Schmidt B, Betts TR, Sievert H, Tamburino C, Teiger E, Pokushalov E, Kische 4255 
S, Schmitz T, Stein KM, Bergmann MW, EWOLUTION investigators. Implant success and safety of 4256 
Page 116 of 148 ESC AF Guidelines 
 
left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the 4257 
EWOLUTION registry. Eur Heart J 2016:[Epub ahead of print]. 4258 
460. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, Flechsenhar J, 4259 
Neugebauer H, Juttler E, Grau A, Palm F, Rother J, Michels P, Hamann GF, Huwel J, Hagemann G, 4260 
Barber B, Terborg C, Trostdorf F, Bazner H, Roth A, Wohrle J, Keller M, Schwarz M, Reimann G, 4261 
Volkmann J, Mullges W, Kraft P, Classen J, Hobohm C, Horn M, Milewski A, Reichmann H, Schneider 4262 
H, Schimmel E, Fink GR, Dohmen C, Stetefeld H, Witte O, Gunther A, Neumann-Haefelin T, Racs 4263 
AE, Nueckel M, Erbguth F, Kloska SP, Dorfler A, Kohrmann M, Schwab S, Huttner HB. Anticoagulant 4264 
reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related 4265 
intracerebral hemorrhage. JAMA 2015;313:824-836. 4266 
461. Budera P, Straka Z, Osmancik P, Vanek T, Jelinek S, Hlavicka J, Fojt R, Cervinka P, Hulman 4267 
M, Smid M, Maly M, Widimsky P. Comparison of cardiac surgery with left atrial surgical ablation vs. 4268 
cardiac surgery without atrial ablation in patients with coronary and/or valvular heart disease plus 4269 
atrial fibrillation: final results of the PRAGUE-12 randomized multicentre study. Eur Heart J 4270 
2012;33:2644-2652. 4271 
462. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, 4272 
Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ. Left Atrial Appendage 4273 
Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage 4274 
occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J 2005;150:288-293. 4275 
463. Tsai YC, Phan K, Munkholm-Larsen S, Tian DH, La Meir M, Yan TD. Surgical left atrial 4276 
appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis. Eur J 4277 
Cardiothorac Surg 2015;47:847-854. 4278 
464. Whitlock RP, Vincent J, Blackall MH, Hirsh J, Fremes S, Novick R, Devereaux PJ, Teoh K, 4279 
Lamy A, Connolly SJ, Yusuf S, Carrier M, Healey JS. Left Atrial Appendage Occlusion Study II 4280 
(LAAOS II). Can J Cardiol 2013;29:1443-1447. 4281 
465. Aryana A, Singh SK, Singh SM, Gearoid O'Neill P, Bowers MR, Allen SL, Lewandowski SL, 4282 
Vierra EC, d'Avila A. Association between incomplete surgical ligation of left atrial appendage and 4283 
stroke and systemic embolization. Heart Rhythm 2015;12:1431-1437. 4284 
466. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ, Jr., Moskowitz AJ, Voisine P, Ailawadi G, 4285 
Bouchard D, Smith PK, Mack MJ, Acker MA, Mullen JC, Rose EA, Chang HL, Puskas JD, Couderc 4286 
JP, Gardner TJ, Varghese R, Horvath KA, Bolling SF, Michler RE, Geller NL, Ascheim DD, Miller MA, 4287 
Bagiella E, Moquete EG, Williams P, Taddei-Peters WC, O'Gara PT, Blackstone EH, Argenziano M, 4288 
CTSN Investigators. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 4289 
2015;372:1399-1409. 4290 
467. Whitlock R, Healey J, Vincent J, Brady K, Teoh K, Royse A, Shah P, Guo Y, Alings M, 4291 
Folkeringa RJ, Paparella D, Colli A, Meyer SR, Legare JF, Lamontagne F, Reents W, Boning A, 4292 
Connolly S. Rationale and design of the Left Atrial Appendage Occlusion Study (LAAOS) III. Ann 4293 
Cardiothorac Surg 2014;3:45-54. 4294 
468. Boersma LV, Castella M, van Boven W, Berruezo A, Yilmaz A, Nadal M, Sandoval E, Calvo 4295 
N, Brugada J, Kelder J, Wijffels M, Mont L. Atrial fibrillation catheter ablation versus surgical ablation 4296 
treatment (FAST): a 2-center randomized clinical trial. Circulation 2012;125:23-30. 4297 
469. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke 4298 
W, Diener H. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German stroke 4299 
data bank. Stroke 2001;32:2559-2566. 4300 
470. Giles MF, Rothwell PM. Risk of stroke early after transient ischaemic attack: a systematic 4301 
review and meta-analysis. Lancet Neurol 2007;6:1063-1072. 4302 
471. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, 4303 
Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, 4304 
Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, Del Zoppo 4305 
GJ, Baigent C, Sandercock P, Hacke W, Stroke Thrombolysis Trialists' Collaborative Group. Effect of 4306 
treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for 4307 
acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 4308 
2014. 4309 
472. Diener HC, Stanford S, Abdul-Rahim A, Christensen L, Hougaard KD, Bakhai A, Veltkamp R, 4310 
Worthmann H. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. 4311 
Expert Rev Neurother 2014;14:1019-1028. 4312 
473. Hankey GJ, Norrving B, Hacke W, Steiner T. Management of acute stroke in patients taking 4313 
novel oral anticoagulants. Int J Stroke 2014;9:627-632. 4314 
474. Xian Y, Liang L, Smith EE, Schwamm LH, Reeves MJ, Olson DM, Hernandez AF, Fonarow 4315 
GC, Peterson ED. Risks of intracranial hemorrhage among patients with acute ischemic stroke 4316 
Page 117 of 148 ESC AF Guidelines 
 
receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA 2012;307:2600-4317 
2608. 4318 
475. Pollack CV, Jr., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, 4319 
Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, 4320 
Wang B, Kam CW, Weitz JI. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015;373:511-520. 4321 
476. Badhiwala JH, Nassiri F, Alhazzani W, Selim MH, Farrokhyar F, Spears J, Kulkarni AV, Singh 4322 
S, Alqahtani A, Rochwerg B, Alshahrani M, Murty NK, Alhazzani A, Yarascavitch B, Reddy K, Zaidat 4323 
OO, Almenawer SA. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. Jama 4324 
2015;314:1832-1843. 4325 
477. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in 4326 
acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007;38:423-430. 4327 
478. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, 4328 
Kirchhof P. European Heart Rhythm Association Practical Guide on the use of new oral 4329 
anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-651. 4330 
479. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PA, Yang S, Xavier D, Di 4331 
Pasquale G, Yusuf S. Dabigatran compared with warfarin in patients with atrial fibrillation and 4332 
previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 4333 
2010;9:1157-1163. 4334 
480. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, Diener HC, Donnan 4335 
GA, Halperin JL, Mahaffey KW, Mas JL, Massaro A, Norrving B, Nessel CC, Paolini JF, Roine RO, 4336 
Singer DE, Wong L, Califf RM, Fox KA, Hacke W, ROCKET AF Steering Committee Investigators. 4337 
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient 4338 
ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-322. 4339 
481. Easton JD, Lopes RD, Bahit MC, Wojdyla DM, Granger CB, Wallentin L, Alings M, Goto S, 4340 
Lewis BS, Rosenqvist M, Hanna M, Mohan P, Alexander JH, Diener HC, ARISTOTLE Committees 4341 
and Investigators. Apixaban compared with warfarin in patients with atrial fibrillation and previous 4342 
stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 4343 
2012;11:503-511. 4344 
482. Ntaios G, Papavasileiou V, Diener HC, Makaritsis K, Michel P. Nonvitamin-K-antagonist oral 4345 
anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a 4346 
systematic review and meta-analysis of randomized controlled trials. Stroke 2012;43:3298-3304. 4347 
483. Paciaroni M, Agnelli G. Should oral anticoagulants be restarted after warfarin-associated 4348 
cerebral haemorrhage in patients with atrial fibrillation? Thromb Haemost 2014;111:14-18. 4349 
484. Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY. Restarting 4350 
Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the 4351 
Impact on Recurrent Stroke, Mortality, and Bleeding: A Nationwide Cohort Study. Circulation 4352 
2015;132:517-525. 4353 
485. Weber R, Brenck J, Diener HC. Antiplatelet therapy in cerebrovascular disorders. Handb Exp 4354 
Pharmacol 2012:519-546. 4355 
486. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, 4356 
Horrow J, Halperin JL. Risks and benefits of combining aspirin with anticoagulant therapy in patients 4357 
with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in 4358 
atrial fibrillation (SPORTIF) trials. Am Heart J 2006;152:967-973. 4359 
487. Yung D, Kapral MK, Asllani E, Fang J, Lee DS, Investigators of the Registry of the Canadian 4360 
Stroke Network. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and 4361 
mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding 4362 
(BRAIN) study. Can J Cardiol 2012;28:33-39. 4363 
488. Roskell NS, Samuel M, Noack H, Monz BU. Major bleeding in patients with atrial fibrillation 4364 
receiving vitamin K antagonists: a systematic review of randomized and observational studies. 4365 
Europace 2013;15:787-797. 4366 
489. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, 4367 
De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent 4368 
S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, 4369 
Zannad F, Redon J, Dominiczak A, Narkiewicz K, Nilsson PM, Burnier M, Viigimaa M, Ambrosioni E, 4370 
Caufield M, Coca A, Olsen MH, Schmieder RE, Tsioufis C, van de Borne P, Zamorano JL, Achenbach 4371 
S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes 4372 
AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski 4373 
P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Clement DL, Coca A, 4374 
Gillebert TC, Tendera M, Rosei EA, Ambrosioni E, Anker SD, Bauersachs J, Hitij JB, Caulfield M, De 4375 
Buyzere M, De Geest S, Derumeaux GA, Erdine S, Farsang C, Funck-Brentano C, Gerc V, Germano 4376 
Page 118 of 148 ESC AF Guidelines 
 
G, Gielen S, Haller H, Hoes AW, Jordan J, Kahan T, Komajda M, Lovic D, Mahrholdt H, Olsen MH, 4377 
Ostergren J, Parati G, Perk J, Polonia J, Popescu BA, Reiner Z, Ryden L, Sirenko Y, Stanton A, 4378 
Struijker-Boudier H, Tsioufis C, van de Borne P, Vlachopoulos C, Volpe M, Wood DA. 2013 ESH/ESC 4379 
guidelines for the management of arterial hypertension: the Task Force for the Management of 4380 
Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of 4381 
Cardiology (ESC). Eur Heart J 2013;34:2159-2219. 4382 
490. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings 4383 
M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of 4384 
bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial 4385 
fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. 4386 
Circulation 2011;123:2363-2372. 4387 
491. Goodman SG, Wojdyla DM, Piccini JP, White HD, Paolini JF, Nessel CC, Berkowitz SD, 4388 
Mahaffey KW, Patel MR, Sherwood MW, Becker RC, Halperin JL, Hacke W, Singer DE, Hankey GJ, 4389 
Breithardt G, Fox KA, Califf RM, ROCKET AF Investigators. Factors associated with major bleeding 4390 
events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition 4391 
compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J 4392 
Am Coll Cardiol 2014;63:891-900. 4393 
492. Chang HY, Zhou M, Tang W, Alexander GC, Singh S. Risk of gastrointestinal bleeding 4394 
associated with oral anticoagulants: population based retrospective cohort study. BMJ 4395 
2015;350:h1585. 4396 
493. Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND. Comparative 4397 
risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort 4398 
study. Bmj 2015;350:h1857. 4399 
494. Björck F, Renlund H, Lip GYH, Wester P, Svensson PJ, Själander A. Outcomes in a Warfarin-4400 
Treated Population With Atrial Fibrillation. JAMA Cardiology 2016. 4401 
495. Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke 4402 
prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage 4403 
dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother 2009;7:159-4404 
166. 4405 
496. Banerjee A, Clementy N, Haguenoer K, Fauchier L, Lip GY. Prior history of falls and risk of 4406 
outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Am J Med 2014;127:972-978. 4407 
497. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to 4408 
identify such patients. Thromb Haemost 2009;102:268-278. 4409 
498. van Schie RM, Wadelius MI, Kamali F, Daly AK, Manolopoulos VG, de Boer A, Barallon R, 4410 
Verhoef TI, Kirchheiner J, Haschke-Becher E, Briz M, Rosendaal FR, Redekop WK, Pirmohamed M, 4411 
Maitland van der Zee AH. Genotype-guided dosing of coumarin derivatives: the European 4412 
pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 4413 
2009;10:1687-1695. 4414 
499. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, 4415 
Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson 4416 
JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 4417 
2009;360:753-764. 4418 
500. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, 4419 
Stein CM. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 4420 
2008;358:999-1008. 4421 
501. Tang T, Liu J, Zuo K, Cheng J, Chen L, Lu C, Han S, Xu J, Jia Z, Ye M, Pei E, Zhang X, Li M. 4422 
Genotype-Guided Dosing of Coumarin Anticoagulants: A Meta-analysis of Randomized Controlled 4423 
Trials. J Cardiovasc Pharmacol Ther 2015;20:387-394. 4424 
502. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, 4425 
Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL, BRIDGE 4426 
Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med 4427 
2015;373:823-833. 4428 
503. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant 4429 
activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 2014;64:1128-1139. 4430 
504. Niessner A, Tamargo J, Morais J, Koller L, Wassmann S, Husted SE, Torp-Pedersen C, 4431 
Kjeldsen K, Lewis BS, Drexel H, Kaski JC, Atar D, Storey RF, Lip GY, Verheugt FW, Agewall S. 4432 
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available 4433 
evidence and recommendations for clinical management-a joint position paper of the European 4434 
Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of 4435 
Cardiology Working Group on Thrombosis. Eur Heart J 2015:[Epub ahead of print]. 4436 
Page 119 of 148 ESC AF Guidelines 
 
505. Hanley JP. Warfarin reversal. J Clin Pathol 2004;57:1132-1139. 4437 
506. Parry-Jones AR, Di Napoli M, Goldstein JN, Schreuder FH, Tetri S, Tatlisumak T, Yan B, van 4438 
Nieuwenhuizen KM, Dequatre-Ponchelle N, Lee-Archer M, Horstmann S, Wilson D, Pomero F, 4439 
Masotti L, Lerpiniere C, Godoy DA, Cohen AS, Houben R, Salman RA, Pennati P, Fenoglio L, 4440 
Werring D, Veltkamp R, Wood E, Dewey HM, Cordonnier C, Klijn CJ, Meligeni F, Davis SM, 4441 
Huhtakangas J, Staals J, Rosand J, Meretoja A. Reversal strategies for vitamin K antagonists in acute 4442 
intracerebral hemorrhage. Ann Neurol 2015;78:54-62. 4443 
507. Goldstein JN, Refaai MA, Milling TJ, Jr., Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. 4444 
Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in 4445 
patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, 4446 
randomised trial. Lancet 2015;385:2077-2087. 4447 
508. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS, Castillo J, 4448 
Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa for the Reversal of Factor Xa 4449 
Inhibitor Activity. N Engl J Med 2015;373:2413-2424. 4450 
509. Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future 4451 
potential. Arterioscler Thromb Vasc Biol 2015;35:1736-1745. 4452 
510. Staerk L, Lip GY, Olesen JB, Fosbol EL, Pallisgaard JL, Bonde AN, Gundlund A, Lindhardt 4453 
TB, Hansen ML, Torp-Pedersen C, Gislason GH. Stroke and recurrent haemorrhage associated with 4454 
antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide 4455 
cohort study. BMJ 2015;351:h5876. 4456 
511. Felmeden DC, Lip GY. Antithrombotic therapy in hypertension: a Cochrane Systematic 4457 
review. J Hum Hypertens 2005;19:185-196. 4458 
512. Sharma M, Cornelius VR, Patel JP, Davies JG, Molokhia M. Efficacy and Harms of Direct 4459 
Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention 4460 
of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation 2015;132:194-204. 4461 
513. Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J, Gimeno JR, Sogorb F, 4462 
Valdes M, Lip GYH. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation 4463 
undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk 4464 
and prognosis. J Am Coll Cardiol 2008;51:818-825. 4465 
514. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason 4466 
GH, Folke F, Andersen SS, Schramm TK, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. 4467 
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients 4468 
with atrial fibrillation. Arch Intern Med 2010;170:1433-1441. 4469 
515. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, Kober L, Torp-4470 
Pedersen C, Gislason GH, Hansen ML. Bleeding after initiation of multiple antithrombotic drugs, 4471 
including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary 4472 
intervention: a nationwide cohort study. Circulation 2012;126:1185-1193. 4473 
516. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head 4474 
SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, 4475 
Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski 4476 
A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial 4477 
Revascularization of the European Society of Cardiology (ESC) and the European Association for 4478 
Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European 4479 
Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619. 4480 
517. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, Akl EA, 4481 
Lansberg MG, Guyatt GH, Spencer FA, American College of Chest Physicians. Primary and 4482 
secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of 4483 
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice 4484 
Guidelines. Chest 2012;141:e637S-668S. 4485 
518. Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marin F, Bhatt DL, Lip GYH. The 4486 
optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 4487 
10th Anniversary Overview. Thromb Haemost 2014;112:1080-1087. 4488 
519. Oldgren J, Wallentin L, Alexander JH, James S, Jonelid B, Steg G, Sundstrom J. New oral 4489 
anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a 4490 
systematic review and meta-analysis. Eur Heart J 2013;34:1670-1680. 4491 
520. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, 4492 
Capodanno D, Gilard M, Zeymer U, Lane D, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, 4493 
Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, 4494 
Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute 4495 
coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint 4496 
Page 120 of 148 ESC AF Guidelines 
 
consensus document of the European Society of Cardiology Working Group on Thrombosis, 4497 
European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular 4498 
Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the 4499 
Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J 4500 
2014;35:3155-3179. 4501 
521. Mega JL, Braunwald E, Mohanavelu S, Burton P, Poulter R, Misselwitz F, Hricak V, 4502 
Barnathan ES, Bordes P, Witkowski A, Markov V, Oppenheimer L, Gibson CM, ATLAS ACS-TIMI 46 4503 
study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-4504 
TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;374:29-38. 4505 
522. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy 4506 
with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and 4507 
an indication for oral anticoagulation. J Am Coll Cardiol 2013;61:2060-2066. 4508 
523. Jackson LR, 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, Baker BA, Effron M, 4509 
Peterson ED, Wang TY. Outcomes of Patients With Acute Myocardial Infarction Undergoing 4510 
Percutaneous Coronary Intervention Receiving an Oral Anticoagulant and Dual Antiplatelet Therapy: 4511 
A Comparison of Clopidogrel Versus Prasugrel From the TRANSLATE-ACS Study. JACC Cardiovasc 4512 
Interv 2015;8:1880-1889. 4513 
524. Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, 4514 
Adriaenssens T, Vrolix M, Heestermans AACM, Vis MM, Tijsen JGP, van 't Hof AW, ten Berg JM. Use 4515 
of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing 4516 
percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 4517 
2013;381:1107-1115. 4518 
525. Braun OÖ, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P, Schersten F, Jovinge S, 4519 
Svensson PJ, Gustav Smith J, van der Pals J. Concomitant use of warfarin and ticagrelor as an 4520 
alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res 4521 
2015;135:26-30. 4522 
526. Nikolaidou T, Channer KS. Chronic atrial fibrillation: a systematic review of medical heart rate 4523 
control management. Postgrad Med J 2009;85:303-312. 4524 
527. Tamariz LJ, Bass EB. Pharmacological rate control of atrial fibrillation. Cardiol Clin 4525 
2004;22:35-45. 4526 
528. Segal JB, McNamara RL, Miller MR, Kim N, Goodman SN, Powe NR, Robinson K, Yu D, 4527 
Bass EB. The evidence regarding the drugs used for ventricular rate control. In. J Fam Practice; 2000, 4528 
47-59. 4529 
529. Schreck DM, Rivera AR, Tricarico VJ. Emergency management of atrial fibrillation and flutter: 4530 
intravenous diltiazem versus intravenous digoxin. Ann Emerg Med 1997;29:135-140. 4531 
530. Siu CW, Lau CP, Lee WL, Lam KF, Tse HF. Intravenous diltiazem is superior to intravenous 4532 
amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial 4533 
fibrillation. Crit Care Med 2009;37:2174-2179; quiz 2180. 4534 
531. Tisdale JE, Padhi ID, Goldberg AD, Silverman NA, Webb CR, Higgins RS, Paone G, Frank 4535 
DM, Borzak S. A randomized, double-blind comparison of intravenous diltiazem and digoxin for atrial 4536 
fibrillation after coronary artery bypass surgery. Am Heart J 1998;135:739-747. 4537 
532. Scheuermeyer FX, Grafstein E, Stenstrom R, Christenson J, Heslop C, Heilbron B, McGrath 4538 
L, Innes G. Safety and efficiency of calcium channel blockers versus beta-blockers for rate control in 4539 
patients with atrial fibrillation and no acute underlying medical illness. Acad Emerg Med 2013;20:222-4540 
230. 4541 
533. Darby AE, Dimarco JP. Management of atrial fibrillation in patients with structural heart 4542 
disease. Circulation 2012;125:945-957. 4543 
534. Elkayam U. Calcium channel blockers in heart failure. Cardiology 1998;89 Suppl 1:38-46. 4544 
535. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive 4545 
heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience 4546 
Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60. 4547 
536. Clemo HF, Wood MA, Gilligan DM, Ellenbogen KA. Intravenous amiodarone for acute heart 4548 
rate control in the critically ill patient with atrial tachyarrhythmias. Am J Cardiol 1998;81:594-598. 4549 
537. Delle Karth G, Geppert A, Neunteufl T, Priglinger U, Haumer M, Gschwandtner M, 4550 
Siostrzonek P, Heinz G. Amiodarone versus diltiazem for rate control in critically ill patients with atrial 4551 
tachyarrhythmias. Crit Care Med 2001;29:1149-1153. 4552 
538. Hou ZY, Chang MS, Chen CY, Tu MS, Lin SL, Chiang HT, Woosley RL. Acute treatment of 4553 
recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A 4554 
randomized, digoxin-controlled study. Eur Heart J 1995;16:521-528. 4555 
Page 121 of 148 ESC AF Guidelines 
 
539. National Institute for Health and Care Excellence (NICE). Atrial fibrillation: management. 4556 
NICE guidelines [CG180]. http://www.nice.org.uk/guidance/cg180/. Date last accessed 5 May 4557 
2016 Accessed 15/09/2014; http://www.nice.org.uk/guidance/cg180/ 4558 
540. Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins P, Packer M, 4559 
Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby A, Andersson B, Lip GYH, 4560 
van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD, Beta-Blockers in Heart Failure 4561 
Collaborative Group. Effect of age and sex on efficacy and tolerability of β blockers in patients with 4562 
heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 4563 
2016;353:i1855. 4564 
541. Ulimoen SR, Enger S, Carlson J, Platonov PG, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal 4565 
K, Tveit A. Comparison of four single-drug regimens on ventricular rate and arrhythmia-related 4566 
symptoms in patients with permanent atrial fibrillation. Am J Cardiol 2013;111:225-230. 4567 
542. Ulimoen SR, Enger S, Pripp AH, Abdelnoor M, Arnesen H, Gjesdal K, Tveit A. Calcium 4568 
channel blockers improve exercise capacity and reduce N-terminal Pro-B-type natriuretic peptide 4569 
levels compared with beta-blockers in patients with permanent atrial fibrillation. Eur Heart J 4570 
2014;35:517-524. 4571 
543. Goldberger ZD, Alexander GC. Digitalis use in contemporary clinical practice: refitting the 4572 
foxglove. JAMA Intern Med 2014;174:151-154. 4573 
544. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients 4574 
with heart failure. N Engl J Med 1997;336:525-533. 4575 
545. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW, Love TE, Aronow WS, Adams 4576 
KF, Jr., Gheorghiade M. Effects of digoxin on morbidity and mortality in diastolic heart failure: the 4577 
ancillary digitalis investigation group trial. Circulation 2006;114:397-403. 4578 
546. Ziff OJ, Kotecha D. Digoxin: The good and the bad. Trends in Cardiovascular Medicine 4579 
2016:[Epub ahead of print]. 4580 
547. Turakhia MP, Santangeli P, Winkelmayer WC, Xu X, Ullal AJ, Than CT, Schmitt S, Holmes 4581 
TH, Frayne SM, Phibbs CS, Yang F, Hoang DD, Ho PM, Heidenreich PA. Increased mortality 4582 
associated with digoxin in contemporary patients with atrial fibrillation: findings from the TREAT-AF 4583 
study. J Am Coll Cardiol 2014;64:660-668. 4584 
548. Hallberg P, Lindback J, Lindahl B, Stenestrand U, Melhus H. Digoxin and mortality in atrial 4585 
fibrillation: a prospective cohort study. Eur J Clin Pharmacol 2007;63:959-971. 4586 
549. Whitbeck MG, Charnigo RJ, Khairy P, Ziada K, Bailey AL, Zegarra MM, Shah J, Morales G, 4587 
Macaulay T, Sorrell VL, Campbell CL, Gurley J, Anaya P, Nasr H, Bai R, Di Biase L, Booth DC, 4588 
Jondeau G, Natale A, Roy D, Smyth S, Moliterno DJ, Elayi CS. Increased mortality among patients 4589 
taking digoxin--analysis from the AFFIRM study. Eur Heart J 2013;34:1481-1488. 4590 
550. Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, Patel K, 4591 
Aban IB, Aronow WS, Anker SD, Ahmed A. Lack of evidence of increased mortality among patients 4592 
with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the 4593 
AFFIRM trial. Eur Heart J 2013;34:1489-1497. 4594 
551. Flory JH, Ky B, Haynes K, S MB, Munson J, Rowan C, Strom BL, Hennessy S. Observational 4595 
cohort study of the safety of digoxin use in women with heart failure. BMJ Open 2012;2:e000888. 4596 
552. Andrey JL, Romero S, Garcia-Egido A, Escobar MA, Corzo R, Garcia-Dominguez G, Lechuga 4597 
V, Gomez F. Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study. 4598 
Int J Clin Pract 2011;65:1250-1258. 4599 
553. Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, Gersh BJ, Go AS, 4600 
Hylek EM, Kowey PR, Mahaffey KW, Chang P, Peterson ED, Piccini JP, ORBIT-AF Investigators. 4601 
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. 4602 
J Am Coll Cardiol 2015;65:2691-2698. 4603 
554. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in 4604 
combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am 4605 
Coll Cardiol 2003;42:1944-1951. 4606 
555. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic 4607 
atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five 4608 
drug regimens. J Am Coll Cardiol 1999;33:304-310. 4609 
556. Koh KK, Kwon KS, Park HB, Baik SH, Park SJ, Lee KH, Kim EJ, Kim SH, Cho SK, Kim SS. 4610 
Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control 4611 
ventricular rate in chronic atrial fibrillation. Am J Cardiol 1995;75:88-90. 4612 
557. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart 4613 
rate and exercise tolerance in digitalised patients with chronic atrial fibrillation. J Cardiovasc 4614 
Pharmacol 1989;13:1-6. 4615 
Page 122 of 148 ESC AF Guidelines 
 
558. Tsuneda T, Yamashita T, Fukunami M, Kumagai K, Niwano S, Okumura K, Inoue H. Rate 4616 
control and quality of life in patients with permanent atrial fibrillation: the Quality of Life and Atrial 4617 
Fibrillation (QOLAF) Study. Circ J 2006;70:965-970. 4618 
559. ClinicalTrials.gov. Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-4619 
AF). https://clinicaltrials.gov/ct2/show/NCT02391337. Date last accessed 5 May 2016  4620 
560. Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, Hillege HL, 4621 
Bergsma-Kadijk JA, Cornel JH, Kamp O, Tukkie R, Bosker HA, Van Veldhuisen DJ, Van den Berg 4622 
MP, RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J 4623 
Med 2010;362:1363-1373. 4624 
561. Groenveld HF, Crijns HJ, Van den Berg MP, Van Sonderen E, Alings AM, Tijssen JG, Hillege 4625 
HL, Tuininga YS, Van Veldhuisen DJ, Ranchor AV, Van Gelder IC, RACE II Investigators. The effect 4626 
of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II 4627 
(Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol 2011;58:1795-1803. 4628 
562. Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, Crijns HJ, 4629 
RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation? 4630 
An analysis of pooled data from the RACE and AFFIRM studies. Europace 2006;8:935-942. 4631 
563. Queiroga A, Marshall HJ, Clune M, Gammage MD. Ablate and pace revisited: long term 4632 
survival and predictors of permanent atrial fibrillation. Heart 2003;89:1035-1038. 4633 
564. Lim KT, Davis MJ, Powell A, Arnolda L, Moulden K, Bulsara M, Weerasooriya R. Ablate and 4634 
pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial. Europace 2007;9:498-505. 4635 
565. Geelen P, Brugada J, Andries E, Brugada P. Ventricular fibrillation and sudden death after 4636 
radiofrequency catheter ablation of the atrioventricular junction. Pacing Clin Electrophysiol 4637 
1997;20:343-348. 4638 
566. Wang RX, Lee HC, Hodge DO, Cha YM, Friedman PA, Rea RF, Munger TM, Jahangir A, 4639 
Srivathsan K, Shen WK. Effect of pacing method on risk of sudden death after atrioventricular node 4640 
ablation and pacemaker implantation in patients with atrial fibrillation. Heart Rhythm 2013;10:696-701. 4641 
567. Chatterjee NA, Upadhyay GA, Ellenbogen KA, McAlister FA, Choudhry NK, Singh JP. 4642 
Atrioventricular nodal ablation in atrial fibrillation: a meta-analysis and systematic review. Circ 4643 
Arrhythm Electrophysiol 2012;5:68-76. 4644 
568. Bradley DJ, Shen WK. Overview of management of atrial fibrillation in symptomatic elderly 4645 
patients: pharmacologic therapy versus AV node ablation. Clin Pharmacol Ther 2007;81:284-287. 4646 
569. Wood MA, Brown-Mahoney C, Kay GN, Ellenbogen KA. Clinical outcomes after ablation and 4647 
pacing therapy for atrial fibrillation : a meta-analysis. Circulation 2000;101:1138-1144. 4648 
570. Ozcan C, Jahangir A, Friedman PA, Patel PJ, Munger TM, Rea RF, Lloyd MA, Packer DL, 4649 
Hodge DO, Gersh BJ, Hammill SC, Shen WK. Long-term survival after ablation of the atrioventricular 4650 
node and implantation of a permanent pacemaker in patients with atrial fibrillation. N Engl J Med 4651 
2001;344:1043-1051. 4652 
571. Hess PL, Jackson KP, Hasselblad V, Al-Khatib SM. Is cardiac resynchronization therapy an 4653 
antiarrhythmic therapy for atrial fibrillation? A systematic review and meta-analysis. Curr Cardiol Rep 4654 
2013;15:330. 4655 
572. Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JG, Freemantle N, Erdmann E. 4656 
Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart 4657 
failure. Circulation 2006;114:18-25. 4658 
573. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland 4659 
J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, 4660 
Sutton R, Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, 4661 
Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti 4662 
P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, 4663 
Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch 4664 
D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, 4665 
Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, 4666 
Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM. 2013 ESC Guidelines on cardiac 4667 
pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and 4668 
resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration 4669 
with the European Heart Rhythm Association (EHRA). Eur Heart J 2013;34:2281-2329. 4670 
574. Chatterjee NA, Upadhyay GA, Ellenbogen KA, Hayes DL, Singh JP. Atrioventricular nodal 4671 
ablation in atrial fibrillation: a meta-analysis of biventricular vs. right ventricular pacing mode. Eur J 4672 
Heart Fail 2012;14:661-667. 4673 
Page 123 of 148 ESC AF Guidelines 
 
575. Lewis RV, Irvine N, McDevitt DG. Relationships between heart rate, exercise tolerance and 4674 
cardiac output in atrial fibrillation: the effects of treatment with digoxin, verapamil and diltiazem. Eur 4675 
Heart J 1988;9:777-781. 4676 
576. Mulder BA, Van Veldhuisen DJ, Crijns HJ, Tijssen JG, Hillege HL, Alings M, Rienstra M, Van 4677 
den Berg MP, Van Gelder IC, RACE II Investigators. Digoxin in patients with permanent atrial 4678 
fibrillation: data from the RACE II study. Heart Rhythm 2014;11:1543-1550. 4679 
577. Koh KK, Song JH, Kwon KS, Park HB, Baik SH, Park YS, In HH, Moon TH, Park GS, Cho SK, 4680 
Kim SS. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination 4681 
with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J 4682 
Cardiol 1995;52:167-174. 4683 
578. Chatterjee S, Sardar P, Lichstein E, Mukherjee D, Aikat S. Pharmacologic rate versus rhythm-4684 
control strategies in atrial fibrillation: an updated comprehensive review and meta-analysis. PACE 4685 
2013;36:122-133. 4686 
579. de Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in 4687 
patients with atrial fibrillation: a meta-analysis. Arch Intern Med 2005;165:258-262. 4688 
580. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for 4689 
maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 4690 
2012;5:CD005049. 4691 
581. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, 4692 
Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of 4693 
Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920. 4694 
582. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton 4695 
AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le 4696 
Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault 4697 
B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 4698 
2008;358:2667-2677. 4699 
583. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, 4700 
Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J 4701 
Med 2007;357:987-999. 4702 
584. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, 4703 
Steinbeck G, Treszl A, Wegscheider K, Breithardt G. Short-term versus long-term antiarrhythmic drug 4704 
treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, 4705 
blinded endpoint assessment trial. Lancet 2012;380:238-246. 4706 
585. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson H, Kongstad O, 4707 
Pehrson S, Englund A, Hartikainen J, Mortensen LS, Hansen PS. Radiofrequency ablation as initial 4708 
therapy in paroxysmal atrial fibrillation. N Engl J Med 2012;367:1587-1595. 4709 
586. Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, Macle L, Daoud EG, 4710 
Calkins H, Hall B, Reddy V, Augello G, Reynolds MR, Vinekar C, Liu CY, Berry SM, Berry DA, 4711 
ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency 4712 
catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 4713 
2010;303:333-340. 4714 
587. Arbelo E, Brugada J, Hindricks G, Maggioni AP, Tavazzi L, Vardas P, Laroche C, Anselme F, 4715 
Inama G, Jais P, Kalarus Z, Kautzner J, Lewalter T, Mairesse GH, Perez-Villacastin J, Riahi S, 4716 
Taborsky M, Theodorakis G, Trines SA, Atrial Fibrillation Ablation Pilot Study Investigators. The atrial 4717 
fibrillation ablation pilot study: a European Survey on Methodology and results of catheter ablation for 4718 
atrial fibrillation conducted by the European Heart Rhythm Association. Eur Heart J 2014;35:1466-4719 
1478. 4720 
588. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. 4721 
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-678. 4722 
589. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, 4723 
Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in 4724 
patients with atrial fibrillation. N Engl J Med 2002;347:1825-1833. 4725 
590. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata 4726 
JI, Timmermans AJ, Tijssen JG, Crijns HJ, Rate Control versus Electrical Cardioversion for Persistent 4727 
Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with 4728 
recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-1840. 4729 
591. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk 4730 
P, Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm 4731 
control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat 4732 
Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476-486. 4733 
Page 124 of 148 ESC AF Guidelines 
 
592. Kong MH, Shaw LK, O'Connor C, Califf RM, Blazing MA, Al-Khatib SM. Is rhythm-control 4734 
superior to rate-control in patients with atrial fibrillation and diastolic heart failure? Ann Noninvasive 4735 
Electrocardiol 2010;15:209-217. 4736 
593. Kotecha D, Kirchhof P. Rate and rhythm control have comparable effects on mortality and 4737 
stroke in atrial fibrillation but better data are needed. Evid Based Med 2014;19:222-223. 4738 
594. ClinicalTrials.gov. Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation 4739 
Trial (CABANA). https://clinicaltrials.gov/ct2/show/NCT00911508. Date last accessed 5 May 4740 
2016 NLM Identifier: NCT00911508 [Accessed 20-May-2015] 4741 
595. Khan IA. Oral loading single dose flecainide for pharmacological cardioversion of recent-onset 4742 
atrial fibrillation. Int J Cardiol 2003;87:121-128. 4743 
596. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone 4744 
versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. 4745 
J Am Coll Cardiol 2003;41:255-262. 4746 
597. Letelier LM, Udol K, Ena J, Weaver B, Guyatt GH. Effectiveness of amiodarone for 4747 
conversion of atrial fibrillation to sinus rhythm: a meta-analysis. Arch Intern Med 2003;163:777-785. 4748 
598. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-4749 
onset atrial fibrillation. Int J Cardiol 2003;89:239-248. 4750 
599. Thomas SP, Guy D, Wallace E, Crampton R, Kijvanit P, Eipper V, Ross DL, Cooper MJ. 4751 
Rapid loading of sotalol or amiodarone for management of recent onset symptomatic atrial fibrillation: 4752 
a randomized, digoxin-controlled trial. Am Heart J 2004;147:E3. 4753 
600. Vijayalakshmi K, Whittaker VJ, Sutton A, Campbell P, Wright RA, Hall JA, Harcombe AA, 4754 
Linker NJ, Stewart MJ, Davies A, de Belder MA. A randomized trial of prophylactic antiarrhythmic 4755 
agents (amiodarone and sotalol) in patients with atrial fibrillation for whom direct current cardioversion 4756 
is planned. Am Heart J 2006;151:863 e861-866. 4757 
601. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, 4758 
Atwood JE, Jacobson AK, Lewis HD, Jr., Raisch DW, Ezekowitz MD. Amiodarone versus sotalol for 4759 
atrial fibrillation. N Engl J Med 2005;352:1861-1872. 4760 
602. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen 4761 
SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ. Vernakalant hydrochloride for rapid conversion 4762 
of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 2008;117:1518-1525. 4763 
603. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, 4764 
Bochenek A, Toft E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after 4765 
cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol 4766 
2009;2:652-659. 4767 
604. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G. 4768 
A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone 4769 
in recent-onset atrial fibrillation. J Am Coll Cardiol 2011;57:313-321. 4770 
605. Bash LD, Buono JL, Davies GM, Martin A, Fahrbach K, Phatak H, Avetisyan R, Mwamburi M. 4771 
Systematic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators 4772 
in patients with atrial fibrillation. Cardiovasc Drugs Ther 2012;26:167-179. 4773 
606. Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic 4774 
agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators 4775 
[see comments]. J Am Coll Cardiol 1997;29:385-390. 4776 
607. Dankner R, Shahar A, Novikov I, Agmon U, Ziv A, Hod H. Treatment of stable atrial fibrillation 4777 
in the emergency department: a population-based comparison of electrical direct-current versus 4778 
pharmacological cardioversion or conservative management. Cardiology 2009;112:270-278. 4779 
608. Chen WS, Gao BR, Chen WQ, Li ZZ, Xu ZY, Zhang YH, Yang K, Guan XQ. Comparison of 4780 
pharmacological and electrical cardioversion in permanent atrial fibrillation after prosthetic cardiac 4781 
valve replacement: a prospective randomized trial. J Int Med Res 2013;41:1067-1073. 4782 
609. Gitt AK, Smolka W, Michailov G, Bernhardt A, Pittrow D, Lewalter T. Types and outcomes of 4783 
cardioversion in patients admitted to hospital for atrial fibrillation: results of the German RHYTHM-AF 4784 
Study. Clin Res Cardiol 2013;102:713-723. 4785 
610. Cristoni L, Tampieri A, Mucci F, Iannone P, Venturi A, Cavazza M, Lenzi T. Cardioversion of 4786 
acute atrial fibrillation in the short observation unit: comparison of a protocol focused on electrical 4787 
cardioversion with simple antiarrhythmic treatment. Emerg Med J 2011;28:932-937. 4788 
611. Bellone A, Etteri M, Vettorello M, Bonetti C, Clerici D, Gini G, Maino C, Mariani M, Natalizi A, 4789 
Nessi I, Rampoldi A, Colombo L. Cardioversion of acute atrial fibrillation in the emergency 4790 
department: a prospective randomised trial. Emerg Med J 2012;29:188-191. 4791 
612. Crijns HJ, Weijs B, Fairley AM, Lewalter T, Maggioni AP, Martin A, Ponikowski P, Rosenqvist 4792 
M, Sanders P, Scanavacca M, Bash LD, Chazelle F, Bernhardt A, Gitt AK, Lip GY, Le Heuzey JY. 4793 
Page 125 of 148 ESC AF Guidelines 
 
Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF 4794 
study. Int J Cardiol 2014;172:588-594. 4795 
613. Lip GY, Gitt AK, Le Heuzey JY, Bash LD, Morabito CJ, Bernhardt AA, Sisk CM, Chazelle F, 4796 
Crijns HJ. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial 4797 
fibrillation (the RHYTHM-AF study). Am J Cardiol 2014;113:480-484. 4798 
614. Reisinger J, Gatterer E, Lang W, Vanicek T, Eisserer G, Bachleitner T, Niemeth C, Aicher F, 4799 
Grander W, Heinze G, Kuhn P, Siostrzonek P. Flecainide versus ibutilide for immediate cardioversion 4800 
of atrial fibrillation of recent onset. Eur Heart J 2004;25:1318-1324. 4801 
615. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT. Efficacy 4802 
and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. 4803 
Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-1621. 4804 
616. Torp-Pedersen C, Camm AJ, Butterfield NN, Dickinson G, Beatch GN. Vernakalant: 4805 
conversion of atrial fibrillation in patients with ischemic heart disease. Int J Cardiol 2013;166:147-151. 4806 
617. Savelieva I, Graydon R, Camm AJ. Pharmacological cardioversion of atrial fibrillation with 4807 
vernakalant: evidence in support of the ESC Guidelines. Europace 2014;16:162-173. 4808 
618. Simon A, Niederdoeckl J, Skyllouriotis E, Schuetz N, Herkner H, Weiser C, Laggner AN, 4809 
Domanovits H, Spiel AO. Vernakalant is superior to ibutilide for achieving sinus rhythm in patients 4810 
with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. 4811 
Europace 2016;10.1093/europace/euw052:[Epub ahead of print]. 4812 
619. Reisinger J, Gatterer E, Heinze G, Wiesinger K, Zeindlhofer E, Gattermeier M, Poelzl G, 4813 
Kratzer H, Ebner A, Hohenwallner W, Lenz K, Slany J, Kuhn P. Prospective comparison of flecainide 4814 
versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 1998;81:1450-1454. 4815 
620. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, 4816 
Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-4817 
pocket" approach. N Engl J Med 2004;351:2384-2391. 4818 
621. Saborido CM, Hockenhull J, Bagust A, Boland A, Dickson R, Todd D. Systematic review and 4819 
cost-effectiveness evaluation of 'pill-in-the-pocket' strategy for paroxysmal atrial fibrillation compared 4820 
to episodic in-hospital treatment or continuous antiarrhythmic drug therapy. Health Technol Assess 4821 
2010;14:iii-iv, 1-75. 4822 
622. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-4823 
onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-547. 4824 
623. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial 4825 
fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997;79:418-423. 4826 
624. Hughes C, Sunderji R, Gin K. Oral propafenone for rapid conversion of recent onset atrial 4827 
fibrillation - A review. CAN J CARDIOL. Canadian Journal of Cardiology 1997;13:839-842. 4828 
625. Zhang N, Guo JH, Zhang H, Li XB, Zhang P, Xn Y. Comparison of intravenous ibutilide vs. 4829 
propafenone for rapid termination of recent onset atrial fibrillation. Int J Clin Pract 2005;59:1395-1400. 4830 
626. Mittal S, Ayati S, Stein KM, Schwartzman D, Cavlovich D, Tchou PJ, Markowitz SM, Slotwiner 4831 
DJ, Scheiner MA, Lerman BB. Transthoracic cardioversion of atrial fibrillation: comparison of 4832 
rectilinear biphasic versus damped sine wave monophasic shocks. Circulation 2000;101:1282-1287. 4833 
627. Kirchhof P, Eckardt L, Loh P, Weber K, Fischer RJ, Seidl KH, Böcker D, Breithardt G, 4834 
Haverkamp W, Borggrefe M. Anterior-posterior versus anterior-lateral electrode positions for external 4835 
cardioversion of atrial fibrillation: a randomised trial. Lancet 2002;360:1275-1279. 4836 
628. Kirchhof P, Monnig G, Wasmer K, Heinecke A, Breithardt G, Eckardt L, Bocker D. A trial of 4837 
self-adhesive patch electrodes and hand-held paddle electrodes for external cardioversion of atrial 4838 
fibrillation (MOBIPAPA). Eur Heart J 2005;26:1292-1297. 4839 
629. Furniss SS, Sneyd JR. Safe sedation in modern cardiological practice. Heart 2015;101:1526-4840 
1530. 4841 
630. Alp N, Rahman S, Bell J, Shahi M. Randomised comparison of antero-lateral versus antero-4842 
posterior paddle positions for DC cardioversion of persistent atrial fibrillation. Int J Cardiol 4843 
2000;75:211-216. 4844 
631. Singh SN, Tang XC, Reda D, Singh BN. Systematic electrocardioversion for atrial fibrillation 4845 
and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 2009;6:152-155. 4846 
632. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, Muthusamy R, Rhoden 4847 
WE, Saeed BT, Batin P, Brooksby WP, Wilson I, Grant S. A randomized placebo-controlled trial of 4848 
pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC 4849 
cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-150. 4850 
633. Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F. Facilitating 4851 
transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 4852 
1999;340:1849-1854. 4853 
Page 126 of 148 ESC AF Guidelines 
 
634. Mussigbrodt A, John S, Kosiuk J, Richter S, Hindricks G, Bollmann A. Vernakalant-facilitated 4854 
electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced 4855 
electrical cardioversion of atrial fibrillation after failed electrical cardioversion. Europace 2016;18:51-4856 
56. 4857 
635. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone 4858 
administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J 4859 
Am Coll Cardiol 1996;28:700-706. 4860 
636. Nergardh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with 4861 
metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a 4862 
randomized double-blind placebo-controlled study. Eur Heart J 2007;28:1351-1357. 4863 
637. Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ, Bosker HA, Wiesfeld 4864 
AC, Van den Berg MP, Ranchor AV, Van Gelder IC. Verapamil versus digoxin and acute versus 4865 
routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am 4866 
Coll Cardiol 2006;48:1001-1009. 4867 
638. Villani GQ, Piepoli MF, Terracciano C, Capucci A. Effects of diltiazem pretreatment on direct-4868 
current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled 4869 
study. Am Heart J 2000;140:e12. 4870 
639. De Simone A, Stabile G, Vitale DF, Turco P, Di Stasio M, Petrazzuoli F, Gasparini M, De 4871 
Matteis C, Rotunno R, Di Napoli T. Pretreatment with verapamil in patients with persistent or chronic 4872 
atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-814. 4873 
640. The Digitalis in Acute Atrial Fibrillation (DAAF) Trial Group. Intravenous digoxin in acute atrial 4874 
fibrillation. Results of a randomized, placebo-controlled multicentre trial in 239 patients. Eur Heart J 4875 
1997;18:649-654. 4876 
641. Atarashi H, Inoue H, Fukunami M, Sugi K, Hamada C, Origasa H. Double-blind placebo-4877 
controlled trial of aprindine and digoxin for the prevention of symptomatic atrial fibrillation. Circ J 4878 
2002;66:553-556. 4879 
642. Airaksinen KE, Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Biancari F, Hartikainen JE. 4880 
Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish 4881 
CardioVersion) study. J Am Coll Cardiol 2013;62:1187-1192. 4882 
643. Hansen ML, Jepsen RM, Olesen JB, Ruwald MH, Karasoy D, Gislason GH, Hansen J, Kober 4883 
L, Husted S, Torp-Pedersen C. Thromboembolic risk in 16 274 atrial fibrillation patients undergoing 4884 
direct current cardioversion with and without oral anticoagulant therapy. Europace 2015;17:18-23. 4885 
644. Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht 4886 
JG. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting 4887 
nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. Am J Cardiovasc 4888 
Drugs 2007;7:199-217. 4889 
645. Schmidt-Lucke C, Paar WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel 4890 
WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke JA. Quality of anticoagulation with unfractionated 4891 
heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for 4892 
non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using 4893 
Enoxaparin (ACE) trial. Thromb Res 2007;119:27-34. 4894 
646. Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge 4895 
A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke JA. Safety and efficacy of enoxaparin compared with 4896 
unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in 4897 
cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin 4898 
(ACE) trial. Circulation 2004;109:997-1003. 4899 
647. Nuotio I, Hartikainen JE, Gronberg T, Biancari F, Airaksinen KE. Time to cardioversion for 4900 
acute atrial fibrillation and thromboembolic complications. JAMA 2014;312:647-649. 4901 
648. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, 4902 
Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF. Use of transesophageal 4903 
echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 4904 
2001;344:1411-1420. 4905 
649. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, 4906 
Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, 4907 
Hohnloser SH, Investigators XV. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial 4908 
fibrillation. Eur Heart J 2014;35:3346-3355. 4909 
650. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen JB, Svendsen JH. 4910 
Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial 4911 
fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 4912 
2014;35:3356-3364. 4913 
Page 127 of 148 ESC AF Guidelines 
 
651. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, Massie BM, Colling 4914 
C, Lazzeri D. Amiodarone in patients with congestive heart failure and asymptomatic ventricular 4915 
arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 4916 
1995;333:77-82. 4917 
652. Kirchhof P, Franz MR, Bardai A, Wilde AM. Giant T-U waves precede torsades de pointes in 4918 
long QT syndrome: a systematic electrocardiographic analysis in patients with acquired and 4919 
congenital QT prolongation. J Am Coll Cardiol 2009;54:143-149. 4920 
653. Goldschlager N, Epstein AE, Naccarelli GV, Olshansky B, Singh B, Collard HR, Murphy E. A 4921 
practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm 2007;4:1250-4922 
1259. 4923 
654. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009;16:43-48. 4924 
655. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, Bosker HA, Lok DJ, Van 4925 
Veldhuisen DJ, Van Gelder IC. Continuous vs episodic prophylactic treatment with amiodarone for the 4926 
prevention of atrial fibrillation: a randomized trial. JAMA 2008;300:1784-1792. 4927 
656. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, Van Kempen L. 4928 
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of 4929 
dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 4930 
2008;156:527 e521-529. 4931 
657. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J, 4932 
Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N 4933 
Engl J Med 2008;358:2678-2687. 4934 
658. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, 4935 
Blomstrom P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, 4936 
Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, 4937 
Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, 4938 
Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen 4939 
L, Tomcsanyi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-4940 
Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in 4941 
high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268-2276. 4942 
659. Tschuppert Y, Buclin T, Rothuizen LE, Decosterd LA, Galleyrand J, Gaud C, Biollaz J. Effect 4943 
of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol 2007;64:785-791. 4944 
660. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of 4945 
encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial 4946 
infarction. N Engl J Med 1989;321:406-412. 4947 
661. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment 4948 
comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of 4949 
atrial fibrillation. Europace 2011;13:329-345. 4950 
662. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. 4951 
Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic 4952 
cardiomyopathy. J Am Coll Cardiol 2005;45:1251-1258. 4953 
663. Sirak TE, Sherrid MV. Oral disopyramide for the acute treatment of severe outflow obstruction 4954 
in hypertrophic cardiomyopathy in the ICU setting. Chest 2008;133:1243-1246. 4955 
664. Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, Homel P, Balaram SK, Swistel 4956 
DG. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-4957 
line therapy with beta-blockade or verapamil. Circ Heart Fail 2013;6:694-702. 4958 
665. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, 4959 
Schwartz PJ, Veltri EP. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after 4960 
recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. 4961 
Lancet 1996;348:7-12. 4962 
666. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of 4963 
dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a 4964 
Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 4965 
2001;104:292-296. 4966 
667. Shamiss Y, Khaykin Y, Oosthuizen R, Tunney D, Sarak B, Beardsall M, Seabrook C, Frost L, 4967 
Wulffhart Z, Tsang B, Verma A. Dofetilide is safe and effective in preventing atrial fibrillation 4968 
recurrences in patients accepted for catheter ablation. Europace 2009;11:1448-1455. 4969 
668. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, 4970 
Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by non-anti-4971 
arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European 4972 
Society of Cardiology. Cardiovasc Res 2000;47:219-233. 4973 
Page 128 of 148 ESC AF Guidelines 
 
669. Kääb S, Hinterseer M, Näbauer M, Steinbeck G. Sotalol testing unmasks altered 4974 
repolarization in patients with suspected acquired long-QT-syndrome-a case-control pilot study using 4975 
i.v. sotalol. Eur Heart J 2003;24:649-657. 4976 
670. Fabritz L, Kirchhof P. Predictable and less predictable unwanted cardiac drugs effects: 4977 
individual pre-disposition and transient precipitating factors. Basic Clin Pharmacol Toxicol 4978 
2010;106:263-268. 4979 
671. Choy AM, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation after 4980 
cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396-401. 4981 
672. Patten M, Maas R, Bauer P, Luderitz B, Sonntag F, Dluzniewski M, Hatala R, Opolski G, 4982 
Muller HW, Meinertz T. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. 4983 
Eur Heart J 2004;25:1395-1404. 4984 
673. Burashnikov A, Barajas-Martinez H, Hu D, Nof E, Blazek J, Antzelevitch C. Atrial-selective 4985 
prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel 4986 
activity. J Cardiovasc Pharmacol 2012;59:539-546. 4987 
674. Ford J, Milnes J, Wettwer E, Christ T, Rogers M, Sutton K, Madge D, Virag L, Jost N, Horvath 4988 
Z, Matschke K, Varro A, Ravens U. Human electrophysiological and pharmacological properties of 4989 
XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol 2013;61:408-415. 4990 
675. Loose S, Mueller J, Wettwer E, Knaut M, Ford J, Milnes J, Ravens U. Effects of IKur blocker 4991 
MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial 4992 
fibrillation. Front Pharmacol 2014;5:26. 4993 
676. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-4994 
channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004;142:1300-4995 
1308. 4996 
677. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation 4997 
in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 1996;93:135-142. 4998 
678. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, 4999 
Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with 5000 
novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-5001 
segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine 5002 
for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial 5003 
Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007;116:1647-1652. 5004 
679. Scirica BM, Belardinelli L, Chaitman BR, Waks JW, Volo S, Karwatowska-Prokopczuk E, 5005 
Murphy SA, Cheng ML, Braunwald E, Morrow DA. Effect of ranolazine on atrial fibrillation in patients 5006 
with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. 5007 
Europace 2015;17:32-37. 5008 
680. Reiffel JA, Camm AJ, Belardinelli L, Zeng D, Karwatowska-Prokopczuk E, Olmsted A, Zareba 5009 
W, Rosero S, Kowey P, HARMONY Investigators. The HARMONY Trial: Combined Ranolazine and 5010 
Dronedarone in the Management of Paroxysmal Atrial Fibrillation: Mechanistic and Therapeutic 5011 
Synergism. Circ Arrhythm Electrophysiol 2015;8:1048-1056. 5012 
681. Fragakis N, Koskinas KC, Katritsis DG, Pagourelias ED, Zografos T, Geleris P. Comparison 5013 
of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-5014 
onset atrial fibrillation. Am J Cardiol 2012;110:673-677. 5015 
682. Simopoulos V, Tagarakis GI, Daskalopoulou SS, Daskalopoulos ME, Lenos A, Chryssagis K, 5016 
Skoularingis I, Molyvdas PA, Tsilimingas NB, Aidonidis I. Ranolazine enhances the antiarrhythmic 5017 
activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery. 5018 
Angiology 2014;65:294-297. 5019 
683. Koskinas KC, Fragakis N, Katritsis D, Skeberis V, Vassilikos V. Ranolazine enhances the 5020 
efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace 2014;16:973-979. 5021 
684. De Ferrari GM, Maier LS, Mont L, Schwartz PJ, Simonis G, Leschke M, Gronda E, Boriani G, 5022 
Darius H, Guillamon Toran L, Savelieva I, Dusi V, Marchionni N, Quintana Rendon M, Schumacher K, 5023 
Tonini G, Melani L, Giannelli S, Alberto Maggi C, Camm AJ, RAFFAELLO Investigators. Ranolazine in 5024 
the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial 5025 
Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm 2015;12:872-878. 5026 
685. Martin RI, Pogoryelova O, Koref MS, Bourke JP, Teare MD, Keavney BD. Atrial fibrillation 5027 
associated with ivabradine treatment: meta-analysis of randomised controlled trials. Heart 5028 
2014;100:1506-1510. 5029 
686. Okin PM, Wachtell K, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Lindholm LH, 5030 
Nieminen MS, Edelman JM, Hille DA, Dahlof B. Regression of electrocardiographic left ventricular 5031 
hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. 5032 
JAMA 2006;296:1242-1248. 5033 
Page 129 of 148 ESC AF Guidelines 
 
687. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of 5034 
atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology 5035 
guidelines. Part II: secondary prevention. Europace 2011;13:610-625. 5036 
688. Kuhlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol 5037 
CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, 5038 
double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-146. 5039 
689. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy 5040 
for patients undergoing cardiac surgery. Cochrane Database Syst Rev 2012;4:Cd008493. 5041 
690. Kuhn EW, Liakopoulos OJ, Stange S, Deppe AC, Slottosch I, Choi YH, Wahlers T. 5042 
Preoperative statin therapy in cardiac surgery: a meta-analysis of 90,000 patients. Eur J Cardiothorac 5043 
Surg 2014;45:17-26; discussion 26. 5044 
691. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, 5045 
Collins R, Casadei B. Perioperative Rosuvastatin in Cardiac Surgery. N Engl J Med 2016;374:1744-5046 
1753. 5047 
692. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane 5048 
PW, PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of 5049 
published and unpublished evidence from randomised controlled trials. BMJ 2011;342:d1250. 5050 
693. Pinho-Gomes AC, Reilly S, Brandes RP, Casadei B. Targeting inflammation and oxidative 5051 
stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with 5052 
statins. Antioxid Redox Signal 2014;20:1268-1285. 5053 
694. Bianconi L, Calo L, Mennuni M, Santini L, Morosetti P, Azzolini P, Barbato G, Biscione F, 5054 
Romano P, Santini M. n-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence 5055 
after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, 5056 
multicentre study. Europace 2011;13:174-181. 5057 
695. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of 5058 
prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a 5059 
randomized controlled trial. JAMA 2010;304:2363-2372. 5060 
696. Mozaffarian D, Marchioli R, Macchia A, Silletta MG, Ferrazzi P, Gardner TJ, Latini R, Libby P, 5061 
Lombardi F, O'Gara PT, Page RL, Tavazzi L, Tognoni G, OPERA Investigators. Fish oil and 5062 
postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial 5063 
Fibrillation (OPERA) randomized trial. JAMA 2012;308:2001-2011. 5064 
697. Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, Ohe T, Ohtsu H, Kato T, 5065 
Kamakura S, Kumagai K, Kurachi Y, Koretsune Y, Saikawa T, Sakurai M, Sato T, Sugi K, Nakaya H, 5066 
Hirai M, Hirayama A, Fukatani M, Mitamura H, Yamazaki T, Watanabe E, Ogawa S, J-RHYTHM II 5067 
Investigators. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel 5068 
blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). 5069 
Europace 2011;13:473-479. 5070 
698. Macchia A, Grancelli H, Varini S, Nul D, Laffaye N, Mariani J, Ferrante D, Badra R, Figal J, 5071 
Ramos S, Tognoni G, Doval HC, GESICA Investigators. Omega-3 fatty acids for the prevention of 5072 
recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess 5073 
Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) trial. J Am Coll 5074 
Cardiol 2013;61:463-468. 5075 
699. Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A, Kazimierska B, 5076 
Wozniak J, Zareba W, Szwed H. Effect of combined spironolactone-β-blocker ± enalapril treatment on 5077 
occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial 5078 
fibrillation (SPIR-AF study). Am J Cardiol 2010;106:1609-1614. 5079 
700. Ito Y, Yamasaki H, Naruse Y, Yoshida K, Kaneshiro T, Murakoshi N, Igarashi M, Kuroki K, 5080 
Machino T, Xu D, Kunugita F, Sekiguchi Y, Sato A, Tada H, Aonuma K. Effect of eplerenone on 5081 
maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial 5082 
fibrillation. Am J Cardiol 2013;111:1012-1018. 5083 
701. Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, Vincent J, Pitt B, 5084 
EMPHASIS-Hf Study Investigators. Eplerenone and atrial fibrillation in mild systolic heart failure: 5085 
results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in 5086 
Heart Failure) study. J Am Coll Cardiol 2012;59:1598-1603. 5087 
702. Coll-Vinent B, Sala X, Fernandez C, Bragulat E, Espinosa G, Miro O, Milla J, Sanchez M. 5088 
Sedation for cardioversion in the emergency department: analysis of effectiveness in four protocols. 5089 
Ann Emerg Med 2003;42:767-772. 5090 
703. del Arco C, Martin A, Laguna P, Gargantilla P. Analysis of current management of atrial 5091 
fibrillation in the acute setting: GEFAUR-1 study. Ann Emerg Med 2005;46:424-430. 5092 
Page 130 of 148 ESC AF Guidelines 
 
704. Scheuermeyer FX, Grafstein E, Heilbron B, Innes G. Emergency department management 5093 
and 1-year outcomes of patients with atrial flutter. Ann Emerg Med 2011;57:564-571 e562. 5094 
705. Goldner BG, Baker J, Accordino A, Sabatino L, DiGiulio M, Kalenderian D, Lin D, Zambrotta 5095 
V, Stechel J, Maccaro P, Jadonath R. Electrical cardioversion of atrial fibrillation or flutter with 5096 
conscious sedation in the age of cost containment. Am Heart J 1998;136:961-964. 5097 
706. Martinez-Marcos FJ, Garcia-Garmendia JL, Ortega-Carpio A, Fernandez-Gomez JM, Santos 5098 
JM, Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion 5099 
of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000;86:950-953. 5100 
707. Buccelletti F, Iacomini P, Botta G, Marsiliani D, Carroccia A, Gentiloni Silveri N, Franceschi F. 5101 
Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines 5102 
agency approval: systematic review and meta-analysis. J Clin Pharmacol 2012;52:1872-1878. 5103 
708. Cappato R, Ezekowitz MD, Klein AL, Camm AJ, Ma CS, Le Heuzey JY, Talajic M, 5104 
Scanavacca M, Vardas PE, Kirchhof P, Hemmrich M, Lanius V, Meng IL, Wildgoose P, van Eickels M, 5105 
Hohnloser SH, X-VeRT Investigators. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial 5106 
fibrillation. Eur Heart J 2014. 5107 
709. Nagarakanti R, Ezekowitz MD, Oldgren J, Yang S, Chernick M, Aikens TH, Flaker G, Brugada 5108 
J, Kamensky G, Parekh A, Reilly PA, Yusuf S, Connolly SJ. Dabigatran versus warfarin in patients 5109 
with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011;123:131-136. 5110 
710. Steinberg JS, Sadaniantz A, Kron J, Krahn A, Denny DM, Daubert J, Campbell WB, Havranek 5111 
E, Murray K, Olshansky B, O'Neill G, Sami M, Schmidt S, Storm R, Zabalgoitia M, Miller J, Chandler 5112 
M, Nasco EM, Greene HL. Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up 5113 
Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1973-1980. 5114 
711. Andersen HR, Nielsen JC, Thomsen PE, Thuesen L, Mortensen PT, Vesterlund T, Pedersen 5115 
AK. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-5116 
sinus syndrome. Lancet 1997;350:1210-1216. 5117 
712. Connolly SJ, Kerr CR, Gent M, Roberts RS, Yusuf S, Gillis AM, Sami MH, Talajic M, Tang 5118 
AS, Klein GJ, Lau C, Newman DM. Effects of physiologic pacing versus ventricular pacing on the risk 5119 
of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. 5120 
N Engl J Med 2000;342:1385-1391. 5121 
713. Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. 5122 
Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic 5123 
literature reviews and meta-analyses. Circ Arrhythm Electrophysiol 2009;2:349-361. 5124 
714. Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA. Reduced incidence 5125 
of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens 5126 
2008;26:403-411. 5127 
715. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ, Jr., 5128 
Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, 5129 
Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, 5130 
Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, 5131 
Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, 5132 
Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D. 2012 HRS/EHRA/ECAS Expert Consensus 5133 
Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient 5134 
selection, procedural techniques, patient management and follow-up, definitions, endpoints, and 5135 
research trial design. Europace 2012;14:528-606. 5136 
716. Kuck KH, Hoffmann BA, Ernst S, Wegscheider K, Treszl A, Metzner A, Eckardt L, Lewalter T, 5137 
Breithardt G, Willems S, Gap-AF–AFNET 1 Investigators. Impact of Complete Versus Incomplete 5138 
Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial 5139 
Fibrillation: Results From the Gap-Atrial Fibrillation-German Atrial Fibrillation Competence Network 1 5140 
Trial. Circ Arrhythm Electrophysiol 2016;9:e003337. 5141 
717. Mont L, Bisbal F, Hernandez-Madrid A, Perez-Castellano N, Vinolas X, Arenal A, Arribas F, 5142 
Fernandez-Lozano I, Bodegas A, Cobos A, Matia R, Perez-Villacastin J, Guerra JM, Avila P, Lopez-5143 
Gil M, Castro V, Arana JI, Brugada J, SARA investigators. Catheter ablation vs. antiarrhythmic drug 5144 
treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur 5145 
Heart J 2014;35:501-507. 5146 
718. Schreiber D, Rostock T, Frohlich M, Sultan A, Servatius H, Hoffmann BA, Luker J, Berner I, 5147 
Schaffer B, Wegscheider K, Lezius S, Willems S, Steven D. Five-year follow-up after catheter ablation 5148 
of persistent atrial fibrillation using the stepwise approach and prognostic factors for success. Circ 5149 
Arrhythm Electrophysiol 2015;8:308-317. 5150 
719. Scherr D, Khairy P, Miyazaki S, Aurillac-Lavignolle V, Pascale P, Wilton SB, Ramoul K, 5151 
Komatsu Y, Roten L, Jadidi A, Linton N, Pedersen M, Daly M, O'Neill M, Knecht S, Weerasooriya R, 5152 
Page 131 of 148 ESC AF Guidelines 
 
Rostock T, Manninger M, Cochet H, Shah AJ, Yeim S, Denis A, Derval N, Hocini M, Sacher F, 5153 
Haissaguerre M, Jais P. Five-year outcome of catheter ablation of persistent atrial fibrillation using 5154 
termination of atrial fibrillation as a procedural endpoint. Circ Arrhythm Electrophysiol 2015;8:18-24. 5155 
720. Al Halabi S, Qintar M, Hussein A, Alraies MC, Jones DG, Wong T, MacDonald MR, Petrie 5156 
MC, Cantillon D, Tarakji KG, Kanj M, Bhargava M, Varma N, Baranowski B, Wilkoff BL, Wazni O, 5157 
Callahan T, Saliba W, Chung MK. Catheter Ablation for Atrial Fibrillation in Heart Failure Patients: A 5158 
Meta-Analysis of Randomized Controlled Trials. JACC Clin Electrophysiol 2015;1:200-209. 5159 
721. Hakalahti A, Biancari F, Nielsen JC, Raatikainen MJ. Radiofrequency ablation vs. 5160 
antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review 5161 
and meta-analysis. Europace 2015;17:370-378. 5162 
722. Morillo CA, Verma A, Connolly SJ, Kuck KH, Nair GM, Champagne J, Sterns LD, Beresh H, 5163 
Healey JS, Natale A, RAAFT-2 Investigators. Radiofrequency ablation vs antiarrhythmic drugs as first-5164 
line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA 2014;311:692-700. 5165 
723. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, Bash D, Schweikert 5166 
R, Brachmann J, Gunther J, Gutleben K, Pisano E, Potenza D, Fanelli R, Raviele A, Themistoclakis 5167 
S, Rossillo A, Bonso A, Natale A. Radiofrequency ablation vs antiarrhythmic drugs as first-line 5168 
treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-2640. 5169 
724. Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi F, Jr., Bates ER, Lehmann MH, 5170 
Vicedomini G, Augello G, Agricola E, Sala S, Santinelli V, Morady F. Circumferential pulmonary-vein 5171 
ablation for chronic atrial fibrillation. N Engl J Med 2006;354:934-941. 5172 
725. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, Turco P, Pascotto P, 5173 
Fazzari M, Vitale DF. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a 5174 
prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial 5175 
Fibrillation Study). Eur Heart J 2006;27:216-221. 5176 
726. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, De Sanctis V, Pappalardo A, 5177 
Laurenzi F, Avella A, Casella M, Dello Russo A, Romeo F, Pelargonio G, Tondo C. Catheter ablation 5178 
of atrial fibrillation in patients with diabetes mellitus type 2: results from a randomized study 5179 
comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 5180 
2009;20:22-28. 5181 
727. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, 5182 
Packer D, Skanes A, Ambrogi F, Biganzoli E. Updated worldwide survey on the methods, efficacy, 5183 
and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol 2010;3:32-38. 5184 
728. Ganesan AN, Shipp NJ, Brooks AG, Kuklik P, Lau DH, Lim HS, Sullivan T, Roberts-Thomson 5185 
KC, Sanders P. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and 5186 
meta-analysis. J Am Heart Assoc 2013;2:e004549. 5187 
729. McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, Wong MC, Walters TE, Lee 5188 
JM, Looi KL, Halloran K, Stiles MK, Lever NA, Fynn SP, Heck PM, Sanders P, Morton JB, Kalman 5189 
JM, Kistler PM. A minimal or maximal ablation strategy to achieve pulmonary vein isolation for 5190 
paroxysmal atrial fibrillation: a prospective multi-centre randomized controlled trial (the Minimax 5191 
study). Eur Heart J 2015;36:1812-1821. 5192 
730. Verma A, Sanders P, Macle L, Deisenhofer I, Morillo CA, Chen J, Jiang CY, Ernst S, 5193 
Mantovan R. Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial-Part II (STAR AF 5194 
II): design and rationale. Am Heart J 2012;164:1-6 e6. 5195 
731. Nery PB, Belliveau D, Nair GM, Bernick J, Redpath CJ, Szczotka A, Sadek MM, Green MS, 5196 
Wells G, Birnie DH. Relationship Between Pulmonary Vein Reconnection and 5197 
Atrial Fibrillation Recurrence. JACC Clin Electrophysiol 2016:[Epub ahead of print]. 5198 
732. Luik A, Radzewitz A, Kieser M, Walter M, Bramlage P, Hormann P, Schmidt K, Horn N, 5199 
Brinkmeier-Theofanopoulou M, Kunzmann K, Riexinger T, Schymik G, Merkel M, Schmitt C. 5200 
Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial 5201 
Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. Circulation 5202 
2015;132:1311-1319. 5203 
733. Schmidt M, Dorwarth U, Andresen D, Brachmann J, Kuck KH, Kuniss M, Lewalter T, Spitzer 5204 
S, Willems S, Senges J, Junger C, Hoffmann E. Cryoballoon versus RF ablation in paroxysmal atrial 5205 
fibrillation: results from the German Ablation Registry. J Cardiovasc Electrophysiol 2014;25:1-7. 5206 
734. Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, Elvan A, Arentz T, 5207 
Bestehorn K, Pocock SJ, Albenque JP, Tondo C, FIRE AND ICE Investigators. Cryoballoon or 5208 
Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. N Engl J Med 2016:[Epub ahead of print]. 5209 
735. Verma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, Macle L, Morillo CA, 5210 
Haverkamp W, Weerasooriya R, Albenque JP, Nardi S, Menardi E, Novak P, Sanders P, STAR AF II 5211 
Page 132 of 148 ESC AF Guidelines 
 
Investigators. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 5212 
2015;372:1812-1822. 5213 
736. Dong JZ, Sang CH, Yu RH, Long DY, Tang RB, Jiang CX, Ning M, Liu N, Liu XP, Du X, Tse 5214 
HF, Ma CS. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise 5215 
approach for catheter ablation of persistent atrial fibrillation. Europace 2015;17:1798-1806. 5216 
737. Hunter RJ, McCready J, Diab I, Page SP, Finlay M, Richmond L, French A, Earley MJ, 5217 
Sporton S, Jones M, Joseph JP, Bashir Y, Betts TR, Thomas G, Staniforth A, Lee G, Kistler P, 5218 
Rajappan K, Chow A, Schilling RJ. Maintenance of sinus rhythm with an ablation strategy in patients 5219 
with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012;98:48-53. 5220 
738. Providencia R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K, Ahsan S, Khan FZ, 5221 
Chow AW, Rowland E, Lowe M, Segal OR. Is There Still a Role for Complex Fractionated Atrial 5222 
Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and 5223 
Persistent Atrial Fibrillation? Meta-Analysis of 1415 Patients. Circ Arrhythm Electrophysiol 5224 
2015;8:1017-1029. 5225 
739. Mohanty S, Gianni C, Mohanty P, Halbfass P, Metz T, Trivedi C, Deneke T, Tomassoni G, Bai 5226 
R, Al-Ahmad A, Bailey S, Burkhardt JD, Gallinghouse GJ, Horton R, Hranitzky PM, Sanchez JE, Di 5227 
Biase L, Natale A. Impact of Rotor Ablation in Non-Paroxysmal AF Patients: Results from a 5228 
Randomized Trial (OASIS). J Am Coll Cardiol 2016. 5229 
740. Rolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, Gaspar T, Bollmann A, Altmann D, 5230 
Piedra C, Hindricks G, Piorkowski C. Tailored atrial substrate modification based on low-voltage areas 5231 
in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol 2014;7:825-833. 5232 
741. Shah AJ, Pascale P, Miyazaki S, Liu X, Roten L, Derval N, Jadidi AS, Scherr D, Wilton SB, 5233 
Pedersen M, Knecht S, Sacher F, Jais P, Haissaguerre M, Hocini M. Prevalence and types of pitfall in 5234 
the assessment of mitral isthmus linear conduction block. Circ Arrhythm Electrophysiol 2012;5:957-5235 
967. 5236 
742. Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, Arentz T, Deisenhofer I, 5237 
Veenhuyzen G, Scavee C, Jais P, Puererfellner H, Levesque S, Andrade JG, Rivard L, Guerra PG, 5238 
Dubuc M, Thibault B, Talajic M, Roy D, Nattel S, ADVICE trial investigators. Adenosine-guided 5239 
pulmonary vein isolation for the treatment of paroxysmal atrial fibrillation: an international, multicentre, 5240 
randomised superiority trial. Lancet 2015;386:672-679. 5241 
743. Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y, Ozawa T, Kurotobi T, 5242 
Morishima I, Miura F, Watanabe T, Masuda M, Naito M, Fujimoto H, Nishida T, Furukawa Y, 5243 
Shirayama T, Tanaka M, Okajima K, Yao T, Egami Y, Satomi K, Noda T, Miyamoto K, Haruna T, 5244 
Kawaji T, Yoshizawa T, Toyota T, Yahata M, Nakai K, Sugiyama H, Higashi Y, Ito M, Horie M, Kusano 5245 
KF, Shimizu W, Kamakura S, Kimura T, UNDER-ATP Trial Investigators. Adenosine triphosphate-5246 
guided pulmonary vein isolation for atrial fibrillation: the UNmasking Dormant Electrical Reconduction 5247 
by Adenosine TriPhosphate (UNDER-ATP) trial. Eur Heart J 2015;36:3276-3287. 5248 
744. Berntsen RF, Haland TF, Skardal R, Holm T. Focal impulse and rotor modulation as a stand-5249 
alone procedure for treatment of paroxysmal atrial fibrillation. A within-patient controlled study with 5250 
implanted cardiac monitoring. Heart Rhythm 2016. 5251 
745. Lee G, Sparks PB, Morton JB, Kistler PM, Vohra JK, Medi C, Rosso R, Teh A, Halloran K, 5252 
Kalman JM. Low risk of major complications associated with pulmonary vein antral isolation for atrial 5253 
fibrillation: results of 500 consecutive ablation procedures in patients with low prevalence of structural 5254 
heart disease from a single center. J Cardiovasc Electrophysiol 2011;22:163-168. 5255 
746. Wynn GJ, Das M, Bonnett LJ, Panikker S, Wong T, Gupta D. Efficacy of catheter ablation for 5256 
persistent atrial fibrillation: a systematic review and meta-analysis of evidence from randomized and 5257 
nonrandomized controlled trials. Circ Arrhythm Electrophysiol 2014;7:841-852. 5258 
747. Seaburg L, Hess EP, Coylewright M, Ting HH, McLeod CJ, Montori VM. Shared decision 5259 
making in atrial fibrillation: where we are and where we should be going. Circulation 2014;129:704-5260 
710. 5261 
748. Dagres N, Hindricks G, Kottkamp H, Sommer P, Gaspar T, Bode K, Arya A, Husser D, 5262 
Rallidis LS, Kremastinos DT, Piorkowski C. Complications of atrial fibrillation ablation in a high-volume 5263 
center in 1,000 procedures: still cause for concern? J Cardiovasc Electrophysiol 2009;20:1014-1019. 5264 
749. Deneke T, Jais P, Scaglione M, Schmitt R, L DIB, Christopoulos G, Schade A, Mugge A, 5265 
Bansmann M, Nentwich K, Muller P, Krug J, Roos M, Halbfass P, Natale A, Gaita F, Haines D. Silent 5266 
cerebral events/lesions related to atrial fibrillation ablation: a clinical review. J Cardiovasc 5267 
Electrophysiol 2015;26:455-463. 5268 
750. Gupta A, Perera T, Ganesan A, Sullivan T, Lau DH, Roberts-Thomson KC, Brooks AG, 5269 
Sanders P. Complications of catheter ablation of atrial fibrillation: a systematic review. Circ Arrhythm 5270 
Electrophysiol 2013;6:1082-1088. 5271 
Page 133 of 148 ESC AF Guidelines 
 
751. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH, Klein G, Natale A, 5272 
Packer D, Ricci C, Skanes A, Ranucci M. Delayed cardiac tamponade after radiofrequency catheter 5273 
ablation of atrial fibrillation: a worldwide report. J Am Coll Cardiol 2011;58:2696-2697. 5274 
752. Haeusler KG, Kirchhof P, Endres M. Left atrial catheter ablation and ischemic stroke. Stroke 5275 
2012;43:265-270. 5276 
753. Kosiuk J, Kornej J, Bollmann A, Piorkowski C, Myrda K, Arya A, Sommer P, Richter S, Rolf S, 5277 
Husser D, Gaspar T, Lip GY, Hindricks G. Early cerebral thromboembolic complications after 5278 
radiofrequency catheter ablation of atrial fibrillation: incidence, characteristics, and risk factors. Heart 5279 
Rhythm 2014;11:1934-1940. 5280 
754. Gaita F, Leclercq JF, Schumacher B, Scaglione M, Toso E, Halimi F, Schade A, Froehner S, 5281 
Ziegler V, Sergi D, Cesarani F, Blandino A. Incidence of silent cerebral thromboembolic lesions after 5282 
atrial fibrillation ablation may change according to technology used: comparison of irrigated 5283 
radiofrequency, multipolar nonirrigated catheter and cryoballoon. J Cardiovasc Electrophysiol 5284 
2011;22:961-968. 5285 
755. Hsu LF, Jais P, Hocini M, Sanders P, Scavee C, Sacher F, Takahashi Y, Rotter M, Pasquie 5286 
JL, Clementy J, Haissaguerre M. Incidence and prevention of cardiac tamponade complicating 5287 
ablation for atrial fibrillation. Pacing Clin Electrophysiol 2005;28 Suppl 1:S106-109. 5288 
756. Michowitz Y, Rahkovich M, Oral H, Zado ES, Tilz R, John S, Denis A, Di Biase L, Winkle RA, 5289 
Mikhaylov EN, Ruskin JN, Yao Y, Josephson ME, Tanner H, Miller JM, Champagne J, Della Bella P, 5290 
Kumagai K, Defaye P, Luria D, Lebedev DS, Natale A, Jais P, Hindricks G, Kuck KH, Marchlinski FE, 5291 
Morady F, Belhassen B. Effects of sex on the incidence of cardiac tamponade after catheter ablation 5292 
of atrial fibrillation: results from a worldwide survey in 34 943 atrial fibrillation ablation procedures. Circ 5293 
Arrhythm Electrophysiol 2014;7:274-280. 5294 
757. Nair KK, Shurrab M, Skanes A, Danon A, Birnie D, Morillo C, Chauhan V, Mangat I, Ayala-5295 
Paredes F, Champagne J, Nault I, Tang A, Verma A, Lashevsky I, Singh SM, Crystal E. The 5296 
prevalence and risk factors for atrioesophageal fistula after percutaneous radiofrequency catheter 5297 
ablation for atrial fibrillation: the Canadian experience. J Interv Card Electrophysiol 2014;39:139-144. 5298 
758. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, 5299 
rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J Am Coll Cardiol 5300 
2012;59:143-149. 5301 
759. Straube F, Dorwarth U, Schmidt M, Wankerl M, Ebersberger U, Hoffmann E. Comparison of 5302 
the first and second cryoballoon: high-volume single-center safety and efficacy analysis. Circ 5303 
Arrhythm Electrophysiol 2014;7:293-299. 5304 
760. Di Biase L, Burkhardt JD, Santangeli P, Mohanty P, Sanchez JE, Horton R, Gallinghouse GJ, 5305 
Themistoclakis S, Rossillo A, Lakkireddy D, Reddy M, Hao S, Hongo R, Beheiry S, Zagrodzky J, 5306 
Rong B, Mohanty S, Elayi CS, Forleo G, Pelargonio G, Narducci ML, Dello Russo A, Casella M, 5307 
Fassini G, Tondo C, Schweikert RA, Natale A. Periprocedural Stroke and Bleeding Complications in 5308 
Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation 5309 
Management: Results From the Role of Coumadin in Preventing Thromboembolism in Atrial 5310 
Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation 5311 
2014;129:2638-2644. 5312 
761. Di Biase L, Lakkireddy D, Trivedi C, Deneke T, Martinek M, Mohanty S, Mohanty P, Prakash 5313 
S, Bai R, Reddy M, Gianni C, Horton R, Bailey S, Sigmund E, Derndorfer M, Schade A, Mueller P, 5314 
Szoelloes A, Sanchez J, Al-Ahmad A, Hranitzky P, Gallinghouse GJ, Hongo RH, Beheiry S, 5315 
Purerfellner H, Burkhardt JD, Natale A. Feasibility and safety of uninterrupted periprocedural 5316 
apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: 5317 
Results from a multicenter study. Heart Rhythm 2015;12:1162-1168. 5318 
762. Hohnloser SH, Camm AJ. Safety and efficacy of dabigatran etexilate during catheter ablation 5319 
of atrial fibrillation: a meta-analysis of the literature. Europace 2013;15:1407-1411. 5320 
763. Lakkireddy D, Reddy YM, Di Biase L, Vallakati A, Mansour MC, Santangeli P, Gangireddy S, 5321 
Swarup V, Chalhoub F, Atkins D, Bommana S, Verma A, Sanchez JE, Burkhardt JD, Barrett CD, 5322 
Baheiry S, Ruskin J, Reddy V, Natale A. Feasibility and safety of uninterrupted rivaroxaban for 5323 
periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: 5324 
results from a multicenter prospective registry. J Am Coll Cardiol 2014;63:982-988. 5325 
764. Providencia R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais 5326 
J, Boveda S. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. 5327 
Europace 2014;16:1137-1144. 5328 
765. Stepanyan G, Badhwar N, Lee RJ, Marcus GM, Lee BK, Tseng ZH, Vedantham V, Olgin J, 5329 
Scheinman M, Gerstenfeld EP. Safety of new oral anticoagulants for patients undergoing atrial 5330 
fibrillation ablation. J Interv Card Electrophysiol 2014;40:33-38. 5331 
Page 134 of 148 ESC AF Guidelines 
 
766. Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, 5332 
Bhandari Y, Donato A. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or 5333 
dabigatran in patients undergoing catheter ablation for atrial fibrillation. Am J Cardiol 2014;114:577-5334 
582. 5335 
767. Kaess BM, Ammar S, Reents T, Dillier R, Lennerz C, Semmler V, Grebmer C, Bourier F, 5336 
Buiatti A, Kolb C, Deisenhofer I, Hessling G. Comparison of safety of left atrial catheter ablation 5337 
procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus 5338 
phenprocoumon. Am J Cardiol 2015;115:47-51. 5339 
768. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber DJ, Ma CS, Hess 5340 
S, Wells DS, Juang G, Vijgen J, Hugl BJ, Balasubramaniam R, De Chillou C, Davies DW, Fields LE, 5341 
Natale A, VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. uninterrupted vitamin K 5342 
antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J 2015;36:1805-1811. 5343 
769. Wu S, Yang YM, Zhu J, Wan HB, Wang J, Zhang H, Shao XH. Meta-Analysis of Efficacy and 5344 
Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients 5345 
Undergoing Catheter Ablation for Atrial Fibrillation. Am J Cardiol 2016;117:926-934. 5346 
770. Santarpia G, De Rosa S, Polimeni A, Giampa S, Micieli M, Curcio A, Indolfi C. Efficacy and 5347 
Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral 5348 
Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-5349 
Analysis. PLoS One 2015;10:e0126512. 5350 
771. Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt M, Ozcan C, Torp-5351 
Pedersen C, Hansen ML. Oral anticoagulation therapy after radiofrequency ablation of atrial fibrillation 5352 
and the risk of thromboembolism and serious bleeding: long-term follow-up in nationwide cohort of 5353 
Denmark. Eur Heart J 2015;36:307-314a. 5354 
772. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, Di Biase L, 5355 
Schweikert RA, Saliba WI, Horton R, Mohanty P, Patel D, Burkhardt DJ, Wazni OM, Bonso A, Callans 5356 
DJ, Haissaguerre M, Raviele A, Natale A. The risk of thromboembolism and need for oral 5357 
anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010;55:735-743. 5358 
773. Bunch TJ, May HT, Bair TL, Weiss JP, Crandall BG, Osborn JS, Mallender C, Anderson JL, 5359 
Muhlestein BJ, Lappe DL, Day JD. Atrial fibrillation ablation patients have long-term stroke rates 5360 
similar to patients without atrial fibrillation regardless of CHADS2 score. Heart Rhythm 2013;10:1272-5361 
1277. 5362 
774. Nedios S, Kornej J, Koutalas E, Bertagnolli L, Kosiuk J, Rolf S, Arya A, Sommer P, Husser D, 5363 
Hindricks G, Bollmann A. Left atrial appendage morphology and thromboembolic risk after catheter 5364 
ablation for atrial fibrillation. Heart Rhythm 2014;11:2239-2246. 5365 
775. Reynolds MR, Gunnarsson CL, Hunter TD, Ladapo JA, March JL, Zhang M, Hao SC. Health 5366 
outcomes with catheter ablation or antiarrhythmic drug therapy in atrial fibrillation: results of a 5367 
propensity-matched analysis. Circ Cardiovasc Qual Outcomes 2012;5:171-181. 5368 
776. Gallo C, Battaglia A, Anselmino M, Bianchi F, Grossi S, Nangeroni G, Toso E, Gaido L, 5369 
Scaglione M, Ferraris F, Gaita F. Long-term events following atrial fibrillation rate control or 5370 
transcatheter ablation: a multicenter observational study. J Cardiovasc Med (Hagerstown) 5371 
2016;17:187-193. 5372 
777. Di Biase L, Mohanty P, Mohanty S, Santangeli P, Trivedi C, Lakkireddy D, Reddy M, Jais P, 5373 
Themistoclakis S, Dello Russo A, Casella M, Pelargonio G, Narducci ML, Schweikert R, Neuzil P, 5374 
Sanchez J, Horton R, Beheiry S, Hongo R, Hao S, Rossillo A, Forleo G, Tondo C, Burkhardt JD, 5375 
Haissaguerre M, Natale A. Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in 5376 
Patients With Congestive Heart Failure and an Implanted Device: Results From the AATAC 5377 
Multicenter Randomized Trial. Circulation 2016. 5378 
778. Hunter RJ, Berriman TJ, Diab I, Kamdar R, Richmond L, Baker V, Goromonzi F, Sawhney V, 5379 
Duncan E, Page SP, Ullah W, Unsworth B, Mayet J, Dhinoja M, Earley MJ, Sporton S, Schilling RJ. A 5380 
randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart 5381 
failure (the CAMTAF trial). Circ Arrhythm Electrophysiol 2014;7:31-38. 5382 
779. MacDonald MR, Connelly DT, Hawkins NM, Steedman T, Payne J, Shaw M, Denvir M, 5383 
Bhagra S, Small S, Martin W, McMurray JJ, Petrie MC. Radiofrequency ablation for persistent atrial 5384 
fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a 5385 
randomised controlled trial. Heart 2011;97:740-747. 5386 
780. Dagres N, Varounis C, Gaspar T, Piorkowski C, Eitel C, Iliodromitis EK, Lekakis JP, Flevari P, 5387 
Simeonidou E, Rallidis LS, Tsougos E, Hindricks G, Sommer P, Anastasiou-Nana M. Catheter 5388 
ablation for atrial fibrillation in patients with left ventricular systolic dysfunction. A systematic review 5389 
and meta-analysis. J Card Fail 2011;17:964-970. 5390 
Page 135 of 148 ESC AF Guidelines 
 
781. Piorkowski C, Kottkamp H, Tanner H, Kobza R, Nielsen JC, Arya A, Hindricks G. Value of 5391 
different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the 5392 
curative treatment of atrial fibrillation. J Cardiovasc Electrophysiol 2005;16:1286-1292. 5393 
782. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, Morillo CA, Khaykin Y, 5394 
Birnie D. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation 5395 
before and after catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med 5396 
2013;173:149-156. 5397 
783. Cox JL, Boineau JP, Schuessler RB, Ferguson TB, Jr., Cain ME, Lindsay BD, Corr PB, Kater 5398 
KM, Lappas DG. Successful surgical treatment of atrial fibrillation. Review and clinical update. JAMA 5399 
1991;266:1976-1980. 5400 
784. Cox JL, Schuessler RB, D'Agostino HJ, Jr., Stone CM, Chang BC, Cain ME, Corr PB, 5401 
Boineau JP. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical 5402 
procedure. J Thorac Cardiovasc Surg 1991;101:569-583. 5403 
785. Stulak JM, Suri RM, Burkhart HM, Daly RC, Dearani JA, Greason KL, Joyce LD, Park SJ, 5404 
Schaff HV. Surgical ablation for atrial fibrillation for two decades: are the results of new techniques 5405 
equivalent to the Cox maze III procedure? J Thorac Cardiovasc Surg 2014;147:1478-1486. 5406 
786. Basu S, Nagendran M, Maruthappu M. How effective is bipolar radiofrequency ablation for 5407 
atrial fibrillation during concomitant cardiac surgery? Interact Cardiovasc Thorac Surg 2012;15:741-5408 
748. 5409 
787. Lin Z, Shan ZG, Liao CX, Chen LW. The effect of microwave and bipolar radio-frequency 5410 
ablation in the surgical treatment of permanent atrial fibrillation during valve surgery. Thorac 5411 
Cardiovasc Surg 2011;59:460-464. 5412 
788. McCarthy PM, Kruse J, Shalli S, Ilkhanoff L, Goldberger JJ, Kadish AH, Arora R, Lee R. 5413 
Where does atrial fibrillation surgery fail? Implications for increasing effectiveness of ablation. J 5414 
Thorac Cardiovasc Surg 2010;139:860-867. 5415 
789. Abreu Filho CA, Lisboa LA, Dallan LA, Spina GS, Grinberg M, Scanavacca M, Sosa EA, 5416 
Ramires JA, Oliveira SA. Effectiveness of the maze procedure using cooled-tip radiofrequency 5417 
ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation 5418 
2005;112:I20-25. 5419 
790. Blomstrom-Lundqvist C, Johansson B, Berglin E, Nilsson L, Jensen SM, Thelin S, Holmgren 5420 
A, Edvardsson N, Kallner G, Blomstrom P. A randomized double-blind study of epicardial left atrial 5421 
cryoablation for permanent atrial fibrillation in patients undergoing mitral valve surgery: the SWEDish 5422 
Multicentre Atrial Fibrillation study (SWEDMAF). Eur Heart J 2007;28:2902-2908. 5423 
791. Chevalier P, Leizorovicz A, Maureira P, Carteaux JP, Corbineau H, Caus T, DeBreyne B, 5424 
Mabot P, Dechillou C, Deharo JC, Barry S, Touboul P, Villemot JP, Obadia JF. Left atrial 5425 
radiofrequency ablation during mitral valve surgery: a prospective randomized multicentre study 5426 
(SAFIR). Arch Cardiovasc Dis 2009;102:769-775. 5427 
792. Deneke T, Khargi K, Grewe PH, Laczkovics A, von Dryander S, Lawo T, Muller KM, Lemke B. 5428 
Efficacy of an additional MAZE procedure using cooled-tip radiofrequency ablation in patients with 5429 
chronic atrial fibrillation and mitral valve disease. A randomized, prospective trial. Eur Heart J 5430 
2002;23:558-566. 5431 
793. Doukas G, Samani NJ, Alexiou C, Oc M, Chin DT, Stafford PG, Ng LL, Spyt TJ. Left atrial 5432 
radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation: a randomized 5433 
controlled trial. JAMA 2005;294:2323-2329. 5434 
794. Schuetz A, Schulze CJ, Sarvanakis KK, Mair H, Plazer H, Kilger E, Reichart B, Wildhirt SM. 5435 
Surgical treatment of permanent atrial fibrillation using microwave energy ablation: a prospective 5436 
randomized clinical trial. Eur J Cardiothorac Surg 2003;24:475-480; discussion 480. 5437 
795. Liu X, Tan HW, Wang XH, Shi HF, Li YZ, Li F, Zhou L, Gu JN. Efficacy of catheter ablation 5438 
and surgical CryoMaze procedure in patients with long-lasting persistent atrial fibrillation and 5439 
rheumatic heart disease: a randomized trial. Eur Heart J 2010;31:2633-2641. 5440 
796. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, Gammie JS, Nitta T, Wolf RK, 5441 
Puskas JD. Surgical ablation for atrial fibrillation in cardiac surgery: a meta-analysis and systematic 5442 
review. Innovations (Phila) 2010;5:84-96. 5443 
797. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a 5444 
meta-analysis. J Thorac Cardiovasc Surg 2006;131:1029-1035. 5445 
798. Ad N, Henry L, Massimiano P, Pritchard G, Holmes SD. The state of surgical ablation for 5446 
atrial fibrillation in patients with mitral valve disease. Curr Opin Cardiol 2013;28:170-180. 5447 
799. Gammie JS, Haddad M, Milford-Beland S, Welke KF, Ferguson TB, Jr., O'Brien SM, Griffith 5448 
BP, Peterson ED. Atrial fibrillation correction surgery: lessons from the Society of Thoracic Surgeons 5449 
National Cardiac Database. Ann Thorac Surg 2008;85:909-914. 5450 
Page 136 of 148 ESC AF Guidelines 
 
800. Chen MC, Chang JP, Chang HW. Preoperative atrial size predicts the success of 5451 
radiofrequency maze procedure for permanent atrial fibrillation in patients undergoing concomitant 5452 
valvular surgery. Chest 2004;125:2129-2134. 5453 
801. Sunderland N, Maruthappu M, Nagendran M. What size of left atrium significantly impairs the 5454 
success of maze surgery for atrial fibrillation? Interact Cardiovasc Thorac Surg 2011;13:332-338. 5455 
802. Chaiyaroj S, Ngarmukos T, Lertsithichai P. Predictors of sinus rhythm after radiofrequency 5456 
maze and mitral valve surgery. Asian Cardiovasc Thorac Ann 2008;16:292-297. 5457 
803. Gillinov AM, Bhavani S, Blackstone EH, Rajeswaran J, Svensson LG, Navia JL, Pettersson 5458 
BG, Sabik JF, 3rd, Smedira NG, Mihaljevic T, McCarthy PM, Shewchik J, Natale A. Surgery for 5459 
permanent atrial fibrillation: impact of patient factors and lesion set. Ann Thorac Surg 2006;82:502-5460 
513; discussion 513-504. 5461 
804. Beukema WP, Sie HT, Misier AR, Delnoy PP, Wellens HJ, Elvan A. Predictive factors of 5462 
sustained sinus rhythm and recurrent atrial fibrillation after a radiofrequency modified Maze 5463 
procedure. Eur J Cardiothorac Surg 2008;34:771-775. 5464 
805. Gillinov AM, Bakaeen F, McCarthy PM, Blackstone EH, Rajeswaran J, Pettersson G, Sabik 5465 
JF, 3rd, Najam F, Hill KM, Svensson LG, Cosgrove DM, Marrouche N, Natale A. Surgery for 5466 
paroxysmal atrial fibrillation in the setting of mitral valve disease: a role for pulmonary vein isolation? 5467 
Ann Thorac Surg 2006;81:19-26; discussion 27-18. 5468 
806. Onorati F, Mariscalco G, Rubino AS, Serraino F, Santini F, Musazzi A, Klersy C, Sala A, 5469 
Renzulli A. Impact of lesion sets on mid-term results of surgical ablation procedure for atrial fibrillation. 5470 
J Am Coll Cardiol 2011;57:931-940. 5471 
807. Saint LL, Bailey MS, Prasad S, Guthrie TJ, Bell J, Moon MR, Lawton JS, Munfakh NA, 5472 
Schuessler RB, Damiano RJ, Jr., Maniar HS. Cox-Maze IV results for patients with lone atrial 5473 
fibrillation versus concomitant mitral disease. Ann Thorac Surg 2012;93:789-794; discussion 794-785. 5474 
808. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, Damiano RJ, Jr. A 5475 
minimally invasive Cox maze IV procedure is as effective as sternotomy while decreasing major 5476 
morbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955-961; discussion 962-952. 5477 
809. Edgerton JR, Brinkman WT, Weaver T, Prince SL, Culica D, Herbert MA, Mack MJ. 5478 
Pulmonary vein isolation and autonomic denervation for the management of paroxysmal atrial 5479 
fibrillation by a minimally invasive surgical approach. J Thorac Cardiovasc Surg 2010;140:823-828. 5480 
810. McClelland JH, Duke D, Reddy R. Preliminary results of a limited thoracotomy: new approach 5481 
to treat atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:1289-1295. 5482 
811. Castella M, Pereda D, Mestres CA, Gomez F, Quintana E, Mulet J. Thoracoscopic pulmonary 5483 
vein isolation in patients with atrial fibrillation and failed percutaneous ablation. J Thorac Cardiovasc 5484 
Surg 2010;140:633-638. 5485 
812. Krul SP, Driessen AH, van Boven WJ, Linnenbank AC, Geuzebroek GS, Jackman WM, Wilde 5486 
AA, de Bakker JM, de Groot JR. Thoracoscopic video-assisted pulmonary vein antrum isolation, 5487 
ganglionated plexus ablation, and periprocedural confirmation of ablation lesions: first results of a 5488 
hybrid surgical-electrophysiological approach for atrial fibrillation. Circ Arrhythm Electrophysiol 5489 
2011;4:262-270. 5490 
813. La Meir M, Gelsomino S, Lorusso R, Luca F, Pison L, Parise O, Wellens F, Gensini GF, 5491 
Maessen J. The hybrid approach for the surgical treatment of lone atrial fibrillation: one-year results 5492 
employing a monopolar radiofrequency source. J Cardiothorac Surg 2012;7:71. 5493 
814. Wang S, Liu L, Zou C. Comparative study of video-assisted thoracoscopic surgery ablation 5494 
and radiofrequency catheter ablation on treating paroxysmal atrial fibrillation: a randomized, controlled 5495 
short-term trial. Chin Med J (Engl) 2014;127:2567-2570. 5496 
815. Phan K, Phan S, Thiagalingam A, Medi C, Yan TD. Thoracoscopic surgical ablation versus 5497 
catheter ablation for atrial fibrillation. Eur J Cardiothorac Surg 2016;49:1044-1051. 5498 
816. Hu QM, Li Y, Xu CL, Han J, Zhang HB, Han W, Meng X. Analysis of risk factors for 5499 
recurrence after video-assisted pulmonary vein isolation of lone atrial fibrillation-results of 5 years of 5500 
follow-up. J Thorac Cardiovasc Surg 2014;148:2174-2180. 5501 
817. Edgerton JR, Edgerton ZJ, Weaver T, Reed K, Prince S, Herbert MA, Mack MJ. Minimally 5502 
invasive pulmonary vein isolation and partial autonomic denervation for surgical treatment of atrial 5503 
fibrillation. Ann Thorac Surg 2008;86:35-38; discussion 39. 5504 
818. Wang J, Li Y, Shi J, Han J, Xu C, Ma C, Meng X. Minimally invasive surgical versus catheter 5505 
ablation for the long-lasting persistent atrial fibrillation. PLoS One 2011;6:e22122. 5506 
819. Wang JG, Xin M, Han J, Li Y, Luo TG, Wang J, Meng F, Meng X. Ablation in selective 5507 
patients with long-standing persistent atrial fibrillation: medium-term results of the Dallas lesion set. 5508 
Eur J Cardiothorac Surg 2014;46:213-220. 5509 
Page 137 of 148 ESC AF Guidelines 
 
820. Sirak JH, Schwartzman D. Interim results of the 5-box thoracoscopic maze procedure. Ann 5510 
Thorac Surg 2012;94:1880-1884. 5511 
821. Kasirajan V, Spradlin EA, Mormando TE, Medina AE, Ovadia P, Schwartzman DS, Gaines 5512 
TE, Mumtaz MA, Downing SW, Ellenbogen KA. Minimally invasive surgery using bipolar 5513 
radiofrequency energy is effective treatment for refractory atrial fibrillation. Ann Thorac Surg 5514 
2012;93:1456-1461. 5515 
822. Weimar T, Vosseler M, Czesla M, Boscheinen M, Hemmer WB, Doll KN. Approaching a 5516 
paradigm shift: endoscopic ablation of lone atrial fibrillation on the beating heart. Ann Thorac Surg 5517 
2012;94:1886-1892. 5518 
823. La Meir M, Gelsomino S, Luca F, Pison L, Parise O, Colella A, Gensini GF, Crijns H, Wellens 5519 
F, Maessen JG. Minimally invasive surgical treatment of lone atrial fibrillation: early results of hybrid 5520 
versus standard minimally invasive approach employing radiofrequency sources. Int J Cardiol 5521 
2013;167:1469-1475. 5522 
824. Gelsomino S, Van Breugel HN, Pison L, Parise O, Crijns HJ, Wellens F, Maessen JG, La Meir 5523 
M. Hybrid thoracoscopic and transvenous catheter ablation of atrial fibrillation. Eur J Cardiothorac 5524 
Surg 2014;45:401-407. 5525 
825. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ. Hybrid thoracoscopic 5526 
surgical and transvenous catheter ablation of atrial fibrillation. J Am Coll Cardiol 2012;60:54-61. 5527 
826. De Maat GE, Van Gelder IC, Rienstra M, Quast AF, Tan ES, Wiesfeld AC, Pozzoli A, Mariani 5528 
MA. Surgical vs. transcatheter pulmonary vein isolation as first invasive treatment in patients with 5529 
atrial fibrillation: a matched group comparison. Europace 2014;16:33-39. 5530 
827. Vadmann H, Nielsen PB, Hjortshoj SP, Riahi S, Rasmussen LH, Lip GY, Larsen TB. Atrial 5531 
flutter and thromboembolic risk: a systematic review. Heart 2015;101:1446-1455. 5532 
828. Stulak JM, Dearani JA, Daly RC, Zehr KJ, Sundt TM, 3rd, Schaff HV. Left ventricular 5533 
dysfunction in atrial fibrillation: restoration of sinus rhythm by the Cox-maze procedure significantly 5534 
improves systolic function and functional status. Ann Thorac Surg 2006;82:494-501. 5535 
829. Chen YW, Bai R, Lin T, Salim M, Sang CH, Long DY, Yu RH, Tang RB, Guo XY, Yan XL, Nie 5536 
JG, Du X, Dong JZ, Ma CS. Pacing or ablation: which is better for paroxysmal atrial fibrillation-related 5537 
tachycardia-bradycardia syndrome? Pacing Clin Electrophysiol 2014;37:403-411. 5538 
830. Khaykin Y, Marrouche NF, Martin DO, Saliba W, Schweikert R, Wexman M, Strunk B, Beheiry 5539 
S, Saad E, Bhargava M, Burkhardt JD, Joseph G, Tchou P, Natale A. Pulmonary vein isolation for 5540 
atrial fibrillation in patients with symptomatic sinus bradycardia or pauses. J Cardiovasc Electrophysiol 5541 
2004;15:784-789. 5542 
831. Ad N, Henry L, Hunt S. Current role for surgery in treatment of lone atrial fibrillation. Semin 5543 
Thorac Cardiovasc Surg 2012;24:42-50. 5544 
832. Weimar T, Schena S, Bailey MS, Maniar HS, Schuessler RB, Cox JL, Damiano RJ, Jr. The 5545 
cox-maze procedure for lone atrial fibrillation: a single-center experience over 2 decades. Circ 5546 
Arrhythm Electrophysiol 2012;5:8-14. 5547 
833. Ad N, Henry L, Hunt S, Holmes SD. Do we increase the operative risk by adding the Cox 5548 
Maze III procedure to aortic valve replacement and coronary artery bypass surgery? J Thorac 5549 
Cardiovasc Surg 2012;143:936-944. 5550 
834. Prakash A, Saksena S, Krol RB, Filipecki A, Philip G. Catheter ablation of inducible atrial 5551 
flutter, in combination with atrial pacing and antiarrhythmic drugs ("hybrid therapy") improves rhythm 5552 
control in patients with refractory atrial fibrillation. J Interv Card Electrophysiol 2002;6:165-172. 5553 
835. Tai CT, Chiang CE, Lee SH, Chen YJ, Yu WC, Feng AN, Ding YA, Chang MS, Chen SA. 5554 
Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: 5555 
electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction [see 5556 
comments]. J Cardiovasc Electrophysiol 1999;10:1180-1187. 5557 
836. Stabile G, De Simone A, Turco P, La Rocca V, Nocerino P, Astarita C, Maresca F, De Matteis 5558 
C, Di Napoli T, Stabile E, Vitale DF. Response to flecainide infusion predicts long-term success of 5559 
hybrid pharmacologic and ablation therapy in patients with atrial fibrillation. J Am Coll Cardiol 5560 
2001;37:1639-1644. 5561 
837. Anastasio N, Frankel DS, Deyell MW, Zado E, Gerstenfeld EP, Dixit S, Cooper J, Lin D, 5562 
Marchlinski FE, Callans DJ. Nearly uniform failure of atrial flutter ablation and continuation of 5563 
antiarrhythmic agents (hybrid therapy) for the long-term control of atrial fibrillation. J Interv Card 5564 
Electrophysiol 2012;35:57-61. 5565 
838. Garcia Seara J, Raposeiras Roubin S, Gude Sampedro F, Balboa Barreiro V, Martinez Sande 5566 
JL, Rodriguez Manero M, Gonzalez Juanatey JR. Failure of hybrid therapy for the prevention of long-5567 
term recurrence of atrial fibrillation. Int J Cardiol 2014;176:74-79. 5568 
Page 138 of 148 ESC AF Guidelines 
 
839. Saksena S, Prakash A, Ziegler P, Hummel JD, Friedman P, Plumb VJ, Wyse DG, Johnson E, 5569 
Fitts S, Mehra R. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing 5570 
and antiarrhythmic drug therapy. J Am Coll Cardiol 2002;40:1140-1150; discussion 1151-1142. 5571 
840. Wharton JM, Sorrentino RA, Campbell P, Gonzalez-Zuelgaray J, Keating E, Curtis A, Grill C, 5572 
Hafley G, Lee K. Effect of pacing modality on atrial tachyarrhythmia recurrence in the tachycardia-5573 
bradycardia syndrome: preliminary results of the Pacemaker Atrial Tachycardia Trial. Circulation 5574 
1998;98 (suppl I):I-494 (abstract). 5575 
841. Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial 5576 
fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol 2010;56:827-837. 5577 
842. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, Radford MJ. Adverse 5578 
outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic 5579 
atrial fibrillation. Stroke 2000;31:822-827. 5580 
843. Andreotti F, Rocca B, Husted S, Ajjan RA, Ten Berg J, Cattaneo M, Collet JP, De Caterina R, 5581 
Fox KA, Halvorsen S, Huber K, Hylek EM, Lip GY, Montalescot G, Morais J, Patrono C, Verheugt FW, 5582 
Wallentin L, Weiss TW, Storey RF, ESC Thrombosis Working Group. Antithrombotic therapy in the 5583 
elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. 5584 
Eur Heart J 2015;36:3238-3249. 5585 
844. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, 5586 
Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou 5587 
N, Norekval TM, Spaulding C, Van Veldhuisen DJ. 2015 ESC Guidelines for the management of 5588 
patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for 5589 
the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac 5590 
Death of the European Society of Cardiology (ESC). Endorsed by: Association for European 5591 
Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-2867. 5592 
845. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont 5593 
A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, 5594 
Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC Guidelines on diagnosis and 5595 
management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of 5596 
Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 5597 
2014;35:2733-2779. 5598 
846. Johnson JN, Tester DJ, Perry J, Salisbury BA, Reed CR, Ackerman MJ. Prevalence of early-5599 
onset atrial fibrillation in congenital long QT syndrome. Heart Rhythm 2008;5:704-709. 5600 
847. Kirchhof P, Eckardt L, Franz MR, Monnig G, Loh P, Wedekind H, Schulze-Bahr E, Breithardt 5601 
G, Haverkamp W. Prolonged atrial action potential durations and polymorphic atrial tachyarrhythmias 5602 
in patients with long QT syndrome. J Cardiovasc Electrophysiol 2003;14:1027-1033. 5603 
848. Zellerhoff S, Pistulli R, Monnig G, Hinterseer M, Beckmann BM, Kobe J, Steinbeck G, Kaab 5604 
S, Haverkamp W, Fabritz L, Gradaus R, Breithardt G, Schulze-Bahr E, Bocker D, Kirchhof P. Atrial 5605 
Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study. J 5606 
Cardiovasc Electrophysiol 2009;20:401-407. 5607 
849. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ, Towbin JA, 5608 
Vincent GM, Lehmann MH. ECG T-wave patterns in genetically distinct forms of the hereditary long 5609 
QT syndrome. Circulation 1995;92:2929-2934. 5610 
850. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, 5611 
Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, 5612 
Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, 5613 
Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in 5614 
the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation 5615 
2001;103:89-95. 5616 
851. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T, Breithardt G, Haverkamp 5617 
W, Borggrefe M. Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J 5618 
Cardiovasc Electrophysiol 2001;12:680-685. 5619 
852. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT 5620 
syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT 5621 
syndrome. Heart Rhythm 2009;6:S51-55. 5622 
853. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y, Guerchicoff 5623 
A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP, Jr., Burashnikov E, Wu Y, Sargent JD, 5624 
Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M, Schimpf R, Borggrefe M, Wolpert C. 5625 
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized 5626 
by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007;115:442-5627 
449. 5628 
Page 139 of 148 ESC AF Guidelines 
 
854. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC, Pfahnl AE, 5629 
Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R, Ackerman MJ, McNamara 5630 
DM, Weiss R, Dudley SC, Jr. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) 5631 
decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007;116:2260-2268. 5632 
855. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ, Demolombe S, 5633 
Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S, Wichmann HE, Hasdemir C, 5634 
Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium channel beta1 subunit mutations associated 5635 
with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008;118:2260-5636 
2268. 5637 
856. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM, Brugada 5638 
J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff A, Bianchi F, Giustetto C, 5639 
Schimpf R, Brugada P, Antzelevitch C. Sudden death associated with short-QT syndrome linked to 5640 
mutations in HERG. Circulation 2004;109:30-35. 5641 
857. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi E, 5642 
Borggrefe M. Short QT Syndrome: a familial cause of sudden death. Circulation 2003;108:965-970. 5643 
858. Giustetto C, Di Monte F, Wolpert C, Borggrefe M, Schimpf R, Sbragia P, Leone G, Maury P, 5644 
Anttonen O, Haissaguerre M, Gaita F. Short QT syndrome: clinical findings and diagnostic-therapeutic 5645 
implications. Eur Heart J 2006;27:2440-2447. 5646 
859. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC, Alders M, 5647 
Postma AV, van Langen I, Mannens MM, Wilde AA. Expanding spectrum of human RYR2-related 5648 
disease: new electrocardiographic, structural, and genetic features. Circulation 2007;116:1569-1576. 5649 
860. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic 5650 
ventricular tachycardia. Heart Rhythm 2007;4:675-678. 5651 
861. Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of 5652 
catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol 2007;18:791-797. 5653 
862. Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of 5654 
hypertrophic cardiomyopathy in Taiwan--a tertiary center experience. Clin Cardiol 2007;30:177-182. 5655 
863. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D'Alessandro G, Cacace A, 5656 
Tocchetti CG, Barbati G, Chiariello M. Determinants of atrial fibrillation development in patients with 5657 
hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895-900. 5658 
864. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, 5659 
Bongioanni S, Spirito P. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J 5660 
Am Coll Cardiol 2002;39:301-307. 5661 
865. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R. Novel 5662 
PRKAG2 mutation responsible for the genetic syndrome of ventricular preexcitation and conduction 5663 
system disease with childhood onset and absence of cardiac hypertrophy. Circulation 2001;104:3030-5664 
3033. 5665 
866. Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun A, Lam J, 5666 
Wilde AA, Lekanne Deprez RH, Moorman AF. A gain-of-function TBX5 mutation is associated with 5667 
atypical Holt-Oram syndrome and paroxysmal atrial fibrillation. Circ Res 2008;102:1433-1442. 5668 
867. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: 5669 
a practical guide for physicians. J Am Coll Cardiol 2013;61:1945-1948. 5670 
868. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic right 5671 
ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J Cardiol 2010;106:720-722. 5672 
869. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ, Campbell 5673 
WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson WG, Tomaselli GF, 5674 
Antman EM, Smith SC, Jr., Alpert JS, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Hiratzka LF, 5675 
Hunt SA, Jacobs AK, Russell RO, Jr., Priori SG, Blanc JJ, Budaj A, Burgos EF, Cowie M, Deckers 5676 
JW, Garcia MA, Klein WW, Lekakis J, Lindahl B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe 5677 
HJ, European Society of Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC 5678 
guidelines for the management of patients with supraventricular arrhythmias--executive summary. a 5679 
report of the American college of cardiology/American heart association task force on practice 5680 
guidelines and the European society of cardiology committee for practice guidelines (writing 5681 
committee to develop guidelines for the management of patients with supraventricular arrhythmias) 5682 
developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol 2003;42:1493-1531. 5683 
870. Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ, Klein GJ. When should we 5684 
recommend catheter ablation for patients with the Wolff-Parkinson-White syndrome? Curr Opin 5685 
Cardiol 2008;23:32-37. 5686 
871. Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and electrophysiological study 5687 
of asymptomatic Wolff-Parkinson-White syndrome]. Ann Cardiol Angeiol (Paris) 2007;56:237-240. 5688 
Page 140 of 148 ESC AF Guidelines 
 
872. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G, Gulletta S, 5689 
Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A randomized study of prophylactic 5690 
catheter ablation in asymptomatic patients with the Wolff-Parkinson-White syndrome. N Engl J Med 5691 
2003;349:1803-1811. 5692 
873. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation 5693 
in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial 5694 
fibrillatory cycle length. J Am Coll Cardiol 1990;16:1408-1414. 5695 
874. O'Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. A comparison of intravenous 5696 
propafenone and flecainide in the treatment of tachycardias associated with the Wolff-Parkinson-5697 
White syndrome. Pacing Clin Electrophysiol 1991;14:2028-2034. 5698 
875. Manolis AS, Estes NA, 3rd. Supraventricular tachycardia. Mechanisms and therapy. Arch 5699 
Intern Med 1987;147:1706-1716. 5700 
876. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of amiodarone for 5701 
rate control in Wolff-Parkinson-White and atrial fibrillation. Intern Emerg Med 2010;5:421-426. 5702 
877. Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and 5703 
thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 5704 
2014;100:465-472. 5705 
878. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation 5706 
on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-2524. 5707 
879. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-5708 
sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic 5709 
cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 5710 
1998;79:331-336. 5711 
880. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, Rea RF, Shen WK, 5712 
Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL. Substrate and procedural 5713 
predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic 5714 
cardiomyopathy. J Cardiovasc Electrophysiol 2008;19:1009-1014. 5715 
881. Di Donna P, Olivotto I, Delcre SD, Caponi D, Scaglione M, Nault I, Montefusco A, Girolami F, 5716 
Cecchi F, Haissaguerre M, Gaita F. Efficacy of catheter ablation for atrial fibrillation in hypertrophic 5717 
cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 2010;12:347-5718 
355. 5719 
882. Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A, Caponi D, Conte MR, 5720 
Nistri S, Cecchi F. Usefulness and safety of transcatheter ablation of atrial fibrillation in patients with 5721 
hypertrophic cardiomyopathy. Am J Cardiol 2007;99:1575-1581. 5722 
883. Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A, Bozbas H, Andrews 5723 
MW, Beheiry S, Hao S, Cummings JE, Marrouche NF, Lakkireddy D, Wazni O, Yamaji H, Saenz LC, 5724 
Saliba W, Schweikert RA, Natale A. Efficacy of catheter ablation of atrial fibrillation in patients with 5725 
hypertrophic obstructive cardiomyopathy. Heart Rhythm 2006;3:275-280. 5726 
884. McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E, Lowe MD, Chow 5727 
AW. Predictors of recurrence following radiofrequency ablation for persistent atrial fibrillation. 5728 
Europace 2011;13:355-361. 5729 
885. Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S, Roden DM, Darbar D. 5730 
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with 5731 
familial atrial fibrillation. J Am Coll Cardiol 2012;60:1173-1181. 5732 
886. Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G, Ohanian M, Zodgekar P, Smith 5733 
RA, Wouters MA, Subbiah R, Walker B, Kuchar D, Sanders P, Griffiths L, Vandenberg JI, Fatkin D. 5734 
Epistatic effects of potassium channel variation on cardiac repolarization and atrial fibrillation risk. J 5735 
Am Coll Cardiol 2012;59:1017-1025. 5736 
887. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E, Giachino D, Bianchi 5737 
F, Barbonaglia L, Ferraro A. Atrial fibrillation in a large population with Brugada electrocardiographic 5738 
pattern: prevalence, management, and correlation with prognosis. Heart Rhythm 2014;11:259-265. 5739 
888. Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, George AL, Jr., 5740 
Roden DM. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation 5741 
2008;117:1927-1935. 5742 
889. Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC, Rodeheffer 5743 
RJ, Anderson JL. Sodium channel mutations and susceptibility to heart failure and atrial fibrillation. 5744 
JAMA 2005;293:447-454. 5745 
890. Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA. Mutations in the long 5746 
QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart 2004;90:1487-1488. 5747 
Page 141 of 148 ESC AF Guidelines 
 
891. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, 5748 
Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, 5749 
Tracy C, Ackerman M, Belhassen B, Estes NA, 3rd, Fatkin D, Kalman J, Kaufman E, Kirchhof P, 5750 
Schulze-Bahr E, Wolpert C, Vohra J, Refaat M, Etheridge SP, Campbell RM, Martin ET, Quek SC. 5751 
Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and 5752 
management of patients with inherited primary arrhythmia syndromes. Europace 2013;15:1389-1406. 5753 
892. Antz M, Weiss C, Volkmer M, Hebe J, Ernst S, Ouyang F, Kuck KH. Risk of sudden death 5754 
after successful accessory atrioventricular pathway ablation in resuscitated patients with Wolff-5755 
Parkinson-White syndrome. J Cardiovasc Electrophysiol 2002;13:231-236. 5756 
893. Timmermans C, Smeets JL, Rodriguez LM, Vrouchos G, van den Dool A, Wellens HJ. 5757 
Aborted sudden death in the Wolff-Parkinson-White syndrome. Am J Cardiol 1995;76:492-494. 5758 
894. Bromberg BI, Lindsay BD, Cain ME, Cox JL. Impact of clinical history and electrophysiologic 5759 
characterization of accessory pathways on management strategies to reduce sudden death among 5760 
children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1996;27:690-695. 5761 
895. Al-Khatib SM, Arshad A, Balk EM, Das SR, Hsu JC, Joglar JA, Page RL. Risk stratification for 5762 
arrhythmic events in patients with asymptomatic pre-excitation: A systematic review for the 2015 5763 
ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: A 5764 
Report of the American College of Cardiology/American Heart Association Task Force on Clinical 5765 
Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016;13:e222-237. 5766 
896. Maron BJ, Ommen SR, Semsarian C, Spirito P, Olivotto I, Maron MS. Hypertrophic 5767 
cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. J Am 5768 
Coll Cardiol 2014;64:83-99. 5769 
897. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial 5770 
fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 1990;15:1279-1285. 5771 
898. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial 5772 
fibrillation in older adults: the cardiovascular health study. Circulation 2008;118:800-807. 5773 
899. Elosua R, Arquer A, Mont L, Sambola A, Molina L, Garcia-Moran E, Brugada J, Marrugat J. 5774 
Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol 2006;108:332-5775 
337. 5776 
900. Mont L, Sambola A, Brugada J, Vacca M, Marrugat J, Elosua R, Pare C, Azqueta M, Sanz G. 5777 
Long-lasting sport practice and lone atrial fibrillation. Eur Heart J 2002;23:477-482. 5778 
901. Abdulla J, Nielsen JR. Is the risk of atrial fibrillation higher in athletes than in the general 5779 
population? A systematic review and meta-analysis. Europace 2009;11:1156-1159. 5780 
902. Thelle DS, Selmer R, Gjesdal K, Sakshaug S, Jugessur A, Graff-Iversen S, Tverdal A, Nystad 5781 
W. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study 5782 
of 309,540 men and women. Heart 2013;99:1755-1760. 5783 
903. Wilhelm M, Roten L, Tanner H, Wilhelm I, Schmid JP, Saner H. Atrial remodeling, autonomic 5784 
tone, and lifetime training hours in nonelite athletes. Am J Cardiol 2011;108:580-585. 5785 
904. Guasch E, Benito B, Qi X, Cifelli C, Naud P, Shi Y, Mighiu A, Tardif JC, Tadevosyan A, Chen 5786 
Y, Gillis MA, Iwasaki YK, Dobrev D, Mont L, Heximer S, Nattel S. Atrial fibrillation promotion by 5787 
endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll 5788 
Cardiol 2013;62:68-77. 5789 
905. Andersen K, Farahmand B, Ahlbom A, Held C, Ljunghall S, Michaelsson K, Sundstrom J. 5790 
Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study. Eur Heart J 5791 
2013;34:3624-3631. 5792 
906. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously 5793 
exercising middle aged men: case-control study. BMJ 1998;316:1784-1785. 5794 
907. Biffi A, Maron BJ, Culasso F, Verdile L, Fernando F, Di Giacinto B, Di Paolo FM, Spataro A, 5795 
Delise P, Pelliccia A. Patterns of ventricular tachyarrhythmias associated with training, deconditioning 5796 
and retraining in elite athletes without cardiovascular abnormalities. Am J Cardiol 2011;107:697-703. 5797 
908. Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, 5798 
Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in 5799 
endurance athletes. Europace 2010;12:30-36. 5800 
909. Koopman P, Nuyens D, Garweg C, La Gerche A, De Buck S, Van Casteren L, Alzand B, 5801 
Willems R, Heidbuchel H. Efficacy of radiofrequency catheter ablation in athletes with atrial fibrillation. 5802 
Europace 2011;13:1386-1393. 5803 
910. Heidbuchel H, Panhuyzen-Goedkoop N, Corrado D, Hoffmann E, Biffi A, Delise P, 5804 
Blomstrom-Lundqvist C, Vanhees L, Ivarhoff P, Dorwarth U, Pelliccia A. Recommendations for 5805 
participation in leisure-time physical activity and competitive sports in patients with arrhythmias and 5806 
Page 142 of 148 ESC AF Guidelines 
 
potentially arrhythmogenic conditions Part I: Supraventricular arrhythmias and pacemakers. Eur J 5807 
Cardiovasc Prev Rehabil 2006;13:475-484. 5808 
911. Silversides CK, Harris L, Haberer K, Sermer M, Colman JM, Siu SC. Recurrence rates of 5809 
arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and 5810 
neonatal outcomes. Am J Cardiol 2006;97:1206-1212. 5811 
912. Salam AM, Ertekin E, van Hagen IM, Al Suwaidi J, Ruys TPE, Johnson MR, Gumbiene L, 5812 
Frogoudaki AA, Sorour KA, Iserin L, Ladouceur M, van Oppen ACC, Hall R, Roos-Hesselink JW. 5813 
Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the 5814 
ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015;1:284-292. 5815 
913. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis 5816 
MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, 5817 
Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E. ESC Guidelines for the management of 5818 
grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-2957. 5819 
914. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995;130:871-876. 5820 
915. Magee LA, Duley L. Oral beta-blockers for mild to moderate hypertension during pregnancy. 5821 
Cochrane Database Syst Rev 2003;3:CD002863. 5822 
916. Mitani GM, Steinberg I, Lien EJ, Harrison EC, Elkayam U. The pharmacokinetics of 5823 
antiarrhythmic agents in pregnancy and lactation. Clin Pharmacokinet 1987;12:253-291. 5824 
917. Gowda RM, Khan IA, Mehta NJ, Vasavada BC, Sacchi TJ. Cardiac arrhythmias in pregnancy: 5825 
clinical and therapeutic considerations. Int J Cardiol 2003;88:129-133. 5826 
918. Joint Formulary Committee. British National Formulary (online). 5827 
http://www.medicinescomplete.com. Date last accessed 02/12/2014 2014 5828 
919. Bartalena L, Bogazzi F, Braverman LE, Martino E. Effects of amiodarone administration 5829 
during pregnancy on neonatal thyroid function and subsequent neurodevelopment. J Endocrinol 5830 
Invest 2001;24:116-130. 5831 
920. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA, Rammeloo L, McCrindle BW, Ryan G, 5832 
Manlhiot C, Blom NA. Comparison of transplacental treatment of fetal supraventricular 5833 
tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. 5834 
Circulation 2011;124:1747-1754. 5835 
921. Tromp CHN, Nanne ACM, Pernet PJM, Tukkie R, Bolte AC. Electrical cardioversion during 5836 
pregnancy: safe or not? Neth Heart J 2011;19:134-136. 5837 
922. Ghosh N, Luk A, Derzko C, Dorian P, Chow CM. The acute treatment of maternal 5838 
supraventricular tachycardias during pregnancy: a review of the literature. J Obstet Gynaecol Can 5839 
2011;33:17-23. 5840 
923. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American 5841 
College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: 5842 
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians 5843 
Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e691S-736S. 5844 
924. Ahlsson AJ, Bodin L, Lundblad OH, Englund AG. Postoperative atrial fibrillation is not 5845 
correlated to C-reactive protein. Ann Thorac Surg 2007;83:1332-1337. 5846 
925. Arsenault KA, Yusuf AM, Crystal E, Healey JS, Morillo CA, Nair GM, Whitlock RP. 5847 
Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. 5848 
Cochrane Database Syst Rev 2013;1:Cd003611. 5849 
926. Mathew JP, Fontes ML, Tudor IC, Ramsay J, Duke P, Mazer CD, Barash PG, Hsu PH, 5850 
Mangano DT. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 2004;291:1720-5851 
1729. 5852 
927. Steinberg BA, Zhao Y, He X, Hernandez AF, Fullerton DA, Thomas KL, Mills R, Klaskala W, 5853 
Peterson ED, Piccini JP. Management of postoperative atrial fibrillation and subsequent outcomes in 5854 
contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons 5855 
CAPS-Care Atrial Fibrillation Registry. Clin Cardiol 2014;37:7-13. 5856 
928. Khan MF, Wendel CS, Movahed MR. Prevention of post-coronary artery bypass grafting 5857 
(CABG) atrial fibrillation: efficacy of prophylactic beta-blockers in the modern era: a meta-analysis of 5858 
latest randomized controlled trials. Ann Noninvasive Electrocardiol 2013;18:58-68. 5859 
929. Burgess DC, Kilborn MJ, Keech AC. Interventions for prevention of post-operative atrial 5860 
fibrillation and its complications after cardiac surgery: a meta-analysis. Eur Heart J 2006;27:2846-5861 
2857. 5862 
930. Chatterjee S, Sardar P, Mukherjee D, Lichstein E, Aikat S. Timing and route of amiodarone 5863 
for prevention of postoperative atrial fibrillation after cardiac surgery: a network regression meta-5864 
analysis. Pacing Clin Electrophysiol 2013;36:1017-1023. 5865 
Page 143 of 148 ESC AF Guidelines 
 
931. Zhu J, Wang C, Gao D, Zhang C, Zhang Y, Lu Y, Gao Y. Meta-analysis of amiodarone versus 5866 
beta-blocker as a prophylactic therapy against atrial fibrillation following cardiac surgery. Intern Med J 5867 
2012;42:1078-1087. 5868 
932. Fauchier L, Clementy N, Babuty D. Statin therapy and atrial fibrillation: systematic review and 5869 
updated meta-analysis of published randomized controlled trials. Curr Opin Cardiol 2013;28:7-18. 5870 
933. Zheng H, Xue S, Hu ZL, Shan JG, Yang WG. The use of statins to prevent postoperative 5871 
atrial fibrillation after coronary artery bypass grafting: a meta-analysis of 12 studies. J Cardiovasc 5872 
Pharmacol 2014;64:285-292. 5873 
934. Casadei B, OTHERS. Statin Therapy In Cardiac Surgery (STICS) Trial. N Engl J Med 5874 
2016;TO BE ADDED. 5875 
935. Cook RC, Yamashita MH, Kearns M, Ramanathan K, Gin K, Humphries KH. Prophylactic 5876 
magnesium does not prevent atrial fibrillation after cardiac surgery: a meta-analysis. Ann Thorac Surg 5877 
2013;95:533-541. 5878 
936. De Oliveira GS, Jr., Knautz JS, Sherwani S, McCarthy RJ. Systemic magnesium to reduce 5879 
postoperative arrhythmias after coronary artery bypass graft surgery: a meta-analysis of randomized 5880 
controlled trials. J Cardiothorac Vasc Anesth 2012;26:643-650. 5881 
937. Costanzo S, di Niro V, Di Castelnuovo A, Gianfagna F, Donati MB, de Gaetano G, Iacoviello 5882 
L. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative 5883 
supplementation of n-3 polyunsaturated fatty acids: an updated meta-analysis. J Thorac Cardiovasc 5884 
Surg 2013;146:906-911. 5885 
938. Farquharson AL, Metcalf RG, Sanders P, Stuklis R, Edwards JR, Gibson RA, Cleland LG, 5886 
Sullivan TR, James MJ, Young GD. Effect of dietary fish oil on atrial fibrillation after cardiac surgery. 5887 
Am J Cardiol 2011;108:851-856. 5888 
939. Heidarsdottir R, Arnar DO, Skuladottir GV, Torfason B, Edvardsson V, Gottskalksson G, 5889 
Palsson R, Indridason OS. Does treatment with n-3 polyunsaturated fatty acids prevent atrial 5890 
fibrillation after open heart surgery? Europace 2010;12:356-363. 5891 
940. Mariani J, Doval HC, Nul D, Varini S, Grancelli H, Ferrante D, Tognoni G, Macchia A. N-3 5892 
polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis 5893 
of randomized controlled trials. J Am Heart Assoc 2013;2:e005033. 5894 
941. Rodrigo R, Korantzopoulos P, Cereceda M, Asenjo R, Zamorano J, Villalabeitia E, Baeza C, 5895 
Aguayo R, Castillo R, Carrasco R, Gormaz JG. A randomized controlled trial to prevent post-operative 5896 
atrial fibrillation by antioxidant reinforcement. J Am Coll Cardiol 2013;62:1457-1465. 5897 
942. Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC. Omega-3 fatty 5898 
acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a 5899 
randomized, double-blind, placebo-controlled clinical trial. Circ Arrhythm Electrophysiol 2010;3:46-53. 5900 
943. Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, 5901 
Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian D. Plasma phospholipid omega-3 5902 
fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. J Am Heart Assoc 5903 
2013;2:e000397. 5904 
944. Xin W, Wei W, Lin Z, Zhang X, Yang H, Zhang T, Li B, Mi S. Fish oil and atrial fibrillation after 5905 
cardiac surgery: a meta-analysis of randomized controlled trials. PLoS One 2013;8:e72913. 5906 
945. Zhang B, Zhen Y, Tao A, Bao Z, Zhang G. Polyunsaturated fatty acids for the prevention of 5907 
atrial fibrillation after cardiac surgery: an updated meta-analysis of randomized controlled trials. J 5908 
Cardiol 2014;63:53-59. 5909 
946. Imazio M, Brucato A, Ferrazzi P, Pullara A, Adler Y, Barosi A, Caforio AL, Cemin R, Chirillo F, 5910 
Comoglio C, Cugola D, Cumetti D, Dyrda O, Ferrua S, Finkelstein Y, Flocco R, Gandino A, Hoit B, 5911 
Innocente F, Maestroni S, Musumeci F, Oh J, Pergolini A, Polizzi V, Ristic A, Simon C, Spodick DH, 5912 
Tarzia V, Trimboli S, Valenti A, Belli R, Gaita F, COPPS-2 Investigators. Colchicine for prevention of 5913 
postpericardiotomy syndrome and postoperative atrial fibrillation: the COPPS-2 randomized clinical 5914 
trial. JAMA 2014;312:1016-1023. 5915 
947. Cappabianca G, Rotunno C, de Luca Tupputi Schinosa L, Ranieri VM, Paparella D. Protective 5916 
effects of steroids in cardiac surgery: a meta-analysis of randomized double-blind trials. J 5917 
Cardiothorac Vasc Anesth 2011;25:156-165. 5918 
948. Viviano A, Kanagasabay R, Zakkar M. Is perioperative corticosteroid administration 5919 
associated with a reduced incidence of postoperative atrial fibrillation in adult cardiac surgery? 5920 
Interact Cardiovasc Thorac Surg 2014;18:225-229. 5921 
949. Kaleda VI, McCormack DJ, Shipolini AR. Does posterior pericardiotomy reduce the incidence 5922 
of atrial fibrillation after coronary artery bypass grafting surgery? Interact Cardiovasc Thorac Surg 5923 
2012;14:384-389. 5924 
Page 144 of 148 ESC AF Guidelines 
 
950. Dunning J, Treasure T, Versteegh M, Nashef SA. Guidelines on the prevention and 5925 
management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 5926 
2006;30:852-872. 5927 
951. LaPar DJ, Speir AM, Crosby IK, Fonner E, Jr., Brown M, Rich JB, Quader M, Kern JA, Kron 5928 
IL, Ailawadi G, Investigators for the Virginia Cardiac Surgery Quality Initiative. Postoperative atrial 5929 
fibrillation significantly increases mortality, hospital readmission, and hospital costs. Ann Thorac Surg 5930 
2014;98:527-533; discussion 533. 5931 
952. Saxena A, Dinh DT, Smith JA, Shardey GC, Reid CM, Newcomb AE. Usefulness of 5932 
postoperative atrial fibrillation as an independent predictor for worse early and late outcomes after 5933 
isolated coronary artery bypass grafting (multicenter Australian study of 19,497 patients). Am J 5934 
Cardiol 2012;109:219-225. 5935 
953. Gialdini G, Nearing K, Bhave PD, Bonuccelli U, Iadecola C, Healey JS, Kamel H. 5936 
Perioperative atrial fibrillation and the long-term risk of ischemic stroke. JAMA 2014;312:616-622. 5937 
954. Ahlsson A, Bodin L, Fengsrud E, Englund A. Patients with postoperative atrial fibrillation have 5938 
a doubled cardiovascular mortality. Scand Cardiovasc J 2009;43:330-336. 5939 
955. Ahlsson A, Fengsrud E, Bodin L, Englund A. Postoperative atrial fibrillation in patients 5940 
undergoing aortocoronary bypass surgery carries an eightfold risk of future atrial fibrillation and a 5941 
doubled cardiovascular mortality. Eur J Cardiothorac Surg 2010;37:1353-1359. 5942 
956. Mariscalco G, Klersy C, Zanobini M, Banach M, Ferrarese S, Borsani P, Cantore C, Biglioli P, 5943 
Sala A. Atrial fibrillation after isolated coronary surgery affects late survival. Circulation 5944 
2008;118:1612-1618. 5945 
957. Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, Lopez JA, Rasekh A, Wilson JM, 5946 
Massumi A. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am 5947 
Coll Cardiol 2004;43:742-748. 5948 
958. Phan K, Ha HS, Phan S, Medi C, Thomas SP, Yan TD. New-onset atrial fibrillation following 5949 
coronary bypass surgery predicts long-term mortality: a systematic review and meta-analysis. Eur J 5950 
Cardiothorac Surg 2015;48:817-824. 5951 
959. El-Chami MF, Kilgo P, Thourani V, Lattouf OM, Delurgio DB, Guyton RA, Leon AR, Puskas 5952 
JD. New-onset atrial fibrillation predicts long-term mortality after coronary artery bypass graft. J Am 5953 
Coll Cardiol 2010;55:1370-1376. 5954 
960. Anderson E, Dyke C, Levy JH. Anticoagulation strategies for the management of 5955 
postoperative atrial fibrillation. Clin Lab Med 2014;34:537-561. 5956 
961. Heldal M, Atar D. Pharmacological conversion of recent-onset atrial fibrillation: a systematic 5957 
review. Scand Cardiovasc J Suppl 2013;47:2-10. 5958 
962. Gillinov AM, Bagiella E, Moskowitz AJ, Raiten JM, Groh MA, Bowdish ME, Ailawadi G, 5959 
Kirkwood KA, Perrault LP, Parides MK, Smith Ii RL, Kern JA, Dussault G, Hackmann AE, Jeffries NO, 5960 
Miller MA, Taddei-Peters WC, Rose EA, Weisel RD, Williams DL, Mangusan RF, Argenziano M, 5961 
Moquete EG, O'Sullivan KL, Pellerin M, Shah KJ, Gammie JS, Mayer ML, Voisine P, Gelijns AC, 5962 
O'Gara PT, Mack MJ, CTSN. Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac 5963 
Surgery. N Engl J Med 2016:[Epub ahead of print]. 5964 
963. Triedman JK. Arrhythmias in adults with congenital heart disease. Heart 2002;87:383-389. 5965 
964. Ammash NM, Phillips SD, Hodge DO, Connolly HM, Grogan MA, Friedman PA, Warnes CA, 5966 
Asirvatham SJ. Outcome of direct current cardioversion for atrial arrhythmias in adults with congenital 5967 
heart disease. Int J Cardiol 2012;154:270-274. 5968 
965. Greason KL, Dearani JA, Theodoro DA, Porter CB, Warnes CA, Danielson GK. Surgical 5969 
management of atrial tachyarrhythmias associated with congenital cardiac anomalies: Mayo Clinic 5970 
experience. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2003;6:59-71. 5971 
966. Payne L, Zeigler VL, Gillette PC. Acute cardiac arrhythmias following surgery for congenital 5972 
heart disease: mechanisms, diagnostic tools, and management. Crit Care Nurs Clin North Am 5973 
2011;23:255-272. 5974 
967. Koyak Z, Harris L, de Groot JR, Silversides CK, Oechslin EN, Bouma BJ, Budts W, 5975 
Zwinderman AH, Van Gelder IC, Mulder BJ. Sudden cardiac death in adult congenital heart disease. 5976 
Circulation 2012;126:1944-1954. 5977 
968. Jensen AS, Idorn L, Norager B, Vejlstrup N, Sondergaard L. Anticoagulation in adults with 5978 
congenital heart disease: The who, the when and the how? Heart 2014. 5979 
969. Fujita S, Takahashi K, Takeuchi D, Manaka T, Shoda M, Hagiwara N, Kurosawa H, Nakanishi 5980 
T. Management of late atrial tachyarrhythmia long after Fontan operation. J Cardiol 2009;53:410-416. 5981 
970. Feltes TF, Friedman RA. Transesophageal echocardiographic detection of atrial thrombi in 5982 
patients with nonfibrillation atrial tachyarrhythmias and congenital heart disease. J Am Coll Cardiol 5983 
1994;24:1365-1370. 5984 
Page 145 of 148 ESC AF Guidelines 
 
971. Nagao K, Tsuchihashi K, Tanaka S, Iimura O. [Studies on atrial arrhythmias in atrial septal 5985 
defect. The influences of aging on atrial fibrillation]. Nihon Ronen Igakkai Zasshi 1995;32:27-32. 5986 
972. Giamberti A, Chessa M, Abella R, Butera G, Negura D, Foresti S, Carminati M, Cappato R, 5987 
Frigiola A. Surgical treatment of arrhythmias in adults with congenital heart defects. Int J Cardiol 5988 
2008;129:37-41. 5989 
973. Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, 5990 
Bogers AJ, Simoons ML. Excellent survival and low incidence of arrhythmias, stroke and heart failure 5991 
long-term after surgical ASD closure at young age. A prospective follow-up study of 21-33 years. Eur 5992 
Heart J 2003;24:190-197. 5993 
974. Yamada T, McElderry HT, Muto M, Murakami Y, Kay GN. Pulmonary vein isolation in patients 5994 
with paroxysmal atrial fibrillation after direct suture closure of congenital atrial septal defect. Circ J 5995 
2007;71:1989-1992. 5996 
975. Van De Bruaene A, Delcroix M, Pasquet A, De Backer J, Paelinck B, Morissens M, Budts W. 5997 
The importance of pulmonary artery pressures on late atrial arrhythmia in transcatheter and surgically 5998 
closed ASD type secundum. Int J Cardiol 2011;152:192-195. 5999 
976. de Salle P, Goenen M, Lecron J, Jaumin P, Tremouroux J. [Rhythm disorders occurring after 6000 
surgical closure of the interatrial communication]. Acta Cardiol 1975;30:239-249. 6001 
977. Scaglione M, Caponi D, Ebrille E, Di Donna P, Di Clemente F, Battaglia A, Raimondo C, 6002 
Appendino M, Gaita F. Very long-term results of electroanatomic-guided radiofrequency ablation of 6003 
atrial arrhythmias in patients with surgically corrected atrial septal defect. Europace 2014;16:1800-6004 
1807. 6005 
978. Kanter RJ, Garson A, Jr. Atrial arrhythmias during chronic follow-up of surgery for complex 6006 
congenital heart disease. Pacing Clin Electrophysiol 1997;20:502-511. 6007 
979. Porter CJ, Garson A. Incidence and management of dysrhythmias after Fontan procedure. 6008 
Herz 1993;18:318-327. 6009 
980. Gelatt M, Hamilton RM, McCrindle BW, Gow RM, Williams WG, Trusler GA, Freedom RM. 6010 
Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol 1994;24:1735-6011 
1741. 6012 
981. Peters NS, Somerville J. Arrhythmias after the Fontan procedure. Br Heart J 1992;68:199-6013 
204. 6014 
982. Kwak JG, Kim WH, Lee JR, Kim YJ. Surgical therapy of arrhythmias in single-ventricle 6015 
patients undergoing Fontan or Fontan conversion. J Card Surg 2009;24:738-741. 6016 
983. Backer CL, Tsao S, Deal BJ, Mavroudis C. Maze procedure in single ventricle patients. Semin 6017 
Thorac Cardiovasc Surg Pediatr Card Surg Annu 2008:44-48. 6018 
984. Deal BJ, Mavroudis C, Backer CL. The role of concomitant arrhythmia surgery in patients 6019 
undergoing repair of congenital heart disease. Pacing Clin Electrophysiol 2008;31 Suppl 1:S13-16. 6020 
985. Gandhi SK. Atrial arrhythmia surgery in congenital heart disease. J Interv Card Electrophysiol 6021 
2007;20:119-125. 6022 
986. Correa R, Sherwin ED, Kovach J, Mah DY, Alexander ME, Cecchin F, Walsh EP, Triedman 6023 
JK, Abrams DJ. Mechanism and ablation of arrhythmia following total cavopulmonary connection. Circ 6024 
Arrhythm Electrophysiol 2015;8:318-325. 6025 
987. Khairy P, Aboulhosn J, Gurvitz MZ, Opotowsky AR, Mongeon FP, Kay J, Valente AM, Earing 6026 
MG, Lui G, Gersony DR, Cook S, Ting JG, Nickolaus MJ, Webb G, Landzberg MJ, Broberg CS, 6027 
Alliance for Adult Research in Congenital Cardiology. Arrhythmia burden in adults with surgically 6028 
repaired tetralogy of Fallot: a multi-institutional study. Circulation 2010;122:868-875. 6029 
988. Kobayashi J, Yamamoto F, Nakano K, Sasako Y, Kitamura S, Kosakai Y. Maze procedure for 6030 
atrial fibrillation associated with atrial septal defect. Circulation 1998;98:II399-402. 6031 
989. Shim H, Yang JH, Park PW, Jeong DS, Jun TG. Efficacy of the maze procedure for atrial 6032 
fibrillation associated with atrial septal defect. Korean J Thorac Cardiovasc Surg 2013;46:98-103. 6033 
990. Gutierrez SD, Earing MG, Singh AK, Tweddell JS, Bartz PJ. Atrial tachyarrhythmias and the 6034 
Cox-maze procedure in congenital heart disease. Congenit Heart Dis 2013;8:434-439. 6035 
991. Sherwin ED, Triedman JK, Walsh EP. Update on interventional electrophysiology in 6036 
congenital heart disease: evolving solutions for complex hearts. Circ Arrhythm Electrophysiol 6037 
2013;6:1032-1040. 6038 
992. Wellens HJ. Contemporary management of atrial flutter. Circulation 2002;106:649-652. 6039 
993. Bertaglia E, Zoppo F, Bonso A, Proclemer A, Verlato R, Coro L, Mantovan R, D'Este D, Zerbo 6040 
F, Pascotto P. Long term follow up of radiofrequency catheter ablation of atrial flutter: clinical course 6041 
and predictors of atrial fibrillation occurrence. Heart 2004;90:59-63. 6042 
Page 146 of 148 ESC AF Guidelines 
 
994. Seara JG, Roubin SR, Gude Sampedro F, Barreiro VB, Sande JM, Manero MR, Grandio PC, 6043 
Alvarez B, Juanatey JG. Risk of atrial fibrillation, stroke, and death after radiofrequency catheter 6044 
ablation of typical atrial flutter. Clin Res Cardiol 2014;103:543-552. 6045 
995. Brembilla-Perrot B, Girerd N, Sellal JM, Olivier A, Manenti V, Villemin T, Beurrier D, de 6046 
Chillou C, Louis P, Selton O, de la Chaise AT. Risk of atrial fibrillation after atrial flutter ablation: 6047 
impact of AF history, gender, and antiarrhythmic drug medication. J Cardiovasc Electrophysiol 6048 
2014;25:813-820. 6049 
996. Bronis K, Metaxa S, Koulouris S, Manolis AS. Vernakalant: review of a novel atrial selective 6050 
antiarrhythmic agent and its place in current treatment of atrial fibrillation. Hosp Chronicles 6051 
2012;7:171-181. 6052 
997. Nair M, George LK, Koshy SK. Safety and efficacy of ibutilide in cardioversion of atrial flutter 6053 
and fibrillation. J Am Board Fam Med 2011;24:86-92. 6054 
998. Reisinger J, Gstrein C, Winter T, Zeindlhofer E, Hollinger K, Mori M, Schiller A, Winter A, 6055 
Geiger H, Siostrzonek P. Optimization of initial energy for cardioversion of atrial tachyarrhythmias with 6056 
biphasic shocks. Am J Emerg Med 2010;28:159-165. 6057 
999. Pinski SL, Sgarbossa EB, Ching E, Trohman RG. A comparison of 50-J versus 100-J shocks 6058 
for direct-current cardioversion of atrial flutter. Am Heart J 1999;137:439-442. 6059 
1000. Manolis AS, Dragazis I, Kapelakis I, Papadimitriou P, Sakellaris N. Transesophageal 6060 
overdrive pacing: A simple and versatile tool. Hosp Chronicles 2013;8:143-145. 6061 
1001. Poulidakis E, Manolis AS. Transvenous temporary cardiac pacing. Rhythmos 2014;9:20-27. 6062 
1002. Spector P, Reynolds MR, Calkins H, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Meta-6063 
analysis of ablation of atrial flutter and supraventricular tachycardia. Am J Cardiol 2009;104:671-677. 6064 
1003. Schmieder S, Ndrepepa G, Dong J, Zrenner B, Schreieck J, Schneider MA, Karch MR, 6065 
Schmitt C. Acute and long-term results of radiofrequency ablation of common atrial flutter and the 6066 
influence of the right atrial isthmus ablation on the occurrence of atrial fibrillation. Eur Heart J 6067 
2003;24:956-962. 6068 
1004. Bandini A, Golia P, Caroli E, Biancoli S, Galvani M. Atrial fibrillation after typical atrial flutter 6069 
ablation: a long-term follow-up. J Cardiovasc Med (Hagerstown) 2011;12:110-115. 6070 
1005. Dewland TA, Glidden DV, Marcus GM. Healthcare utilization and clinical outcomes after 6071 
catheter ablation of atrial flutter. PLoS One 2014;9:e100509. 6072 
1006. Esato M, Hindricks G, Sommer P, Arya A, Gaspar T, Bode K, Bollmann A, Wetzel U, Hilbert 6073 
S, Kircher S, Eitel C, Piorkowski C. Color-coded three-dimensional entrainment mapping for analysis 6074 
and treatment of atrial macroreentrant tachycardia. Heart Rhythm 2009;6:349-358. 6075 
1007. Huo Y, Schoenbauer R, Richter S, Rolf S, Sommer P, Arya A, Rastan A, Doll N, Mohr FW, 6076 
Hindricks G, Piorkowski C, Gaspar T. Atrial Arrhythmias Following Surgical AF Ablation: 6077 
Electrophysiological Findings, Ablation Strategies, and Clinical Outcome. J Cardiovasc Electrophysiol 6078 
2014;25:725-738. 6079 
1008. Institute of Medicine Committee on Quality of Health Care in America. Crossing the Quality 6080 
Chasm: A New Health System for the 21st Century. Washington (DC): National Academies Press 6081 
(US); 2001. 6082 
1009. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic 6083 
illness. JAMA 2002;288:1775-1779. 6084 
1010. Hibbard JH, Greene J. What the evidence shows about patient activation: better health 6085 
outcomes and care experiences; fewer data on costs. Health Aff (Millwood) 2013;32:207-214. 6086 
1011. McCabe PJ. Self-management of atrial fibrillation: a new frontier for nursing research. Prog 6087 
Cardiovasc Nurs 2008;23:37-40. 6088 
1012. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D. Ethnic differences in patient 6089 
perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation 6090 
Project. Stroke 2002;33:238-242. 6091 
1013. Clarkesmith DE, Pattison HM, Lane DA. Educational and behavioural interventions for 6092 
anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev 6093 
2013;6:Cd008600. 6094 
1014. Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves 6095 
anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS One 6096 
2013;8:e74037. 6097 
1015. Smith DE, Xuereb CB, Pattison HM, Lip GY, Lane DA. TRial of an Educational intervention on 6098 
patients' knowledge of Atrial fibrillation and anticoagulant therapy, INR control, and outcome of 6099 
Treatment with warfarin (TREAT). BMC Cardiovasc Disord 2010;10:21. 6100 
1016. Smith MB, Christensen N, Wang S, Strohecker J, Day JD, Weiss JP, Crandall BG, Osborn 6101 
JS, Anderson JL, Horne BD, Muhlestein JB, Lappe DL, Moss H, Oliver J, Viau K, Bunch TJ. Warfarin 6102 
Page 147 of 148 ESC AF Guidelines 
 
knowledge in patients with atrial fibrillation: implications for safety, efficacy, and education strategies. 6103 
Cardiology 2010;116:61-69. 6104 
1017. Aliot E, Breithardt G, Brugada J, Camm J, Lip GY, Vardas PE, Wagner M, Atrial Fibrillation 6105 
AWareness and Risk Education group [comprising the Atrial Fibrillation Association (AFA), the 6106 
European Heart Rhythm Association (EHRA), Stroke Alliance for Europe (SAFE), and the World Heart 6107 
Federation (WHF)]. An international survey of physician and patient understanding, perception, and 6108 
attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. 6109 
Europace 2010;12:626-633. 6110 
1018. Hendriks JM, Crijns HJ, Tieleman RG, Vrijhoef HJ. The atrial fibrillation knowledge scale: 6111 
development, validation and results. Int J Cardiol 2013;168:1422-1428. 6112 
1019. McCabe PJ. What patients want and need to know about atrial fibrillation. J Multidiscip 6113 
Healthc 2011;4:413-419. 6114 
1020. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and 6115 
mechanisms. Ann Behav Med 2003;26:1-7. 6116 
1021. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, Trevena L, 6117 
Elwyn G. Shared decision making: really putting patients at the centre of healthcare. BMJ 6118 
2012;344:e256. 6119 
1022. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, Holmes-Rovner M, Llewellyn-6120 
Thomas H, Lyddiatt A, Thomson R, Trevena L, Wu JH. Decision aids for people facing health 6121 
treatment or screening decisions. Cochrane Database Syst Rev 2014;1:CD001431. 6122 
1023. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, 6123 
Tomson D, Dodd C, Rollnick S, Edwards A, Barry M. Shared decision making: a model for clinical 6124 
practice. J Gen Intern Med 2012;27:1361-1367. 6125 
1024. Van Wagoner DR, Piccini JP, Albert CM, Anderson ME, Benjamin EJ, Brundel B, Califf RM, 6126 
Calkins H, Chen PS, Chiamvimonvat N, Darbar D, Eckhardt LL, Ellinor PT, Exner DV, Fogel RI, Gillis 6127 
AM, Healey J, Hohnloser SH, Kamel H, Lathrop DA, Lip GY, Mehra R, Narayan SM, Olgin J, Packer 6128 
D, Peters NS, Roden DM, Ross HM, Sheldon R, Wehrens XH. Progress toward the prevention and 6129 
treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the 6130 
Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. Heart Rhythm 6131 
2015;12:e5-e29. 6132 
1025. van Nieuwenhuizen KM, van der Worp HB, Algra A, Kappelle LJ, Rinkel GJ, van Gelder IC, 6133 
Schutgens RE, Klijn CJ, APACHE-AF Investigators. Apixaban versus Antiplatelet drugs or no 6134 
antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with 6135 
Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. Trials 2015;16:393. 6136 
1026. Gronberg T, Nuotio I, Nikkinen M, Ylitalo A, Vasankari T, Hartikainen JE, Airaksinen KE. 6137 
Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: the FinCV study. 6138 
Europace 2013;15:1432-1435. 6139 
1027. Tse HF, Lau CP. Does sinus rhythm beget sinus rhythm? Effects of prompt cardioversion on 6140 
the frequency and persistence of recurrent atrial fibrillation. Card Electrophysiol Rev 2003;7:359-365. 6141 
1028. Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early 6142 
restoration and maintenance of sinus rhythm. Europace 2006;8:943-949. 6143 
1029. Liu ZJ, Fu WG, Guo ZY, Shen LG, Shi ZY, Li JH. Updated systematic review and meta-6144 
analysis of randomized clinical trials comparing carotid artery stenting and carotid endarterectomy in 6145 
the treatment of carotid stenosis. Ann Vasc Surg 2012;26:576-590. 6146 
1030. Taylor DW, Barnett HJM, Haynes RB, Ferguson GG, Sackett DL, Thorpe KE, Simard D, 6147 
Silver FL, Hachinski V, Clagett GP, barnes R, Spence JD, ASA and Carotid Endarterectomy (ACE) 6148 
trial collaborators. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid 6149 
endarterectomy: a randomised controlled trial. Lancet 1999;353:2179-2184. 6150 
1031. Watanabe M, Chaudhry SA, Adil MM, Alqadri SL, Majidi S, Semaan E, Qureshi AI. The effect 6151 
of atrial fibrillation on outcomes in patients undergoing carotid endarterectomy or stent placement in 6152 
general practice. J Vasc Surg 2015;61:927-932. 6153 
1032. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, 6154 
Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, 6155 
Mahaffey KW, Fox KA, Califf RM, ROCHET AF Steering Committee & Investigators. Clinical 6156 
characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial 6157 
fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. 6158 
Eur Heart J 2014;35:3377-3385. 6159 
1033. Philippart R, Brunet-Bernard A, Clementy N, Bourguignon T, Mirza A, Babuty D, Angoulvant 6160 
D, Lip GY, Fauchier L. Prognostic value of CHA2DS2-VASc score in patients with 'non-valvular atrial 6161 
Page 148 of 148 ESC AF Guidelines 
 
fibrillation' and valvular heart disease: the Loire Valley Atrial Fibrillation Project. Eur Heart J 6162 
2015;36:1822-1830. 6163 
1034. Breithardt G, Baumgartner H. Valvular heart disease among non-valvular atrial fibrillation: a 6164 
misnomer, in search of a new term. Eur Heart J 2015;36:1794-1797. 6165 
1035. Wolf RK, Schneeberger EW, Osterday R, Miller D, Merrill W, Flege JB, Jr., Gillinov AM. 6166 
Video-assisted bilateral pulmonary vein isolation and left atrial appendage exclusion for atrial 6167 
fibrillation. J Thorac Cardiovasc Surg 2005;130:797-802. 6168 
1036. Yilmaz A, Van Putte BP, Van Boven WJ. Completely thoracoscopic bilateral pulmonary vein 6169 
isolation and left atrial appendage exclusion for atrial fibrillation. J Thorac Cardiovasc Surg 6170 
2008;136:521-522. 6171 
1037. Salzberg SP, Plass A, Emmert MY, Desbiolles L, Alkadhi H, Grunenfelder J, Genoni M. Left 6172 
atrial appendage clip occlusion: early clinical results. J Thorac Cardiovasc Surg 2010;139:1269-1274. 6173 
1038. Papworth Hospital NHS Foundation Trust. A randomised controlled trial to investigate the 6174 
clinical and cost effectiveness of adding an ablation device-based maze procedure as a routine 6175 
adjunct to elective cardiac surgery for patients with pre-existing atrial fibrillation. 6176 
http://www.isrctn.com/ISRCTN82731440. Date last accessed 5 May 2016 ISRCTN82731440 6177 
1039.    Efficacy and safety of ablation for patients with non-paroxysmal atrial fibrillation. doi: 6178 
10.1002/14651858.CD012088.pub2 6179 
1040.    Concomitant atrial fibrillation surgery for people undergoing cardiac surgery. doi: 6180 
10.1002/14651858.CD011814.pub2 6181 
1041.    Hemingway CPRD data (when published) 6182 
1042.    MANTRA-PAF 5 yr outcomes (when published) 6183 
